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SUMMARY OF THE THESIS “NATURAL PRODUCT-RELATED 
MULTITARGET-DIRECTED LIGANDS FOR THE POTENTIAL 
TREATMENT OF NEURODEGENERATIVE DISEASES” 
Introduction 
Neurodegenerative diseases are characterized by the loss of neurons in the brain 
and/or spinal cord and constitute one of the most important health problems 
worldwide. Although these diseases have different etiologies and clinical 
manifestations, they share many mechanistic pathways, including: protein misfolding, 
neuroinflammation, impaired mitochondrial function, increase in oxidative stress, 
mitochondrial disfunction, alterations in calcium homeostasis, etc.  
Objectives 
1. Design, synthesis and characterization of libraries of cyclic analogues of cinnamic 
esters and curcumin in order to study their antioxidant activity and neuroprotective 
profiles. The molecular architecture of these compounds was organized around a 
central 2-pyrrolin-5-one core, which was expected to increase their stability while 
also providing synthetic handles for the preparation of multitarget-directed ligands. 
2.  Design, synthesis and characterization of a library of oxindole-derived dispiro 
compounds as analogues of the neuroprotecive alkaloid rhynchophylline. 
3. Design, synthesis and characterization of a library of compounds derived from the 
2,5,8-quinolinetrione skeleton and containing an indolylethyl side chain. These 
compounds can be considered vinylogs of the natural antioxidant and 
neuroprotectant melatonin, and are expected to show also a multitarget 
neuroprotective profile associated to their heterocyclic quinone moiety. 
4.  Design, synthesis and characterization of hybrid compounds designed to combine 
in a single molecule the frameworks of CGP-37157, a well-known inhibitor of the 
mitochondrial mNCX transporter with neuroprotective activity, and lipoic acid, a 
natural antioxidant. 
5. As part of a collaborative effort, our goal was the synthesis of the heterocyclic 
fragments of a series of heterocyclic carbohydrate hybrids, designed using a 
fragment-based approach and potentially active against neuroinflammation.  
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Results and discussion 
Objectives 1 and 2 required the development of new synthetic methodology for the 
preparation of the core 2-pyrrolidin-5-one nucleus, and this was achieved by a 
modification of the classical Hantzsch three-component pyrrole synthesis. 
Straightforward Knoevenagel condensation and acylation reactions furnished the 
target cinnamic ester and curcumin analogues, respectively. A three-component 1,3-
dipolar cycloaddition reaction between the Knoevenagel adducts, isatin derivatives 
and -amino acids afforded the dispiro compounds designed as rhynchophylline 
analogues.  
 
These libraries were pharmacologically assayed through collaborations with the groups 
led by Dr. Rafael León (Hospital de La Princesa and Instituto Teófilo Hernando, 
Universidad Autónoma de Madrid) and Drs. Sagrario Martín-Aragón and Paloma 
Bermejo (Universidad Complutense). These studies revealed interesting multitarget 
profiles and led to the selection of several compounds as suitable hits for future 
development. 
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The melatonin-quinolinetrione hybrids were synthesized in two stages. First, the 
suitable 2,5,8-quinolinetrione precursors were obtained by routes using as key stages 
the Meth-Cohn or Friedländer quinoline syntheses. Then, the target hybrid compounds 
were obtained by regioselective addition of tryptamine derivatives to the quinone C-6 
position followed by in situ oxidation.   
 
These hybrids are under pharmacological assay through a collaboration with the group 
led by Dr. Pilar Gómez-Serranillos (Universidad Complutense) and so far have shown 
very potent antioxidant activities. 
A seven-step route, based on the use of Ellman’s sulfinamide as a chiral auxiliary,  
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allowed the preparation of all four enantiomers of our target aza CGP-37157 lipoic acid 
hybrid structure, as exemplified for one of them. Their pharmacological study was 
carried out through our collaboration with Dr. Rafael León and showed interesting 
neuroprotective profiles. 
Finally, the heterocyclic moieties of four structurally complex carbohydrate hybrid 
structures designed as galectin ligands were obtained by multistep routes. 
 
Conclusions 
The work performed in this thesis shows that the multitarget approach is promising 
towards the discovery of molecules that can be used as hits in the development of new 
drugs for the treatment of neurodegenerative diseases. 
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RESUMEN DE LA TESIS “LIGANDOS MULTIDIANA 
RELACIONADOS CON PRODUCTOS NATURALES PARA EL 
TRATAMIENTO POTENCIAL DE ENFERMEDADES 
NEURODEGENERATIVAS” 
Introducción 
Las enfermedades neurodegenerativas se caracterizan por la pérdida de neuronas en 
el cerebro y/o en la medula espinal y constituyen uno de los más importantes 
problemas de salud a nivel mundial. A pesar de que estas enfermedades tienen 
diferentes etiologías y manifestaciones clínicas, comparten diversos mecanismos, 
incluyendo: incorrecto plegamiento de proteínas, neuroinflamación, función 
mitocondrial dañada, aumento en el estrés oxidativo, disfunción mitocondrial, 
alteraciones en la homeostasis del calcio, etc.  
Objetivos 
1. Diseño, síntesis y caracterización de librerías de análogos cíclicos de ésteres 
cinámicos y curcumina para el estudio de su actividad antioxidante y su perfile 
neuroprotector. La arquitectura molecular de estos compuestos está organizada 
alrededor de un núcleo central de 2-pirrolin-5-ona, del que se espera que 
incremente su estabilidad a la vez que proporciona accesibilidad sintética para la 
preparación de ligandos multidiana.  
2. Diseño, síntesis y caracterización de una quimiotecas de compuestos 
diespirooxoindol como análogos del alcaloide neuroprotector ricofilina. 
3. Diseño, síntesis y caracterización de una quimiotecas de compuestos derivados del 
esqueleto de 2,5,8-quinolinatriona y conteniendo grupos indoliletilo como cadenas 
laterales. Estos compuestos pueden ser considerados vinílogos de la melatonina, un 
antioxidante natural y neuroprotector, y se espera que muestren además un perfil 
neuroprotector multidiana asociado a la estructura heterocíclica de quinona.   
4. Diseño, síntesis y caracterización de compuestos híbridos que combinan en una sola 
molécula fragmentos clave de CGP-37157, un inhibidor del transportador mNCX con 
actividad neuroprotectora, y el ácido lipoico, un antioxidante natural.  
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5. Síntesis de los fragmentos heterocíclicos de una serie de híbridos de heterociclos 
con carbohidratos, diseñados como moduladores de las galectinas, con potencial 
actividad contra la neuroinflamación  
Resultados y discusión  
Los objetivos 1 y 2 requieren el desarrollo de nuevas metodologías para la preparación 
del núcleo de 2-pirrolin-5-ona, y esto se ha logrado por la modificación de la síntesis 
multicomponente de Hantzsch de pirroles. Empleando reacciones sencillas como la 
condensación de Knoevenagel o reacciones de acilación se obtuvieron los análogos de 
éster cinámico y curcumina, respectivamente. Una cicloadición 1,3-dipolar de tres 
componentes entre el aducto de Knoevenagel, derivados de isatina y α-aminoácidos 
generó los compuestos de tipo biespiro diseñados como análogos de la rincofilina. 
 
Estas quimiotecas han sido ensayadas farmacológicamente en colaboración con los 
grupos liderados por el Dr. Rafael León (Hospital de La Princesa e Instituto Teófilo 
Hernando, Universidad Autónoma de Madrid) y las Dras. Sagrario Martín-Aragón y 
Paloma Bermejo (Universidad Complutense). Estos estudios revelan interesantes 
 ix 
 
perfiles multidiana y han llevado a la selección de diferentes compuestos como 
candidatos adecuados para su futuro desarrollo. 
Los híbridos de melatonina-quinolinatriona han sido sintetizados en dos fases. En la 
primera, la 2,5,8-quinolinatriona precursora se obtuvo empleando las síntesis de 
quinolinas de Meth-Cohn o Friedländer como pasos clave. A continuación, los 
compuestos híbridos objetivo fueron obtenidos por la adición regioselectiva de 
derivados de  triptamina sobre la posición C-6 de la quinona, seguida por una 
oxidación in situ. Estos híbridos se encuentran bajo su estudio farmacológico a través 
de una colaboración con el grupo liderado por la Dra. Pilar Gómez-Serranillos 
(Universidad Complutense) y han mostrado una potente actividad antioxidante.  
 
Una ruta de siete pasos, basada en el uso de la sulfinamida de Ellman como auxiliar 
quiral, ha permitido la obtención de los cuatro enantiómeros del híbrido aza-CGP-
37157-ácido lipoico, como se indica a continuación para uno de ellos. Los estudios 
farmacológicos están siendo llevados a cabo con la colaboración del Dr. Rafael León y 
han mostrado perfiles neuroprotectores interesantes. 
Por último, los fragmentos heterocíclicos correspondientes a cuatro estructuras 
híbridas con carbohidratos relacionadas con galectinas han sido obtenidos en rutas de 
varios pasos que generalmente tienen como etapa clave un acoplamiento catalizado 
por paladio.  
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Conclusiones  
El trabajo llevado a cabo en esta tesis muestra que la aproximación multidiana es una 
estrategia prometedora en el descubrimiento de nuevas moléculas que pueden ser 
empleadas como candidatas en el desarrollo de nuevos fármacos para el tratamiento 
de enfermedades neurodegenerativas. 
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1.1. General comments on dementia 
Dementia is a general term used to describe a decline in intellectual skills that reduces 
the ability of the patient to perform routine daily activities. There are about 50 million 
dementia patients worldwide, and every year 7.7 million new cases are diagnosed. It is 
estimated that the number of cases will reach 65.7 million in 2030 and 115.4 million in 
2050, with nearly 60% patients living in low- and middle-income countries (Figure 1.1). 
The improvement in life expectancy is the main cause for this growth in incidence, 
since advanced age is the main risk factor in the development of dementia.  
 
Figure 1.1. Projected growth in the incidence of dementia in high-income and low and middle-income 
countries. Elaborated from data in reference 1 
 
The most common forms of dementia are, in order of importance, Alzheimer´s disease, 
vascular dementia, dementia with Lewy bodies and frontotemporal dementia. 
However, mixed pathologies seem to be more widespread than the pure ones. Thus, 
the retrospective clinico-pathological study of 1050 elderly patients of dementia 
showed that in 86% of cases it was Alzheimer’s disease-related. However, only 43% of 
patients had pure Alzheimer´s disease, while for the other 67% it was combined with 
 
1  Dementia: a public health priority. World Health Organization. World Health Organization 2012. 
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other neurodegenerative diseases: cerebrovascular (26%), Parkinson´s disease (10%) 
and others (Figure 1.2).2 
 
 
Figure 1.2. Proportion of the different subtypes of dementia in UK female patients    
Neurodegenerative diseases are characterized by the loss of neurons in the brain 
and/or spinal cord. For each particular disease, this loss affects a specific set of 
neurons in particular, driving in a heterogeneous clinical symptomatology and finally 
resulting in the different neurodegenerative diseases. These diseases are multi-
factorial pathologies with different etiologies, molecular mechanisms and clinical 
manifestations. Nevertheless, they share many biochemical pathways, including: 
protein misfolding, neuroinflammation, impaired mitochondrial function, increase in 
oxidative stress, mitochondrial disfunction, loss of neuronal plasticity, etc. For 
instance, Alzheimer´s disease (AD) has several pathogenic mechanisms including 
amyloid β (Aβ) aggregation to form plaques, tau hyperphosphorylation-driven 
formation of neurofibrillary tangles, calcium imbalance, increase in ROS and NOS-
associated stress, Ca2+ ion dehomeostasis, apoptosis disfunction, and deterioration of 
synaptic transmission, particularly at cholinergic neurons. Hundreds of compounds 
addressed at these individual targets have been investigated, including inhibitors of β 
and γ secretase, vaccines or antibodies that clear Aβ, metal chelators or molecular 
chaperones to prevent Aβ aggregation, glycogen synthase kinase 3β inhibitors, ROS 
and NOS scavengers, modulators of calcium channels such as voltage-dependent 
 
2  Jellinger, K. A. J. Alzheimer's Dis. 2006, 9, 61-70. 
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calcium channels blockers, N-methyl-D-aspartate receptor inhibitors, or enhancers of 
cholinergic neurotransmission such as inhibitors of acetylcholinesterase or 
butyrylcholinesterase. 
1.2. Neurodegeneration, oxidative stress and reactive oxygen species 
1.2.1. General aspects of oxidative stress 
Reactive oxygen species (ROS) is a general term that describes the chemical species 
produced in the incomplete reduction of the oxygen molecule.3 These species are, 
among others, the hydroxyl radical (•OH), the superoxide anion (O2•-) and hydrogen 
peroxide (H2O2).  
ROS are intracellular signalling molecules and is has been reported in the literature.3 
Both O2• and •OH are poor signalling molecules due to their instability, inability to 
cross the membranes and the short diffusion distances.4 In contrast, H2O2 can mediate 
signalling pathways due to its high diffusivity, ability to cross membranes and stability. 
Cys residues are the main target for H2O2-dependent downstream signalling, which 
regulates several biochemical pathways such circadian rhythms. An example is the 24 h 
redox cycles of the peroxiredoxin protein that exists in the red blood cells (Figure 1.3).5 
 
Figure 1.3. Reproduced with permission from reference 4 
 
3  D'Autréaux, B.; Toledano, M. B. Nat. Rev. Mol. Cell Biol. 2007, 8, 813-825. 
4  Yang, B.; Chen, Y.; Shi, J. Chem. Rev. 2019, 119, 4881-4985. 
5  O’Neill, J. S.; Reddy, A. B. Nature 2011, 469, 498-503. 
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While ROS have physiological roles as second messengers in moderate concentrations, 
excessive ROS activity leads to oxidative stress. This increase in ROS concentration was 
observed in human fibroblasts and induced a senescence-like state.6 The imbalance in 
ROS concentration and senescence were found to be correlated in several pathological 
processes. Furthermore, oxidative stress is a common hallmark in neurodegenerative 
diseases, as the result of the hyperproduction of ROS combined with the relatively low 
antioxidant levels and low regenerative capacity. This imbalance causes brain tissue 
damage and, as a consequence, neuronal death and neurodegeneration.7, 8 
1.2.2. ROS generation 
The quantum level of ground state O2 molecules is a triplet spin state and consequently 
its interactions with organic compounds are energetically disfavoured. Live organisms 
have developed metal-containing enzymes to convert O2 into ROS, that are able to 
react with organic compounds.  
ROS are generated by two major pathways: 
• Direct interaction between redox-active metals like copper and iron and oxygen 
species via the Fenton and Haber-Weiss reactions. These metal ions exist in 
multiple valence states and this multiple valence occupancy is the reason for the 
presence of these cations in the metalloenzymes responsible for the activation of 
molecular oxygen. The deregulation of the redox-active metals may lead to an 
overproduction of ROS. Several NDD-related proteins including Aβ in AD, SOD1 in 
ALS and α-synuclein in PD, contain Cu2+ or Fe3+ contributing to ROS formation. 
Protein ligation to metal ions rises in the brain with increased age.  
• Indirect activation of calcium dependent metalloenzymes such as 
phospholipases, nitric oxide synthase or xanthine dehydrogenase. NDDs are 
characterized by an intracellular calcium overload, as described previously. This 
calcium homeostasis disruption may trigger several cellular process. The 
interplay between calcium signalling and ROS production is regulated by a 
feedback signalling process, and it is often difficult to differentiate between 
 
6  Serrano, M.; Lin, A. W.; McCurrach, M. E.; Beach, D.; Lowe, S. W. Cell 1997, 88, 593-602. 
7  Lotharius, J.; Brundin, P. Nat. Rev. Neurosci. 2002, 3, 932-942. 
8  Barnham, K. J.; Masters, C. L.; Bush, A. I. Nat. Rev. Drug Discov. 2004, 3, 205-214. 
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cause and effect. An increase in intracellular calcium induces ROS production,9 
but subtoxic ROS levels act as messengers to rise the intracellular calcium 
concentration. As a consequence, the precise role of calcium overload in the 
production of ROS remains controversial. 
1.2.3. Consequences of oxidative stress 
Lipid peroxidation is a sensitive and selective marker of oxidative stress through 
oxidative modifications and peroxidations. The radicals previously formed from O2 
attack the double bonds contained in the unsaturated fatty acids such as linoleic acid 
and arachidonic acid. These highly reactive peroxy radicals initiate a chain reaction of 
attacks on adjacent fatty acid molecules. The chain reaction affords several products 
that are characteristic of specific NDDs like 4-hydroxy-2,3-nonenal (HNE) in AD and 
PD,10, 11 acrolein and F2-isoprostanes in AD12 and malondialdehyde in PD. DNA bases 
are also susceptible to oxidative damage involving carbonylation, nitration and 
hydroxylation reactions. Increased levels of 8-hydroxyguanine and 8-hydroxy-2-
deoxyguanosine were observed in PD brains.13  
These oxidative stress evidences are closely related to the molecular mechanism that 
initiates the neuronal death and neurodegeneration. Acrolein and HNE induce toxicity 
by crosslinking to cysteine, lysine and histidine residues through Michael additions. 
The formation of these adducts causes the impairment of enzymes, receptors and DNA 
mutations leading to malfunction of a variety of biochemical pathways.  
Additionally, ROS imbalance causes intracellular calcium overload, widely described in 
NDDs and associated to an aberrant apoptotic cascade activation.14, 15, 16 The ROS-
induced calcium influx exerts an excitotoxic response,17 driven by the activation of 
glutamate receptors that trigger the apoptotic cascade. The excitotoxic response takes 
 
9  Lewen, A.; Matz, P.; Chan, P. H. J. Neurotrauma 2000, 17, 871-890. 
10  Selley, M. L.; Close, D. R.; Stern, S. E. Neurobiol. Aging 2002, 23, 383-388. 
11  Dexter, D. T.; Carter, C. J.; Wells, F. R.; Javoy‐Agid, F.; Agid, Y.; Lees, A.; Marsden, C. D. J. Neurochem. 
1989, 52, 381-389. 
12  Arlt, S.; Beisiegel, U.; Kontush, A. Curr. Opin. Lipidol. 2002, 13, 289-294. 
13  Alam, Z. I.; Jenner, A.; Daniel, S. E.; Lees, A. J.; Cairns, N.; Marsden, C. D.; Jenner, P.; Halliwell, B. J. 
Neurochem. 1997, 69, 1196-1203. 
14  LaFerla, F. M. Nat. Rev. Neurosci. 2002, 3, 862-872. 
15  Gibson, G. E. Free Radic. Biol. Med. 2002, 32, 1061-1070. 
16  Mattson, M. P.; Chan, S. L. Cell Calcium 2003, 34, 385-397. 
17  Yamamoto, K.; Ishikawa, T.; Sakabe, T.; Taguchi, T.; Kawai, S.; Marsala, M. Neuroreport. 1998, 9, 
1655-1659. 
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place in different neurological disorders including stroke, as well as in NDDs such as 
AD, PD and amyotrophic lateral sclerosis (ALS).18  
A summary of the main processes related to ROS production and their biological 
consequences can be found in Figure 1.4.  
 
 
Figure 1.4.  
1.3. Protein misfolding, proteostasis and neurodegeneration 
1.3.1. Protein misfolding and neurodegenerative disease: General aspects 
The misfolding of specific proteins and the consequent protein aggregation in toxic 
form is the most common feature of NDDs (Table 1.1).19 The misfolded proteins arise 
from cell stress, mutations or protein production mistakes. The integrated cellular 
machinery that regulates the synthesis, proper folding, degradation and clearance of 
proteins is known as proteostasis. The proteostatic system is regulated by two main 
components, the chaperones that refold proteins into a stable conformation and two 
proteolytic pathways, namely the proteasome and the lysosome-autophagy system 
(Figure 1.5). During the ageing process, the proteostatic system collapses due to 
accumulation of misfolded proteins. The imbalance between the wrong folding and the 
 
18  Mattson, M. P. Neuromolecular Med. 2003, 3, 65-94. 
19  Sweeney, P.; Park, H.; Baumann, M.; Dunlop, J.; Frydman, J.; Kopito, R.; Hodgson, R. Transl. 
Neurodegener. 2017, 6, 6. 
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protein degradation pathways leads to the accumulation of ubiquitinated inclusion 
bodies (IBs), which have been observed in several neurodegenerative diseases.20 
Table 1.1. Neurodegenerative disease associated with misfolded proteins 
Misfolded protein Neurodegenerative disease 
Amyloid β; Tau; TDP-43 Alzheimer´s disease 
α-Synuclein; Tau Parkinson´s disease 
Huntingtin with tandem glutamine repeats Huntington´s disease 
Superoxide dismutase 1; TDP-43 Amyotrophic lateral sclerosis 
Prion protein Spongiform encephalopathies 
 
 
Figure 1.5. The proteostatic system. Reproduced with permission from reference 21 
The precise neurotoxic mechanisms caused by misfolded proteins are not still 
completely understood, and differ on the protein species involved. Some examples are 
amyloid-beta, tau, and alpha-synuclein, all of which interfere with synaptic 
signalling;22, 23, 24 mutant tau impairs microtubule function and neuronal transport 
mechanisms 24 and alpha-synuclein causes mitochondrial disfunction.24 Furthermore, 
larger aggregates of these misfolded proteins may cause toxic effects by binding to and 
 
20  Hipp, M. S.; Park, S. H.; Hartl, F. U. Trends Cell Biol. 2014, 24, 506-514. 
21  Kaushik, S.; Cuervo, A. M. Nat. Med. 2015, 21, 1406-1415. 
22  Shankar, G. M.; Li, S.; Mehta, T. H.; Garcia-Muñoz, A.; Shepardson, N. E.; Smith, I.; Brett, F. M.; 
Farrell, M. A.; Rowan, M. J.; Lemere, C. A.; Regan, C. M.; Walsh, D. M.; Sabatini, B. L.; Selkoe, D. J. 
Nat. Med. 2008, 14, 837-842. 
23  Kopeikina, K. J.; Hyman, B. T.; Spires-Jones, T. L. Transl. Neurosci. 2012, 3, 223-233. 
24  Ingelsson, M. Front. Neurosci. 2016, 10, 408. 
Chapter 1. Introduction 
10 
 
sequestering other cytosolic proteins. An example is TAR DNA binding protein-43 (TDP-
43) that has been shown to disrupt nucleocytoplasmic transport of both proteins and 
RNA.25 
1.3.2. Chaperones 
Chaperones interact with proteins in several processes that include folding, assembly, 
transport through membranes and targeting for degradation.26 In some cases, the 
chaperones can refold the protein to its proper conformation and, if the refold is not 
feasible, direct the protein to the proteolytic pathway that each misfolded protein 
should follow.  
1.3.3. Autophagy and proteasome activity 
The proteasome is the most abundant protease in the cytosol and is responsible for 
the rapid degradation of misfolded proteins. The proteasome target are proteins 
labelled with the small protein ubiquitin.27  
Proteins can be hydrolysed through an alternative process known as autophagy. 
Several modalities of autophagic protein degradation have been described, including 
chaperone-mediated autophagy (CMA), micro- and macroautophagy, among others. 
The choice of the degradation pathway depends on the intrinsic protein properties and 
how this protein is recognized by the cell and delivered to lysosomes. For example, a 
single non-aggregated protein could be refolded properly or degraded by any protease 
pathway, although multiple misfolded proteins are aggregated or form oligomeric 
complexes that can only be degraded by macroautophagy.28 
1.3.4. Ageing and altered proteostasis 
The cellular ageing process can be associated with impaired chaperoning activities. 
Some of the key factors in this regard are poor cellular energetics, caused by 
mitochondrial dysfunction, deregulation in lipid and glucose metabolism, etc. The 
lower availability of ATP can explain the repression of ATP-dependent chaperones, 
 
25  Woerner, A. C.; Frottin, F.; Hornburg, D.; Feng, L. R.; Meissner, F.; Patra, M.; Tatzelt, J.; Mann, M.; 
Winklhofer, K. F.; Hartl, F. U.; Hipp, M. S. Science 2016, 351, 173-176.  
26  Feldman, D. E.; Frydman, J. Curr. Opin. Struct. Biol. 2000, 10, 26-33. 
27  Navon, A.; Ciechanover, A. J. Biol. Chem. 2009, 284, 33713-33718. 
28  Lamark, T.; Johansen, T. Int. J. Biochem. Cell Biol. 2012, 2012, 736905. 
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leading to an increase in protein misfolding and a reduction in the cargo recognition 
and as consequence a proteostasis imbalance.  
Age-depending changes are not restricted to chaperone function or expression. 
Degradation mechanisms including autophagy and proteasomal activity are both 
diminished with ageing. Conversely, an overexpression of proteasome subunits or 
essential autophagy genes increases lifespan and confers stress resistance.28 Also, 
calory restriction, rapamycin, resveratrol and spermidine extend lifespan and have 
been proven to improve autophagy through several mechanism.29 
1.3.5. Protein misfolding propagation and toxicity 
NDDs are characterized by the accumulation of misfolded proteins, which proteins 
have the ability to recruiting normally folded proteins and induce the wrong-folded, 
pathogenic conformation via a prion-like mechanism. This pathogenic misfolding 
propagation acts in a interneuronal way or between neuron and glial cells, involving 
activity-dependent secretion by exosomes30 and chaperone-mediated pathways.31,32 
1.4. Neuroinflammation 
The central nervous system is protected against external harmful situations (infections, 
traumas, xenobiotics, etc.) by different physical barriers (blood-brain barrier and 
cerebrospinal fluid); this anatomic compartmentalization provides CNS with a 
privileged environment. Furthermore, CNS is endowed with its own immune system, 
formed by microglia and astrocytes, although in some cases the peripheral immune 
cells can provide additional protection to the CNS.  
The inflammation process plays a fundamental role in the protection process against 
tumours, infections and is important for the reparation of tissues; however, chronical 
inflammation can be detrimental. When inflammation happens in the CNS it is called 
neuroinflammation, and several studies have found strong evidences that the 
 
29  Madeo, F.; Zimmermann, A.; Maiuri, M. C.; Kroemer, G. J. Clin. Investig. 2015, 125, 85-93. 
30  Wu, J. W.; Hussaini, S. A.; Bastille, I. M.; Rodriguez, G. A.; Mrejeru, A.; Rilett, K.; Sanders, D. W.; Cook, 
C.; Fu, H.; Boonen, R. A.; Herman, M.; Nahmani, E.; Emrani, S.; Figueroa, Y. H.; Diamond, M. I.; 
Clelland, C. L.; Wray, S.; Duff, K. E. Nat. Neurosci. 2016, 19, 1085-1092. 
31  Fontaine, S. N.; Zheng, D.; Sabbagh, J. J.; Martin, M. D.; Chaput, D.; Darling, A.; Trotter, J. H.; Stothert, 
A. R.; Nordhues, B. A.; Lussier, A.; Baker, J.; Shelton, L.; Kahn, M.; Blair, L. J.; Stevens, S. M. Jr.; Dickey, 
C. A. EMBO J. 2016, 35, 1537-1549. 
32  Lee, J. G.; Takahama, S.; Zhang, G.; Tomarev, S. I.; Ye, Y. Nat. Cell Biol. 2016, 18, 765-776. 
Chapter 1. Introduction 
12 
 
neuroinflammation is a key process in neurodegeneration and is a common hallmark in 
NDDs.  
Neuroinflammation processes are mediated by microglial cells, which are the 
macrophages in the CNS but differ from other macrophages in several features such as 
the ramifications that are present in the cell surface. These ramifications can be used 
to communicate the microglial cell with surrounding neurons and glial cells.33 
Microglia cells can switch from a resting state (M0) to two different activate states (M1 
or M2) by a classical or alternative activation. Bacteria or toxic by-products of cellular 
metabolism and proinflammatory cytokines promote a classical activation of microglia 
and lead to the M1 phenotype. This phenotype is proinflammatory, predominates in 
the damaged site and releases proinflammatory cytokines such as IL-1β, IL-6, TNF-α 
and ROS. An alternative activation route promotes the M2 state, which is characterized 
by the production of anti-inflammatory cytokines (IL-4, IL-10 and IL-13 ) to antagonize 
the proinflammatory ones. The M2 phenotype is neuroprotective, immunosuppressive 
and anti-inflammatory and is involved in the tissue regeneration process.34 Imbalances 
in M1/M2 phenotypes are being extensively studied to understand the complex role of 
microglia as a neuroprotector or neurodegenerative factor.35 
 
Figure 1.6. Reproduced with permission from reference 36 
 
33  González, H.; Elgueta, D.; Montoya, A.; Pacheco, R. J. Neuroimmunol. 2014, 274, 1-13. 
34  Orihuela, R.; McPherson, C. A.; Harry, G. J. Br. J. Pharmacol. 2016, 173, 649-665. 
35  Tang, Y.; Le, W. Mol. Neurobiol. 2016, 53, 1181-1194. 
36  Prinz, M.; Priller, J. Nat. Rev. Neurosci. 2014, 15, 300-312. 
Chapter 1. Introduction 
13 
 
The classical activation and M1 phenotypic differentiation is accomplished by the 
activation of several surface receptors that are responsible for the recognition of 
pathogen-associated molecular patterns (PAMPs). These pattern-recognition receptors 
(PRRs) include toll-like receptors (TLRs), NOD-like receptors (NLRs) and C-type lectin 
receptors. Microglia expresses all TLRs and they act as the primary PAMP sensors in 
the CNS, a representative example being the recognition of lipopolysaccharide (LPS) by 
TLR4. However, the TLR function is not limited to their role as PAMPs receptor. TLRs 
also recognize damage-associated molecular patterns (DAMPs), such as metabolic 
products produced by stressed cells or by dead cells like high-mobility group box 1 
(HMGB1) and nucleotides.  
Prolonged activation of TLRs on microglia by danger signals may have important roles 
in pathological forms of inflammation and non-apoptotic activation37 that contribute 
to neurodegenerative diseases.  
TLR4 triggering by LPS was shown to sequentially activate caspase 8, followed by 
caspase 3 and caspase 7. This caspase activation cascade does not induce microglial 
cell apoptosis but rather contributes to the downstream signalling of TLR4 in microglia. 
Activated caspase 3 cleaves protein kinase Cδ (PKCδ), and cleaved PKCδ modulates the 
activation of nuclear factor κB (NF-κB) and the production of neurotoxic pro-
inflammatory mediators such as IL-1β, tumour necrosis factor (TNF-α) and nitric 
oxide.37 The inhibition of this caspase was shown to protect neurons in animal models 
of Alzheimer’s and Parkinson’s diseases. 
The neuron-autonomous toxicity of amyloid β and oligomerized or aggregated 
pathological forms of amyloid β is associated to the activation of microglia through 
many receptors, including toll-like receptors (TLRs). Following the recognition of 
amyloid β, cells induce the production of pro-inflammatory mediators, which are 
known to be neurotoxic.38 
 
37  Burguillos, M. A.; Deierborg, T.; Kavanagh, E.; Persson, A.; Hajji, N.; García-Quintanilla, A.; Cano, J.; 
Brundin, P.; Englund, E.; Venero, J. L.; Joseph, B. Nature 2011, 472, 319-324. 
38  Saijo, K.; Glass, C. K. Nat. Rev. Immunol. 2011, 11, 775-787. 
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Figure 1.7 
 
1.5. Neuronal calcium signalling and neurodegeneration 
1.5.1. An overview of the neuronal roles of calcium 
Calcium is a universal second messenger in eukaryotic cells that regulates several 
common functions like the control of metabolism, phosphorylation, motility, gene 
transcription and programmed cell death, among others. However, calcium signalling 
has a particularly important function in neurons that involves the release of 
neurotransmitters, learning and the formation and consolidation of memory.39 These 
process are the result of the direct coupling between plasma membrane depolarization 
and the increase of intracellular calcium through voltage-dependent and ligand-gated 
calcium channels.40,41,42  
Glutamate, the major excitatory neurotransmitter in the central nervous system, 
induces an increase in the concentration of cytoplasmic Ca2+ by directly activating α-
amino-3-hydroxy-5-methylisoxazole-4-propionate acid (AMPA) and N-methyl-D-
aspartate (NMDA) receptor channels and by indirectly activating voltage-dependent 
 
39  Brini, M.; Calì, T.; Ottolini, D.; Carafoli, E. Cell. Mol. Life Sci. 2014, 71, 2787-2814. 
40  Yuste, R.; Majewska, A.; Holthoff, K. Nat. Neurosci. 2000, 3, 653-659. 
41  Burnashev, N.; Rozov, A. Cell Calcium 2005, 37, 489-495. 
42  Hartmann, J.; Konnerth, A. Cell Calcium 2005, 37, 459-466. 
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Ca2+ channels (VDCC). Accordingly, antagonists of AMPA and NMDA receptors, or 
VDCC, have been reported as effective in protecting CNS neurons against glutamate-
mediated neuronal death (excitotoxicity).43, 44  
1.5.2. Ageing-associated mitochondrial dysfunction and impaired neuronal calcium 
homeostasis 
Under physiological conditions, neurons increase their intracellular Ca2+ levels only 
transiently and this has no damaging effect in neurons. However, ageing compromises 
the ability to recover the physiological Ca2+ concentration, leading to cell impairment.  
Mitochondria play a central role in the production of metabolic energy, ROS 
generation and intracellular calcium storage. Alterations in this organelle such us 
membrane depolarization, Ca2+ overload and release of apoptotic mediators, have a 
high contribution in the development of NDDs.45  
The normal ageing process is related with the impairment in the cellular energetic 
metabolism and an increase in oxidative stress caused, among other factors, by a 
mitochondrial dysfunction.46, 47 Some studies in brain cells of animals of different ages 
have demonstrated increased levels of oxidative modifications of proteins, lipids and 
DNA, and reduced energetic mitochondrial production during ageing.47 
ROS can cause alterations in proteins such as the VDCC and NMDA receptors, as well as 
oxidative damage to mitochondrial DNA, contributing to intracellular calcium overload 
and excitotoxicity.48 
Mitochondrial ATP biosynthesis decreases upon ageing. Also, the neuronal ionic 
gradient is an ATP-dependent process, which requires that cells spend large amounts 
of energy in its maintenance. As a consequence of prolonged membrane 
depolarization and the lack of ionic gradient regeneration, neural ATP is depleted, 
leading to other hallmarks of neurodegenerative disease such as proteostasis 
dysfunction and increased ROS formation.49 
 
43  Mattson, M. P. Neuromolecular Med. 2003, 3, 65-94. 
44  Weiss, J. H.; Hartley, D. M.; Koh, J.; Choi, D. W. Science 1990, 247, 1474-1477. 
45  Mattson, M. P. Nature 2004, 430, 631-639. 
46  Drew, B.; Leeuwenburgh, C. Acta Physiol. Scand. 2004, 182, 333-341. 
47  Floyd, R. A.; Hensley, K. Neurobiol. Aging 2002, 23, 795-807. 
48  Lee, H. M.; Wang, C.; Hu, Z.; Greeley, G. H.; Makalowski, W.; Hellmich, H. L.; Englander, E. W.; J. 
Neurochem. 2002, 80, 928-937. 
49  Mattson, M, P.; Kroemer, G. Trends Mol. Med. 2003, 9, 196-205. 
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Figure 1.8 
1.6. Tracking pathologic processes in NDD and feedback loops between 
NDD hallmarks 
The multifactorial nature of NDD hinders the temporal evolution in the order of 
appearance of NDD hallmarks. Tracking these events is fundamental in the design of 
new drugs and to establish proper clinical trials to maximize the probability of success. 
However, this has not been possible so far for NDDs, which could be due to the lack of 
suitable biomarkers. A model was proposed for AD based on five well-established 
biomarkers related to different pathologic characteristics of the disease: Aβ deposition 
measured in cerebrospinal fluid (CSF), Aβ42 and PET amyloid imaging, increased 
concentrations of tau and phosphorylated tau (p-tau) in cerebrospinal fluid (CSF), 
hypometabolism measured by a decreased uptake of fluorodeoxyglucose (FDG) and 
PET imaging and atrophy on structural MRI.50  
Several studies show the existence of temporal stages in AD. In a first stage, 5-10 years 
before dementia diagnosis, Aβ42 becomes drastically abnormal, while CSF tau increases 
more progressively. 51  Changes in CSF Aβ42 are an early event that precedes 
 
50  Jack Jr, C. R.; Knopman, D. S.; Jagust, W. J.; Petersen, R. C.; Weiner, M. W.; Aisen, P. S.; Shaw L. M.; 
Vemuri, P.; Wiste, H. J.; Weigand, S. D.; Lesnick, T. G.; Pankratz, V. S.; Donohue, M. C.; Trojanowski, J. 
Q. Lancet Neurol. 2013, 12, 207-216. 
51  Buchhave, P.; Minthon, L.; Zetterberg, H.; Wallin, Å. K.; Blennow, K.; Hansson, O. JAMA Psychiatry 
2012, 69, 98-106. 
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hippocampal atrophy and hypometabolism.52 After that, the amyloid PET shows little 
change in the Aβ42 deposition, which becomes static, whereas FDG PET displays an 
expansion in hypometabolism.53 
 
 
Figure 1.9 
In summary, Aβ42 and tau become abnormal first, followed by a hypometabolic state 
and finally neurodegeneration, atrophy and clinical symptoms. However, in some cases 
the order of appearance of these temporal events may change. For instance, in young 
adult and middle-aged apolipoprotein E (APOE) ε4 carriers, hypometabolism precedes 
Aβ aggregation.54, 55 
New functional MRI techniques such as task-free functional MRI (TF-fMRI) are being 
employed to measure the connectivity and network dynamics. TF-fMRI disturbances 
were described in AD and mild cognitive impairment,56 in elderly APOE ε4 carriers who 
have normal amyloid PET scans57 and in cognitively normal people who are amyloid-
positive.58  
 
52  Lo, R. Y.; Hubbard, A. E.; Shaw, L. M.; Trojanowski, J. Q.; Petersen, R. C.; Aisen, P. S.; Weiner, M. W.; 
Jagust, W. J. Arch. Neurol. 2011, 68, 1257-1266. 
53  Förster, S.; Grimmer, T.; Miederer, I.; Henriksen, G.; Yousefi, B. H.; Graner, P.; Wester, H.-J.; Förstl, 
H.; Kurz, A.; Dickerson, B. C.; Bartenstein, P.; Drzezga, A. Biol. Psychiatry 2012, 71, 792-797. 
54  Morris, J. C.; Roe, C. M.; Xiong, C.; Fagan, A. M.; Goate, A. M.; Holtzman, D. M.; Mintun, M. A. Ann. 
Neurol. 2010, 67, 122-131.  
55  Vemuri, P.; Wiste, H. J.; Weigand, S. D.; Knopman, D. S.; Shaw, L. M.; Trojanowski, J. Q.; Asien P. S.; 
Weiner, M.; Petersen, R. C.; Jack, C. R. Ann. Neurol. 2010, 67, 308-316. 
56  Seeley, W. W.; Crawford, R. K.; Zhou, J.; Miller, B. L.; Greicius, M. D. Neuron 2009, 62, 42-52. 
57  Sheline, Y. I.; Morris, J. C.; Snyder, A. Z.; Price, J. L.; Yan, Z.; D'Angelo, G.;  Liu, C.; Dixit, S.; Benzinger, 
T.; Fagan, A.; Goate, A. J. Neurosci. 2010, 30, 17035-17040. 
58  Sperling, R. A.; LaViolette, P. S.; O'Keefe, K.; O'Brien, J.; Rentz, D. M.; Pihlajamaki, M.; Marshall, G.; 
Hyman, B. T.; Selkoe, D. J.; Hedden, T.; Buckner, R. L.; Becker, J. A.; Keith A.; Johnson, K. A. Neuron 
2009, 63, 178-188. 
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TF-fMRI studies show a reduced functional connectivity in young transgenic AD mice in 
the same locations where amyloid deposits appear later in life.59 These findings 
suggest that TF-fMRI might locate abnormalities before amyloid biomarkers become 
abnormal and establish a cause-and-effect relation: a higher synaptic activity generally 
leads to a higher amyloid deposition.60 However, this relationship is subject to inter-
individual variability.  
The temporal sequence of appearance of events is unclear for all NDDs and more 
research about this issue is needed to improve efficiency in drug design. On the other 
hand, there is a great deal of evidence about feedback loops between the hallmarks of 
NDDs and neurodegeneration. 
• Oxidative stress feedback: Oxidative stress may cause modifications of proteins, 
lipids and DNA, and reduced energetic mitochondrial production during ageing.61 
ROS induce alterations in proteins that lead to their misfolding and aggregation. 
They also cause malfunction of receptors such as VDCC and NMDA, contributing 
to intracellular calcium overload and excitotoxicity.48 Furthermore, oxidative 
stress activates redox-sensitive pathways, leading to sustained M1 microglial 
activation.62 
• Protein aggregation and proteostasis impairment: The accumulation of misfolded 
proteins may cause calcium signalling abnormalities, mitochondrial dysfunction, 
oxidative stress, and neuroinflammation. However, the relationship between 
misfolded proteins and other signs of cellular distress is bidirectional, and they 
are believed to be a cause as well as a consequence of neurodegeneration. For 
example, amyloid-β, α-synuclein, and mHtt all cause acute oxidative stress in 
neurons and/or astrocytes, neuroinflammation and disrupt the anti-oxidant 
astroglia defences.63, 64 Conversely, oxidative stress promotes the aggregation of 
 
59  Bero, A. W.; Yan, P.; Roh, J. H.; Cirrito, J. R.; Stewart, F. R.; Raichle, M. E.; Lee, J. M.; Holtzman, D. M. 
Nat. Neurosci. 2011, 14, 750-756. 
60  Jagust, W. J.; Mormino, E. C. Trends Cogn. Sci. 2011, 15, 520-526. 
61  Floyd, R. A.; Hensley, K. Neurobiol. Aging 2002, 23, 795-807. 
62  Rojo, A. I.; McBean, G.; Cindric, M.; Egea, J.; López, M. G.; Rada, P.; Zarkovic, N.; Cuadrado, A. 
Antioxid. Redox Signal. 2014, 21, 1766-1801. 
63  Jiang, T.; Sun, Q.; Chen, S. Prog. Neurobiol. 2016, 147, 1-19.  
64  Angelova, P. R.; Abramov, A. Y. Biochem. Biophys. Res. Commun. 2017, 483, 1110-1115.  
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disease proteins, and contributes to age- and disease-related proteostatic 
collapse.65  
• Calcium overload feedback: The increase in intracellular calcium concentrations 
may promote conformational changes in some calcium sensitive proteins, 
leading to a misfolded structure and protein aggregation. Also, the maintenance 
of calcium gradient under this continued calcium influx may cause ATP depletion 
and the subsequent energetic deficiency causes ROS formation and proteasome 
dysfunction.  
• Microglial inflammation feedback: The sustained activation of M1 microglia 
contributes to a high oxidative stress status in the cells, mediated by 
proinflammatory cytokines. There is also some evidence that some cytokines 
possess the ability to block autophagy in microglia, promoting protein misfolding 
and aggregation. Also, long-term cytokine activation causes neuronal death. 
All these hallmarks are interconnected and thus acting selectively in single one is likely 
to be an unsuccessful strategy, since the interrelated feedback loops can elude the 
blocked target by an alternative pathway ultimately leading to neurodegeneration. For 
this reason, the polypharmacology approach has attracted much interest in NDDs and 
other multifactorial diseases, since acting in several pathways may exert a more 
efficient neuroprotective effect.  
1.7. Multitarget drug discovery 
The “one target, one drug” approach to drug discovery currently dominates research in 
the pharmaceutical industry. However, there is a current trend towards a paradigm 
shift caused by the lack of success in drug development in the area of multifactorial 
diseases. As summarized above, these diseases are characterized by multiple genetic 
and environmental alterations leading to a pathological state, and hence targeting 
several diseases checkpoints could lead to a better system regulation.66 Multitarget 
kinase inhibitors exemplify the success of this approach in the therapy of a 
multifactorial disease, namely cancer.67  
 
65  Höhn, A.; Weber, D.; Jung, T.; Ott, C.; Hugo, M.; Kochlik, B.; Kehm, R.; König, J.; Grune, T.; Castro, J. P. 
Redox Biol. 2016, 11, 482-501.  
66  Bolognesi, M. L. Curr. Med. Chem. 2013, 20, 1639-1645. 
67  Morphy, R.; Rankovic, Z. Curr. Pharm. Des. 2009, 15, 587-600. 
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This challenging approach to modify multiple targets simultaneously 
(polypharmacology) can be achieved by three strategies.68 
1. Drug cocktails.   
2. Combination of several drugs in the same formulation.   
3. Multitarget Directed Ligands (MTDL): in this strategy, a single chemical entity 
possess the ability to modify multiple targets.  
 
Figure 1.10 
MTDLs have a profoundly different risk-benefit profile compared with coformulated 
drugs or drug cocktails. In the first stages of the drug discovery process, it is 
significantly more difficult to adjust the ratio of activities at the different targets. 
However, this increased complexity in this initial, less expensive stage, is more than 
compensated, in terms of the risks and costs involved, at the clinical development 
phase, which is in principle not different from the development of any other single 
entity, in comparison with the very complex development required for drug 
combinations. Another advantage is a lower risk of drug-drug interactions compared to 
cocktails or multicomponent drugs,69 and the avoidance of poor patient compliance 
issues, one of the drawbacks of drug cocktails. 
MTDLs can be classified into three groups according to the design strategy used. 
“Conjugates” or “hybrids” are MTDLs that contain pharmacophores for each target 
bound by a linker. Usually these conjugates contain a metabolically stable linker, but it 
also could be cleavable to release both active fragments in vivo (mutual prodrugs). In 
this strategy, the molecular weight is usually high, which could be a limitation. The 
 
68  Morphy, R.; Rankovic, Z. J. Med. Chem. 2005, 48, 6523-6543. 
69  Edwards, I. R.; Aronson, J. K. Lancet 2000, 356, 1255-1259. 
Chapter 1. Introduction 
21 
 
“fused” MTDLs arise from the same logical design, but the linker between the active 
frameworks is removed. The most attractive and complex approach is the “merged” 
MTDL that combines multiple activities in a single framework formed by combining 
structural fragments key for the two sought activities without requiring the presence 
of complete molecules addressed at each target. 
 
Figure 1.11 
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Objective 1  
Some natural products that contain carbonyl groups or -dicarbonyl fragments 
conjugated to one or two styryl chains (ferulic and caffeic acid esters, 
dehydrozingerone, curcumin) have shown promising neuroprotective activities 
associated to multiple mechanisms. In this context, our first goal was to design and 
synthesize libraries of cyclic analogues of cinnamic esters and curcumin in order to 
study their antioxidant activity and neuroprotective profiles. The molecular 
architecture of these compounds was organized around a central 2-pyrrolin-5-one 
core, which was expected to increase their stability while also providing synthetic 
handles for the preparation of multitarget-directed ligands (Figure 2.1). 
 
Figure 2.1 
This objective can be divided into the following tasks: 
1.1. Development of a suitable synthetic method for the preparation of the 2-pyrrolin-
5-one core. In view of the current importance of multicomponent reactions as a 
fast and flexible route to molecular diversity, we planned a three-component 
reaction from primary amines, -dicarbonyl compounds and -haloesters, related 
to the Hantzsch pyrrole synthesis. 
1.2. Development of suitable conditions for the Knoevenagel reaction of the C-4 
position of the pyrrolinone derivatives with aromatic aldehydes, to obtain the 
cyclic cinnamic-like compounds. 
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1.3. Development of suitable conditions for the acylation of the pyrrolinone C-4 
position with cinnamyl chlorides, to obtain the curcumin analogues. 
1.4. Pharmacological study of the libraries thus generated, establishment of structure-
activity relationships and selection of candidate compounds for further studies.  
 
Objective 2 
The spiro oxindole family of alkaloids provides another interesting natural model in the 
search for neuroprotective agents. Rhynchophylline, in particular, activates the 
PI3K/Akt/mTOR signalling pathway and has shown neuroprotection in a variety of 
neurodegenerative disease models. We have designed a library of oxindole-derived 
dispiro compounds as rhynchophylline analogues (Figure 2.2). 
 
Figure 2.2 
This objective can be divided into the following tasks: 
2.1. Development of a suitable synthetic method for the preparation of the dispiro 
oxindoles, based on a 1,3-dipolar cycloaddition reaction. 
2.2. Pharmacological study of the dispirooxindoles library, including SAR correlations 
and the selection of compounds for further study. 
The synthetic aspects of objectives 1 and 2 are summarized in Scheme 2.1. 
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Scheme 2.1 
Objective 3 
Quinone moieties are present in several natural and unnatural compounds with 
neuroprotective activity. We have designed a library of compounds derived from the 
2,5,8-quinolinetrione skeleton and containing an indolylethyl side chain. These 
compounds can be considered vinylogs of the natural antioxidant and neuroprotectant 
melatonin and are expected to show the multitarget profile summarized in Figure 2.3. 
Objective 4 
The dysregulation of calcium homeostasis plays a central role in neurodegenerative 
diseases. Neuronal calcium levels depend on the activity of a large number of proteins 
(the “calcium signalling toolkit”) in membranes of the cell, the endoplasmic reticulum 
and the mitochondria. The hybrid compound shown in Figure 2.4 was designed to 
combine in a single molecule the frameworks of CGP-37157, a well-known inhibitor of 
the mitochondrial mNCX transporter with neuroprotective activity, and lipoic acid, a 
natural antioxidant. Both structural fragments of the target hybrid bear stereogenic 
centres, but only lipoic acid is commercially available in both enantiomeric forms. 
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Figure 2.3 
This objective can be divided into the following tasks: 
2.1. Development of suitable synthetic methods for the preparation of CGP-37157 and 
its aza analogue in enantiomerically pure form to allow the coupling of either 
enantiomer with both (R) and (S) lipoic acid. 
2.2. Pharmacological study of each of the four enantiomers of the target hybrid 
compound. 
 
Figure 2.4 
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Objective 5 
Galectins are carbohydrate-binding molecules present in the cell surface that have key 
roles in a variety of physiological processes, including neuroinflammation. Our goal in 
this area was the synthesis of the heterocyclic fragments of the hybrid carbohydrate 
derivatives shown in Figure 2.5. 
 
Figure 2.5 
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3.1. Oxidative stress and neurodegeneration: A closer look 
The imbalance in ROS production leads to oxidative stress, as was discussed previously 
in Chapter 1. While ROS have physiological roles as second messengers in moderate 
concentrations, the over-production of ROS and senescence were found to be 
correlated in several pathological processes. Oxidative stress is thus a major hallmark 
in neurodegeneration, as the result of the hyperproduction of ROS combined with the 
impairment of antioxidant defences. This imbalance between ROS production and 
quenching causes brain tissue damage and, as a consequence, neuronal death and 
neurodegeneration.70, 71 
Cells have developed a number of adaptive defences to reduce ROS, while keeping 
cellular redox homeostasis. These antioxidant systems act through a series of 
antioxidant molecules and detoxifying enzymes that can provide control over these 
reactive species either by quickly removing or detoxifying them. 
Several antioxidant systems are involved in redox homeostasis, and some of them are 
mediated by transcription factors. The nuclear factor erythroid 2-related factor 2 
(Nrf2) is a master regulator in cellular redox homeostasis and the activation of this 
pathway an effective mechanism against oxidative or electrophilic stress.72 
 
3.2. The Keap1-Nrf2-ARE pathway  
3.2.1. The phase II antioxidant response 
Electrophilic or oxidative stimuli induce the biosynthesis of a battery of cytoprotective 
genes by the Nrf2 transcription factor. Nrf2 is bound to Keap1 in the cytosol under 
physiological conditions. Keap1 acts as a negative regulatory system, maintaining Nrf2 
in the cytoplasm by an interaction with the cytoskeleton and binds to the E3 ligase, 
leading to ubiquitination Nrf2 and thus promoting its proteasomal degradation.73 In 
summary, Nrf2 is constitutively synthesized and rapidly degraded by the proteasome 
 
70  Lotharius, J.; Brundin, P. Nat. Rev. Neurosci. 2002, 3,932-942. 
71  Barnham, K. J.; Masters, C. L.; Bush, A. I. Nat. Rev. Drug Discov. 2004, 3, 205-214. 
72  Kumar, H.; Koppula, S.; Kim, I. S.; More, S. V.; Kim B. W.; Choi, D. K. CNS Neurol. Disord.: Drug Targets 
2012, 11, 1015-1029. 
73  Cullinan, S. B.; Gordan, J. D.; Jin, J.; Harper, J. W.; Diehl, J. A. Mol. Cell. Biol. 2004, 24, 8477-8486. 
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under unstressed conditions. However, in response to oxidative stress, Nrf2 is released 
from Keap1 following a conformational change of the latter associated to the oxidation 
to cystine of two cysteine residues in the “sensor” region of the protein (Figure 3.1). 
Alternatively, the sensor region of Keap1 may also be activated by reaction of the 
cysteine residues in the sensor region with electrophiles. Once liberated from Keap1, 
Nrf2 is translocated into the nucleus, where it promotes the transcription of 
cytoprotective genes by binding to the ARE sequence of DNA (antioxidant response 
element),73 with participation of several coactivator proteins. 
 
Figure 3.1 
 
The classical Nrf2 target genes encode enzymes distributed in several organelles and 
subcellular compartments. These enzymes participate in metabolic reactions that that 
scavenges ROS and neutralizes electrophiles, such as superoxide dismutase (SOD), 
glutathione peroxidase, catalase, glutathione reductase (GR), glutamate cysteine ligase 
(GCL), NAD(P)H/quinone oxidoreductase 1 (NQO1).74 Nrf2 also plays a critical role in 
the induction of genes involved in drug metabolism and distribution, including multiple 
genes encoding non-cytochrome P450 phase-I and phase-II drug metabolism 
enzymes75 Some enzymes are involved in the generation of antioxidant molecules such 
as glutathione synthase, which is needed for the biosynthesis of glutathione (GSH), the 
most abundant small-molecule antioxidant, that also takes part in the neutralization of 
electrophiles.  
 
74  Cuadrado, A.; Rojo, A. I.; Wells, G.; Hayes, J. D.; Cousin, S. P.; Rumsey, W. L.; Attucks, O. C.; Franklin, 
S.; Levonen, A. - L.; Kensler, T. W.; Dinkova-Kostova, A. T. Nat. Rev. Drug Discov. 2019, 18, 295–317 
and references therein. 
75  Wu K. C.; Cui J. Y.; Klaassen C. D.; PLOS One 2012, 7, e39006. 
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3.2.2. Nrf2 activation as a useful approach to neurodegenerative disease therapy 
Due to its key role in the management of oxidative stress, the Nrf2/ARE pathway has 
emerged as a promising target for neurodegenerative diseases, including Alzheimer’s 
disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), multiple sclerosis 
(MS) and amyotrophic lateral sclerosis (ALS).76, 77 Furthermore, Nrf2 deficiency has 
been found in several neurodegenerative diseases and thus AD patients show a 
dramatic decrease in nuclear Nrf2 in hippocampal neurons,78 experimental animal 
models in a Nrf2-knockout mice of PD shows a specific loss of dopaminergic neurons79, 
80  and post-mortem studies of patients with ALS show an increased Keap1 mRNA in 
the motor cortex,81 leading to a decline in Nrf2 activity. 
In this context, it is not surprising that Nrf2 activation has been demonstrated to 
extend survival in AD,82 PD83 and ALS84 animal models. Therefore, small-molecule 
modulators of the Keap1-Nrf2-ARE pathway should be potential preventive and 
therapeutic agents. Nrf2 activation can in principle be achieved by three mechanisms: 
• Activation of the sensor region of Keap1 with electrophilic compounds that 
have a suitable safety profile. 
• Interference with the Keap1-Nrf2 interaction with non-electrophilic compounds 
that behave as protein-protein interaction inhibitors (PPI). 
• Indirect mechanisms based on the activation of certain signalling pathways. 
  
 
76  Kumar, H.; Koppula, S.; Kim, I. S.; More, S. V.; Kim B. W.; Choi, D. K. CNS Neurol. Disord.: Drug Targets 
2012, 11, 1015-1029. 
77  Zhang, M.; An, C.; Gao, Y.; Leak, R. K.; Chen J.; Zhang, F. Prog. Neurobiol. 2013, 100, 30-47. 
78  Ramsey, C. P.; Glass, C. A.; Montgomery, M. B.; Lindl, K. A.; Ritson, G. P.; Chia, L. A.; Hamilton, R. L.; 
Chu C. T.; Jordan-Sciutto, K. L. J. Neuropathol. Exp. Neurol. 2007, 66, 75-85. 
79  Burton, N. C.; Kensler T. W.; Guilarte, T. R. Neurotoxicology 2006, 27, 1094-1100. 
80  Chen, P. C.; Vargas, M. R.; Pani, A. K.; Smeyne, R. J.; Johnson, D. A.; Kan Y. W.; Johnson, J. A. Proc. 
Natl. Acad. Sci. U. S. A. 2009, 106, 2933-2938. 
81  Sarlette, A.; Kramp, K.; Grothe, C.; Neuhoff, N.; Dengler R.; Petri, S. J. Neuropathol. Exp. Neurol. 2008, 
67, 1055-1062. 
82  Dumont, M.; Wille, E.; Calingasan, N. Y.; Tampellini, D.; Williams, C.; Gouras, G. K.; Liby, K.; Sporn, M.; 
Nathan, C.; Flint Beal M.; Lin, M. T. J. Neurochem. 2009, 109, 502-512. 
83  Kaidery, N. A.; Banerjee, R.; Yang, L.; Smirnova, N. A.; Hushpulian, D. M.; Liby, K. T.; Williams, C. R.; 
Yamamoto, M.; Kensler, T. W.; Ratan, R. R.; Sporn, M. B.; Beal, M. F.; Gazaryan I. G.; Thomas, B. 
Antioxid. Redox Signaling 2013, 18, 139-157. 
84  Neymotin, A.; Calingasan, N. Y.; Wille, E.; Naseri, N.; Petri, S.; Damiano, M.; Liby, K. T.; Risingsong, R.; 
Sporn, M.; Beal M. F.; Kiaei, M. Free Radical Biol. Med. 2011, 51, 88-96. 
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3.2.3. Non-electrophilic Nrf2 activation 
The first group of Nrf2 activators act by non-electrophilic, non-covalent direct 
interference with the protein–protein interaction between Keap1 and Nrf2. Bis-
sulphonamide compounds, obtained from a high-throughput screening campaign, are 
the most efficient inhibitors of the Nrf2–Keap1 interaction.85 The availability of the 
Keap1 crystal structure (pdb 4XMB) has enabled the rational design and optimization of 
new PPI inhibitors and afforded new lead compounds such as CPUY192018.86 
 
Figure 3.2 
3.2.4. Electrophilic Nrf2 activation 
As mentioned above, electrophilic compounds bind to cysteine residues present in 
Keap1 and induce a conformational change that releases Nrf2. Electrophiles have an 
advantage over scavenger antioxidant molecules because their action is more 
sustained and amplified by transcription-mediated signalling pathways.87 
Electrophilic compounds, leading to covalent drug-target interactions, often have a 
reputation for high toxicity, but nevertheless there is a recent surge in interest in 
rationally designed covalent inhibitors.88  Electrophilic compounds can have both 
protective and toxic effects on cells in a dose-dependent manner (Figure 3.3). Low-
 
85  Marcotte, D.; Zeng, W.; , Hus J.-C.; McKenzie, A.; Hession, C.; Ji, P.; Bergeron, C.; Lugovskoy, A.; 
Enyedy, I.; Cuervo, H.; , Wang, D.; Atmanene, C.; Roecklin, D.; Vecchi, M.; Vivat, V.;  Kraemer, J.; 
Winkle, D.; Hong, V.; Chao, J.; , Lukashev, M.; Silvian, L. Bioorg. Med. Chem. 2013, 21, 4011-4019. 
86  Jiang, Z. Y.; Lu, M. C.; Xu, L. L.; Yang, T. T.; Xi, M. Y.; Xu, X. L.; Sun, H. P. J. Med. Chem. 2014, 57, 2736-
2745. 
87  Taguchi, K.; Motohashi, H.; Yamamoto, M. Genes Cells 2011, 16, 123-140. 
88  For selected reviews of covalent drugs, see: (a) Singh, J.; Petter, R. C.; Baillie, T. A.; Whitty, A. Nat. 
Rev. Drug Discov. 2011, 10, 307-317. (b) Baillie, T. A. Angew. Chem. Int. Ed. 2016, 55, 13408-13421. 
(c) De Cesco, S.; Kurian, J.; Dufresne, C.; Mittermaier, A. K.; Moitessier, N. Eur. J. Med. Chem. 2017, 
138, 96-114.  
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dose stimulation most likely represents an adaptive biological response leading an 
increase in neuroprotection and longevity. 89 , 90  However, high-dose stimulation 
promotes indiscriminate reaction with thiol groups, resulting in a harmful effect.91  
  
Figure 3.3 
 
A successful example for electrophilic Nrf2 activation against an oxidative stress-
connected disease is dimethyl fumarate (DMF, Tecfidera®), which was approved by the 
FDA in 2014 for the treatment of multiple sclerosis and has a good safety profile.92 
Dimethyl fumarate acts as a prodrug that, after its in vivo hydrolysis, generates 
monomethyl fumarate (MMF), which reacts with the Cys-151 residue in Keap1 
releasing Nrf2. 93  Based on this metabolic conversion, several biopharmaceutical 
companies are now developing new formulations for the slow and sustained release of 
MMF.   
 
89  Birringer, M. Pharm. Res. 2011, 28, 2680-2694. 
90  Satoh, T.; Rezaie, T.; Seki, M.; Sunico, C. R.; Tabuchi, T.; Kitagawa, T.; Yanagitai, M.; Senzaki, M.; 
Kosegawa, C.; Taira, H.; McKercher, S. R.; Hoffman, J. K.; Roth, G. P.; Lipton, S. A. J. Neurochem. 2011, 
119, 569-578. 
91  Groeger, A. L.; Freeman, B. A. Mol. Interven. 2010, 10, 39-50. 
92  Dodson, M.; De La Vega, M. R.; Cholanians, A. B.; Schmidlin, C. J.; Chapman, E.; Zhang, D. D.  Annu. 
Rev. Pharmacol. Toxicol. 2019, 59, 555-575. 
93  Linker, R. A.; Lee D. H.; Ryan, S.; van Dam A. M.; Conrad, R.; Bista, P.; Zeng, W.; Hronowsky, X.; Buko, 
A.; Chollate, S.; Ellrichmann, G.; Brück, W.; Dawson, K.; Goelz, S.; Wiese, S.; Scannevin, R. H.; 
Lukashev, M.; Gold, R. Brain 2011, 134, 678-692. 
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3.2.5. Natural products targeting the Keap1-Nrf2-ARE pathway  
Natural products can also inspire the development of analogues with improved 
bioavailability. Curcumin, a yellow pigment from turmeric (Curcuma longa), is a well-
known antioxidant due to the presence of two phenolic functional groups responsible 
for the direct scavenging of ROS.94 Curcumin contains two electrophilic positions that 
can react readily with cysteine residues of Keap1 and promotes the Nrf2 translocation 
to nucleus increasing the cytoprotective proteins biosynthesis.95 Curcumin has also 
shown to indirectly activate the ARE system by stimulating upstream kinase 
pathways,96 and is also an epigenetic Nrf2 modulator.97 Finally, curcumin has been 
shown to possess a number of additional relevant therapeutic properties including 
anti-inflammatory, metal chelation and protein aggregation inhibition properties.98  
Dehydrozingerone is a known metabolic product of curcumin with a simpler structure 
that has a better pharmacokinetics than its parent compound.99 Dehydrozingerone and 
curcumin both bear styryl ketone moieties with similar substitutions on the phenyl 
ring.100  
Another family of natural products structurally very close to dehydrozyngerone are the 
cinnamic acid esters, such as caffeic acid phenethyl ester and ferulic acid ethyl ester. 
These α,β-unsaturated esters were shown to induce the ARE system with comparable 
potency to curcumin. 101  Caffeic acid ester shows antiinflammatory and 
immunomodulatory properties.102 Ferulic acid and its derivatives are found in many 
 
94  Ak, T.; Gülçin, I. Chem. Biol. Interact. 2008, 174, 27–37. 
95  Scapagnini, G.; Colombrita, C.; Amadio, M.; D’Agata, V.; Arcelli, E.; Sapienza, M.; Quattrone, A.; 
Calabrese, V. Antioxid. Redox. Signal 2006, 8, 395–403. 
96  Thangapazham, R. L.; Sharma, A.; Maheshwari, R. K. AAPS J. 2006, 8, 443–449. 
97  Khor, T. O., Huang, Y., Wu, T.-Y., Shu, L., Lee, J., Kong, A.-N.T. Biochem. Pharmacol. 2011, 82, 1073–
1078. 
98  Lee, W. H.; Loo, C. Y.; Bebawy, M.; Luk, F.; Mason, R. S.; Rohanizadeh, R. Curr. Neuropharmacol. 
2013, 11, 338-378. 
99  Priyadarsini, K. I.; Devasagayam, T. P.; Rao, M. N.; Guha, S. N. Radiat. Phys. Chem. 1999, 54, 551-558. 
100  Rajakumar, D. V.; Rao, M. N. Mol. Cell. Biochem. 1994, 140, 73-79. 
101  Balogun, E.; Hoque, M.; Gong, P.; Killeen, E.; Green, C. J.; Foresti, R.; Alam, J.; Motterlini, R. Biochem J 
2003, 371, 887–895. 
102  Michaluart, P.; Masferrer, J. L.; Carothers, A. M.; Subbaramaiah, K.; Zweifel, B. S.; Koboldt, C.; 
Mestre, J. R.; Grunberger, D.; Sacks P. G.; Tanabe, T.; Dannenberg, A. J. Cancer Res. 1999, 59, 2347–
2352. 
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fruits and vegetables and are known to confer a strong protection against oxidation of 
proteins and lipids.103 
 
Figure 3.4 
 
3.3. Design of cyclic analogues of cinnamic esters and curcumin 
Despite the interesting pharmacological profile and versatile potential applications of 
curcumin, its weak bioavailability and high degradation suffered upon oral 
administration hampers its use as a successful therapeutic agent.104 This unsuitable 
pharmacokinetic profile of curcumin is due its rapid metabolism,105 which mainly 
comprises: (a) successive reductions of the C=C and C=O double bonds; (b) the 
enzymatic cleavage of the -diketone moiety,106 mediated in vivo by several aldo–keto 
reductases;107 (c) conjugation with glutathione via Michael addition; (d) conjugation of 
the phenolic hydroxyls or the secondary alcohols arising from the reduction reactions 
with glucuronic acid. Curcumin also suffers from in vitro chemical instability at neutral 
and basic pH.108  
Some strategies to increase the bioavailability of curcumin have been described (Figure 
3.5). Its methylation at the 2 and 6 positions decreases the reductive metabolism of 
curcumin.109 Also, the bioisosteric replacement of the diketone by a pyrazole (CNB-
 
103  Scapagnini, G.; Butterfield, D. A.; Colombrita, C.; Sultana, R.; Pascale, A.; Calabrese, V. Antioxid. 
Redox. Signal 2004, 6, 811-818. 
104  Anand, P.; Kunnumakkara, A. B.; Newman, R. A.; Aggarwal, B. B. Mol. Pharm. 2007, 4, 807-818. 
105  Metzler, M.; Pfeiffer, E.; Schulz, S. I.; Dempe, J. S. Biofactors 2013, 39, 14-20. 
106  Nagpure, B. A. L.; Gupta, R. K. Indian J. Chem., Sect. B Org. Med. Chem. 2011, 50, 1119. 
107  Rosemond, M. J. C.; St. John-Williams, L.; Yamaguchi, T.; Fujishita, T.; Walsh, J. S. Chem. Biol. Interact. 
2004, 147, 129-139. 
108  Tomren, M. A.; Másson, M.; Loftsson, T.; Tønnesen, H. H. Int. J. Pharm. 2007, 338, 27-34. 
109  Koo, H. J.; Shin, S.; Choi, J. Y.; Lee, K. H.; Kim, B. T.; Choe, Y. S. Sci. Rep. 2015, 5, 14205. 
Chapter 3. Neuroprotective compounds related to cinnamic esters and curcumin 
40 
 
001) improves the pharmacokinetics of curcumin and maintains or improves some 
activities such as amyloid β aggregation inhibition.110  
 
Figure 3.5 
 
Against this backdrop, we envisioned that cinnamic ester and curcumin analogues with 
a structure restricted by a heterocyclic core in order to reduce their metabolic 
degradation and improve their bioavailability (Figure 3.6). Also, this methodology 
introduces additional points of diversity in the structure that in principle allow to 
generate new multi-target directed ligands against neurodegenerative diseases. Once 
access to the pyrrolinone core 1 is achieved, compounds 3, containing a cinnamic acid 
amide embedded into the pyrrolone fragment, should be accessible by a simple 
Knoevenagel condensation. A similar approach, with an acylation reaction as the final 
step, would be employed to obtain compounds 4, containing a curcumin structural 
fragment. Our goal was to achieve the preparation of the starting materials 1 by 
application of a multicomponent strategy based on the classical Hantzsch pyrrole 
synthesis (see below). 
 
 
110  Joseph, A. I.; Edwards, R. L.; Luis, P. B.; Presley, S. H.; Porter, N. A.; Schneider, C. Org. Biomol. Chem. 
2018, 16, 3273-3281. 
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Figure 3.6 
3.4. Multicomponent synthesis of the pyrrolin-5-one core 
3.4.1. Multicomponent reactions: A brief introduction 
Multicomponent reactions (MCRs) are defined as chemical processes where three or 
more reagents are combined, leading to a final compound containing significant 
fragments from all starting materials.111 Ideally, all the reagents are combined by 
simultaneous addition, but very often, in order to avoid side reactions, the addition of 
reagents in a certain order may be necessary to improve the regio- and 
chemoselectivity, and such transformations are known as sequential multicomponent 
reactions.  
MCRs have emerged as powerful synthetic strategies because of their efficiency, atom 
economy, high selectivity and potential to allow the convenient construction of 
multiple new bonds; these characteristics are part of the requirements for the ideal 
synthesis concept.112 Furthermore, multicomponent reactions are an effective and 
agile synthetic methodology to introduce diversity in bioactive molecules. From the 
point of view of the generation of molecular diversity, the development of MCRs with 
a broad range of functional group tolerance is crucial. In this context, ideal MCRs 
should be compatible with complexity-generating post-MCR transformations, such as 
cyclizations, giving rapid access to combinatorial libraries of complex organic molecules 
for efficient lead structure identification and optimization in drug discovery.113, 114 
 
111  For monographs on multicomponent reactions, see: (a) Zhu, J.; Bienaymé, H. (eds.), Multicomponent 
Reactions. Wiley-VCH, 2005; (b) Zhu, J.; Wang, Q.; Wang, M. (eds.), Multicomponent Reactions in 
Organic Synthesis. Wiley-VCH, 2014 
112  Wender, P. A.; Miller, B. L. Nature 2009, 460, 197-201. 
113  Sunderhaus J. D.; Martin, S. F. Chem. Eur. J. 2009, 15, 1300-1308. 
114  Sahn, J. J.; Granger B. A.; Martin S. F. Org. Biomol. Chem. 2014, 12, 7659-7672. 
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Thus, the renaissance of MCRs and their application in the context of diversity-
oriented synthesis can be viewed as one of the changes that have taken place in 
pharmaceutical industry, at the same level as combinatorial chemistry, high-
throughput screening and omics. 
Many of the best-known MCRs, including the classical Strecker,115 Biginelli116, Mannich 
reactions and the Hantzsch dihydropyridine117 syntheses were described during the 
second half of the XIX century and the beginning of the XX century. These classical 
MCRs have been developed and drastically improved, and new MCRs have been 
discovered in the last decades. Representative examples are the isonitrile-based 
multicomponent reactions, including the Passerini and Ugi reactions,118 and MCRs 
having a [3+2] dipolar cycloaddition as the key step. 
The earliest example of the preparation of a pyrrole derivative via a multicomponent 
strategy119, 120 was the Hantzsch pyrrole synthesis, which in its initial version involved 
the reaction of acetyl acetoacetate, 2-chloroacetophenone and ammonia to give a 
derivative of 2,5-dimethylpyrrole (Scheme 3.1).121 In spite of its status as a classical 
name reaction, this transformation has received relatively little attention until very 
recently.122 
 
Scheme 3.1 
 
115  Strecker, A. Liebigs Ann. 1850, 75, 27-45. 
116  Biginelli, P. Chem. Ber. 1891, 24, 1317-1319. 
117  Hantzsch, A. Chem. Ber. 1881, 14, 1637-1638. 
118 (a) Dömling, A.; Ugi, I. Angew. Chem., Int. Ed. 2000, 39, 3168-3210; (b) Ugi, A. Pure Appl. Chem. 2001, 
73, 187-191. 
119  For reviews of the use of muticomponent reactions for the synthesis of pirroles, see: (a) Estévez, V.; 
Villacampa, M.; Menéndez, J. C. Chem. Soc. Rev. 2010, 39, 4402–4421. (b) Estévez, V.; Villacampa, 
M.; Menéndez, J. C. Chem. Soc. Rev. 2014, 43, 4633-4657. 
120  For general reviews of the synthesis of pyrroles, see: (a) Ferreira, V. F.; de Souza, M. C. B. V.; Cunha, 
A. C.; Pereira, L. O. R.; Ferreira, M. L. G. Org. Prep. Prod. Int. 2001, 33, 411-454. (b) Joshi, S. D.; More, 
U. A.; Kulkarni, V. H.; Aminabhavi, T. M. Curr. Org. Chem. 2013, 17, 2279-2304. (c) Gulevich, A. V.; 
Dudnik, A. S.; Chernyak, N.; Gevorgyan, V. Chem. Rev. 2013, 113, 3084-3213. 
121  Hantzsch, A. Ber. Dtsch. Chem. Ges. 1890, 23, 1474-1476. 
122  For a review of the Hantzsch pyrrole synthesis, see: Leonardi, M.; Estévez, V.; Villacampa M.; 
Menéndez, J. C. Synthesis 2019, 51, 816-828. 
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3.4.2. Literature precedent for the synthesis of 2-pyrrolin-5-ones 
In spite of much recent progress, some pharmacologically promising pyrrole-derived 
simple frameworks have received very little attention because of their poor synthetic 
accessibility. This is the case of the 2-pyrrolin-5-one system, which has been reported 
only a few times, and has normally been accessed by complex multistep routes in very 
modest yields.123  
Encouraged by the experience of our group in the Hantzsch pyrrole synthesis,124 we 
envisioned that it should be possible to adapt this classical reaction for our purpose. 
This would involve developing the three-component reaction between primary 
amines, α-haloesters and β-dicarbonyl compounds to furnish compounds 1. As shown 
in Scheme 3.2, a two-component process somewhat related to ours and involving the 
reaction of β-enamino esters with α-ketoaldehydes afforded either of the two possible 
4-oxo- or 5-oxo regioisomers (for ketoaldehydes and glyoxal, respectively), while N-
hydroxyethyl or N-hydroxypropyl enamino esters gave the 5-oxo derivative, 
 
Scheme 3.2 
 
123  (a) Wasserman, H. H.; Liberles, A. J. Am. Chem. Soc. 1960, 82, 2086-2086. (b) Takamizawa, A.; 
Harada, H.; Makino, I. Chem. Pharm. Bull. 1978, 26, 722-735. (c) Gelin, S.; Gelin, R. J. Org. Chem. 
1979, 44, 808-810. (d) Eiden, F.; Grusdt, U. Arch. Pharm. 1987, 320, 1020-1031. 
124   For a generalization of the Hantzsch pyrrole synthesis under mechanochemical conditions, see: (a) 
Estévez, V.; Villacampa M.; Menéndez, J. C. Chem. Commun. 2014, 43, 4633-4657. (b) Estévez, V.; 
Sridharan, V.; Sabaté, S.; Villacampa, M.; Menéndez, J. C. Asian J. Org. Chem. 2016, 2016, 5, 652-662. 
(c) Leonardi, M.; Villacampa M.; Menéndez, J. C. Beilstein J. Org. Chem. 2017, 13, 1957-1962. (d) 
Leonardi, M.; Villacampa M.; Menéndez, J. C. J. Org. Chem. 2017, 82, 52570-2578. (e) Leonardi, M.; 
Villacampa M.; Menéndez, J. C. Adv. Synth. Catal. 2019, 361, 2054-2074. 
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presumably because of its stabilization by intramolecular hydrogen bonding.125, 126 A 
three-component variation of this reaction, starting from primary amines, α-
ketoaldehydes and β-dicarbonyl compounds gives exclusively 4-hydroxypyrroles.127 
3.4.3. Hantzsch-like, multicomponent approach to 2-pyrrolin-ones  
We started our optimization study by examining the model preparation of compound 
1a from butylamine, ethyl bromoacetate and ethyl acetoacetate (Scheme 3.3 and 
Table 3.1). In our first experiments, these starting materials were combined in ethanol 
in the presence of 5% Ce(IV) ammonium nitrate (CAN) as a Lewis acid,128 initially at 
room temperature and then under reflux conditions, but no reaction was observed 
(entries 1 and 2). The use of focused microwave irradiation was also unsuccessful 
(entries 3 and 4). However, when the reaction was performed under solvent-free 
conditions, compound 1a was obtained in 53% yield (entry 5), with no improvement 
being observed upon increase of the catalyst load (entry 6). Lanthanide triflates, 
represented by yttrium and ytterbium triflates, were also assayed, again with no 
improvement (entries 7 and 8). Boron trifluoride etherate failed to catalyze the 
reaction (entry 9), and aluminium trichloride gave only modest yields, even with 10% 
catalyst load (entries 10 and 11). Finally, indium trichloride was found to improve the 
results obtained with CAN, giving a 60% yield of 1a with a 5% loading (entry 12) and 
almost the same result with 10% of the catalyst (entry 13). One final attempt was 
made using Montmorillonite K10, a clay with acidic properties that is compatible with 
microwave irradiation,129 but it failed to promote our reaction (entry 14). 
 
Scheme 3.3 
 
125  San Feliciano, A.; Caballero, E.; Pereira, J. A. P., Puebla, P. Tetrahedron 1989, 45, 6553-6562. 
126  Caballero, E.; Puebla, P.; Domercq, M.; Medarde, M.; López, J. L.; San Feliciano, A. Tetrahedron 1994, 
50, 7849-7856. 
127  Khalili, B.; Jajarmi, P.; Eftekhari-Sis, B.; Hashemi, M. M. J. Org. Chem. 2008, 73, 2090-2095. 
128  For a review of the use of CAN as a catalyst in organic synthesis, see: Sridharan, V.; Menéndez, J. C. 
Chem. Rev. 2010, 110, 3805-3849. 
129  For a recent example from our group, see: Rocchi, D.; González, J. F.; Menéndez, J. C. Molecules 
2014, 19, 7317-7326. 
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Table 3.1. Optimization of the synthesis of compound 1a 
Entry Catalyst (%) Temp (°C) Time (h) Solvent Yield (%) 
1 CAN (5) r.t. 20 EtOH 0a 
2 CAN (5) 80 14 EtOH 0 
3 CAN (5) 80 (MW) 0.5 EtOH 0 
4 CAN (5) 120 (MW) 0.5 EtOH 0 
5 CAN (5) 120 (MW) 0.5 -- 53 
6 CAN (10) 120 (MW) 0.5 -- 52 
7 Y(OTf)3 (5) 120 (MW) 0.5 -- 50 
8 Yb(OTf)3 (10) 120 (MW) 0.5 -- 26 
9 BF3.Et2O (10) 120 (MW) 0.5 -- Traces 
10 AlCl3 (5) 120 (MW) 0.5 -- 19 
11 AlCl3 (10) 120 (MW) 0.5 -- 29 
12 InCl3 (5) 120 (MW) 0.5 -- 60 
13 InCl3 (10) 120 (MW) 0.5 -- 58 
14 Montmorillonite K10 120 (MW) 0.5 -- Traces 
 
These optimal conditions (5% InCl3, solvent-free microwave irradiation, 120 °C) were 
applied to obtain a library of diversely substituted pyrrolinones in a 40-76% range of 
yields (Scheme 3.4 and Table 3.2), employing simple and commercially available 
starting materials. The scope of the R1 substituent on nitrogen included a variety of 
groups such as alkyl (entries 1-4, 7-9 and 13), arylalkyl (entries 5, 6, 12 and 18-22), allyl 
(entry 10) and functionalized alkyl (entry 11). The R2 chain was chosen among several 
primary alkyl chains, including methyl, ethyl (entry 7) and propyl (entries 4 and 9). The 
reaction was compatible with the presence of ester or ketone functions at C-3. While 
most compounds 1 were unsubstituted at C-4 because our planned subsequent 
application involved a condensation at this position, we also demonstrated the 
possibility to prepare a C4-phenyl derivative (entry 13). In this case, the α-haloester 
component was an iodide, and aluminium trichloride proved to be more efficient in 
promoting the reaction than indium trichloride. Finally, we also examined several 
reactions starting from ethyl β-aminocrotonate. Thus, its reaction with ethyl 2-
bromoacetate gave the N-unsubstituted pyrrolinone 1n in 55% yield (entry 14). This is 
a significant result because a previous preparation of this compound by reaction of the 
same aminocrotonate with glyoxal required a 7 h reflux in ethanol and afforded 1n in 
only 29% yield.125 Three additional examples of N-unsubstituted pyrrolinones were 
obtained by the same 
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 Scheme 3.4. Sequential multicomponent synthesis of 2-pyrrolin-5-ones 1 
Table 3.2. Results of the synthesis of compounds 1 
Entry Cmpd R1 R2 R3 R4 Yield (%) 
1 1a n-Bu Me OEt H 60 
2 1b n-Bu Me OMe H 50 
3 1c n-Bu Me Me H 42 
4 1d n-Bu n-Pr OEt H 52 
5 1e Bn Me OEt H 52 
6 1f Bn Me OMe H 55 
7 1g n-Bu Et OEt H 59 
8 1h Me Me OEt H 76 
9 1i n-Hex n-Pr OEt H 72 
10 1j Allyl Me OMe H 50 
11 1k 2-Hydroxyethyl Me OMe H 43 
12 1l 
 
Me OMe H 52 
13 1m n-Bu Me OEt Ph 58b 
14 1n H Me OEt H 55 c 
15 1o H Me OEt Me 43 c 
16 1p H Me OEt Et 40 c 
17 1q H Me OEt Ph 41 c 
18 1r 
 
Me OMe H 54 
19 1s 
 
Me OMe H 49 
20 1t 
 
Me OMe H 56 
21 1u 
 
Me OMe H 36 
22 1v 
 
Me OMe H 41 
a The X leaving group was Br in all cases except for entry 13, where X = I. b In this case the catalyst was 
aluminium trichloride (10%). c From ethyl β-aminocrotonate and the suitable α-bromoester. 
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method (entries 15-17). Interestingly, we did not observe the isomerization of 2-
pyrrolin-5-ones to their regioisomeric 4-hydroxypyrroles noticed by previous 
authors.126Mechanistically, our three-component process was expected to proceed via 
a Hantzsch-type mechanism that is depicted in Scheme 3.5 for the reaction leading to 
compound 1a. Thus, the reaction would start with the InCl3-catalyzed formation of a β-
enamino ester,130 which would then react with the α-haloester to give intermediate I, 
which can tautomerize to species II or III. However, only the E isomer II can undergo 
cyclization, thus driving these equilibria to the final product. 
An alternative Paal-Knorr-like mechanism would involve the formation of a 1,4-
dicarbonyl species IV that would then react with the primary amine to give the 
previous intermediate II. However, we verified that ethyl acetoacetate and ethyl 
bromoacetate did not react at all in the presence of InCl3 under our conditions. 
Furthermore, we found that treatment of the known131 ethyl acetosuccinate IV with n-
butylamine failed to give the 2-pyrrolin-5-one 1a under our conditions. On the 
contrary, the isolated β-enamino ester arising from n-butylamine and ethyl 
acetoacetate132 furnished compound 1a when treated with ethyl bromoacetate in the 
presence of InCl3 under our usual conditions. 
Scheme 3.5 
 
 
130  The Z configuration of the intermediate β-enamino esters was established by the NH chemical shift 
and NOE studies, and is probably stabilized by an intramolecular hydrogen bond. See: (a) Zhuo, J.-C.; 
Schenk, K. Helv. Chim. Acta 1997, 80, 2137-2147. (b) Vohra, R. K.; Renaud, J.-L.; Bruneau, C. Synthesis 
2007, 2007,731-738. (c) Thorwith, R.; Stolle, A. Synlett 2011, 2011, 2200-2202. 
131  Kádas, I.; Morvai, V.; Árvai, G.; Tőke, L.; Szöllősy, Á.; Tóth G.; Bihari, M. Monatsch. Chem. 1995, 126, 
107. 
132  Sridharan, V.; Avendaño C.; Menéndez, J. C. Synlett 2007, 2007, 881-884. 
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3.5. Pyrrolones with embedded cinnamic acid structural fragments  
3.5.1. Synthesis of compounds 3 
Pyrrolin-5-ones 1, obtained via the multicomponent procedure described above, were 
reacted with the appropriate aromatic aldehydes 2 by a piperidine-catalyzed 
Knoevenagel condensation to afford the target 4-arylmethylene-2-pyrrolyn-5-ones 3 
(Scheme 3.6).   
  
Scheme 3.6 
The selection of the side chains was based on commercial availability of the 
corresponding aldehydes or by their presence in molecules of interest as 
neuroprotectants connected with tau protein aggregation.133Most of the required 
aromatic aldehydes were commercially available, but some of them (2a-d) had to be 
synthesized by a Williamson reaction, as shown in Scheme 3.7. 
 
Scheme 3.7 
The structures and yields of compounds 3 are summarized in Figure 3.7.  
 
133  Gandini, A.; Bartolini, M.; Tedesco, D.; Martínez-González, L.; Roca, C.; Campillo, N. E.; Zaldívar-Díez, 
J.; Pérez, C.; Zuccheri, G.; Miti, A.; Feoli, A.; Castellano, S.; Petralla, S.; Monti, M.; Rossi, M.; Moda, F.; 
Legname, G.; Martínez, A.; Bolognesi, M. L. J. Med. Chem. 2018, 61, 7640-7656. 
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Figure 3.7 
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3.5.2. Pharmacological evaluation of compounds 3  
The pharmacological study of compounds 3 was carried out by Sheila Abril at the group 
of Dr. Rafael León (Hospital Universitario de la Princesa and Instituto Teófilo Hernando, 
Universidad Autónoma de Madrid). 
 (a) SHSY5Y cytotoxicity 
An exacerbated Nrf2 induction results in harmful effects for cells, and neurons are 
particularly susceptible to toxicity. Therefore, the evaluation of a potential 
neurotoxicity for these compounds, by this or by alternative mechanisms, was 
necessary prior to the pharmacological study. The cell viability for all compounds was 
studied in the neuroblastoma SHSY5Y cell line and measured as MTT reduction, and 
most compounds showed a good safety profile with a LD50 above 100 µM. Compound 
3i, showing LD50 = 92.8 ± 4.6 µM, can also be considered to have a suitable toxicity 
profile, but 3l and 3n were regarded as too toxic (Table 3.3).  
Table 3.3 
Entry Compound LD50 (μM) 
1 3a  > 100 
2 3b  > 100 
3 3c  > 100 
4 3d  > 100 
5 3e  > 100 
6 3f  > 100 
7 3g  > 100 
8 3h  > 100 
9 3i  92.8 ± 4.6 
10 3j  >100 
11 3k  >100 
12 3l  63.7 ± 12.8 
13 3m  >100 
14 3n 75.4 ± 1 5.6 
15 3o  >100 
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(b) Nrf2 induction in the AREc32 cell line 
Nrf2 induction was evaluated in the AREc32 cell line, an MCF7 stable clone transfected 
with 8 x luciferase reporter after the ARE sequence.134 Nrf2 activation promotes the 
transcription of the ARE-dependent phase II genes, expressing luciferase to the same 
extent. Thus, the increase in luciferase, measured by a luminescence assay, and Nrf2 
induction potency are directly correlated. AREc32 cells were incubated during 24 h 
with increasing concentrations of compounds 3a-3o (0.3, 3, 10, 30 and 60 M) and 
luminescence was recorded to obtain CD values for each compound. These CD values 
represent the concentration of compound necessary to double the luciferase activity 
compared to its basal expression. As shown by the results collected in Table 3.4, all 
compounds are good Nrf2 inducers, with 3b, 3d, 3g and 3i showing excellent activities 
around 10 M CD. Compound 3j was the most potent of the library, with a CD value of 
3.18. As a reference for comparison, the CD value for caffeic acid is comprised 
between 6.5 and 11.75 M, and that of curcumin between 3.5 and 6.5 M.135 
 
Table 3.4 
Entry Compound CD (μM) 
1 Caffeic acid 6.5 - 11.75 
2 Curcumin 3.5 - 6.5 
3 3a  17.86 ± 8.58 
4 3b  10.38 ± 0.80 
5 3c  31.06 ± 6.21 
6 3d  11.91 ± 2.83 
7 3e  14.26 ± 3.89 
8 3f  13.97 ± 4.45 
9 3g  7.58 ± 4.35 
10 3h  21.41 ± 5.72 
11 3i  7.51 ± 3.45 
12 3j  3.18 ± 1.16 
13 3k  36.07 ± 418 
 
134  Wang, X. J.; Hayes, J. D.; Wolf, C. R. Cancer Res. 2006, 66, 10983-10994. 
135  Wu, K.; McDonald, P.; Liu, J.; Klaassen, C. Planta Medica 2013, 80, 97–104. 
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Entry Compound CD (μM) 
14 3l  30.22 ± 1.89 
15 3m  17.96 ± 1.84 
16 3n  15.00 ± 0.80 
17 3o  35.98 ± 10.56 
 
(c) Nitrogen radical scavenging in DPPH assay 
As part of the characterization of our compounds as antioxidants, their radical 
scavenging activity was studied by the DPPH assay, which measures the ability of the 
compounds to scavenge the 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical, which is 
purple and absorbs at 517 nm. Compounds with radical scavenging properties donate 
a hydrogen atom to DPPH, and the resulting 1,1-diphenyl-2-picrylhydrazine specie is 
yellow (Scheme 3.8). 
 
Scheme 3.8 
Compounds 3a-o were initially evaluated at two different concentrations (0.1 and 1 
mM), and for the more active compounds IC50 values were obtained (Table 3.5). 
Melatonin and ascorbic acid, two widely described anti-oxidant compounds, were used 
as reference and trolox as a positive control. Only phenolic compounds 3i and 3k 
possessed a potent radical scavenging activity comparable to ascorbic acid. However, 
for the remaining pirrolones 3 only a modest activity was detected.  
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Table 3.5 
Entry Compound 
% Scavenging  
at 0.1 mM 
% Scavenging   
at 1 mM 
IC50 μM 
1 Trolox   11.4±1.0 (9) 
2 Ascorbic acid   16.2±0.7 (9) 
3 Melatonin   1988±1397 (2) 
4 3a  40.5 ± 5.0 41.6 ± 4.1 - 
5 3b  6.33 ± 4.2 27.0 ± 2.6 - 
6 3c  9.7 ± 0.6 9.7 ± 2.2 - 
7 3d  4.3 ± 2.1 31.3 ± 3.3 - 
8 3e  22.8 ± 0.2 85.5 ± 2.7 334.3±22.9 (3) 
9 3f  11.3 ± 2.6 63.5 ± 2.2 712.2±5.4 (3) 
10 3g  7.3 ±1.4 27.3 ± 1.0 - 
11 3h  12.7 ± 3.5 73.6 ± 0.7 552.1±17.4 (3) 
12 3i  90.9 ± 0.5 - 7.5±0.4 (3) 
13 3j  8.1 ± 4.7 46.5 ± 2.3 - 
14 3k  89.0 ± 0.4 - 26.3±2.1 (3) 
15 3l  9.7 ± 3.8 47.5 ± 4.9 - 
16 3m  6.5 ± 4.5 27.2 ± 6.4 - 
17 3n  3.7 ± 3.8 36.6 ± 3.4 - 
18 3o  12.7 ± 1.9 49.9 ± 3.4 - 
 
As part of the characterization of the compounds as potential  multitarget-directed 
ligands, they were also investigated as inhibitors of acetylcholinesterase, an interesting 
target in Alzheimer’s disease. Initially, the whole library was studied at a single 
concentration (10 M), and IC50 was also determined for the most active compounds 
(Table 3.6). Only three of the compounds showed significant activity in this assay and 
therefore this aspect of the characterization of our compounds was not pursued 
further. 
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Table 3.6 
Entry Compound 
% Inhibition of 
EeAChE at 10μM 
IC50 (μM) 
1 3a  25.21  
2 3b  24.32  
3 3c  29.29  
4 3d  15.96  
5 3e  17.59  
6 3f  26.20  
7 3g  40.09 22.4 ± 3.2 
(3) 8 3h  31.77  
9 3i  27.21  
10 3j  11.62  
11 3k  24.25  
12 3l  27.36  
13 3m  36.27 29.7 ± 3.0 
(3) 14 3n  33.47  
15 3o  39.84 12.5 ± 1.4 
(3)  
(d) Neuroprotection in a rotenone/oligomycin A oxidative stress model 
The good Nrf2 induction found for the whole library and the radical scavenging 
properties of derivatives 3i and 3k encouraged us to study their potential 
neuroprotective role against oxidative stress. An intracellular model of oxidative stress 
was generated by a combination of rotenone and oligomycin A (R/O) (30/10 M) in the 
neuroblastoma SH-SY5Y cell line. Rotenone and oligomycin A inhibit complexes I and V 
of the mitochondrial electron transport chain, respectively, disrupting ATP synthesis. 
Their combination (R/O) constitutes a good model of oxidative stress and 
neurodegeneration with a mitochondrial origin and has been widely used to evaluate 
potential protective drugs for neurodegenerative diseases.136, 137 Moreover, exposure 
of laboratory animals to rotenone is well-known to reproduce features of Parkinson's 
 
136  Buendia, I.; Navarro, E.; Michalska, P.; Gameiro, I.; Egea, J.; Abril, S.; López, A.; González-Lafuente, L.; 
López, M. G.; León, R. Future Med. Chem. 2015, 7, 1961-1969. 
137  Tenti, G.; Parada, E.; León, R.; Egea, J.; Martínez-Revelles, S.; Briones, A. M.; Martínez-Revelles, S.; 
Briones, A. M.; Sridharan, V.; López, M. G.; Ramos, M. T.; Menéndez, J. C. J. Med. Chem. 2014, 57, 
4313-4323. 
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disease, 138  including selective nigrostriatal dopaminergic degeneration and the 
appearance of α-synuclein cytoplasmic inclusions. These effects were determined to 
be associated to oxidative damage.139  
Compounds 3a-o demonstrated neuroprotective properties against the rotenone-
oligomycin oxidative insult in a concentration-dependent manner (Table 3.7 and Figure 
3.8). Compounds 3i, 3n and 3o, in particular, showed a very good neuroprotective 
profile, with a significantly higher activity than melatonin, a well-known 
Table 3.7a 
Entry Compound 
% Survival  SEM  
at 1 M 
% Neuroprotection 
  SEM at 1 M 
Statistical  
significance 
1 Basal 100 100 
 
2 R/O (30/10 µM) 43.27  1.97  ### 
3 Melatonin 78.14  5.70 61.41  8.75 *** 
4 3a  70.65  5.68 49.79  9.46 ** 
5 3b  71.99  9.21 50.32  16.34 ** 
6 3c  72.44  9.48 50.99  16.93 ** 
7 3d  72.53  8.79 51.19  15.49 ** 
8 3e  81.95  13.82 69.40  23.95 ** 
9 3f  76.12  14.94 79.76  8.28 * 
10 3g  77.20  12.25 60.26  20.86 ** 
11 3h  67.00  10.26 41.18  18.85 * 
12 3i  94.27  18.81 90.40  32.38 ** 
13 3j  72.01 15.76 74.47  7.19 * 
14 3k  69.39  11.13 46.23  18.89 ** 
15 3l  68.51  7.81 44.33  13.57 ** 
16 3m  82.05  18.09 68.05  31.51 * 
17 3n  96.24  13.30 94.91  24.25 *** 
18 3o  94.16  4.99 90.12  8.80 *** 
a Data are expressed as mean  SEM of three experiments by triplicate. One way ANOVA 
Newman Keuls post test ### p < 0.001; compared to basal. * p < 0.05, ** p < 0.01; *** p < 
0.001; compared to toxic. 
 
138  For a review of rotenone models of Parkinson's disease, see: Johnson, M. E.; Bobrovskaya, L. 
Neurotoxicology 2015, 46, 101-116. 
139  (a) Sherer, T. B.; Betarbet, R.; Testa, C. M.; Seo, B. B.; Richardson, J. R.; Kim, J. H.; Miller, G. W.; Yagi, 
T.; Matsuno-Yagi, A.; Greenamyre, T. J. J. Neurosci. 2003, 23, 10756-10764. (b) Xiong, N.; Xiong, J.; 
Jia, M.; Liu, L.; Zhang, X.; Chen, Z.; Huang, J.; Zhang, Z.; Hou, L.; Luo, Z.; Ghoorah, D.; Li, Z.; Wang, T. 
Behav. Brain Funct. 2013, 9, 13. 
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Figure 3.8 Neuroprotective effect of compounds 3a-3o (1 µM) against toxicity elicited by the 
combination of rotenone (30 µM) and olygomycin A (10 µM) in SH-SY5Y cells.  
neuroprotective agent with an excellent antioxidant profile, 140  at the same 
concentration. 
 
 (e) Neuroprotection against tau hyperphosphorylation induced by okadaic acid  
Okadaic acid induces tau hyperphosphorylation by inhibition of protein phosphatase 
2A (PP2A), and can be used as a model of neurodegenerative disease-associated tau 
hyperphosphorylation. Although tau hyperphosphorylation is best known as a feature 
of Alzheimer’s disease, other NDDs, collectively known as taupathies, are characterized 
by pathological tau aggregation in neurofibrillary tangles. Recently, increasing evidence 
of the involvement of tau pathology in Parkinson’s disease is accumulating, including 
the abnormal hyperphosphorylation of tau protein, the formation in about 50% of PD 
brains of tau aggregates, which seem to be transported from neuron to neuron, and 
the interaction between tau and α-synuclein.141 
Compounds 3a-o were tested on SH-SY5Y cells treated with okadaic acid, and some of 
them (3b, 3e, 3i, 3j, 3l) gave a similar neuroprotection to melatonin. The best results 
were obtained with the phenolic compound 3k, which showed an excellent 
neuroprotection against the okadaic acid-induced insult (Table 3.8 and Figure 3.9). 
 
 
 
140  For a review of the neuroprotective role of melatonin in neurological disorders, see: Almghandi, B. S. 
J. Neurosci. Res. 2018, 96, 1136–1149. 
141 Zhang, X.; Gao, F.; Wang, D.; Li, C.; Fu, Y.; He, W.; Zhang, J. Front. Neurol. 2018, 9, 809. 
Chapter 3. Neuroprotective compounds related to cinnamic esters and curcumin 
57 
 
Table 3.8a 
Entry Compound 
% survival  
SEM at 1 M 
% Neuroprotection  
 SEM at 1 M 
Statistical  
significance 
1 Basal 100 
  
2 OA (20 nM) 60.32  5.48  ### 
3 Melatonin 85.48  7.77 67.70  13.95 ** 
4 3a  77.83  7.38 52.71  17.20 * 
5 3b  85.14  5.02 62.77  8.00 ** 
6 3c  81.19  4.61 48.30  10.99 ** 
7 3d  73.16  8.91 31.82  15.21 
 
8 3e  84.28  8.18 61.39  15.75 ** 
9 3f  82.09  7.51 51.07  18.36 ** 
10 3g  82.40  11.06 57.14  22.31 * 
11 3h  76.41  6.63 40.72  9.85 * 
12 3i  85.25  8.33 60.87  23.33 ** 
13 3j  87.70  9.95 65.73  29.07 ** 
14 3k  91.94  11.82 81.86  28.54 * 
15 3l  84.94  9.03 68.05  22.01 * 
16 3m  82.20  4.65 54.15  14.26 ** 
17 3n  80.30  6.20 52.77  9.96 ** 
18 3o  76.75  8.63 46.27  13.57 * 
a Data are expressed as mean  SEM of three experiments by triplicate. One way ANOVA 
Newman Keuls post test ### p < 0.001; compared to basal. * p < 0.05, ** p < 0.01; *** p < 
0.001; compared to toxic. 
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Figure 3.9 Neuroprotective effect of compounds 3a-3o (1 µM) against toxicity elicited by the okadaic 
acid (20 nM) in SH-SY5Y cells.   
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In summary, our 4-(arylmethylene)-2-pyrrolin-5-one derivatives have an interesting 
profile as neuroprotective agents. Most of them lack cytotoxicity and are good 
inductors of the Nrf2-initiated phase II antioxidant response. Some compounds have 
also shown good neuroprotective properties against toxicity induced by treatment 
with rotenone/oligomycin or okadaic acid. Compound 3i, in particular, has a well-
balanced multitarget profile and can be considered a good candidate for further 
development against neurodegenerative diseases. 
 
3.6. Curcumin analogues with a pyrrolinone core 
3.6.1. Synthesis of compounds 4 
The curcumin analogues 4e-f were obtained by acylation of pyrrolinones 1 with the 
suitable cinnamyl chloride derivative, using LiHMDS as base (Scheme 3.9).  
 
 
Scheme 3.9 
The synthesis of the required cinnamyl chloride derivatives required some 
experimentation. Several attempts to use thionyl chloride were unsuccessful, but the 
reaction could be finally performed with a mixture of oxalyl chloride and hexane, 
where the generated oxalyl chloride was transferred to the apolar phase. Thus, despite 
the simplicity of the acylation reaction, its scope and yield is limited because of the 
requirement for hexane solubility of the required cinnamoyl chlorides. The structures 
and yields of the compounds obtained are summarized in Figure 3.10. 
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Figure 3.10 
3.6.2. Pharmacological evaluation of compounds 4 
The initial pharmacological evaluation of compounds 4a-f was carried out by Drs. 
Paloma Bermejo and Sagrario Martín-Aragón, at the Departamento de Farmacología, 
Facutad de Farmacia, Universidad Complutense. The HEK293-Tau3R cell line was kindly 
supplied by Dr. Jesús Ávila, Centro de Biología Molecular Severo Ochoa, Madrid. 
Further characterization of the pharmacological profile of these compounds is in 
progress. 
(a) Cellular viability in Hek-Tau cell line (MTT) 
Firstly, neurotoxicity for compounds 4a-f was determined by MTT assay in Hek-Tau 
cells, which are characterized by the overexpression of tau protein. Compounds 4a-f 
were tested at 10 and 5 µM concentrations for 24 h and then cellular viability was 
determined. No toxicity was detected at 5 µM. Compounds 4e and 4f show some 
neurotoxicity at 10 µM, although lower than that of curcumin (Figure 3.11). 
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Figure 3.11. Cell viability assay of compounds 4; p < 0.05 indicates statistically significative differences 
with the control, using the Newman-Keuls test 
(b) Free radical scavenging in the Hek-Tau cell line (DCFA-DA) 
Radical oxygen scavenging was tested in HEK293-Tau3R using a cellular antioxidant 
activity assay. The cells were exposed to hydrogen peroxide (200 µM) and treated with 
the non-fluorescent compound 2,7-dichlorofluorescin acetate (DFCA), a probe that is 
trapped within cells following its hydrolysis by cellular esterases. The resulting 2,7-
dichlorofluorescin (DFCH) is still non-fluorescent, but upon oxidation by ROS becomes 
the more rigid, highly fluorescent dichlorofluorescein (DCF). Thus, the fluorescence 
observed in the assay is in an inverse relationship with the scavenging ability of the 
compounds under assay (Scheme 3.10). 
 
Scheme 3.10 
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Using this essay, variations in the fluorescence signal after addition of the compounds 
4a-f in different concentrations (0.1 to 10 µM) were measured. In these experiments, 
all compounds showed similar or higher antioxidant activities than curcumin. 
Particularly interesting results were obtained for compounds 4b, 4c and 4d, which 
showed a highly increased antioxidant activity compared with the curcumin reference 
(Figure 3.12). 
  
  
  
 
Figure 3.12 
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(c) Tau aggregation inhibition 
The N-acetylated and C-amidated hexapeptide AcPHF6 (MeCOVQIVYK-NH2), derived 
from the native tau-hexapeptide sequence 306VQIVYK311, is involved in the aggregation 
processes in fibrils with β-sheet conformation and represents a suitable model to study 
tau protein aggregation inhibition.142  
Our curcumin analogues (4a-f) were shown to reduce the aggregation of the AcPHF6 
peptide (Figure 3.13 for the behaviour of individual compounds towards the 
aggregation of the AcPHF6 peptide and Figure 3.14 for a summary). Compounds 4a, 4b 
and 4d show a similar antiaggregating activity compared with the parent compound 
curcumin. On the other hand, the curcumin-related phenolic compound 4f showed the 
least potent aggregation inhibition. 
 
 
  
Figure 3.13 
 
 
 
142  See, for instance: Mohamed, T.; Hoang, T.; Jelokhani-Niaraki, M.; Rao, P. P. N. ACS Chem. Neurosci. 
2013, 4, 1559−1570. 
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Figure 3.13 (continued) 
 
Figure 3.14 
 
In summary, compounds 4b and 4d are attractive multitarget directed ligands against 
oxidative stress and act as tau protein aggregation inhibitors, with a safe toxicity 
profile.  
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3.7. Experimental section 
General experimental details 
All reagents and solvents were of commercial quality and were used as received. 
Reactions were monitored by thin layer chromatography on aluminium plates coated 
with silica gel and fluorescent indicator. Microwave-assisted reactions were performed 
on a CEM Discover focused microwave reactor. Separations by flash chromatography 
were performed using a Combiflash Teledyne automated flash chromatograph or on 
conventional silica gel columns. Melting points were measured with a Kofler-type 
heating platine microscope from Reichert, 723 model, and are uncorrected. Infrared 
spectra were recorded with an Agilent Cary630 FTIR spectrophotometer with a 
diamond ATR accessory for solid and liquid samples, requiring no sample preparation; 
wavenumbers are given in cm−1. NMR spectroscopic data were obtained using 
spectrometers maintained by the CAI de Resonancia Magnética, UCM, operating at 
250, 300, 400 and 700 MHz for 1H NMR and, 63, 100 and 176 MHz for 13C NMR; 
chemical shifts are given in (δ) parts per million and coupling constants (J) in hertz. 
Elemental analyses were determined by the CAI de Microanálisis, Universidad 
Complutense, using a Leco CHNS-932 combustion microanalyzer. The enantiomeric 
excess analysis has been conducted in a HPLC Agilent 1220 Infinity LC with a chiral 
column ULTRON ES. 
 
3.7.1. General procedure for the synthesis of 2-pyrrolin-5-one derivatives 1 
 
 
 
To a suspension of indium trichloride (5% mmol) in the corresponding β-
dicarbonyl compound (1 eq.), placed in a microwave reaction vial, was added 
the suitable amine (1-1.2 eq.). The mixture was stirred at room temperature for 
30 minutes and monitored by TLC. After the reaction completion, the excess of 
amine was evaporated under reduced pressure. Then, the non-isolated enamino 
ester and the appropriate α-haloester (1 eq.) were exposed to focused 
microwave irradiation at 120 °C for 30 minutes. Once the reaction was 
completed, the mixture was diluted with CHCl3 (20 mL) and washed with water 
(2 x 5 mL). The organic phase was dried over anhydrous sodium sulphate and 
then evaporated under reduced pressure. The mixture was chromatographed on 
silica gel eluting with a gradient from hexane to 4:1 hexane-ethyl acetate. 
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Ethyl 1-butyl-2-methyl-5-oxo-4,5-dihydro-1H-pyrrole-3-carboxylate (1a) 
 
Prepared from ethyl acetoacetate (1 mmol), butylamine (1.2 mmol) and 
ethyl bromoacetate (1 mmol); orange solid (135 mg, 60%); mp 62-68 °C; 
1H-NMR (250 MHz, CDCl3) δ 4.21 (q, J = 7.2 Hz, 2H), 3.55-3.49 (m, 2H), 
3.27 (q, J = 2.4 Hz, 2H), 2.47 (t, J = 2.4 Hz, 3H), 1.61-1.49 (m, 2H), 1.43-
1.24 (m, 2H), 1.31 (t, J = 7.2 Hz, 3H), 0.96 (t, J = 7.2 Hz, 3H); 13C-NMR (63 
MHz, CDCl3) δ 176.4, 163.9, 159.8, 103.3, 59.6, 37.0, 36.6, 31.5, 20.1, 14.4, 13.7, 
12.9; IR (neat, cm-1): 1725, 1691, 1226; elemental analysis (%) calcd. for 
C12H19NO3: C 63.98, H 8.50, N 6.22; found: C 63.66, H 8.33, N 5.97. 
 
Methyl 1-butyl-2-methyl-5-oxo-4,5-dihydro-1H-pyrrole-3-carboxylate (1b) 
 
Prepared from methyl acetoacetate (1 mmol), butylamine (1.2 mmol) 
and ethyl bromoacetate (1 mmol); yellow oil (111 mg, 50%); 1H NMR 
(250 MHz, CDCl3) δ 3.72 (s, 3H), 3.50 (t, J = 7.2 Hz, 2H), 3.24 (q, J = 2.3 
Hz, 2H), 2.44 (t, J = 2.3 Hz, 3H), 1.59-1.45 (m, 2H), 1.43-1.23 (m, 2H), 
0.93 (t, J = 7.2 Hz, 3H); 13C NMR (63 MHz, CDCl3) δ 176.4, 165.1, 155.0, 
103.4, 51.4, 40.4, 37.0, 31.8, 20.5, 14.1, 12.7; IR (neat, cm-1): 1723, 1690, 1223; 
elemental analysis (%) calcd. for C11H17NO3: C 62.54, H 8.11, N 6.63; found: C 
62.43, H 7.89, N 6.19. 
 
4-Acetyl-1-butyl-5-methyl-1,3-dihydro-2H-pyrrole-2-one (1c) 
 
Prepared from acetylacetone (1 mmol), butylamine (1.2 mmol) and 
ethyl bromoacetate (1 mmol); yellow oil (82 mg, 42%); 1H-NMR (250 
MHz, CDCl3) δ 3.57-3.51 (m, 2H), 3.34 (q, J = 2.3 Hz, 2H), 2.50 (t, J = 2.3 
Hz, 3H), 2.22 (s, 3H), 1.58 -1.49 (m, 2H), 1.44-1.29 (m, 2H), 0.96 (t, J = 
7.0 Hz, 3H); 13C-NMR (63 MHz, CDCl3) δ 192.8, 175.4, 154.0, 111.8, 39.8, 
37.1, 31.2, 29.5, 20.0, 13.6, 12.8; IR (neat, cm-1): 1721, 1659; elemental analysis 
(%) calcd. for C11H17NO2: C 67.66, H 8.78, N 7.17; found: C 67.32, H 8.44, N 6.81. 
 
Ethyl 1-butyl-5-oxo-2-propyl-4,5-dihydro-1H-pyrrole-3-carboxylate (1d) 
 
Prepared from ethyl 3-oxohexanoate (1 mmol), butylamine (1.2 mmol) 
and ethyl bromoacetate (1 mmol);range oil (132 mg, 52%); 1H-NMR: 
(250 MHz, CDCl3) δ 4.18 (q, J = 7.1 H, 2H), 3.50-3.44 (m, 2H), 3.24 (s, 
2H), 2.82-2.76 (m, 2H), 1.64-1.48 (m, 4H), 1.40-1.23 (m, 2H), 1.28 (t, J = 
7.1 Hz, 3H), 1.03 (t, J = 7.3 Hz, 3H), 0.93 (t, J = 7.2 Hz, 3H); 13C-NMR: (63 
MHz, CDCl3) δ 176.3, 163.9, 158.3, 102.9, 59.6, 40.0, 36.6, 31.3, 27.6, 22.0, 20.0, 
14.3, 14.0, 13.6; IR (neat, cm-1): 1728, 1694, 1218; elemental analysis (%) calcd. 
for C14H23NO3: C 66.37, H 9.15, N 5.53; found: C 65.33, H 9.00, N 5.36. 
 
Ethyl 1-benzyl-2-methyl-5-oxo-4,5-dihydro-1H-pyrrole-3-carboxylate (1e) 
 
Prepared from ethyl acetoacetate (1 mmol), benzylamine (1 mmol) and 
ethyl bromoacetate (1 mmol); yellow oil (135 mg, 52%); 1H-NMR: (250 
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MHz, CDCl3) δ 7.39-7.30 (m, 3H), 7.22 (dd, J = 8.0 Hz, J = 1.8 Hz, 2H), 4.79 (s, 2H), 
4.22 (q, J = 7.1 Hz, 2H), 3.41 (q, J = 2.4 Hz, 2H), 2.37 (t, J = 2.4 Hz, 3H), 1.32 (t, J = 
7.1 Hz, 3H); 13C-NMR: (63 MHz, CDCl3) δ 176.0, 164.2, 154.0, 136.5, 128.9 (2C), 
127.7, 126.8 (2C), 103.7, 59.8, 43.4, 36.6, 14.4, 12.6; IR (neat, cm-1): 1726, 1693, 
1227; elemental analysis (%) calcd. for C15H17NO3: C 69.48, H 6.61, N 5.40; 
found: C 69.16, H 6.89, N 5.31. 
 
Methyl 1-benzyl-2-methyl-5-oxo-4,5-dihydro-1H-pyrrole-3-carboxylate (1f) 
 
Prepared from methyl acetoacetate (1 mmol), benzylamine (1 mmol) 
and ethyl bromoacetate (1 mmol); pale brown solid (135 mg, 55%); mp 
82-84 °C; 1H NMR (250 MHz, CDCl3) δ 7.42-7.15 (m, 5H), 4.79 (s, 2H), 
3.75 (s, 3H), 3.40 (q, J = 2.4 Hz, 2H), 2.37 (t, J = 2.4 Hz, 3H); 13C NMR (63 
MHz, CDCl3) δ 176.4, 154.8, 136.9, 129.3 (2C), 128.2, 127.3 (2C), 103.8, 51.5, 
43.9, 37.0, 13.0; IR (neat, cm-1): 1727, 1685, 1250; elemental analysis (%) calcd. 
for C14H15NO3: C 68.56, H 6.16, N 5.71; found: C 68.53, H 6.08, N 5.78. 
 
Ethyl 1-butyl-2-ethyl-5-oxo-4,5-dihydro-1H-pyrrole-3-carboxylate (1g) 
 
Prepared from ethyl propionylacetate (1 mmol), butylamine (1.2 mmol) 
and ethyl bromoacetate (1 mmol); yellow oil (142 mg, 59%); 1H-NMR: 
(250 MHz, CDCl3) δ 4.22 (q, J = 7.1 Hz, 2H), 3.55-3.48 (m, 2H), 3.27 (s, 
2H), 2.90-2.83 (m, 2H), 1.65-1.40 (m, 4H), 1.39-1.23 (m, 6H), 0.93 (t, J = 
7.2 Hz, 3H); 13C-NMR: (63 MHz, CDCl3) δ 176.4, 163.9, 159.8, 102.9, 
59.6, 40.0, 36.6, 31.5, 20.1, 19.2, 14.4, 13.7, 12.9; IR (neat, cm-1): 1726, 1693, 
1228; elemental analysis (%) calcd. for C13H21NO3: C 65.25, H 8.84, N 5.85; 
found: C 65.16, H 8.89, N 5.79. 
 
 
Ethyl 1,2-dimethyl-5-oxo-4,5-dihydro-1H-pyrrole-3-carboxylate (1h) 
 
Prepared from ethyl acetoacetate (1 mmol), methylamine (1.2 mmol) 
and ethyl bromoacetate (1 mmol); yellow oil (140 mg, 76%); 1H-NMR: 
(250 MHz, CDCl3) δ 4.17 (q, J = 7.1 Hz, 2H), 3.05 (s, 3H), 3.23 (q, J = 2.4 
Hz, 2H), 2.42 (t, J = 7.1 Hz, 3H), 1.27 (t, 3H, J = 2.4 Hz); 13C-NMR: (63 MHz, CDCl3) 
δ 176.0, 164.2, 154.1, 103.2, 59.7, 36.5, 26.3, 14.3, 12.4; IR (neat, cm-1): 1725, 
1692, 1228; elemental analysis (%) calcd. for C9H13NO3: C 59.00, H 7.15, N 7.65; 
found: C 59.22, H 7.30, N 7.52. 
Ethyl 1-hexyl-5-oxo-2-propyl-4,5-dihydro-1H-pyrrole-3-carboxylate (1i) 
 
Prepared from ethyl 3-oxohexanoate (1 mmol), hexylamine (1 mmol) 
and ethyl bromoacetate (1 mmol); orange oil (203 mg, 72%); 1H-NMR: 
(250 MHz, CDCl3): δ 4.20 (q, J = 7.1 Hz, 2H), 3.57-3.48 (m, 2H), 3.27 
(s,2H), 2.82-2.76 (m, 2H), 1.63-1.57 (m, 4H), 1.34-1.26 (m, 6H), 1.29 (t, J 
= 7.1 Hz, 3H), 1.05 (t, J = 7.5 Hz, 3H), 0.91 (t, J = 7.0 Hz, 3H); 13C-NMR: 
(63 MHz, CDCl3) δ 176.4, 163.9, 158.3, 102.9, 59.6, 40.3, 36.6, 31.3, 29.3, 27.7, 
26.5, 22.5, 22.0, 14.4, 14.1, 14.0; IR (neat, cm-1): 1726, 1702, 1227; elemental 
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analysis (%) calcd. for C16H27NO3: C 68.29, H 9.67, N 4.98; found: C 68.22, H 
9.30, N 4.82. 
 
 
Methyl 1-allyl-2-methyl-5-oxo-4,5-dihydro-1H-pyrrole-3-carboxylate (1j) 
 
Prepared from ethyl acetoacetate (1 mmol), allylamine (1. mmol) and 
ethyl bromoacetate (1 mmol); yellow oil (98 mg, 50%); 1H NMR (250 
MHz, CDCl3) δ 5.84-5.62 (m, 1H), 5.16-4.96 (m, 2H), 4.11 (dt, J = 5.0, 1.7 
Hz, 2H), 3.67 (s, 3H), 3.24 (q, J = 2.4 Hz, 2H), 2.36 (t, J = 2.4 Hz, 3H); 13C 
NMR (63 MHz, CDCl3) δ 174.6, 163.6, 153.5, 131.3, 115.8, 102.1, 50.1, 41.0, 
35.5, 11.2; IR (neat, cm-1): 1720, 1685, 1228; elemental analysis (%) calcd. for 
C10H13NO3: C 61.53, H 6.71, N 7.18; found: C 61.19, H 6.65, N 6.98. 
 
Methyl 1-(2-hydroxyethyl)-2-methyl-5-oxo-4,5-dihydro-1H-pyrrole-3-
carboxylate (1k) 
 
Prepared from methyl acetoacetate (1 mmol), hydroxyethylamine (1 
mmol) and ethyl bromoacetate (1 mmol); pale red solid (86 mg, 43%); 
mp 111-114 °C; NMR data are identical to those found in the 
literature.143 IR (neat, cm-1): 3482, 2940, 1715, 1669, 1616, 1231; 
elemental analysis (%) calcd. for C9H13NO: C 54.26, H, 6.58, N, 7.03; found: C 
54.14, H 6.39, N 6.79. 
 
Methyl 1-(3,4-dimethoxyphenethyl)-2-methyl-5-oxo-4,5-dihydro-1H-pyrrole-3-
carboxylate (1l) 
 
Prepared from methyl acetoacetate (1 mmol), 3,4-
dimethoxyphenethylamine (1 mmol) and ethyl bromoacetate (1 
mmol); beige solid (166 mg, 52%); mp 99-103 °C; 1H NMR (250 MHz, 
CDCl3) δ 6.73 (d, J = 8.0 Hz, 1H), 6.65 (d, J = 1.9 Hz, 1H), 6.60-6.59 (m, 
1H), 3.79 (s, 3H), 3.78 (s, 3H), 3.68-3.59 (m, 5H), 3.19 (q, J = 2.3 Hz, 2H), 
2.75 (t, J = 7.3 Hz, 2H), 2.13 (t, J = 2.4 Hz, 3H); 13C NMR (63 MHz, CDCl3) 
δ 175.0, 163.6, 153.5, 148.0, 146.9, 129.4, 119.8, 110.9, 110.3, 101.8, 88.8, 54.9, 
50.0, 41.1, 35.5, 33.7, 11.0; IR (neat, cm-1): 1717, 1685, 1220; elemental analysis 
(%) calcd. for C17H21NO5: C 63.94, H 6.63, N 4.39; found: C 63.77, H 6.47, N 4.29.  
 
Ethyl 1-butyl-2-methyl-5-oxo-4-phenyl-4,5-dihydro-1H-pyrrole-3-carboxylate 
(1m) 
 
Prepared from ethyl acetoacetate (1 mmol) ), butylamine (1.2 mmol) 
and methyl α-bromophenylacetate (1 mmol); orange oil (175 mg, 
58%); 1H NMR (250 MHz, CDCl3) δ 7.35-7.15 (m, 5H), 4.36 (q, J = 2.0 
Hz, 1H), 4.13-3.97 (m, 2H), 3.58 (m, 2H), 2.48 (d, J = 2.0 Hz, 3H), 1.65-
1.53 (m, 2H), 1.41-1.28 (m, 2H), 1.06 (t, J = 7.2 Hz, 3H), 0.95 (t, J = 7.0 Hz, 3H); 
 
143  Caballero, E.; Puebla, P.; Domercq, M.; Medarde, M.; López J. L.; San Feliciano, A. Tetrahedron 1994, 
50, 7849-7856. 
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13C NMR (63 MHz, CDCl3) δ 177.8, 164.5, 155.0, 137.0, 129.0 (2C), 128.3 (2C), 
127.6, 108.9, 60.0, 53.2, 40.4, 31.8, 20.4, 14.5, 14.1, 12.7; IR (neat, cm-1): 1721, 
1696, 1218.; elemental analysis (%) calcd. for C18H23NO3: C 71.73, H 7.69, N, 
4.65; found: C 71.65, H 7.64, N 4.69. 
Ethyl 2-methyl-5-oxo-4,5-dihydro-1H-pyrrole-3-carboxylate (1n) 
 
Prepared from ethyl 3-aminocrotonate (1 mmol) and ethyl 
bromoacetate (1 mmol); beige solid (93 mg, 55%); mp 119-123 °C; 1H 
NMR (250 MHz, CDCl3) δ 8.72 (br s, 1H), 4.22 (q, J = 7.1 Hz, 2H), 3.32 (q, 
J = 2.3 Hz, 2H), 2.39 (t, J = 2.3 Hz, 3H), 1.32 (t, J = 7.1 Hz, 3H); 13C NMR (63 MHz, 
CDCl3) δ 178.7, 164.6, 152.0, 104.9, 60.3, 38.0, 14.8, 13.9; IR (neat, cm-1): 3165, 
1702, 1682, 1251; elemental analysis (%) calcd. for C8H11NO3: C 56.80, H 6.55, N 
8.28; found: C 56.42, H 6.36, N 7.90. 
 
Ethyl 2,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrrole-3-carboxylate (1o) 
 
Prepared from ethyl 3-aminocrotonate (1 mmol) and methyl α-
bromomethylacetate (1 mmol); yellow oil (79 mg, 43%); 1H NMR (250 
MHz, CDCl3) δ 8.11 (br s, 1H), 4.42-4.09 (m, 2H), 3.29 (qq, J = 7.6, 2.1 
Hz, 1H), 2.40 (d, J = 2.1 Hz, 3H), 1.44 (d, J = 7.6 Hz, 3H), 1.33 (t, J = 7.1 Hz, 3H); 
13C NMR (63 MHz, CDCl3) δ 182.1, 164.7, 150.9, 110.7, 60.1, 43.5, 15.6, 14.8, 
14.0; IR (neat, cm-1): 3186, 1721, 1686, 1249; elemental analysis (%) calcd. for 
C9H13NO3: C 59.00, H 7.15, N 7.65; found: C 58.79, H 6.95, N 7.73. 
 
 
Ethyl 4-ethyl-2-methyl-5-oxo-4,5-dihydro-1H-pyrrole-3-carboxylate (1p) 
 
Prepared from ethyl 3-aminocrotonate (1 mmol) and methyl α-
bromoethylacetate (1 mmol); yellow oil (79 mg, 40%); 1H NMR (250 
MHz, CDCl3) δ 8.22 (br s, 1H), 4.34-4.14 (m, 2H), 3.43-3.29 (m, 1H), 
2.41 (d, J = 2.2 Hz, 3H), 2.18-1.88 (m, 2H), 1.33 (t, J = 7.1 Hz, 3H), 0.83 (t, J = 7.5 
Hz, 3H); 13C NMR (63 MHz, CDCl3) δ 181.5, 164.7, 151.8, 108.1, 60.1, 48.9, 22.7, 
14.8, 14.1, 9.4; IR (neat, cm-1): 3257, 1715, 1689, 1223; elemental analysis (%) 
calcd. for C10H15NO3: C 60.90, H 7.67, N 7.10; found: C 60.88, H 7.48, N 7.13. 
 
Ethyl 2-methyl-5-oxo-4-phenyl-4,5-dihydro-1H-pyrrole-3-carboxylate (1q) 
 
Prepared from ethyl 3-aminocrotonate (1 mmol) and methyl α-
bromophenylacetate (1 mmol); yellow oil (101 mg, 41%); 1H NMR (250 
MHz, CDCl3) δ 8.21 (br s, 1H), 7.44-7.15 (m, 5H), 4.42 (app. d, J = 2.2 
Hz, 1H), 4.18-3.93 (m, 2H), 2.47 (d, J = 2.2 Hz, 3H), 1.09 (t, J = 7.1 Hz, 3H); 13C 
NMR (63 MHz, CDCl3) δ 179.4, 164.3, 152.9, 136.4, 129.1 (2C), 128.3 (2C), 127.9, 
109.8, 60.1, 54.2, 14.5, 14.0; IR (neat, cm-1): 3238, 1719, 1687, 1223; elemental 
analysis (%) calcd. for C14H15NO3: C 68.56, H 6.16, N 5.71; found: C 68.41, H 
6.16, N 5.57. 
Methyl 2-methyl-5-oxo-1-phenethyl-4,5-dihydro-1H-pyrrole-3-carboxylate (1r) 
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Prepared from methyl acetoacetate (1 mmol), phenethylamine (1 
mmol) and ethyl bromoacetate; light brown solid (140 mg, 54%); mp 
99-103 °C; 1H NMR (250 MHz, CDCl3) δ 7.20-6.91 (m, 5H), 3.56 (t, J = 7.3 
Hz, 2H), 3.53 (s, 3H), 3.08 (q, J = 2.2 Hz, 2H), 2.69 (t, J = 7.3 Hz, 2H), 2.00 
(t, J = 2.2 Hz, 3H); 13C NMR (63 MHz, CDCl3) δ 175.0, 163.6, 153.5, 137.0, 
127.8 (2C), 127.7 (2C), 125.9, 101.9, 50.0, 41.0, 35.5, 34.2, 11.0; IR (neat, cm-1): 
1703, 1669, 1230; elemental analysis (%) calcd. for C15H17NO3: C 69.48, H 6.61, 
N 5.40; found: C 69.19, H 6.50, N 5.15. 
 
Methyl 1-(4-fluorobenzyl)-2-methyl-5-oxo-4,5-dihydro-1H-pyrrole-3-
carboxylate (1s) 
 
Prepared from methyl acetoacetate (1 mmol), 4-fluorobenzylamine (1 
mmol) and ethyl bromoacetate (1 mmol); brown solid (129mg, 49%); mp 61-
62°C; 1H NMR (250 MHz, CDCl3) δ 7.21 – 7.11 (m, 2H), 7.07 – 6.95 (m, 3H), 
4.72 (s, 2H), 3.72 (s, 3H), 3.36 (q, J = 2.4 Hz, 2H), 2.34 (t, J = 2.4 Hz, 3H); 13C 
NMR (63 MHz, CDCl3) δ 176.1, 164.7, 162.4 (d, J = 246.8 Hz), 154.2, 132.4(d, 
J = 3.3 Hz), 128.8 (d, J = 8.2 Hz, 2C), 116.0 (d, J = 21.7 Hz, 2C), 103.7, 51.3, 43.0, 36.7, 
12.8; IR (neat, cm-1): 1690, 1630, 1219; elemental analysis (%) calcd. for C14H14FNO3: C 
63.87, H 5.36, N 5.32; found: C 62.53, H 5.18, N 5.34. 
 
Methyl 2-methyl-5-oxo-1-(4-flourophenethyl)-4,5-dihydro-1H-pyrrole-3-
carboxylate (1t) 
 
Prepared from methyl acetoacetate (1 mmol), 4-fluorophenethylamine 
(1 mmol) and ethyl bromoacetate; brown solid (156mg, 56%); mp 74-75 
°C; 1H NMR (250 MHz, CDCl3) δ 7.15 – 7.07 (m, 2H), 7.02 – 6.94 (m, 2H), 
3.75 – 3.64 (m, 5H), 3.25 (q, J = 2.3 Hz, 2H), 2.84 (t, J = 7.3 Hz, 2H), 2.20 
(t, J = 2.3 Hz, 3H); 13C NMR (63 MHz, CDCl3) δ 176.1, 161.9 (d, J = 245.8 
Hz), 156.0, 154.3, 133.7 (d, J = 3.2 Hz), 130.4 (d, J = 8.0 Hz, 2C), 115.8 (d, 
J = 21.4 Hz, 2C), 103.1, 51.2, 42.1 (d, J = 1.2 Hz), 36.6, 34.5, 12.2; IR (neat, cm-1): 
1687, 1622, 1213; elemental analysis (%) calcd. for C15H16FNO3: C 64.97, H 5.82, 
N 5.05; found: C 64.74, H 5.55, N 5.01. 
 
Methyl 1-(2-(1H-indol-3-yl)ethyl)-2-methyl-5-oxo-4,5-dihydro-1H-pyrrole-3-
carboxylate (1u) 
 
Prepared from methyl acetoacetate (1 mmol), tryptamine (1 mmol) and 
ethyl bromoacetate; light brown solid (107mg, 36%); mp 157 °C; 1H 
NMR (250 MHz, CDCl3) δ 8.29 (s, 1H), 7.60 (d, J = 7.6 Hz, 1H), 7.38 – 7.32 
(m, 1H), 7.24 – 7.16 (m, 1H), 7.16 – 7.07 (m, 1H), 6.98 (d, J = 2.3 Hz, 1H), 
3.82-3.76 (m, 2H), 3.71 (s, 3H), 3.27 (q, J = 2.3 Hz, 2H), 3.08 – 2.97 (m, 
2H),  2.18 (t, J = 2.3 Hz, 3H); 13C NMR (63 MHz, CDCl3) δ 176.2, 164.8, 154.9, 
136.3, 127.2, 122.4, 122.3, 119.7, 118.4, 112.1, 111.5, 102.8, 51.1, 41.2, 36.7, 
24.9, 12.2; IR (neat, cm-1): 3356, 1691, 1622, 1231; elemental analysis (%) calcd. 
for C17H18N2O3: C 68.44, H 6.08, N 9.39; found: C 68.52,H 5.97, N 9.23. 
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Methyl 1-(2-(5-methoxy-1H-indol-3-yl)ethyl)-2-methyl-5-oxo-4,5-dihydro-1H-
pyrrole-3-carboxylate (1v) 
 
Prepared from methyl acetoacetate (1 mmol), 5-methoxytryptamine (1 
mmol) and ethyl bromoacetate; light brown solid (135 mg, 41%); mp 155-
156 °C; 1H NMR (250 MHz, CDCl3) δ 8.13 (br s, 1H), 7.24 (d, J = 8.7 Hz, 1H), 
7.05 (d, J = 2.4 Hz, 1H), 6.95 (d, J = 2.3 Hz, 1H), 6.86 (dd, J = 8.7, 2.4 Hz, 
1H), 3.86 (s, 3H), 3.78 (t, J = 7.3 Hz, 2H), 3.70 (s, 3H), 3.26 (q, J = 2.3 Hz, 
2H), 2.99 (t, J = 7.3 Hz, 2H), 2.18 (t, J = 2.3 Hz, 3H); 13C NMR (63 MHz, CDCl3) δ 176.3, 
164.8, 155.0, 154.2, 131.4, 127.6, 123.1, 112.5, 112.2, 111.8, 102.8, 100.2, 56.0, 51.2, 
41.1, 36.7, 25.0, 12.2; IR (neat, cm-1): 3393, 3322, 1692, 1672, 1628, 1222; elemental 
analysis (%) calcd. for C18H20N2O4: C 65.84, H 6.14, N 8.53; found: C 65.62,H 6.09, N 
8.73. 
3.7.2. Synthesis of 4-benzyloxy-3-methoxybenzaldehydes 2 
To a solution of vanillin and the suitable benzyl chloride in acetonitrile (10 mL) were 
added K2CO3 and IK and the mixture was stirred at reflux for 3 h. The reaction was 
cooled to room temperature, diluted with ethyl acetate (20 mL) and washed with brine 
(2 x 20 mL). The organic layer was dried over sodium sulphate, filtered and the solvent 
was removed under reduced pressure. The solid residue was pulverized and washed 
twice with hexane (3 x 10 mL) to afford the desired aldehydes.  
 
 
4-[(4-Chlorobenzyl)oxy]-3-methoxybenzaldehyde (2a) 
 
Prepared from vanillin (1.41 mmol) and 4-chlorobenzyl chloride (1.55 
mmol); yellow solid (370 mg, 95%); mp: 82 °C; 1H NMR (250 MHz, 
CDCl3) δ 9.87 (s, 1H), 7.46 (d, J = 1.8 Hz, 1H), 7.45 – 7.38 (m, 5H), 6.99 
(d, J = 8.1 Hz, 1H), 5.23 (s, 2H), 3.98 (s, 3H); 13C NMR (63 MHz, CDCl3) δ 191.1, 153.4, 
150.2, 134.6, 134.2, 130.6, 129.1 (2C), 128.7 (2C), 126.7, 112.5, 109.5, 70.2, 56.2; IR 
(neat, cm-1): 1668.3, 1580.4, 1504.2, 1258.3, 1227.2; elemental analysis (%) calcd. for 
C15H13ClO3: C 65.11, H 4.74; found: C 65.22, H 4.68. 
 
4-[(2-Chlorobenzyl)oxy]-3-methoxybenzaldehyde (2b) 
Prepared from vanillin (3.16 mmol) and 2-chlorobenzyl chloride (3.48 
mmol); yellow solid (813 mg, 93%); mp: 48 °C; 1H NMR (250 MHz, 
CDCl3) δ 9.85 (s, 1H), 7.58 – 7.49 (m, 1H), 7.47 – 7.35 (m, 3H), 7.32 – 
7.23 (m, 2H), 6.97 (d, J = 8.1 Hz, 1H), 5.34 (s, 2H), 3.97 (s, 3H); 13C NMR (63 MHz, CDCl3) 
δ 191.1, 153.3, 150.2, 133.8, 132.4, 130.6, 129.6, 129.4, 128.6, 127.3, 126.8, 112.5, 
109.5, 68.0, 56.2; IR (neat, cm-1): 1681.4, 1587.5, 1507.6, 1265.2; elemental analysis 
(%) calcd. for C15H13ClO3: C 65.11, H 4.74; found: C 65.27, H 4.61. 
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4-[(2-Fluorobenzyl)oxy]-3-methoxybenzaldehyde (2c) 
 
Prepared from vanillin (3 mmol) and 2-fluorobenzyl chloride (3.3 
mmol); yellow solid (757 mg, 97%); mp: 62-63 °C; 1H NMR (250 MHz, 
CDCl3) δ 9.67 (s, 1H), 7.34 (td, J = 7.5, 1.7 Hz, 1H), 7.27 – 7.21 (m, 2H), 
7.13 (ddd, J = 7.4, 5.5, 2.0 Hz, 1H), 7.05 – 6.93 (m, 1H), 6.93 – 6.87 (m, 1H), 6.86 (d, J = 
8.2 Hz, 1H), 5.13 (s, 2H), 3.77 (s, 3H); 13C NMR (63 MHz, CDCl3) δ 191.1, 160.4 (d, J = 
246.9 Hz), 153.4, 150.2, 130.6, 130.1 (d, J = 8.2 Hz), 129.6 (d, J = 3.8 Hz), 126.8, 124.6 
(d, J = 3.6 Hz), 123.3 (d, J = 14.1 Hz), 115.6 (d, J = 21.1 Hz), 112.3, 109.5, 64.6 (d, J = 4.6 
Hz), 56.2; IR (neat, cm-1): 1693.9, 1582.9, 1499.6, 1260.5, 1228.9; elemental analysis 
(%) calcd. for C15H13FO3: C 69.22, H 5.03; found: C 68.99, H 4.89. 
 
4-[(4-Fluorobenzyl)oxy]-3-methoxybenzaldehyde (2d) 
 
Prepared from vanillin (2.3 mmol) and 4-fluorobenzyl chloride(2.5 
mmol); yellow solid (573 mg,  88%); mp: 74-75°C; 1H NMR (250 MHz, 
CDCl3) δ 9.84 (s, 1H), 7.49 – 7.33 (m, 4H), 7.14 – 7.02 (m, 2H), 6.98 (d, J 
= 8.0 Hz, 1H), 5.19 (s, 2H), 3.94 (s, 3H); 13C NMR (63 MHz, CDCl3) δ 191.1, 162.8 (d, J = 
246.8 Hz), 153.5, 150.2, 131.9 (d, J = 3.2 Hz), 130.6, 129.3 (d, J = 8.3 Hz, 2C), 126.7, 
115.8 (d, J = 21.6 Hz, 2C), 112.5, 109.5, 70.4, 56.2; IR (neat, cm-1): 1678.9, 1584.5, 
1508.1, 1263.7, 1222.9; elemental analysis (%) calcd. for C15H13FO3: C 69.22, H 5.03; 
found: C 69.05, H 4.95. 
 
3.7.3. General synthesis of 4-arylmethylen-2-pyrrolin-5-ones 3 
In a round bottom flask the suitable 2-pyrrolin-5-one (0.25 mmol, 1 eq) was suspended 
in ethanol (10 mL). Then, the corresponding aldehyde (0.28 mmol, 1.1 eq) and 
piperidine (0.5 mmol, 2 eq) were added. The mixture was refluxed and monitored by 
TLC. Once the 2-pyrrolin-5-one was no longer detected, the reaction was cooled to 
room temperature, diluted with ethyl acetate (20 mL) and washed with water (2 x 
10mL). The organic phase was dried over anhydrous sodium sulphate and then the 
solvent was removed under reduced pressure. The residue was purified by column 
chromatography on silica gel eluting with a gradient from hexane to 1:1 hexane-ethyl 
acetate. 
 
 
 
Methyl (Z)-4-benzylidene-2-methyl-5-oxo-1-phenethyl-4,5-dihydro-1H-pyrrole-3-
carboxylate (3a)  
 
Prepared from pyrrolinone 1r (1 mmol) and piperonal (1.1 mmol); yellow 
solid (235 mg, 60%); mp: 179 °C; 1H NMR (250 MHz, CDCl3) δ 8.17 (d, J = 
1.6Hz, 1H), 8.13 (s, 1H), 7.56 (dd, J = 8.2, 1.6 Hz, 1H), 7.38 – 7.11 (m, 5H), 
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6.88 (d, J = 8.2 Hz, 1H), 6.05 (s, 2H), 3.87 (t, J = 7.3 Hz, 2H), 3.85 (s, 3H), 2.93 (t, J = 7.3 
Hz, 2H,), 2.25 (s, 3H); 13C NMR (63 MHz, CDCl3) δ 166.1, 165.3, 151.9, 149.9, 147.8, 
141.9, 138.6, 129.6, 129.3 (2C), 129.1 (2C), 127.2, 125.1, 111.7, 108.3, 103.9, 101.9, 
51.3, 42.5, 35.8, 13.4; IR (neat, cm-1): 1672.7, 1264.8; elemental analysis (%) calcd. for 
C23H11NO5: C 70.58, H 5.41, N 3.58; found: C 70.38, H 5.32, N 3.36.  
 
Methyl (Z)-4-(2,4-dimethoxybenzylidene)-2-methyl-5-oxo-1-phenethyl-4,5-dihydro-
1H-pyrrole-3-carboxylate (3b)  
 
Prepared from pyrrolinone 1r (0.25 mmol) and 2,4-
dimethoxybenzaldehyde (0.28 mmol); yellow solid (42 mg, 41%); mp: 
126 °C; 1H NMR (250 MHz, CDCl3) δ 8.48 (d, J = 8.8 Hz, 1H), 8.41 (s, 
1H), 7.35 – 7.07 (m, 5H), 6.55 (dd, J = 8.8, 2.4 Hz, 1H), 6.44 (d, J = 2.4 
Hz, 1H), 3.87 (s, 3H), 3.86 (s, 3H), 3.85 – 3.77 (m, 5H), 2.91 – 2.82 (m, 
2H), 2.22 (s, 3H); 13C NMR (63 MHz, CDCl3) δ 166.1, 165.2, 163.2, 160.2, 151.3, 138.5, 
136.6, 133.3, 129.1 (2C), 128.9 (2C), 126.9, 124.2, 116.8, 104.1, 97.9, 55.9, 55.6, 51.0, 
42.2, 35.6, 13.0; IR (neat, cm-1): 1680.6, 1594.6, 1268.6, 1205.0; elemental analysis (%) 
calcd. for C24H25NO5: C 70.75, H 6.18, N 3.44; found: C 70.93, H 6.09, N 3.20. 
 
Methyl (Z)-2-methyl-5-oxo-1-phenethyl-4-(2,4,5-trimethoxybenzylidene)-4,5-
dihydro-1H-pyrrole-3-carboxylate (3c)  
 
Prepared from pyrrolinone 1r (0.25 mmol) and 2,4,5-
trimethoxybenzaldehyde (0.28 mmol); yellow solid (51 mg, 47%); mp: 
141 °C; 1H NMR (250 MHz, CDCl3) δ 8.55 (s, 2H), 7.33 – 7.12 (m, 5H), 
6.49 (s, 1H), 3.95 (m, 6H), 3.90 (s, 3H), 3.85 – 3.79 (m, 5H), 2.89 (t, J = 
7.3 Hz, 2H), 2.20 (s, 3H); 13C NMR (63 MHz, CDCl3) δ 166.0, 165.2, 
155.0, 152.5, 150.9, 142.2, 138.6, 135.8, 129.1 (2C), 128.8 (2C), 126.9, 123.7, 115.9, 
114.8, 104.2, 95.9, 56.8, 56.6, 56.1, 51.0, 42.1, 35.6, 13.0; IR (neat, cm-1): 1675.3, 
1587.8, 1278.9, 1205.3; elemental analysis (%) calcd. for C25H27NO6: C 68.64, H 6.22, N 
3.20; found: C 68.45, H 6.19, N 3.31. 
 
Methyl (Z)-4-[4-[(2-fluorobenzyl)oxy]-3-methoxybenzylidene]-2-methyl-5-oxo-1-
phenethyl-4,5-dihydro-1H-pyrrole-3-carboxylate (3d)  
 
Prepared from pyrrolinone 1r (0.25 mmol) and aldehyde 2c (0.28 
mmol); yellow solid (35 mg, 28%); mp: 94-95°C; 1H NMR (250 MHz, 
CDCl3) δ 8.29 (d, J = 2.0 Hz, 1H), 8.14 (s, 1H), 7.63 (dd, J = 8.7, 1.8 
Hz, 1H), 7.52 (td, J = 7.5, 1.7 Hz, 1H), 7.35 – 7.26 (m, 3H), 7.15 (m, 
4H), 6.93 (d, J = 8.5 Hz, 1H), 6.86 (d, J = 11.2 Hz, 1H), 5.30 (s, 2H), 
3.99 (s, 3H), 3.89 – 3.81 (m, 5H), 2.90 (t, J = 7.2 Hz, 2H), 2.21 (s, 3H); 13C NMR (63 MHz, 
CDCl3) δ 166.0, 165.1, 160.4 (d, J = 246.1 Hz), 151.5, 149.9, 148.8, 141.8, 138.4, 129.8 
(d, J = 8.14 Hz),129.6 (d, J = 3.9 Hz), 129.1 (2C), 128.8 (2C), 128.7, 127.2, 126.9, 124.8, 
124.5 (d, J = 3.6 Hz), 124.0 (d, J = 14.2 Hz), 115.4 (d, J = 21.1 Hz), 115.2, 112.5, 103.7, 
64.4 (d, J = 4.6 Hz), 56.3, 51.0, 42.2, 35.5, 13.2; IR (neat, cm-1): 1675.5, 1586.8, 1267.7, 
1140.2; elemental analysis (%) calcd. for C30H28FNO5: C 71.84,  H 5.63, N 2.79; found: C 
71.64, H 5.62, N 2.81. 
Chapter 3. Neuroprotective compounds related to cinnamic esters and curcumin 
73 
 
 
Methyl (Z)-4-[4-[(4-chlorobenzyl)oxy]-3-methoxybenzylidene]-1-(3,4-
dimethoxyphenethyl)-2-methyl-5-oxo-4,5-dihydro-1H-pyrrole-3-carboxylate (3e)   
 
Prepared from pyrrolinone 1l (0.25 mmol) and aldehyde 2a 
(0.28 mmol); yellow solid (62 mg, 43%); mp: 70 °C; 1H NMR (250 
MHz, CDCl3) δ 8.06 (d, J = 2.0 Hz, 1H), 7.94 (s, 1H), 7.41 (dd, J = 
8.6, 1.8 Hz, 1H), 7.21 – 7.09 (m, 5H), 7.04 (s, 1H), 6.70 – 6.40 (m, 
6H), 4.97 (s, 2H), 3.78 (s, 3H), 3.68 – 3.55 (m, 11H), 2.65 (t, J = 
6.7 Hz, 2H), 1.98 (s, 3H); 13C NMR (63 MHz, CDCl3) δ 166.0, 165.0, 151.6, 149.9, 149.1, 
148.8, 145.0, 141.7, 135.3, 133.9, 131.0, 128.9, 128.8, 128.7, 127.0, 124.9, 121.0, 
115.2, 112.7, 112.2, 111.5, 103.6, 70.1, 56.2, 56.0, 56.0, 51.0, 42.3, 35.0, 13.3; IR (neat, 
cm-1): 1685.9, 1590.4, 1259.1, 1248.0; elemental analysis (%) calcd. for C32H32ClNO7: C 
66.49, H 5.58, N 2.42; found: C 66.74, H 5.41, N 2.41. 
 
Methyl (Z)-4-[4-[(4-chlorobenzyl)oxy]-3-methoxybenzylidene]-2-methyl-5-oxo-1-
phenethyl-4,5-dihydro-1H-pyrrole-3-carboxylate (3f)  
 
Prepared from pyrrolinone 1r (0.25 mmol) and aldehyde 2a (0.28 
mmol); yellow solid (49 mg, 38%); mp: 68-70 °C; 1H NMR (250 
MHz, CDCl3) δ 8.21 (d, J = 2.0 Hz, 1H), 8.06 (s, 1H), 7.54 (dd, J = 
8.7, 1.9 Hz, 1H), 7.37 – 7.05 (m, 9H), 6.78 (d, J = 8.5 Hz, 1H), 5.10 
(s, 2H), 3.91 (s, 3H), 3.81 – 3.72 (m, 5H), 2.82 (t, J = 7.3 Hz, 2H), 
2.13 (s, 3H); 13C NMR (63 MHz, CDCl3) δ 165.9, 165.1, 151.5, 149.9, 148.8, 141.7, 138.4, 
135.3, 133.8, 129.1, 128.9, 128.8, 128.7, 127.0, 126.9, 124.8, 115.2, 112.6, 103.7, 70.0, 
56.2, 51.0, 42.1, 35.5, 13.2; IR (neat, cm-1): 1686.2, 1592.8, 1260.3; elemental analysis 
(%) calcd. for C30H28ClNO5: C 69.56,  H 5.45, N 2.70; found: C 69.22, H 5.27, N 2.68. 
 
Methyl (Z)-4-[4-[(2-chlorobenzyl)oxy]-3-methoxybenzylidene]-2-methyl-5-oxo-1-
phenethyl-4,5-dihydro-1H-pyrrole-3-carboxylate (3g)  
 
Prepared from pyrrolinone 1r (0.25 mmol) and  aldehyde 2b (0.28 
mmol); yellow solid (47 mg, 37%); mp: 112-113 °C; 1H NMR (250 
MHz, CDCl3) δ 8.31 (d, J = 2.0 Hz, 1H), 8.14 (s, 1H), 7.65 – 7.51 (m, 
2H), 7.43 – 7.36 (m, 1H), 7.33 – 7.13 (m, 7H), 6.86 (d, J = 8.5 Hz, 1H), 
5.34 (s, 2H), 4.01 (s, 3H), 3.90 – 3.76 (m, 5H), 2.90 (t, J = 7.3 Hz, 2H), 
2.21 (s, 3H); 13C NMR (63 MHz, CDCl3) δ 166.0, 165.1, 151.5, 149.9, 148.8, 141.8, 138.4, 
134.5, 132.3, 129.5, 129.1, 129.1 (2C), 128.9 (2C), 128.7, 128.6, 127.2 (2C), 126.9, 
124.8, 115.2, 112.6, 103.7, 67.8, 56.3, 51.0, 42.2, 35.5, 13.2; IR (neat, cm-1): 1674.3, 
1586.3, 1274.1; elemental analysis (%) calcd. for C30H28ClNO5: C 66.49,  H 5.58, N 2.42; 
found: C 66.65, H 5.38, N 2.60. 
 
Methyl (Z)-4-[4-[(2-chlorobenzyl)oxy]-3-methoxybenzylidene]-1-(3,4-
dimethoxyphenethyl)-2-methyl-5-oxo-4,5-dihydro-1H-pyrrole-3-carboxylate (3h) 
Prepared from pyrrolinone 1l (0.25 mmol) and  aldehyde 2b (0.28 
mmol); yellow solid (67 mg, 46%); mp 100-101 °C 1H NMR (250 
MHz, CDCl3) δ 8.23 (d, J = 2.0 Hz, 1H), 8.08 (s, 1H), 7.55 (dd, J = 
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8.7, 1.8 Hz, 1H), 7.51 – 7.43 (m, 1H), 7.35 – 7.29 (m, 1H), 7.22 – 7.15 (m, 2H), 6.79 (d, J 
= 8.5 Hz, 1H), 6.72 (d, J = 8.2 Hz, 1H), 6.64 (dd, J = 8.1, 1.9 Hz, 1H), 6.56 (d, J = 1.9 Hz, 
1H), 5.26 (s, 2H), 3.94 (s, 3H), 3.81 – 3.71 (m, 11H), 2.78 (t, J = 7.1 Hz, 2H), 2.12 (s, 3H); 
13C NMR (63 MHz, CDCl3) δ 166.0, 165.0, 151.5, 149.9, 149.1, 148.8, 147.9, 141.8, 
134.5, 132.3, 131.0, 129.4, 129.0, 128.7, 128.6, 127.2 (2C), 124.8, 121.0, 115.2, 112.6, 
112.2, 111.4, 103.6, 67.8, 56.3, 56.0, 56.0, 51.0, 42.3, 35.0, 13.3; IR (neat, cm-1): 
1685.9, 1590.2, 1260.3, 1232.4; elemental analysis (%) calcd. for C32H32ClNO7: C 66.49,  
H 5.58, N 2.42; found: C 66.65, H 5.38, N 2.60. 
 
Methyl (Z)-4-(3,4-dihydroxybenzylidene)-2-methyl-5-oxo-1-phenethyl-4,5-dihydro-
1H-pyrrole-3-carboxylate (3i)  
 
Prepared from pyrrolinone 1r (0.25 mmol) and  3,4-
dihydroxybenzaldehyde (0.28 mmol); yellow solid (23 mg, 24 %); mp: 
159-160 °C; 1H NMR (250 MHz, CDCl3) δ 8.23 (d, J = 1.8 Hz, 1H), 8.15 (s, 
1H), 7.45 (dd, J = 8.3, 1.7 Hz, 1H), 7.32 – 7.19 (m, 3H), 7.17 – 7.09 (m, 
2H), 6.92 (d, J = 8.3 Hz, 1H), 3.98 – 3.75 (m, J = 9.3 Hz, 5H), 2.87 (t, J = 
7.4 Hz, 2H), 2.24 (s, 3H); 13C NMR (63 MHz, CDCl3) δ 166.2, 165.1, 150.7, 147.5, 143.6, 
142.9, 138.2, 129.0 (2C), 128.9 (2C), 127.9, 127.6, 127.0, 124.1, 118.4, 115.0, 104.3, 
51.2, 42.3, 35.5, 13.1; IR (neat, cm-1): 1689.9, 1650.4, 1595.7, 1289.7, 1169.6; 
elemental analysis (%) calcd. for C22H21NO5: C 69.65,  H 5.58, N 3.69; found: C 69.31, H 
5.31, N 3.49. 
 
Methyl (Z)-2-methyl-5-oxo-1-phenethyl-4-(3,4,5-trimethoxybenzylidene)-4,5-
dihydro-1H-pyrrole-3-carboxylate (3j)  
 
Prepared from pyrrolinone 1r (0.25 mmol) and 2,4,5-
trimethoxybenzaldehyde (0.28 mmol); yellow solid (58 mg, 53%); mp: 
170 °C; 1H NMR (250 MHz, CDCl3) δ 8.15 (s, 1H), 7.64 (s, 2H), 7.35 – 
7.12 (m, 5H), 3.93 (s, 6H), 3.91 (s, 3H), 3.88 – 3.82 (m, 5H), 2.90 (t, J = 
7.2 Hz, 2H), 2.20 (s, 3H); 13C NMR (63 MHz, CDCl3) δ 165.8, 165.0, 
152.6 (2C), 152.1, 141.7, 140.1, 138.4, 130.3, 129.1 (2C), 128.8 (2C), 126.9 (2C), 125.9, 
109.8, 103.5, 61.1, 56.4 (2C), 51.1, 42.1, 35.5, 13.3; IR (neat, cm-1): 3255.4, 1688.5, 
1651.8, 1593.2, 1386.6, 1365.7, 1226.7; elemental analysis (%) calcd. for C25H27NO6: C 
74.59,  H 5.74, N 7.25; found: C 73.45, H 5.66, N 7.22. 
 
Methyl (Z)-4-(3-hydroxy-4-methoxybenzylidene)-2-methyl-5-oxo-1-phenethyl-4,5-
dihydro-1H-pyrrole-3-carboxylate (3k)  
 
Prepared from pyrrolinone 1r (0.25 mmol) and 3-hydroxy-4-
methoxybenzaldehyde (0.28 mmol); yellow solid (35 mg, 36%); mp: 
192 °C; 1H NMR (250 MHz, CDCl3) δ 9.72 (br s, 1H), 8.35 (s, 1H), 7.38 (d, 
J = 8.8 Hz, 1H), 7.35 – 7.22 (m, 3H), 7.20 – 7.11 (m, 2H), 6.67 (d, J = 2.6 
Hz, 1H), 6.60 (dd, J = 8.8, 2.6 Hz, 1H), 4.00 – 3.89 (m, 2H), 3.85 (s, 3H), 
3.83 (s, 3H), 2.93 (t, J = 7.3 Hz, 2H), 2.27 (s, 3H), 13C NMR (63 MHz, CDCl3) δ 168.1, 
164.9, 164.3, 161.1, 148.9, 141.4, 138.0, 137.9, 129.0 (2C), 128.9 (2C), 127.01, 121.7, 
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118.8, 109.5, 105.4, 105.4, 55.7, 51.2, 42.7, 35.4, 12.8.; IR (neat, cm-1): 1651.1, 1588.5, 
1286.1, 1195.3; elemental analysis (%) calcd. for C23H23NO5: C  
 
Methyl (Z)-1-benzyl-4-benzylidene-2-methyl-5-oxo-4,5-dihydro-1H-pyrrole-3-
carboxylate (3l)  
 
Prepared from pyrrolinone 1f (1 mmol) and benzaldehyde (1.1 mmol); 
yellow solid (167 mg, 50%); mp: 83-86 °C; 1H NMR (250 MHz, CDCl3) δ 
8.28 (s, 1H), 8.22-8.11 (m, 2H), 7.54-7.14 (m, 8H), 4.90 (s, 2H), 3.87 (s, 3H), 
2.45 (s, 3H); 13C NMR (63 MHz, CDCl3) δ 166.2, 165.2, 153.4, 142.2, 137.1, 
135.0, 132.1 (2C), 130.5, 129.3 (2C), 128.4 (2C), 128.0, 127.2 (2C), 126.8, 104.3, 51.4, 
43.8, 14.2; IR (neat, cm-1): 1684, 1599, 1193; elemental analysis (%) calcd. for 
C21H19NO3: C 75.66, H 5.74, N 4.20; found: C 75.55, H 5.68, N 4.18. 
 
Methyl (Z)-1-benzyl-4-(4-methoxybenzylidene)-2-methyl-5-oxo-4,5-dihydro-1H-
pyrrole-3-carboxylate (3m) 
 
Prepared from pyrrolinone 1f (1 mmol) and 4-methoxybenzaldehyde 
(1.1 mmol); yellow solid (218 mg, 60%); mp: 121-124 °C; 1H NMR (250 
MHz, CDCl3) δ 8.39-8.08 (m, 3H), 7.47-7.10 (m, 5H), 7.03-6.83 (m, 2H), 
4.93 (s, 2H), 3.89 (s, 3H), 3.86 (s, 3H), 2.44 (s, 3H); 13C NMR (63 MHz, 
CDCl3) δ 166.1, 165.1, 161.5, 151.3, 142.1, 137.0, 134.5 (2C), 132.4, 129.0 (2C), 127.7, 
126.9 (2C), 124.3, 113.6 (2C), 104.2, 55.5, 51.0, 43.5, 13.8; IR (neat, cm-1): 1679.0, 
1589.4, 1254.4; elemental analysis (%) calcd. for C22H21NO4: C 72.71, H 5.82, N 3.85; 
found: C 72.46, H 5.84, N 3.92. 
 
Methyl (Z)-1-benzyl-4-(4-chlorobenzylidene)-2-methyl-5-oxo-4,5-dihydro-1H-pyrrole-
3-carboxylate (3n)  
 
Prepared from pyrrolinone 1f (1 mmol) and 4-chlorobenzaldehyde (1.1 
mmol); yellow solid (166 mg, 45%); mp: 97-100 °C; 1H NMR (250 MHz, 
CDCl3) δ 8.09 (s, 1H), 8.00 (d, J = 8.4 Hz, 2H), 7.35-7.20 (m, 5H), 7.16-
7.06 (m, 2H), 4.81 (s, 2H), 3.76 (s, 3H), 2.36 (d, J = 0.6 Hz, 3H); 13C NMR 
(63 MHz, CDCl3) δ 166.2, 165.1, 153.6, 140.6, 136.9, 136.3, 133.4 (2C), 129.4, 129.3 
(2C), 128.7 (2C), 128.1, 127.3, 127.1 (2C), 104.2, 51.4, 43.8, 14.2; IR (neat, cm-1): 1691, 
1677, 1602, 1196; elemental analysis (%) calcd. for C21H18ClNO3: C 68.57, H 4.93, N 
3.81; found: C 68.20, H 4.88, N 3.81. 
 
Methyl (Z)-4-[(1H-indol-3-yl)methylene]-2-methyl-5-oxo-1-phenethyl-4,5-dihydro-1H-
pyrrole-3-carboxylate (3o)  
 
Prepared from pyrrolinone 1r (0.25 mmol) and  indol-3-carboxaldehyde 
(0.28 mmol); yellow solid (28 mg, 30%); mp: 223-224°C; 1H NMR (250 
MHz, d6-DMSO) δ 12.08 (br s, 1H), 9.42 (d, J = 2.8 Hz, 1H), 8.56 (s, 1H), 
7.83 – 7.71 (m, 1H), 7.58 – 7.48 (m, 1H), 7.38 – 7.12 (m, 7H), 3.89 (t, J = 
7.3 Hz, 2H), 3.81 (s, 3H), 2.87 (t, J = 7.3 Hz, 2H), 2.32 (s, 3H); 13C NMR (63 
MHz, d6-DMSO) δ 165.3, 164.5, 148.8, 138.6, 136.0, 133.2, 129.5, 128.9 (2C), 128.5 
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(2C), 128.4, 126.5, 122.6, 121.0, 119.3, 117.4, 112.5, 111.7, 102.1, 50.8, 41.3, 34.7, 
12.6; ; IR (neat, cm-1): 1702.4, 1583.3, 1326.7, 1230.4; elemental analysis (%) calcd. for 
C24H22N2O3: C 68.64,  H 6.22, N 3.20; found: C 68.49, H 6.02, N 3.32. 
 
Methyl (Z)-4-benzylidene-1-butyl-2-methyl-5-oxo-4,5-dihydro-1H-pyrrole-3-
carboxylate (3p)  
 
Prepared from pyrrolinone 1b (1 mmol) and benzaldehyde (1.1 mmol); 
yellow solid (210 mg, 70%), mp: 84-87 °C; 1H NMR (250 MHz, CDCl3) δ 
8.14 (s, 1H), 8.11-7.99 (m, 2H), 7.45-7.30 (m, 3H), 3.84 (s, 3H), 3.68-3.52 
(m, 2H), 2.53 (d, J = 0.5 Hz, 3H), 1.67-1.47 (m, 2H), 1.44-1.22 (m, 2H), 0.93 
(t, J = 7.2 Hz, 3H); 13C NMR (63 MHz, CDCl3) δ 166.1, 165.3, 155.9, 153.5, 141.6, 135.1, 
131.9 (2C), 130.3, 128.3 (2C), 127.1, 51.3, 40.4, 31.9, 20.6, 14.2, 13.8; IR (neat, cm-1): 
1699, 1689, 1601, 1213; elemental analysis (%) calcd. for C18H21NO3: C 72.22, H 7.07, 
N 4.68; found: C 72.17, H 6.94, N 4.59. 
 
Ethyl (Z)-4-benzylidene-1-butyl-2-methyl-5-oxo-4,5-dihydro-1H-pyrrole-3-carboxylate 
(3q) 
 
Prepared from pyrrolinone 1a (1 mmol) and benzaldehyde (1.1 mmol); 
yellow solid (179 mg, 57%); mp: 161-163 °C; 1H NMR (250 MHz, CDCl3) δ 
8.20 (s, 1H), 7.41 (dd, J = 4.8, 2.5 Hz, 2H), 7.43-7.29 (m, 3H), 4.35 (q, J = 7.1 
Hz, 2H), 3.64 (t, J = 7.6 Hz, 2H), 2.56 (s, 3H), 1.66-1.51 (m, 2H), 1.42 (t, J = 
7.1 Hz, 3H), 1.42-1.30 (m, 2H), 0.96 (t, J = 7.2 Hz, 3H); 13C NMR (63 MHz, CDCl3) δ 
166.2, 164.8, 153.3, 141.6, 135.1, 131.9 (2C), 130.3, 128.4 (2C), 127.2, 103.9, 60.2, 
40.3, 31.9, 20.6, 14.9, 14.2, 13.8; IR (neat, cm-1): 1672, 1158; elemental analysis (%) 
calcd. for C19H23NO3: C 72.82, H 7.40, N 4.47; found: C 72.85, H 7.34, N 4.51. 
 
Methyl (Z)-1-benzyl-4-(4-bromobenzylidene)-2-methyl-5-oxo-4,5-dihydro-1H-pyrrole-
3-carboxylate (3r) 
 
Prepared from pyrrolinone 1f (1 mmol) and 4-bromobenzaldehyde (1.1 
mmol); yellow solid (219 mg, 53%); mp: 136 °C; 1H NMR (250 MHz, 
CDCl3) δ 8.16 (s, 1H), 8.02 (d, J = 8.5 Hz, 2H), 7.55 (d, J = 8.5, 2H), 7.48-
7.14 (m, 5H), 4.90 (s, 2H), 3.86 (s, 3H), 2.45 (s, 3H); 13C NMR (63 MHz, 
CDCl3) δ 166.2, 165.1, 153.7, 140.6, 136.9, 133.8, 133.6 (2C), 131.6 (2C), 129.3 (2C), 
128.1, 127.3, 127.2 (2C), 124.9, 104.2, 51.4, 43.8, 14.2; IR (neat, cm-1): 1691.8, 1674.4, 
1602.0, 1196.6; elemental analysis (%) calcd. for C21H18BrNO3: C 61.18, H 4.40, N 3.40; 
found: C 60.99, H 4.38, N 3.26. 
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3.7.4. Curcumin analogues 4 
 
 
 
a) Preparation of the cinnamoyl chloride derivatives144 
The suitable cinnamic acid derivative (1 mmol) was suspended in hexane (3.0 mL) and 
anhydrous DMF (0.008 mL, 0.1 mmol) and oxalyl chloride (0.17 mL, 2 mmol) were 
added. The reaction mixture was stirred at rt for 2 h. The hexane was removed under 
vacuum to provide the crude cinnamoyl chloride derivative, which was immediately 
used in the next step without further purification. 
 
b) Synthesis of curcumin analogues 4  
A solution of the corresponding pyrrolinone derivative 1 (0.5 mmol) in THF (5 mL) was 
cooled to -78 °C and a 1.0 M solution of lithium hexamethyldisilazide (1.5 mL, 1.5 
mmol) in THF was added. After 30 min, a solution of the adequate cinnamoyl chloride 
derivative (1 mmol) in THF (2 mL) was cannulated into the reaction, and the mixture 
was stirred for 30 min. Then, saturated aqueous NH4Cl solution was added, and the 
reaction was warmed to room temperature. The mixture was acidified (HCl 1M) and 
extracted with ethyl ether (3 x 20 mL). The combined organic layers were dried over 
anhydrous sodium sulphate, the solvent was removed in vacuo, and the residue was 
purified by column chromatography on silica gel eluting with a gradient from hexane 
to 1:1 hexane-ethyl acetate.145 
 
Methyl (Z)-1-(4-fluorophenethyl)-4-((E)-1-hydroxy-3-(3,4,5-
trimethoxyphenyl)allylidene)-2-methyl-5-oxo-4,5-dihydro-1H-pyrrole-3-carboxylate 
(4a) 
Prepared from pyrrolinone 1t (0.5 mmol) and 3,4,5-
trimethoxycinnamoyl chloride (1 mmol); orange solid (100 mg, 
40%); mp: 143-144 °C; 1H NMR (250 MHz, CDCl3) δ 14.00 (d, J = 
 
144  Kourra, C.; Klotter, F.; Sladojevich, F.; Dixon, D. J. Org. Lett. 2012, 14, 1016-1019. 
145  Riggs, R. L.; Morton, C. J.; Slawin, A. M.; Smith, D. M.; Westwood, N. J.; Austen, W. S.; Stuart, K. E. 
Tetrahedron 2005, 61, 11230-11243. 
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1.5 Hz, 1H), 8.62 (dd, J = 15.8, 1.5 Hz, 1H), 7.64 (d, J = 15.8 Hz, 1H), 7.20 – 7.09 (m, 2H), 
7.01 (t, J = 8.6 Hz, 2H), 6.91 (s, 2H), 3.95 (s, 6H), 3.93 – 3.89 (m, 8H), 2.92 (t, J = 7.1 Hz, 
2H), 2.16 (s, 3H); 13C NMR (63 MHz, CDCl3) δ 170.1, 167.7, 164.7, 162.2 (d, J = 245.4 Hz) 
153.8 (2C), 148.8, 139.8, 139.7, 134.4 (d, J = 3.3 Hz), 132.4, 130.8 (d, J = 3.3 Hz, 2C), 
120.7, 116.2 (d, J = 21.3 Hz, 2C), 105.7 (2C), 103.4, 102.3, 61.4, 56.6 (2C), 53.0, 42.6 (d, 
J = 1.2 Hz), 34.9, 13.9; IR (neat, cm-1):1673.4, 1620.6, 1581.8, 1440.6, 1315.6; 
elemental analysis (%) calcd. for C27H28FNO7: C 65.18, H 5.67, N 2.82; found: C 64.87, 
H 5.69, N 2.88. 
 
Methyl (Z)-1-butyl-4-((E)-1-hydroxy-3-(3,4,5-trimethoxyphenyl)allylidene)-2-methyl-
5-oxo-4,5-dihydro-1H-pyrrole-3-carboxylate (4b) 
 
Prepared from pyrrolinone 1b (0.5 mmol) and 3,4,5-
trimethoxycinnamoyl chloride (1 mmol); orange solid (83 mg, 
38%); mp: 128-129 °C; 1H NMR (250 MHz, CDCl3) δ 13.97 (d, J = 
1.5 Hz, 1H), 8.60 (dd, J = 15.8, 1.5 Hz, 1H), 7.61 (d, J = 15.8 Hz, 1H), 
6.90 (s, 2H), 3.99 – 3.87 (m, 12H), 3.76 – 3.66 (m, 2H), 2.52 (s, 3H), 1.66 – 1.52 (m, 2H), 
1.46 – 1.34 (m, 2H), 0.98 (t, J = 7.2 Hz, 3H); 13C NMR (63 MHz, CDCl3) δ 170.1, 167.8, 
164.4, 153.7 (2C), 149.0, 139.7, 139.4, 132.8, 120.6, 105.6 (2C), 103.6, 102.3, 61.4, 56.6 
(2C), 53.0, 40.6, 32.0, 20.6, 14.3, 14.2; IR (neat, cm-1): 1671.4, 1620.9, 1579.2, 1500.7, 
1314.8, 1120.5; elemental analysis (%) calcd. for C23H29NO7: C 64.02, H 6.77, N 3.25; 
found: C 63.97, H 6.59, N 3.27. 
 
Methyl (Z)-1-benzyl-4-((E)-1-hydroxy-3-(3,4,5-trimethoxyphenyl)allylidene)-2-methyl-
5-oxo-4,5-dihydro-1H-pyrrole-3-carboxylate (4c) 
 
Prepared from pyrrolinone 1f (0.5 mmol) and 3,4,5-
trimethoxycinnamoyl chloride (1 mmol); orange solid (72 mg, 31%); 
mp: 205 °C; 1H NMR (250 MHz, CDCl3) δ 14.02 (br s, 1H), 8.67 (d, J 
= 15.7 Hz, 1H), 7.65 (d, J = 15.7 Hz, 1H), 7.40 – 7.26 (m, 3H), 7.18 (d, 
J = 6.8 Hz, 2H), 6.91 (s, 2H), 5.00 (s, 2H), 3.94 (s, 6H), 3.92 (s, 3H), 3.91 (s, 3H), 2.40 (s, 
3H); 13C NMR (63 MHz, CDCl3) δ 170.2, 167.8, 164.8, 153.7 (2C), 149.1, 139.7, 139.7, 
137.1, 132.4, 129.3 (2C), 127.9, 126.9 (2C), 120.6, 105.6 (2C), 103.4, 102.8, 61.4, 56.6 
(2C), 53.0, 43.8, 14.6; IR (neat, cm-1): 1674.1, 1631.1, 1583.3, 1447.2, 1416.5, 1314.9, 
1117.2; elemental analysis (%) calcd. for C26H27FNO7: C 67.01, H 5.85, N 3.01; found: C 
66.84, H 5.68, N 3.29. 
 
Methyl (Z)-1-(4-fluorobenzyl)-4-((E)-1-hydroxy-3-(3,4,5-trimethoxyphenyl)allylidene)-
2-methyl-5-oxo-4,5-dihydro-1H-pyrrole-3-carboxylate (4d) 
 
Prepared from pyrrolinone 1s (0.5 mmol) and 3,4,5-
trimethoxycinnamoyl chloride (1 mmol); orange solid (50 mg, 
22%); mp: 169-170 °C; 1H NMR (250 MHz, CDCl3) δ 14.02 (d, J = 
1.6 Hz, 1H), 8.65 (dd, J = 15.8, 1.6 Hz, 1H), 7.66 (d, J = 15.8 Hz, 
1H), 7.24 – 7.12 (m, 2H), 7.12 – 6.97 (m, 2H), 6.91 (s, 2H), 4.96 (s, 
2H), 3.97 – 3.92 (m, 9H), 3.91 (s, 3H), 2.41 (s, 3H); 13C NMR (63 MHz, CDCl3) δ 170.1, 
167.8, 165.1, 162.6, (d, J = 246.3 Hz) 153.7 (2C), 148.5, 139.9, 139.8, 132.9 (d, J = 3.2 
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Hz), 132.3, 128.7 (2C, d, J = 8.2 Hz), 120.5, 116.2 (2C, d, J = 21.5 Hz), 105.7 (2C), 103.2, 
103.0, 61.4, 56.6 (2C), 53.1, 43.2, 14.6; IR (neat, cm-1): 1673.4, 1630.4, 1582.9, 1501.3, 
1444.2, 1315.9, 1220.1, 1117.3; elemental analysis (%) calcd. for C26H26FNO7: C 64.54, 
H 5.42, N 2.90; found: C 64.48, H 5.22, N 2.97. 
 
Ethyl (Z)-1-butyl-4-((E)-1-hydroxy-3-(3,4,5-trimethoxyphenyl)allylidene)-2-methyl-5-
oxo-4,5-dihydro-1H-pyrrole-3-carboxylate (4e) 
 
Prepared from pyrrolinone 1a (0.5 mmol) and 3,4,5-
trimethoxycinnamoyl chloride (1 mmol);orange solid (87 mg, 
39%); mp: 131-132 °C; 1H NMR (250 MHz, CDCl3) δ 14.08 (d, J = 
1.5 Hz, 1H), 8.60 (dd, J = 15.7, 1.5 Hz, 1H), 7.60 (d, J = 15.7 Hz, 1H), 
6.89 (s, 2H), 4.39 (q, J = 7.0 Hz, 2H), 3.93 (s, 6H), 3.89 (s, 3H), 3.71 
(t, J = 7.3 Hz, 2H), 2.52 (s, 3H), 1.66 – 1.52 (m, 2H), 1.46 – 1.34 (m, 5H), 0.97 (t, J = 7.0 
Hz, 3H); 13C NMR (63 MHz, CDCl3) δ 169.7, 167.8, 164.4, 153.7 (2C), 148.9, 139.6, 
139.3, 132.5, 120.7, 105.6 (2C), 103.7, 102.5, 62.3, 61.4, 56.6 (2C), 40.5, 32.0, 20.6, 
14.8, 14.3, 14.2; IR (neat, cm-1): 1664.8, 1620.5, 1598.6, 1579.7, 1414.8, 1316.5, 
1121.8; elemental analysis (%) calcd. for C24H31NO7: C 64.70, H 7.01, N 3.14; found: C 
64.50, H 6.84, N 3.43. 
 
Methyl (Z)-1-butyl-4-((E)-1-hydroxy-3-(4-hydroxy-3-methoxyphenyl)allylidene)-2-
methyl-5-oxo-4,5-dihydro-1H-pyrrole-3-carboxylate (4f) 
 
Prepared from pyrrolinone 1b (0.5 mmol) and feruloyl chloride (1 
mmol) ; orange solid (30 mg, 15%); mp: 156-157 °C; 1H NMR (250 
MHz, CDCl3) δ 13.93 (d, J = 1.6 Hz, 1H), 8.55 (dd, J = 15.8, 1.6 Hz, 
1H), 7.60 (d, J = 15.8 Hz, 1H), 7.21 – 7.14 (m, 2H), 6.89 (d, J = 8.7 
Hz, 1H), 5.92 (br s, 1H), 3.94 (s, 3H), 3.91 (s, 3H), 3.73 – 3.63 (m, 2H), 2.48 (s, 3H), 1.61 
– 1.47 (m, 2H), 1.43 – 1.30 (m, 2H), 0.94 (t, J = 7.2 Hz, 3H); 13C NMR (63 MHz, CDCl3) δ 
169.8, 167.4, 164.7, 148.2, 147.3, 146.8, 139.4, 129.2, 123.2, 118.6, 114.7, 109.7, 
102.8, 102.0, 56.2, 52.6, 40.3, 31.7, 20.3, 13.9 (2C); IR (neat, cm-1):2955.8, 2630.3, 
2870.6, 1698.1, 1647.8, 1619.9, 1587.0, 1571.6, 1322.31284.7, 1117.3, 978.3, 748.8; 
elemental analysis (%) calcd. for C21H25NO6: C 65.10, H 6.50, N 3.62; found: C 64.93, H 
6.38, N 3.93. 
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4.1. Neuroprotective spirooxindole alkaloids 
Spirocyclic frameworks are present in many natural products and are increasingly 
recognized as interesting scaffolds in drug discovery programs.146 Spiropyrrolidines, in 
particular, have shown interesting pharmacological activities including 
antiproliferative147 and antitubercular148 properties, as well as acetylcholinesterase 
inhibition,149 among others. Spiropyrrolidine cores are present in numerous natural 
products, such as (−)-horsfiline, spirotryprostatin A and the Uncaria rhynchophylla 
alkaloids.  
The dried stem and hook of Uncaria rhynchophylla, also known as cat’s claw, have a 
variety of uses in traditional herbal medicine including the treatment of convulsions, 
hypertension, headache and dizziness.150, 151, 152 Uncaria rhynchophylla contains a 
broad spectra of spirooxindole alkaloids (Figure 4.1), most notably the one that is 
named after the plant (rhynchophylline). Evidence is accumulating that shows that the 
pharmacological activities of Uncaria rhynchophylla are associated with the presence 
of rhynchophylline and this has encouraged the investigation of this alkaloid as a drug 
candidate for neurodegenerative disorders.151, 153 Recent studies have highlighted the 
ability of rhynchophylline to penetrate the blood-brain barrier.154 This alkaloid exerted 
neuroprotection in CNS disease models, and was proposed to act via a non-
competitive antagonism of NMDA receptors.155 In addition, rhynchophylline improves 
 
146 For a review of the use of  spirocyclic scaffolds in drug discovery, see: Zheng, Y.; Tice, C. M.; Singh, S. 
B. Bioorg. Med. Chem. Lett. 2014, 24, 3673-3682. 
147  Almansour, A. I.; Suresh Kumar, R.; Beevi, F.; Shirazi, A. N.; Osman, H.; Ismail, R.; Choon, T. S.; 
Sullivan, B.; McCaffrey, K.; Nahhas, A.; Parang, K.; Ashraf Ali, M. Molecules 2014, 19, 10033-10055. 
148  (a) Ranjith Kumar, R.; Perumal, S.; Senthilkumar, P.; Yogeeswari, P.; Sriram, D. J. Med. Chem. 2008, 
51, 5731-5735. (b) Kumar, R.; Perumal, S.; Senthilkumar, P.; Yogeeswari, P.; Sriram, D. Eur. J. Med. 
Chem. 2009, 44, 3821-3829. (c) Suresh Kumar, R.; Rajesh, S. M.; Perumal, S.; Banerjee, D.; 
Yogeeswari, P.; Sriram, D. Eur. J. Med. Chem. 2010, 45, 411-422. (d) Rajesh, S. M.; Perumal, S.; 
Menéndez, J. C.; Yogeeswari, P.; Sriram, D. Med. Chem. Commun. 2011, 2, 626-630. 
149  (a) Kia, Y.; Osman, H.; Suresh Kumar, R.; Murugaiyah, V.; Basiri, A.; Perumal, S.; Wahab, H. A.; Bing, C. 
S. Bioorg. Med. Chem. 2013, 21, 1696-1707. (b) Kia, Y.; Osman, H.; Suresh Kumar, R.; Basiri A.; 
Murugaiyah, V. Bioorg. Med. Chem. 2014, 22, 1318-1328. 
150  Zhou, J.; Zhou, S. J. Ethnopharmacol. 2010, 132, 15-27. 
151  Ng, Y. P.; Or, T. C.; Ip, N. Y. Neurochem. Int. 2015, 89, 260-270. 
152  Shao, H.; Yang, Y.; Mi, Z.; Zhu, G. X.; Qi, A. P.; Ji, W. G.; Zhu, Z. R. Neuroscience 2016, 337, 355-369. 
153  Hu, S.; Mak, S.; Zuo, X.; Li, H.; Wang, Y.; Han, Y. Front. Pharmacol. 2018, 9, 768. 
154  Lee, C. J.; Hsueh, T. Y.; Lin, L. C.; Tsai, T. H. Biomed. Chromatogr. 2014, 28, 901-906. 
155  Kang, T. H.; Murakami, Y.; Matsumoto, K.; Takayama, H.; Kitajima, M.; Aimi, N.; Watanabe, H. Eur. J. 
Pharmacol. 2002, 455, 27-34. 
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hippocampal synaptic function in Alzheimer mouse models through the blockade of 
EphA4 signalling.156  
Some recent findings also support the potential beneficial effect of rhynchophylline in 
Parkinson´s disease treatment, as it improves the survival of primary CGNs neurons 
following cellular toxicity caused by 1-methyl-4 phenylpyridium (MPPC). 
 
 
Figure 4.1 
 
Besides NMDA antagonism, rhynchophylline activates the PI3K/Akt/mTOR signalling 
pathway. PI3K activation leads to Akt phosphorylation, and phosphorylated Akt causes 
the inactivation of GSK-3β (Figure 4.2). GSK-3β inhibition has been proved to have a 
neuroprotective effect in several neurodegenerative diseases. Among other effects, 
GSK-3β promotes Nrf2 cytosolic distribution through two different mechanisms of 
control: (a) preventing the translocation of Nrf2 to the nucleus, by phosphorylating 
Nrf2 and promoting its degradation by the proteasome; 157  (b) enhancing Nrf2 
exclusion from the nucleus mediated by the tyrosine kinase Fyn that is, in turn, 
activated by GSK-3β. 158 , 159  Therefore, GSK-3β inhibition promotes the nuclear 
accumulation of Nrf2 and the activation of the ARE transcription.160, 161 
On the other hand, GSK-3β inhibition potentiates the activity of myocyte enhancer 
transcription factor (MEF2D). Extensive evidence has accumulated showing a link 
 
156  Fu, A. K.; Hung, K. W.; Huang, H.; Gu, S.; Shen, Y.; Cheng, E. Y.; Ip, F. C.; Huang, X.; Fu, W. Y.; Ip, N. Y. 
Proc. Natl. Acad. Sci. U.S.A. 2014, 111, 9959-9964. 
157  Chowdhry, S.; Zhang, Y.; McMahon, M.; Sutherland, C.; Cuadrado, A.; Hayes, J. D. Oncogene 2013, 
32, 3765-3781. 
158  Jain, A. K.; Jaiswal, A. K. J. Biol. Chem. 2006, 281, 12132-12142 
159  Jain, A. K.; Jaiswal, A. K. J. Biol. Chem. 2007, 282, 16502-16510. 
160  Rojo, A. I.; de Sagarra, M. R.; Cuadrado, A. J. Neurochem. 2008, 105, 192-202. 
161  Rojo, A. I.; Rada, P.; Egea, J.; Rosa, A. O.; López, M. G.; Cuadrado, A. Mol. Cell. Neurosci. 2008, 39, 
125-132. 
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between MEF2D and PD,162 and that MEF2D levels were robustly decreased in the 
post-mortem brain of Parkinson’s patients.163 Furthermore, various animal and cellular 
models highlighted the importance of MEF2D in neuronal survival. 164, 165 
The PI3K/Akt/mTOR signalling pathway is also involved in autophagy. The 
Rhynchophylla extracts are known to induce autophagy,166 and in particular corynoxine 
has been shown to induce autophagy in an mTOR-dependent manner and promote α-
synuclein clearance.167 Consequently, activation of PI3K/Akt/mTOR signalling pathway 
is a significant mechanism in attenuating neurotoxicity such as damage to 
dopaminergic cells observed after exposure to PD-related toxins. 
 
Figure 4.2 
 
162 Yang, Q.; She, H.; Gearing, M.; Colla, E.; Lee, M.; Shacka, J. J.; Mao, Z. Science 2009, 323, 124-127. 
163 She, H.; Yang, Q.; Shepherd, K.; Smith, Y.; Miller, G.; Testa, C.; Mao, Z. J. Clin. Invest. 2011, 121, 930-
940. 
164 Mount, M. P.; Zhang, Y.; Amini, M.; Callaghan, S.; Kulczycki, J.; Mao, Z.; Slack, R. S.; Anisman, H.; Park, 
D. S. J. Biol. Chem. 2013, 288, 14362-14371. 
165 Guo, B.; Hu, S.; Zheng, C.; Wang, H.; Luo, F.; Li, H.; Cui, W.; Yang, X.; Cui, G.; Mak, S.; Choi, T. C.; Ma, 
E. D.; Wang, Y.; Lee, S. M. Y.; Zhang, Z.; Han, Y. Neuropharmacology 2017, 126, 12-24. 
166 Li, C.; Jiang, F.; Li, Y. L.; Jiang, Y. H.; Yang, W. Q.; Sheng, J.; Xu W. J.; Zhu, Q. J. Acta Pharmacol. Sin. 
2018, 39, 345-356. 
167  Chen, L. L.; Song, J. X.; Lu, J. H.; Yuan, Z. W.; Liu, L. F.; Durairajan, S. S. K.; Li, M. J. Neuroimmune 
Pharmacol. 2014, 9, 380-387. 
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4.2. Compound design 
In this context, we have designed and synthesized two families of related dispiro 
compounds 5 and 6 that show a closely similarity to rhynchophylline in terms of three-
dimensional structure, placing the most characteristic moieties in the same spatial 
region. As shown in Figure 4.3, the oxindole (green) and pyrrolidine (red) rings are 
completely overlapped in both structures. Hydrophobic moieties (blue) such as the 
phenyl group of compound 3a and ethyl from rhynchophylline are placed in the same 
region. The polar ester functions from both structures are also paired in a closely 
similar spatial arrangement (purple). 
 
Figure 4.3 
4.3. Synthesis of dispiroxoindoles 5 and 6 via a multicomponent [3+2] 
dipolar cycloaddition 
We envisaged the possibility to prepare dispiro frameworks 5 and 6 by combining our 
initial Hantzsch-like MCR leading to pyrrolinones with a second one, namely a three-
component reaction involving as the key step a [3+2] dipolar cycloaddition of non-
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stabilized azomethine ylides with activated olefins,168 with the previously described 
Knoevenagel condensation acting as the link between both MCRs. The combination of 
two multicomponent reactions is an excellent approach to the generation of molecular 
diversity, although it has not been widely exploited.169, 170 
The azomethine ylides required as the dipole element of the cycloaddition were 
prepared in situ from isatin derivatives and α-amino acids, and were reacted with 
selected compounds 4, acting as dipolarophiles, under focused microwave irradiation 
at 100 °C in ethanol solution (Scheme 4.1 and Table 4.1). The target dispiro compounds 
were obtained with full regio- and diastereoselection, generally in good yields. 
Probably because of steric hindrance, the reaction was more efficient in the case of 
reactions starting from sarcosine in comparison to those involving the use of proline.  
 
Scheme 4.1 
  
 
168  For a review of the use of multicomponent 1,3-dipolar cycloaddition reactions in the synthesis of 
spiroheterocycles, see: Arumugam, N.; Suresh Kumar, R.; Almansour A. I.; Perumal, S. Curr. Org. 
Chem. 2013, 17, 1929-1956. 
169  For a review of methods for the design of multicomponent reactions towards molecular diversity and 
complexity, see: Ruijter, E.; Scheffelaar, R.; Orru, R. V. A. Angew. Chem. Int. Ed. 2011, 50, 6234-6246. 
170  For a review of the combination of multicomponent and multi-catalysis cascade reactions, see: 
Ramachary, D. B.; Jain, S. Org. Biomol. Chem. 2011, 9, 1277-1300. 
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Table 4.1. Results obtained in the synthesis of dispiro compounds 5 and 6 
Entry Cmpd R1 R2 R3 R4 R5 Yield (%) 
1 5a n-Bu Me H H H 50 
2 5b n-Bu Me H Cl H 56 
3 5c Bn Me H Cl H 73 
4 5d Bn Me H I H 52 
5 5e Bn Me H Me H 55 
6 5f Bn Me H H H 65 
7 5g Bn Me H H Bn 75 
8 5h Bn Me OMe H Bn 68 
9 5i Bn Me OMe H H 55 
10 5j Bn Me OMe Cl H 73 
11 5k Bn Me OMe I H 50 
12 5l Bn Me OMe Me H 54 
13 5m Bn Me Cl H H 78 
14 5n Bn Me Br H H 88 
15 6a n-Bu Me H H H 42 
16 6b n-Bu Et H H H 38 
 
The dispiro compounds thus obtained were fully characterized by NMR studies. Thus, a 
NOESY experiment shows NOE enhancements between the phenyl o-proton and the α-
amino proton in compound 6b, suggesting the endo structure I (see Scheme 4.2 
below). Furthermore, the benzylic proton gives a NOE with one of the CH2 hydrogens, 
which is compatible only with structure I, since in the alternative exo structure II the 
benzyl hydrogen and the CH2 are too distant. The proposed structure was finally 
confirmed by a single-crystal X-Ray diffraction study of compound 6b.171 Figure 4.4 
shows this X-Ray structure, together with a summary of the NOE effects observed in 
the NOESY experiment. 
 
171  Deposited at the Cambridge Crystallographic Data Centre with code CCDC 1456952. 
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Figure 4.4 
A mechanism that explains the regio- and diastereoselective formation of compounds 
5 and 6 is given in Scheme 4.2, using 6b as a representative example. The condensation 
of proline with isatin, followed by decarboxylation,172 furnishes a nitrogen ylide, which 
acts as the 1,3-dipole. In principle, this intermediate would be able to react with the 
dipolarophile following the alternative pathways A and B, affording regioisomers I and 
II, respectively. The exclusive formation of I can be explained by the steric clash 
 
Scheme 4.2 
 
172  For an example of the generation of an azomethine ylide by decarboxylative coupling of an α-amino 
acid and a ketone, see: Suresh Kumar, R.; Osman, H.; Perumal, S.; Menéndez, J. C.; Ashraf Ali, M.; 
Ismail R.; Choon, T. S. Tetrahedron 2011, 67, 3132- 3139. 
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between the phenyl and carbonyl groups of the reacting species in pathway B. Finally, 
the preference for the endo structure I over the exo III (pathway C), can be due to a 
favourable secondary orbital interaction (SOI) between the carbonyl groups of the 
dipolarophile and the dipole in the transition state leading to I.173 
4.4. Pharmacological study of dispiroxoindoles 5 and 6 
As in the case of compounds 3, the pharmacological study of compounds 5 and 6 was 
carried out by Sheila Abril at the group of Dr. Rafael León (Hospital Universitario de la 
Princesa and Instituto Teófilo Hernando, Universidad Autónoma de Madrid). So far, 
only a representative subset of the library (compounds 5h-n and 6a-b) has been 
studied. 
4.4.1. SHSY5Y cytotoxicity 
Compounds 5 and 6 proved to be safe when studied on neuroblastoma SHSY5Y cells, 
showing LD50 values above 100 M in all cases. 
4.4.2. Radical scavenging 
The antioxidant activity of our compounds was examined by the DPPH method, but 
they did not show relevant radical scavenging properties in this assay (Table 4.2). 
Table 4.2 
Entry Compound 
% Scavenging  
at 0.1 mM 
% Scavenging   
at 1 mM 
IC50 (μM) 
1 Trolox   11.4 ± 1.0 (9) 
2 Ascorbic acid   16.2 ± 0.7 (9) 
3 Melatonin   1988 ± 1397 (2) 
4 5g 28.9 ± 8.4 99.1 ± 0.5 218.6 ± 38.4(3) 
5 5h 7.4 ± 2.1 5.9 ± 2.8 - 
6 5l 6.4 ± 8.5 26.6 ± 4.5 - 
7 5n 3.6 ± 2.2 47.9 ± 0.1  
8 6a 43.6 ± 1.1 99.7 ± 2.3 879.6 ± 21.1(3) 
9 6b 6.4 ± 4.5 11.2 ± 3.4 - 
 
 
173  For representative examples of the use of secondary orbital interactions to explain the outcome of 
related 1,3-dipolar cycloadditions, see: (a) Lakshmi, N. V.; Thirumurugan, P.; Perumal, P. T. 
Tetrahedron Lett. 2010, 51, 1064-1068. (b) Arun, Y.; Saranraj, K.; Balachandran, C.; Perumal, P. T. Eur. 
J. Med. Chem. 2014, 74, 50-64. 
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4.4.3. Nrf2 induction in the AREc32 cell line  
The Nrf2 induction assay was carried out as described in Chapter 3. The CD values for 
each compound, i.e., the concentration of compound that doubles the luciferase 
activity compared to its basal expression, are shown in Table 4.3. Only two of the 
compounds (6a and 5g) showed a significant ability to induce Nrf2.  
Table 4.3 
Entry Compound CD (μM) 
1 5g 30.87 ± 3.93 
2 5h > 60 
3 5l > 60 
4 5n > 60 
5 6a 22.91 ± 3.32 
6 6b > 60 
 
4.4.4. Acetylcholinesterase inhibition  
As for other compound libraries, we also examined the ability of compounds 5 and 6 to 
inhibit acetylcholinesterase, a well-known target in Alzheimer’s disease. Most 
compounds showed some degree of activity in this assay, with the exception of 5n, 
although their potency was low. The IC50 values are summarized in Table 4.4.  
Table 4.4 
Entry Compound IC50 (μM), EeAChE 
1 5g 92.6 ± 10.4 (2) 
2 5h 71.7 ± 19.6 (5) 
3 5l >100 (2) 
4 5n 68.1 (1) 
5 6a 71.5 ± 14.4 (5) 
6 6b 73.8 ± 18.4 (5) 
 
4.4.5. Neuroprotection in a rotenone/oligomycin A oxidative stress model 
The rotenone-oligomycin combination generates an intracellular model of oxidative 
stress by inhibiting complexes I and V of the mitochondrial electron transport chain, 
respectively. All our compounds showed an excellent activity in this assay, since all of 
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them provided a higher protection than the well-known neuroprotective agent 
melatonin. Compounds 5h, 5n and 6b are particularly noteworthy in this regard (Table 
4.5 and Figure 4.5).  
Table 4.5a 
Entry Compound 
% Survival  SEM 
at 1 M 
% Neuroprotection 
  SEM at 1 M 
Statistical 
significance 
1 Basal 100 
  
2 R/O (30/10 µM) 43.27  1.97  ### 
3 Melatonin 78.14  5.70 61.41  8.75 *** 
4 5g 88.79  6.61 80.79  11.29 *** 
5 5h 93.31  11.13 89.42  20.02 *** 
6 5l 82.84  4.04 69.56  6.57 *** 
7 5n 96.38  8.07 92.80  15.14 *** 
8 6a 89.12  7.84 81.51  13.09 *** 
9 6b 91.35  6.14 84.46  10.95 *** 
a Data are expressed as mean  SEM of three experiments by triplicate. One way ANOVA 
Newman Keuls post test ### p < 0.001; compared to basal. * p < 0.05, ** p < 0.01; *** p < 
0.001; compared to toxic. 
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Figure 4.5. Neuroprotective effect of compounds 5g-n and 6a-b (1 µM) against toxicity elicited by the 
combination of rotenone (30 µM) and olygomycin A (10 µM) in SH-SY5Y cells.   
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4.4.6. Neuroprotection against tau hyperphosphorylation induced by okadaic acid  
Finally, we also examined the protective effect of our compounds in SH-SY5Y cell line 
treated with okadaic acid. This compound inhibits protein phosphatase 2A and thereby 
induces tau hyperphosphorylation, which is known to be an important feature in 
Alzheimer’s and Parkinson’s disease, and also in a number of degenerative diseases 
known as taupathies. The results obtained in this model are summarized in Table 4.6 
and Figure 4.6, and again show good to excellent neuroprotection for all compounds, 
three of which (6a, 5g and 5n) are more active than melatonin.  
Table 4.6a 
Entry Compound 
% Survival 
 SEM at 1 M 
% Neuroprotection 
 SEM at 1 M 
Statistical 
significance 
1 Basal 100 
  
2 Okadaic acid (20 nM) 60.32   5.48  ### 
3 Melatonin 85.48  7.77 67.70  13.95 ** 
4 5g 90.67  7.02 81.64  16.63 *** 
5 5h 80.47  7.60 51.17  15.71 * 
6 5l 82.49  4.09 56.01  8.17 *** 
7 5n 87.20  4.79 70.49  10.53 *** 
8 6a 91.15  5.33 81.91  10.07 *** 
9 6b 74.93  8.43 40.42  16.04  
a Data are expressed as mean  SEM of three experiments by triplicate. One way ANOVA Newman Keuls 
post test ### p < 0.001; compared to basal. * p < 0.05, ** p < 0.01; *** p < 0.001; compared to toxic. 
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Figure 4.6. Neuroprotective effect of compounds 5g-n and 6a-b (1 µM) against toxicity elicited by the 
okadaic acid (20 nM) in SH-SY5Y cells. 
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In conclusion, compounds 5h-n and 6a-b display highly promising neuroprotective 
properties. 5n, in particular, has shown excellent neuroprotection in both celular 
models tested, and is a suitable candidate for further development. The mechanism of 
the neuroprotective effect is not completely clear and its unravelment will require 
further studies. However, it is significant that the two compounds with the highest 
Nrf2 induction ability also showed the highest neuroprotection against an insult 
caused by the phosphatase inhibitor okadaic acid, which is connected to the activity of 
GSK3 via the control of phosphorylation levels. 
 
4.5. Experimental section 
General experimental details 
All reagents and solvents were of commercial quality and were used as received. 
Reactions were monitored by thin layer chromatography on aluminium plates coated 
with silica gel and fluorescent indicator. Microwave-assisted reactions were performed 
on a CEM Discover focused microwave reactor. Separations by flash chromatography 
were performed using a Combiflash Teledyne automated flash chromatograph or on 
conventional silica gel columns. Melting points were measured with a Kofler-type 
heating platine microscope from Reichert, 723 model, and are uncorrected. Infrared 
spectra were recorded with an Agilent Cary630 FTIR spectrophotometer with a 
diamond ATR accessory for solid and liquid samples, requiring no sample preparation; 
wavenumbers are given in cm−1. NMR spectroscopic data were obtained using 
spectrometers maintained by the CAI de Resonancia Magnética, UCM, operating at 
250, 300, 400 and 700 MHz for 1H NMR and, 63, 100 and 176 MHz for 13C NMR; 
chemical shifts are given in (δ) parts per million and coupling constants (J) in hertz. 
Elemental analyses were determined by the CAI de Microanálisis, Universidad 
Complutense, using a Leco CHNS-932 combustion microanalyzer. The enantiomeric 
excess analysis has been conducted in a HPLC Agilent 1220 Infinity LC with a chiral 
column ULTRON ES. 
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4.5.1. General procedure for the synthesis of dispirooxindoles 5 and 6 
 
 
The suitable isatine (1.5 eq.) and the appropriate amino acid (1.5 eq.) were 
placed in a microwave reaction vial. Then, the corresponding 4-arylmethylen-2-
pyrrolin-5-one (1 eq.) suspended in ethanol (2 mL) was added and irradiated at 
100 °C for 1h. After the reaction completion, the mixture was cooled at room 
temperature and a precipitate was formed. The solid compound was filtered 
and washed twice with cold ethanol. No further purification was needed. 
 
Methyl (3S*,3'R*,4'R*)-1''-butyl-1',5''-dimethyl-2,2''-dioxo-4'-phenyl-1'',2''-
dihydrodispiro[indoline-3,2'-pyrrolidine-3',3''-pyrrole]-4''-carboxylate (5a) 
 
Prepared from pyrrolinone 3p (1 mmol), sarcosine (1.5 mmol) 
and isatine (1.5 mmol); pale brown solid (237 mg, 50%): mp 215-
218 °C; 1H NMR (250 MHz, CDCl3) δ 7.90 (br s, 1H), 7.44-7.29 (m, 
2H), 7.29-7.03 (m, 5H), 6.86 (td, J = 7.7, 0.9 Hz, 1H), 6.74 (d, J = 
7.7 Hz, 1H), 5.34 (dd, J = 10.1, 8.7 Hz, 1H), 4.24 (t, J = 8.7 Hz, 1H), 3.78 (s, 3H), 
3.65 (dd, J = 10.1, 8.7 Hz, 1H), 3.34-3.13 (m, 1H), 3.02-2.78 (m, 1H), 2.34 (s, 3H), 
1.96 (s, 3H), 1.17-0.94 (m, 2H), 0.94-0.79 (m, 2H), 0.79-0.62 (m, 3H); 13C NMR 
(63 MHz, CDCl3) δ 178.1, 175.2, 165.6, 156.0, 142.5, 137.7, 129.7, 129.3 (2C), 
128.3 (2C), 127.1, 126.0, 122.4, 110.2, 103.6, 78.2, 68.2, 56.2, 51.2, 43.5, 39.7, 
36.3, 30.9, 20.0, 14.1, 12.8;  IR (neat, cm-1): 3140, 1725, 1702, 1688,  1602, 
1208; elemental analysis (%) calcd. for C28H31N3O4: C 71.02, H 6.60, N 8.87; 
found: C 70.84, H 6.54, N 8.85. 
 
Methyl (3S*,3'R*,4'R*)-1''-butyl-5-chloro-1',5''-dimethyl-2,2''-dioxo-4'-phenyl-
1'',2''-dihydrodispiro[indoline-3,2'-pyrrolidine-3',3''-pyrrole]-4''-carboxylate 
(5b) 
 
Prepared from pyrrolinone 3p (1 mmol), sarcosine (1.5 mmol) 
and 5-chloroisatine (1.5 mmol); pale brown solid (284 mg, 
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56%): mp 102-104 °C; 1H NMR (250 MHz, CDCl3) δ 8.55 (br s, 1H), 7.35 (dd, J = 
7.9, 1.4 Hz, 2H), 7.29-7.05 (m, 5H), 6.74 (d, J = 8.3 Hz, 1H), 5.34 (dd, J = 9.9, 8.7 
Hz, 1H), 4.22 (t, J = 8.7 Hz, 1H), 3.73 (s, 3H), 3.69-3.56 (m, 1H), 3.23-2.98 (m, 2H), 
2.34 (s, 3H), 1.99 (s, 3H), 1.29-1.07 (m, 1H), 1.07-0.83 (m, 3H), 0.78 (t, J = 6.4 Hz, 
3H); 13C NMR (63 MHz, CDCl3) δ 179.5, 176.3, 166.8, 157.4, 142.5, 138.7, 131.0, 
130.6 (2C), 129.6 (2C), 129.2, 129.2, 128.5, 127.7, 112.7, 104.6, 79.5, 69.6, 57.5, 
52.5, 44.9, 41.2, 37.6, 32.4, 21.4, 15.3, 14.3; IR (neat, cm-1): 3238, 1717, 1689,  
1613, 1210, 1175; elemental analysis (%) calcd. for C28H30ClN3O4: C 66.20, H 
5.95, N 8.27; found: C 66.02, H 5.71, N 8.21. 
 
Methyl (3S*,3'R*,4'R*)-1''-benzyl-5-chloro-1',5''-dimethyl-2,2''-dioxo-4'-
phenyl-1'',2''-dihydrodispiro[indoline-3,2'-pyrrolidine-3',3''-pyrrole]-4''-
carboxylate (5c) 
 
Prepared from pyrrolinone 3l (1 mmol), sarcosine (1.5 mmol) 
and 5-chloroisatine (1.5 mmol); beige solid (396 mg, 73%): mp 
166-169 °C; 1H NMR (250 MHz, CDCl3) δ 8.06 (br s, 1H), 7.49-
7.34 (m, 2H), 7.28-6.89 (m, 8H), 6.67 (d, J = 8.3 Hz, 1H), 6.23 (d, 
J = 7.0 Hz, 2H), 5.37 (dd, J = 10.0, 8.5 Hz, 1H), 4.81 (d, J = 16.3 Hz, 1H), 4.24 (t, J = 
8.5 Hz, 1H), 3.88 (d, J = 16.3 Hz, 1H), 3.77-3.51 (m, 4H), 2.30 (s, 3H), 1.72 (s, 3H); 
13C NMR (63 MHz, CDCl3) δ 177.7, 175.0, 165.4, 156.1, 141.0, 137.3, 136.1, 
129.9, 129.6 (2C), 129.1 (2C), 128.6 (2C), 128.2, 127.9, 127.5, 127.4, 126.2 (2C), 
111.3, 103.7, 78.4, 77.6, 68.8, 56.0, 51.3, 43.5, 43.0, 36.3, 13.2; IR (neat, cm-1): 
3224, 1721, 1692, 1617, 1255, 1181; elemental analysis (%) calcd. for 
C31H28ClN3O4: C 68.69, H 5.21, N 7.75%; found C 68.75, H 5.10, N 7.67. 
 
Methyl (3S*,3'R*,4'R*)-1''-benzyl-5-iodo-1',5''-dimethyl-2,2''-dioxo-4'-phenyl-
1'',2''-dihydrodispiro[indoline-3,2'-pyrrolidine-3',3''-pyrrole]-4''-carboxylate 
(5d) 
 
Prepared from pyrrolinone 3l (1 mmol), sarcosine (1.5 mmol) 
and 5-iodoisatine (1.5 mmol); beige solid (329 mg, 52%): mp 
140-143 °C; 1H NMR (250 MHz, CDCl3) δ 7.70-7.61 (m, 2H), 7.55 
(dd, J = 8.2, 1.8 Hz, 1H), 7.52-7.43 (m, 2H), 7.36-7.27 (m, 3H), 
7.19-7.00 (m, 3H), 6.61 (d, J = 8.2 Hz, 1H), 6.32 (d, J = 6.9 Hz, 2H), 5.44 (dd, J = 
10.1, 8.5 Hz, 1H), 4.96 (d, J = 16.3 Hz, 1H), 4.34 (t, J = 8.5 Hz, 1H), 3.95 (d, J = 16.3 
Hz, 1H), 3.80 (s, 3H), 3.72 (app. t, J = 9.6 Hz, 1H), 2.42 (s, 3H), 1.82 (s, 3H); 13C 
NMR (63 MHz, CDCl3) δ 175.0, 165.3, 156.3, 142.0, 138.7, 138.7, 136.1, 134.7, 
129.6 (2C), 129.2 (2C), 128.7 (2C), 127.5, 127.4, 126.2 (2C), 112.3, 103.6, 85.1, 
78.1, 77.6, 68.8, 56.1, 51.4, 43.4, 43.0, 36.5, 31.4, 13.2; IR (neat, cm-1): 3222, 
1719, 1688, 1607, 1177; elemental analysis (%) calcd. for C31H28IN3O4: C 58.78, 
H 4.46, N 6.63; found C 58.67, H 4.39, N 6.71.  
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Methyl (3S*,3'R*,4'R*)-1''-benzyl-1',5,5''-trimethyl-2,2''-dioxo-4'-phenyl-1'',2''-
dihydrodispiro[indoline-3,2'-pyrrolidine-3',3''-pyrrole]-4''-carboxylate (5e) 
 
Prepared from pyrrolinone 3l (1 mmol), sarcosine (1.5 mmol) 
and 5-methylisatine (1.5 mmol); beige solid (287 mg, 55%): mp 
217 °C; 1H NMR (250 MHz, CDCl3) δ 7.78 (br s, 1H), 7.61-7.42 
(m, 2H), 7.31-7.29 (m, 3H), 7.20-6.93 (m, 5H), 6.70 (d, J = 7.8 
Hz, 1H), 6.30 (d, J = 7.3 Hz, 2H), 5.48 (app. t, J = 8.9 Hz, 1H), 4.86 (d, J = 16.3 Hz, 
1H), 4.33 (app. t, J = 8.9 Hz, 1H), 3.96 (d, J = 16.3 Hz, 1H), 3.81 (s, 3H), 3.72 (app. 
t, J = 9.6 Hz, 1H), 2.40 (s, 3H), 2.26 (s, 3H), 1.80 (s, 3H); 13C NMR (63 MHz, CDCl3) 
δ 177.9, 175.2, 165.5, 155.7, 140.0, 137.7, 136.3, 132.1, 130.1, 129.7 (2C), 129.1 
(2C), 128.6 (2C), 127.5, 127.2, 126.5, 126.1 (2C), 126.0, 110.0, 104.1, 68.7, 56.1, 
51.3, 43.5, 42.8, 36.4, 31.4, 21.5, 13.2; IR (neat, cm-1): 3155, 1705, 1682, 1616, 
1216, 1190; elemental analysis (%) calcd. for C32H31N3O4: C 73.68, H 5.99, N 
8.06; found: C 73.54, H 6.01, N 8.18. 
 
Methyl (3S*,3'R*,4'R*)-1''-benzyl-1',5''-dimethyl-2,2''-dioxo-4'-phenyl-1'',2''-
dihydrodispiro[indoline-3,2'-pyrrolidine-3',3''-pyrrole]-4''-carboxylate (5f) 
 
Prepared from pyrrolinone 3l (1 mmol), sarcosine (1.5 mmol) and 
isatine (1.5 mmol); white solid (330 mg, 65%): mp 200-203 °C; 1H 
NMR (250 MHz, CDCl3) δ 7.74 (br s, 1H), 7.52 (s, 2H), 7.41-6.97 
(m, 8H), 6.91 (t, J = 7.6 Hz, 1H), 6.79 (d, J = 7.6 Hz, 1H), 6.31 (d, J = 
7.3 Hz, 2H), 5.48 (app. t, J = 9.0 Hz, 1H), 4.91 (d, J = 16.3 Hz, 1H), 4.34 (app. t, J = 
8.4 Hz, 1H), 3.91 (d, J = 16.3 Hz, 1H), 3.82 (s, 3H), 3.73 (app. t, J = 9.6 Hz, 1H), 
2.40 (s, 3H), 1.81 (s, 3H); 13C NMR (63 MHz, CDCl3) δ 175.1, 165.5, 155.9, 142.4, 
137.7, 136.3, 129.9, 129.7 (2C), 129.0 (2C), 128.6 (2C), 127.5, 127.2, 126.3 (2C), 
125.9, 125.8, 122.6, 110.2, 104.0, 78.4, 77.6, 68.7, 56.0, 51.3, 43.4, 43.0, 36.3, 
13.1; IR (neat, cm-1): 3139, 1708, 1684, 1614, 1252, 1218; elemental analysis 
(%) calcd. for C31H29N3O5: C 73.35, H 5.76, N 8.28; found: C 73.13, H 5.60, N 8.14. 
 
Methyl (3S*,3'R*,4'R*)-1,1''-dibenzyl-1',5''-dimethyl-2,2''-dioxo-4'-phenyl-
1'',2''-dihydrodispiro[indoline-3,2'-pyrrolidine-3',3''-pyrrole]-4''-carboxylate 
(5g) 
 
Prepared from pyrrolinone 3l (1 mmol), sarcosine (1.5 mmol) and 
1-benzylisatine (1.5 mmol); light yellow solid (448 mg, 75%): mp 
113-115 °C; 1H NMR (250 MHz, CDCl3) δ 7.53-7.54 (m, 2H), 7.39-
7.25 (m, 9H), 7.17-7.02 (m, 4H), 6.89 (t, J = 7.4 Hz, 1H), 6.58 (d, J = 
7.7 Hz, 1H), 6.31 (d, J = 7.2 Hz, 2H), 5.56 (dd, J = 10.0, 8.4 Hz, 1H), 
5.10 (d, J = 15.8 Hz, 1H), 4.92 (d, J = 16.3 Hz, 1H), 4.58 (d, J = 15.8 Hz, 1H), 4.37 (t, 
J = 8.4 Hz, 1H), 3.90 (d, J = 16.3 Hz, 1H), 3.84-3.68 (m, 4H), 2.40 (s, 3H), 1.79 (s, 
3H); 13C NMR (63 MHz, CDCl3) δ 175.7, 175.2, 165.3, 155.3, 144.3, 137.8, 136.3, 
136.1, 129.8, 129.7 (2C), 129.2 (2C), 129.0 (2C), 128.6 (2C), 127.9, 127.6 (2C), 
127.5, 127.2, 126.3, 125.4, 125.2, 122.6, 109.7, 104.2, 78.4, 68.9, 56.2, 51.3, 
44.0, 43.5, 43.0, 36.4, 13.1; IR (neat, cm-1): 1709, 1688, 1260, 1210; elemental 
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analysis (%) calcd. for C38H35N3O4: C 76.36, H 5.90, N 7.03; found: C 76.23, H 
5.81, N 7.16. 
 
Methyl (3S*,3'R*,4'R*)-1,1''-dibenzyl-4'-(4-methoxyphenyl)-1',5''-dimethyl-
2,2''-dioxo-1'',2''-dihydrodispiro[indoline-3,2'-pyrrolidine-3',3''-pyrrole]-4''-
carboxylate (5h) 
 
Prepared from pyrrolinone 3m (1 mmol), sarcosine (1.5 mmol) 
and 1-benzylisatine (1.5 mmol); light yellow solid (427 mg, 68%): 
mp 198-200 °C; 1H NMR (250 MHz, CDCl3) δ 7.37 (d, J = 8.7 Hz, 
2H), 7.30-7.11 (m, 6H), 7.11-6.87 (m, 4H), 6.85-6.68 (m, 3H), 6.48 
(d, J = 7.7 Hz, 1H), 6.21 (d, J = 7.2 Hz, 2H), 5.41 (dd, J = 10.2, 8.4 
Hz, 1H), 5.00 (d, J = 15.8 Hz, 1H), 4.84 (d, J = 16.4 Hz, 1H), 4.48 (d, 
J = 15.8 Hz, 1H), 4.21 (t, J = 8.4 Hz, 1H), 3.81 (d, J = 16.4 Hz, 1H), 3.74 (s, 3H), 
3.71-3.57 (m, 4H), 2.29 (s, 3H), 1.69 (s, 3H); 13C NMR (63 MHz, CDCl3) δ 175.7, 
175.3, 165.3, 158.9, 155.2, 144.3, 136.3, 136.1, 130.8 (2C), 129.8, 129.6, 129.2 
(2C), 128.9 (2C), 127.9, 127.6 (2C), 127.5, 126.3 (2C), 125.4, 125.3, 122.6, 113.9 
(2C), 109.7, 104.2, 78.3, 77.6, 69.0, 56.4, 55.5, 51.3, 44.0, 42.9, 36.4, 13.0; IR 
(neat, cm-1): 1713, 1685,  1605, 1243, 1225; elemental analysis (%) calcd. for 
C39H37N3O5: C 74.62, H 5.94, N 6.69; found C 74.33, H 6.02, N 6.81. 
 
Methyl (3S*,3'R*,4'R*)-1''-benzyl-4'-(4-methoxyphenyl)-1',5''-dimethyl-2,2''-
dioxo-1'',2''-dihydrodispiro[indoline-3,2'-pyrrolidine-3',3''-pyrrole]-4''-
carboxylate (5i) 
 
Prepared from pyrrolinone 3m (1 mmol), sarcosine (1.5 mmol) 
and isatine (1.5 mmol); beige solid (296 mg, 55%): mp 212-214 
°C; 1H NMR (250 MHz, CDCl3): δ 7.57 (br s, 1H), 7.44 (d, J = 8.7 
Hz, 2H), 7.33-6.97 (m, 5H), 6.98-6.68 (m, 4H), 6.31 (d, J = 7.2 Hz, 
2H), 5.43 (dd, J = 10.2, 8.7 Hz, 1H), 4.93 (d, J = 16.3 Hz, 1H), 4.29 
(t, J = 8.7 Hz, 1H), 3.92 (d, J = 16.3 Hz, 1H), 3.83 (s, 3H), 3.82 (s, 3H), 3.70 (dd, J = 
10.2, 8.7 Hz, 1H), 2.39 (s, 3H), 1.81 (s, 3H); 13C NMR (63 MHz, CDCl3) δ 177.9, 
175.4, 165.7, 159.1, 155.9, 142.5, 136.4, 130.9 (2C), 130.0, 129.6, 129.1 (2C), 
127.7, 126.5 (2C), 126.0, 122.8, 114.1, 110.3 (2C), 104.2, 78.5, 77.8, 69.0, 56.4, 
55.7, 51.4, 43.1, 43.0, 36.5, 13.3; IR (neat, cm-1): 3140, 1721, 1702, 1685,  1611, 
1245, 1212; elemental analysis (%) calcd. for C32H31N3O5: C 71.49, H 5.81, N 
7.82; found: C 71.36, H 5.57, N 7.88. 
 
Methyl (3S*,3'R*,4'R*)-1''-benzyl-5-chloro-4'-(4-methoxyphenyl)-1',5''-
dimethyl-2,2''-dioxo-1'',2''-dihydrodispiro[indoline-3,2'-pyrrolidine-3',3''-
pyrrole]-4''-carboxylate (5j) 
 
Prepared from pyrrolinone 3m (1 mmol), sarcosine (1.5 mmol) 
and 5-chloroisatine (1.5 mmol); light yellow solid (418 mg, 
73%): mp 181-185 °C; 1H NMR (250 MHz, CDCl3) δ 8.04 (br s, 
1H), 7.42 (d, J = 8.8 Hz, 2H), 7.33 (d, J = 2.0 Hz, 1H), 7.23-7.01 
(m, 4H), 6.84 (d, J = 8.8 Hz, 2H), 6.76 (d, J = 8.3 Hz, 1H), 6.31 (d, 
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J = 7.1 Hz, 2H), 5.41 (dd, J = 10.0, 8.6 Hz, 1H), 4.94 (d, J = 16.3 Hz, 1H), 4.28 (app. 
t, J = 8.6 Hz, 1H), 3.99 (d, J = 16.4 Hz, 1H), 3.84 (s, 3H), 3.78 (s, 3H), 3.68 (dd, J = 
10.0, 9.2 Hz, 1H), 2.39 (s, 3H), 1.82 (s, 3H); 13C NMR (63 MHz, CDCl3) δ 177.7, 
175.1, 165.4, 159.0, 156.0, 141.0, 136.1, 130.7 (2C), 129.8, 129.1, 129.0 (2C), 
128.2, 128.0, 127.6, 126.2, 126.2 (2C), 114.0 (2C), 111.3, 103.7, 78.3, 68.9, 56.2, 
55.5, 51.4, 42.9, 36.3, 31.4, 13.2; IR (neat, cm-1): 3199, 1721, 1688, 1605, 1245, 
1207. elemental analysis (%) calcd. for C32H30ClN3O5: C 67.19, H 5.29, N 7.35; 
found: C 67.02, H 5.34, N 7.30. 
 
Methyl (3S*,3'R*,4'R*)-1''-benzyl-5-iodo-4'-(4-methoxyphenyl)-1',5''-dimethyl-
2,2''-dioxo-1'',2''-dihydrodispiro[indoline-3,2'-pyrrolidine-3',3''-pyrrole]-4''-
carboxylate (5k) 
 
Prepared from pyrrolinone 3m (1 mmol), sarcosine (1.5 mmol) 
and 5-iodoisatine (1.5 mmol); pale brown solid (331 mg, 50%): 
mp 141-143 °C; 1H NMR (250 MHz, CDCl3) δ 8.35 (br s, 1H), 7.42 
(d, J = 1.8 Hz, 1H), 7.32 (dd, J = 8.2, 1.8 Hz, 1H), 7.21 (d, J = 8.8 
Hz, 2H), 7.00-6.80 (m, 3H), 6.63 (d, J = 8.8 Hz, 2H), 6.44 (d, J = 8.2 
Hz, 1H), 6.10 (d, J = 7.0 Hz, 2H), 5.21 (dd, J = 10.0, 8.6 Hz, 1H), 4.77 (d, J = 16.4 
Hz, 1H), 4.07 (app. t, J = 8.6 Hz, 1H), 3.76 (d, J = 16.4 Hz, 1H), 3.63 (s, 3H), 3.54 (s, 
3H), 3.48 (dd, J = 10.0, 9.1 Hz, 1H), 2.18 (s, 3H), 1.61 (s, 3H); 13C NMR (63 MHz, 
CDCl3) δ 177.5, 175.2, 165.4, 159.0, 156.1, 142.3, 138.6, 136.1, 134.5, 130.7 (2C), 
129.1, 129.0 (2C), 128.5, 127.6, 126.2 (2C), 113.9 (2C), 112.6, 103.6, 85.1, 78.2, 
68.9, 56.3, 55.6, 51.4, 42.8, 42.8, 36.4, 13.3; IR (neat, cm-1): 3164, 1714, 1694, 
1671, 1245, 1176; elemental analysis (%) calcd. for C32H30IN3O5: C 57.93, H 4.56, 
N 6.33; found: C 57.75, H 4.42, N 6.46. 
 
Methyl (3S*,3'R*,4'R*)-1''-benzyl-4'-(4-methoxyphenyl)-1',5,5''-trimethyl-2,2''-
dioxo-1'',2''-dihydrodispiro[indoline-3,2'-pyrrolidine-3',3''-pyrrole]-4''-
carboxylate (5l) 
 
Prepared from pyrrolinone 3m (1 mmol), sarcosine (1.5 mmol) 
and 5-methylisatine (1.5 mmol); light yellow solid (298 mg, 
54%): mp 213-215 °C; 1H NMR (250 MHz, CDCl3) δ 7.41 (br s, 
1H), 7.34 (d, J = 8.7 Hz, 2H), 7.10-6.85 (m, 5H), 6.79-6.68 (m, 
2H), 6.57 (d, J = 7.9 Hz, 1H), 6.22 (d, J = 7.1 Hz, 2H), 5.32 (dd, J = 10.3, 8.6 Hz, 
1H), 4.78 (d, J = 16.3 Hz, 1H), 4.18 (t, J = 8.6 Hz, 1H), 3.88 (d, J = 16.3 Hz, 1H), 
3.74 (s, 3H), 3.72 (s, 3H), 3.59 (dd, J = 10.3, 8.6 Hz, 1H), 2.29 (s, 3H), 2.16 (s, 3H), 
1.70 (s, 3H); 13C NMR (63 MHz, CDCl3) δ 177.7, 175.3, 165.5, 158.9, 155.6, 139.8, 
136.3, 132.1, 130.7 (2C), 130.1, 129.5, 128.9 (2C), 127.5, 126.6, 126.2 (2C), 113.9 
(2C), 109.8, 104.1, 78.3, 77.6, 68.8, 56.3, 55.5, 51.3, 42.9, 42.8, 36.3, 21.5, 13.1; 
IR (neat, cm-1) 3162.5, 1706.6, 1687.8, 1616.8, 1247.0, 1217.0; elemental 
analysis (%) calcd. for C33H33N3O5: C 71.85, H 6.03, N 7.62; found: C 71.91, H 
5.97, N 7.58.  
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Methyl (3S*,3'R*,4'R*)-1''-benzyl-4'-(4-chlorophenyl)-1',5''-dimethyl-2,2''-
dioxo-1'',2''-dihydrodispiro[indoline-3,2'-pyrrolidine-3',3''-pyrrole]-4''-
carboxylate (5m) 
 
Prepared from pyrrolinone 3n (1 mmol), sarcosine (1.5 mmol) 
and isatine (1.5 mmol); white solid (423 mg, 78%): mp 118-120 
°C; 1H NMR (250 MHz, CDCl3) δ 7.45 (d, J = 8.5 Hz, 2H), 7.37 (br s, 
1H), 7.29-7.03 (m, 7H), 6.92 (td, J = 7.6, 0.6 Hz, 1H), 6.78 (d, J = 
7.6 Hz, 1H), 6.39-6.20 (m, 2H), 5.45 (dd, J = 10.1, 8.3 Hz, 1H), 4.93 
(d, J = 16.3 Hz, 1H), 4.28 (t, J = 8.3 Hz, 1H), 3.90 (d, J = 16.3 Hz, 1H), 3.83 (s, 3H), 
3.79-3.66 (m, 1H), 2.40 (s, 3H), 1.82 (s, 3H); 13C NMR (63 MHz, CDCl3) δ 176.6, 
174.1, 164.3, 154.9, 141.3, 135.2, 135.1, 132.1, 130.1 (2C), 129.0, 128.1 (2C), 
127.7 (2C), 126.8, 125.2 (2C), 124.7, 121.7, 109.3, 102.7, 77.4, 67.6, 55.0, 50.4, 
42.0, 41.8, 35.2, 30.4, 12.1; IR (neat, cm-1) 3142, 1724, 1705, 1686, 1615, 1286, 
1209; elemental analysis (%) calcd. for C31H28ClN3O4: C 68.69, H 5.21, N 7.75; 
found: C 68.57, H 5.07, N 7.81. 
 
Methyl (3S*,3'R*,4'R*)-1''-benzyl-4'-(4-bromophenyl)-1',5''-dimethyl-2,2''-
dioxo-1'',2''-dihydrodispiro[indoline-3,2'-pyrrolidine-3',3''-pyrrole]-4''-
carboxylate (5n) 
 
Prepared from pyrrolinone 3r (1 mmol), sarcosine (1.5 mmol) and 
isatine (1.5 mmol); pale brown solid (516 mg, 88%): mp 222 °C; 
1H NMR (250 MHz, d6-DMSO) δ 10.34 (br s, 1H), 7.50 (d, J = 8.6 
Hz, 2H), 7.33 (d, J = 8.6 Hz, 2H), 7.24-7.00 (m, 5H), 6.86 (td, J = 
7.6, 0.9 Hz, 1H), 6.74 (d, J = 7.6 Hz, 1H), 6.32 (d, J = 6.8 Hz, 2H), 
5.32 (dd, J = 10.1, 8.2 Hz, 1H), 4.72 (d, J = 16.6 Hz, 1H), 4.25 – 3.95 (m, 2H), 3.70 
(s, 3H), 3.57-3.46 (m, 1H), 2.15 (s, 3H), 1.71 (s, 3H); 13C NMR (63 MHz, d6-DMSO) 
δ 176.6, 174.4, 164.5, 154.5, 143.7, 137.1, 136.6, 131.4 (2C), 131.3 (2C), 129.9, 
128.6 (2C), 127.3, 125.9 (2C), 125.1, 124.8, 121.6, 120.5, 110.0, 103.2, 77.5, 
67.7, 51.2, 42.0, 41.9, 35.5, 31.1, 12.5; IR (neat, cm-1): 3141, 1724, 1704, 1686, 
1614, 1285, 1208; elemental analysis (%) calcd. for C31H28BrN3O4: C 63.49, H 
4.81, N 7.1;. found: C 63.62, H 4.77, N 7.05. 
 
Methyl (1'R*,2'R*,3S*,7a’S)-1''-butyl-5''-methyl-2,2''-dioxo-1'-phenyl-
1'',2'',5',6',7',7a'-hexahydro-1'H-dispiro[indoline-3,3'-pyrrolizine-2',3''-pyrrole]-
4''-carboxylate (6a) 
 
Prepared from pyrrolinone 3p (1 mmol), proline (1.5 mmol) and 
isatine (1.5 mmol); light yellow solid (210 mg, 42%): mp 156-158 
°C; 1H NMR (250 MHz, CDCl3) δ 7.81 (br s, 1H), 7.46 (d, J = 6.5 Hz, 
2H), 7.38 (d, J = 7.5 Hz, 1H), 7.28-7.09 (m, 4H), 6.90 (t, J = 7.5 Hz, 
1H), 6.71 (d, J = 7.7 Hz, 1H), 4.91 (s, 2H), 3.81 (s, 3H), 3.34-3.16 (m, 1H), 3.11-
2.95 (m, 1H), 2.88 (t, J = 7.1 Hz, 1H), 2.81-2.64 (m, 1H), 2.31-2.00 (m, 4H), 1.94 
(s, 3H), 1.22-1.05 (m, 2H), 1.04-0.88 (m, 2H), 0.80 (t, J = 6.9 Hz, 3H); 13C NMR (63 
MHz, CDCl3) δ 178.7, 175.8, 165.8, 154.8, 141.4, 137.8, 129.4 (2C), 129.3, 128.4 
(2C), 127.1, 126.0, 122.5, 109.8, 104.2, 77.3, 73.2, 68.7, 51.2, 49.7, 47.9, 39.8, 
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32.4, 31.0, 30.5, 20.1, 14.1, 12.7; IR (neat, cm-1): 3138, 1707, 1687, 1615, 1254, 
1205; elemental analysis (%) calcd. for C30H33N3O4: C 72.12, H 6.66, N 8.41; 
found: C 71.98, H 6.55, N 8.46. 
 
Ethyl (1'R*,2'R*,3S*,7a’S)-1''-butyl-5''-methyl-2,2''-dioxo-1'-phenyl-
1'',2'',5',6',7',7a'-hexahydro-1'H-dispiro[indoline-3,3'-pyrrolizine-2',3''-pyrrole]-
4''-carboxylate (6b) 
 
Prepared from pyrrolinone 3q (1 mmol), proline (1.5 mmol) and 
isatine (1.5 mmol); light yellow solid (195 mg, 38%): mp 155-157 
°C; 1H NMR (250 MHz, CDCl3) δ 7.58 (br s, 1H), 7.46 (d, J = 6.9 Hz, 
2H), 7.35 (d, J = 7.5 Hz, 1H), 7.28-7.00 (m, 4H), 6.87 (t, J = 7.7 Hz, 
1H), 6.66 (d, J = 7.7 Hz, 1H), 4.91 (s, 1H), 4.99-4.77 (m, 2H), 4.32 (m, 1H), 4.16 
(m, 1H), 3.29-3.13 (m, 1H), 3.06-2.91 (m, 1H), 2.85 (t, J = 7.5 Hz, 1H), 2.70 (dd, J = 
16.4, 7.9 Hz, 1H), 2.26-1.96 (m, 4H), 1.91 (s, 3H), 1.39 (t, J = 7.1 Hz, 3H), 1.18-
1.01 (m, 2H), 1.01-0.83 (m, 2H), 0.76 (t, J = 6.6 Hz, 3H); 13C NMR (63 MHz, CDCl3) 
δ 178.6, 175.8, 165.4, 154.5, 141.4, 137.8, 129.4 (2C), 128.4 (2C), 128.0, 127.1, 
126.0, 122.5, 109.8, 104.2, 77.3, 73.3, 68.7, 60.6, 49.7, 47.8, 39.8, 32.4, 31.0, 
30.5, 30.1, 20.1, 14.6, 14.1, 12.6; IR (neat, cm-1): 3190, 1708, 1681, 1612, 1249, 
1203; elemental analysis (%) calcd. for C31H35N3O4: C 72.49, H 6.87, N 8.18; 
found: C 72.33, H 6.90, N 7.97. 
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5.1. Biological importance of quinones  
Quinone moieties, in particular 1,2- and 1,4-quinones, are present in several molecules 
involved in physiological processes and can be found in natural products with a broad 
activity spectrum.  
An example of a 1,4-benzoquinone with a remarkable relevance in physiological 
processes is coenzyme Q10 (CoQ), or ubiquinone 10, which takes part in oxidative 
phosphorylation process involved in cell energy production. Also, Q10 participates in 
single electron transfer reactions inside cells. Recent research on Q10 coenzyme shows 
its potential neuroprotective effect in Alzheimer´s disease, since it is able to prevent -
amyloid-induced neural stem cell death.174 These neuroprotective effects have been 
ascribed, at least in part, to Nrf2 induction due to the presence of electrophilic Michael 
acceptors in the quinone moiety. 175  Furthermore, low CoQ10 levels have been 
correlated with a greater risk of dementia in a Japanese general population.176 
Besides Q10, other quinones have attracted attention in the field of medicinal 
chemistry Figure 5.1). An example is the 1,4-naphtoquinone-tryptophan hybrid, with a 
protein aggregation inhibitory activity. 177  Memoquine is another example of a 
successful  
 
Figure 5.1  
 
174  Ko, S.H.; Choi, H.; Park, H.-H.; Lee, K.-Y.; Lee, Y.-J.; Kim, S. H. Alzheimers Dement. 2010, 6, S209. 
175  Magesh, S.; Chen, Y.; Hu, L. Med. Res. Rev. 2012, 32, 687-726. 
176 Momiyama, Y. Atherosclerosis 2014, 237, 433-434. 
177  Krishna Kumar, V. G.; Paul, A.; Gazit, E.; Segal, D. Sci. Rep. 2018, 8, 71. 
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compound developed against neurodegenerative diseases. 178  It shows a broad 
spectrum of activities, including ROS scavenging and inhibition of amyloid-β 
aggregation, beta-secretase 1 activity (BACE-1) and acetylcholinesterase. The 
antioxidant properties of memoquine were evaluated by direct ROS scavenging and via 
its prior transformation into its hydroquinone derivative by the NAD(P)H/quinone 
oxidoreductase 1 (NQO1). The hydroquinone may scavenge ROS to afford again the 
memoquine, which is able to re-start the redox cycle. It is important to note that NQO1 
is overexpressed in hippocampal neurons in AD patients. Furthermore, memoquine 
inhibits AChE and BACE-1 at nanomolar concentrations, thus being able to improve 
cholinergic neuronal survival and decrease in tau hyperphosphorylation. All these 
pharmacological activities and its ability to cross the blood-brain barrier explain its 
ability to afford improvement memory in several animal models (Figure 5.2). 
Memoquine was one of the first examples that suggested that the multitarget 
approach could be a successful strategy to treat multifactorial neurodegenerative 
diseases, while also highlighting the importance of quinones in medicinal chemistry.  
 
 
Figure 5.2 
 
5.2. Design of quinone-melatonin based multitarget ligands 
5-Methoxytryptamine and its N-acetylated derivative (melatonin) are produced in the 
pineal gland and their physiological role is the control of wake-sleep cycles. 
Furthermore, melatonin is a well-known antioxidant acting as a ROS scavenger, and its 
 
178 For a review, see: Bolognesi, M. L.; Cavalli, A.; Melchiorre, C. Neurotherapeutics 2009, 6, 152-162. 
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role in the induction of cytoprotective biochemical pathways is well documented.179, 
180, 181  
On this basis, we designed the tryptamine-quinolinetrione hybrids I. In the first place, 
this hybrid structure contains a vinylogous melatonin structure shown in. The 
quinolinone heterocyclic core possesses two electrophilic positions, presumably able 
to induce the Keap1-Nrf2-ARE pathway,182 and a 1,4-quinone that should be reduced 
by NQO1 to afford a hydroquinone-derivative with an improved antioxidant activity. 
This Keap1-Nrf2-ARE pathway activation induce the synthesis of phase I antioxidant 
enzymes like NQO1, among others. This increase in NQO1, combined with the 
reduction of quinone to an antioxidant hydroquinone for NQO1, is expected to induce 
a redox cycle with a very potent antioxidant effect (Figure 5.3).  
 
Figure 5.3 
 
 
179  Tan, D.-X.; Manchester, L. C.; Terron, M. P.; Flores, L. J.; Reiter, R. J. J. Pineal Res. 2007, 42, 28–42. 
180  Johns, J. R.; Platts, J. A. Org. Biomol. Chem. 2014, 12, 7820–7827. 
181  Reiter, R. J.; Acuña-Castroviejo, D.; Tan, D. X.; Burkhardt, S. Ann. N. Y. Acad. Sci. 2001, 939, 200-215. 
182  For an example of Nrf2 activation by a 2-quinolinone derivative, see: Hur, W.; Sun, Z.; Jiang, T.; 
Mason, D. E.; Peters, E. C.; Zhang, D. D.; Luesch, H.; Schultz, P. G.; Gray, N. S. Chem. Biol. 2010, 17, 
537-547. 
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In order to obtain additional data towards a more meaningful structure-activity 
relationship, alternative linking points between quinone and tryptamine cores were 
also considered (Figure 5.4). 
 
Figure 5.4 
 
Electrophilic compounds such as quinones III can induce toxic effects by alkylation of 
biomolecules in a non-specific way.183 It is relevant to point out that the starting 
quinones selected to obtain these hybrids and structurally related compounds were 
previously synthetized in our group and showed a good safety profile and low 
cytotoxicity.  
 
5.3. Synthesis of tryptamine-quinolinetrione hybrids  
5.3.1 Synthesis of 3-alkyl- and 3-formyl-5,8-dimethoxyquinolin-2-ones184  
Anilides 7a-c were synthetized in good yields by acylation of 2,5-dimethoxyaniline with 
the suitable acyl chloride, after purification by crystallization. The Meth-Cohn method 
was then employed to achieve the synthesis of 2,5-dimethoxyquinolines bearing alkyl 
or carboxaldehyde groups in its C-3 position. In this method, the starting amides were 
treated with the Vilsmeier-Haack reagent, obtained in situ from DMF and POCl3. 
Afterwards, the suitable 2,5-dimetoxianilide 7a-c was added to give the 2-
chloquinoline derivatives 8a-c (Scheme 5.1).  
The usual purification of compound 8a by silica gel chromatography led to extensive 
decomposition. To improve the purification process, the silica gel was deactivated by 
stirring with a 0.1 M aqueous oxalic acid solution, filtration and oven drying. The use of 
 
183  Zheng, H.; Fridkin, M.; Youdim, M. Perspect. Med. Chem. 2015, 7, 1-8. 
184  A method from our group was used: Alonso, M. A.; Blanco, M. M.; Avendaño, C.; Menéndez, J. C. 
Heterocycles 1993, 36, 2315-2325. 
Chapter 5. Melatonin/2,5,8-quinolinetrione hybrids 
109 
 
this oxalic acid pre-treated silica gel led to improved results and increased the isolated 
yield of 2a from 29% to 45%. Compound 8c was sufficiently pure to be used in the next 
step without further purification. 
 
 
Scheme 5.1 
The mechanism of the reaction starts with the formation of the Vilsmeier-Haack 
reagent from DMF and POCl3 via intermediate I. Then, the same reaction takes place 
on the amide of compound 1 to yield the chloroimine intermediate II, which 
tautomerizes to an enamine and attacks the Vilsmeier reagent furnishing intermediate 
III. Finally, an electrophilic aromatic substitution (EAS) and a subsequent 
dimethylamine elimination affords compounds 8b-c (Scheme 5.2). 
 
Scheme 5.2 
This same procedure affords the 3-carboxaldehyde compound 8a when compound 7a 
was the starting material. In this case, two consecutive addition-elimination reactions 
of enamine IV to the Vilsmeier reagent afford intermediate V. Then, an electrophilic 
aromatic substitution (EAS) followed by dimethylamine elimination affords the 2-
cloroquinoline substituted with a carboxaldehyde group in position 3 (compound 8a), 
arising from hydrolysis of the iminium function during aqueous workup (Scheme 5.3).  
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Scheme 5.3 
2-Cloroquinolines 8a-c were finally treated with aqueous AcOH, affording the 5,8-
dimetoxi-2(1H)-quinolinones 9a-c in variable yields, after purification by silica gel 
chromatography (Scheme 5.4). 
 
Scheme 5.4 
5.3.2. Synthesis of 5,8-dimethoxyquinolin-2-ones bearing electron-withdrawing 
groups at C-3185 
The synthesis of bearing electron-withdrawing groups at C-3 was based on the use of 
the Friedländer quinoline synthesis. The o-aminobenzaldehyde 11, a suitable starting 
material for this purpose, was obtained from the corresponding benzaldehyde 
derivative by nitration and subsequent reduction with Fe/HCl. Treatment of 11 with 
several acetate esters bearing electron-withdrawing substituents in a refluxing mixture 
of ethanol and piperidine afforded good yields of compounds 12a,b that precipitated 
from the reaction mixture, allowing their purification by simple filtration (Scheme 5.5). 
 
185  A method from our group was used: Blanco, M. M.; Cabezas, N.; Avendaño, C.; Menéndez, J. C. 
Heterocycles 1993, 36, 1387-1398.  
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Scheme 5.5 
5.3.3. Synthesis of 2,5,8-quinolinetriones  
Finally, the 5,8-dimethoxyquinolines 8 and 12 were transformed into the 
corresponding quinones 13a-d by oxidative demethylation with ceric ammonium 
nitrate (CAN) in a CH3CN/H2O mixture, followed by silica gel chromatography. The 4-
methylquinone 13e, which was available in our laboratory,186 was also examined as a 
control (Scheme 5.6).  
 
Scheme 5.6 
5.3.4. Coupling of tryptamines and 2,5,8-quinolinetriones 
The target hybrid compounds (14) were synthetized from the suitable quinolinetriones 
13 and tryptamine derivatives by a aza-Michael addition/oxidation sequence (Scheme 
5.7), generally in modest yields. (Table 5.1). The reaction can be proposed to involve 
an initial aza-Michael addition of the tryptamine derivative onto the most electrophilic 
position of the quinone at C-6 (see below), to furnish hydroquinone I. This 
intermediate is readily oxidized by a second molecule of the starting quinone, yielding 
the observed final product. The hydroquinone derived from compounds 13, although 
not isolated, could be observed by TLC.   
 
 
186 Alonso, M. A.; López-Alvarado, P.; Avendaño, C.; Menéndez, J. C. Tetrahedron, 2003, 59, 2821-2830 
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Scheme 5.7 
Table 5.1 
Compound R1 R2 R3 Yield (%) 
14a H Me H 24 
14b CN H H 62 
14c COOEt H H 32 
14d CN H OMe 43 
14e Me H H 56 
14f Et H H 47 
14g H Me OMe 47 
 
The 1,4-addition was completely regioselective in favour of position 6, which is more 
electrophilic than C-7 due to its conjugation to a more electrophilic carbonyl group, 
owing to its conjugation to a lactam group that is electron-releasing at its nitrogen and 
electron-withdrawing at its carbonyl. 187  This reasoning was supported by a 
computational study that showed that C-6 has a higher Mulliken charge than C-7 in 
compound 13a (Figure 5.5).  
 
 
187  For precedent of this complete regioselectivity in the addition of amines to 2,5,8-quinolinetriones, 
see: Pascual-Alfonso, E.; Avendaño, C.; Menéndez, J. C. Synlett 2000, 2000, 205-208. 
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Figure 5.5 
 
After the synthesis of compounds 14a-g, another linking mode between tryptamine 
and the 2,5,8-quinolinetrione framework was studied. The synthesis of compound 15 
was readily accomplished by a reductive amination of 9a and 5-meyhoxytryptamine in 
the presence of sodium triacetoxyborohydride. Unfortunately, the attempted oxidative 
demethylation with CAN afforded a complex mixture, and a milder alternative such as 
cobalt trifluoride188 gave a similar result (Scheme 5.8).  
 
Scheme 5.8 
The pharmacological study of compounds 14 is in progress in the group of Dr. Pilar 
Gómez-Serranillos, at the School of Pharmacy in Universidad Complutense. Preliminary 
data show a very potent antioxidant activity in the ORAC assay. 
  
 
188 (a) Tomatsu, A.; Takemura, S.; Hashimoto, K.; Nakata, M. Synlett 1999, 1474–1476. (b) Pascual-
Alfonso, E.; Avendaño, C.; Menéndez, J. C. Tetrahedron Lett. 2003, 44, 6003-6005.   
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5.4. Experimental section 
General experimental details 
All reagents and solvents were of commercial quality and were used as received. 
Reactions were monitored by thin layer chromatography on aluminium plates coated 
with silica gel and fluorescent indicator. Microwave-assisted reactions were performed 
on a CEM Discover focused microwave reactor. Separations by flash chromatography 
were performed using a Combiflash Teledyne automated flash chromatograph or on 
conventional silica gel columns. Melting points were measured with a Kofler-type 
heating platine microscope from Reichert, 723 model, and are uncorrected. Infrared 
spectra were recorded with an Agilent Cary630 FTIR spectrophotometer with a 
diamond ATR accessory for solid and liquid samples, requiring no sample preparation; 
wavenumbers are given in cm−1. NMR spectroscopic data were obtained using 
spectrometers maintained by the CAI de Resonancia Magnética, UCM, operating at 
250, 300, 400 and 700 MHz for 1H NMR and, 63, 100 and 176 MHz for 13C NMR; 
chemical shifts are given in (δ) parts per million and coupling constants (J) in hertz. 
Elemental analyses were determined by the CAI de Microanálisis, Universidad 
Complutense, using a Leco CHNS-932 combustion microanalyzer. The enantiomeric 
excess analysis has been conducted in a HPLC Agilent 1220 Infinity LC with a chiral 
column ULTRON ES. 
 
5.4.1. Synthesis of N-(2,5-dimethoxyphenyl)anilides 7 
 
To a solution of 2,5-dimethoxyaniline (33 mmol, 1 eq.) in anhydrous toluene (50 mL) at 
0 °C and under argon atmosphere was added the suitable acyl chloride (1.2 eq) and the 
mixture was stirred at room temperature for 3 h. Then, a 25% (w/v) sodium carbonate 
solution was added and both phases were separated. The aqueous phase was washed 
with CHCl3 (3 x 50 mL). The combined organic layers were dried over anhydrous 
sodium sulphate, filtered and the solvent was removed under reduce pressure. The 
residue was crystallized from petroleum ether.  
 
N-(2,5-Dimethoxyphenyl)acetamide (7a) 
 
Beige solid (5.3 g, 88%); mp: 90 °C; 1H RMN (250 MHz, CDCl3) δ 8.10 (d, J = 
3.0 Hz, 1H), 7.78 (s, 1H), 6.78 (d, J = 8.9 Hz, 1H,), 6.56 (dd, J = 8.9, 3.0 Hz, 
1H), 3.84 (s, 3H), 3.78 (s, 3H), 2.20 (s, 3H); 13C RMN (63 MHz, CDCl3) δ 
168.4, 153.9, 141.9, 124.7, 110.7, 108.4, 106.1, 56.3, 55.9, 25.1; IR (neat, 
cm-1): 3250, 1663, 1219; elemental analysis (%) calcd. for C10H13NO3: C 
61.53, H 6.71, N 7.18; found: C 61.52, H 6.59, N 7.26 . 
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N-(2,5-Dimethoxyphenyl)propionamide (7b) 
 
Brown solid (6.3 g, 92%); mp: 69-70 °C; 1H RMN (250 MHz, CDCl3) δ 8.14 
(d, J = 3.0 Hz, 1H), 7.80 (s, 1H), 6.76 (d, J = 8.9 Hz, 1H), 6.54 (dd, J = 8.9, 
3.0 Hz, 1H), 3.81 (s, 3H), 3.76 (s, 3H), 2.41 (q, J = 7.5 Hz, 2H), 1.23 (t, J = 
7.5 Hz, 3H); 13C RMN (63 MHz, CDCl3) δ 172.0, 153.9, 141.9, 128.4, 110.6, 
108.4, 105.8, 56.2, 55.8, 25.1, 31.1, 9.7; IR (neat, cm-1): 3245, 1656, 1217; 
elemental analysis (%) calcd. for C11H15NO3: C 63.14, H 7.23, N 6.69; found: C 63.11, H 
7.07, N 6.83. 
 
N-(2,5-Dimethoxyphenyl)butyramide (7c) 
 
Brown solid (6.0 g, 83%); mp: 40 °C; 1H RMN (250 MHz, CDCl3) δ 8.15 
(d, J = 2.9 Hz, 1H), 7.78 (s, 1H), 6.78 (d, J = 8.9 Hz, 1H), 6.55 (dd, J = 8.9, 
3.0 Hz, 1H), 3.83 (s, 3H), 3.77 (s, 3H), 2.37 (t, J = 7.4 Hz, 2H), 1.80 – 1.71 
(m, 2H), 1.00 (t, J = 7.4 Hz, 3H); 13C RMN (63 MHz, CDCl3) δ 171. 3, 
153.9, 141.9, 128.5, 110.7, 108.5, 105.8, 56.3, 55.9, 40.1, 19.1, 13.9; IR 
(neat, cm-1): 3236, 1655, 1211; elemental analysis (%) calcd. for C12H17NO3: C 64.55, H 
7.67, N 6.27; found: C 64.22, H 7.46, N 6.51. 
 
5.4.2. Synthesis of 2-chloro-5,8-dimethoxyquinolines 8  
 
 
Phosphorous oxychloride (7 eq.) was added dropwise to DMF (3 eq.) at 0 °C under 
argon atmosphere and stirred for 30 min. Then the suitable anilide 7 (1 eq.) was added 
and the reaction was heated at 110 °C for 2 h. On completion of the reaction, the 
mixture was poured on ice, basified with 1M ammonium hydroxide solution, and 
extracted with CHCl3 (3 x 50mL). The combined organic layers were dried over 
anhydrous sodium sulphate, filtered and the solvent was removed. The residue was 
purified by column chromatography on silica gel previously treated with a 0.1 M oxalic 
acid solution, eluting with a gradient from 4:1 to 1:1 hexane-ethyl acetate mixture.  
 
 
2-Chloro-5,8-dimethoxyquinoline-3-carbaldehyde (8a) 
 
Prepared from anilide 7a (2.6 mmol); yellow solid (287 mg, 45%); mp: 
155-156 °C; 1H RMN (250 MHz, CDCl3) δ 10.54 (s, 1H), 9.11 (s, 1H), 7.12 
(d, J = 8.6 Hz, 1H), 6.81 (d, J = 8.6 Hz, 1H), 4.03 (s, 3H), 3.97 (s, 3H); 13C 
RMN (63 MHz, CDCl3) δ 189.4, 150.2, 148.4, 141.2, 136.1, 125.9, 120.2, 
112.3, 105.3, 56.5, 56.1; IR (neat, cm-1): 1688, 1263; elemental analysis (%) calcd. for 
C12H10ClNO3: C 58.77, H 4.55, N 5.27, found: C58.39, H 4.24, N 5.75. 
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2-Chloro-3-methyl-5,8-dimethoxyquinoline (8b) 
 
Prepared from anilide 7b (2.4 mmol); beige solid (201 mg, 35%); mp: 108 
°C; 1H RMN (250 MHz, CDCl3) δ 8.33 (q, J = 0.9 Hz, 1H), 6.88 (d, J = 8.5 Hz, 
1H), 6.72 (d, J = 8.5 Hz, 1H), 3.99 (s, 3H), 3.93 (s, 3H), 2.52 (d, J = 0.8 Hz, 
3H); 13C RMN (63 MHz, CDCl3) δ 151.9, 148.6, 148.2, 138.7, 133.1, 130.1, 
121.0, 107.2, 104.3, 56.1, 55.9, 20.3; IR (neat, cm-1): 1262; elemental 
analysis (%) calcd. for C12H12ClNO2: C 60.64, H 5.09, N 5.89; found: C 60.55, H 5.05, N 
6.11.  
 
5.4.3. Synthesis of 5,8-dimethoxy-2(1H)-quinolinones 9 
 
A solution of suitable 2-chloroquinoline (1 eq.) in acetic acid (26 eq.) and water (3 eq.) 
was refluxed for 3 h. On completion of the reaction, the mixture was poured into ice, 
basified until pH = 10-11 with 25% ammonium hydroxide solution, and extracted with 
CHCl3 (3 x 50 mL). The combined organic layers were dried over anhydrous sodium 
sulphate, filtered and the solvent was removed in vacuum. The residue was purified by 
column chromatography on silica gel previously treated with a 0.1 M oxalic acid 
solution, eluting with a gradient from 4:1 to 1:1 hexane-ethyl acetate mixture.  
 
5,8-Dimethoxy-2-oxo-1,2-dihydroquinoline-3-carbaldehyde (9a) 
 
Prepared from chloroquinoline 8a (1.1 mmol); yellow solid (112 mg, 
44%); mp: desc. 231 °C; 1H RMN (250 MHz, CDCl3) δ 10.41 (s, 1H), 9.32 
(br s, 1H), 8.82 (s, 1H), 6.99 (d, J = 8.7 Hz, 1H), 6.50 (d, J = 8.8 Hz, 1H), 
3.94 (s, 3H), 3.91 (s, 3H); 13C RMN (63 MHz, CDCl3) δ 189.6, 161.5, 
152.0, 139.5, 138.6, 131.8, 125.0, 114.1, 110.6, 101.8, 56.5, 56.0; IR 
(neat, cm-1): 3009, 2843, 1685, 1645, 1264; elemental analysis (%) calcd. for 
C12H11NO4: C 63.15, H 5.30, N 5.67; found: C 62.54, H 5.43, N 5.38. 
 
5,8-Dimethoxy-3-methylquinolin-2(1H)-one (9b) 
 
Prepared from chloroquinoline 8b (0.8 mmol); beige solid (133 mg, 77%); 
mp: 158-159 °C; 1H RMN (250 MHz, MeOD) δ 8.00 (q, J = 1.2 Hz, 1H), 6.95 
(d, J = 8.7 Hz, 1H), 6.60 (d, J = 8.7 Hz, 1H), 3.92 (s, 3H), 3.88 (s, 3H), 2.18 
(d, J = 1.2 Hz, 3H); 13C RMN (63 MHz, MeOD) δ 164.8, 150.4, 141.4, 133.6, 
129.8, 129.5, 112.6, 110.8, 102.8, 56.6, 56.3, 17.1; IR (neat, cm-1): 2987, 
1638, 1244; elemental analysis (%) calcd. for C12H13NO3: C 65.74, H 5.98, N 5.39, 
found: C 65.20, H 5.89, N 6.41. 
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5,8-Dimethoxy-3-ethylquinolin-2(1H)-one (9c) 
 
Prepared from chloroquinoline 8c (2 mmol); orange solid (175 mg, 38%); 
mp: 154-155 °C; 1H RMN (250 MHz, CDCl3) δ 9.24 (s, 1H), 7.89 (t, J = 1.2 
Hz, 1H), 6.76 (d, J = 8.7 Hz, 1H), 6.44 (d, J = 8.7 Hz, 1H), 3.87 (s, 3H), 3.86 
(s, 3H), 2.64 (qd, J = 7.4, 1.2 Hz, 2H), 1.25 (t, J = 7.4 Hz, 3H); 13C RMN (63 
MHz, CDCl3) δ 162.3, 149.4, 139.6, 135.2, 130.0, 128.4, 111.3, 109.1, 101.1, 56.2, 55.8, 
23.6, 12.8; IR (neat, cm-1): 3128, 2836, 1639, 1237; elemental analysis (%) calcd. for 
C13H15NO3: C 66.94, H 6.48, N 6.00, found: C 66.50, H 6.45, N 6.07. 
 
5.4.4. Preparation of 3,6-dimethoxy-2-nitrobenzaldehyde 10 
 
 
2,5-Dimethoxybenzaldehyde (5 g, 30 mmol) was dissolved in ethyl ether (50 ml) and 
glacial acetic acid (50 ml) mixture, and 70 % nitric acid (13.5 ml) was added dropwise. 
The reaction was stirred at room temperature overnight. Then, the solvent was 
removed and the residue was dissolved in ethyl ether (100 ml) and washed with water 
(3 x 25 ml). The organic layer was dried over Na2SO4, filtered and the solvent was 
removed. The residue was chromatographed on silica gel, eluting with a 3:2 hexane-
ethyl ether mixture to yield 3.63 g (60 %) of 10. 1H NMR (250 MHz, CDCl3) δ 10.38 (s, 
1H), 7.31 (d, J = 9.5 Hz, 1H), 7.14 (d, J = 9.3 Hz, 1H), 3.97 (s, 3H), 3.89 (s, 3H). NMR data 
are identical to those found in the literature.189 
 
5.4.5. Preparation of 2-amino-3,6-dimethoxybenzaldehyde 11 
 
 
To a solution of 10 (2 g, 9.5 mmol) in EtOH (40 mL) and AcOH (10 mL) was slowly added 
iron powder (2.1 g). The reaction was cooled to 0 °C, treated with 1M HCl solution (10 
mL) and was heated to reflux for 2 h. Then, it was allowed to cool to room 
temperature and the mixture was filtered through a Celite pad and the filtrate 
concentrated. The resulting oil was dissolved in EtOAc (100 mL) and basified to pH 8 
with a 1M NaOH solution. The organic layer was separated and washed with saturated 
aqueous NaHCO3 solution (2 x 30 mL) and brine (30 mL). The organic layer was dried 
 
189  Blanco, M. M.; Avendaño, C.; Cabezas, N.; Menéndez, J. C. Synth. Commun. 1993, 23, 1351-1356. 
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over Na2SO4, filtered and the solvent was removed to provide 1.5 g (87%) of 2-
aminobenzaldehyde 11. 
1H NMR (250 MHz, CDCl3) δ 10.39 (s, 1H), 6.75 (d, J = 8.6 Hz, 1H), 5.97 (d, J = 8.6 Hz, 
1H), 3.80 (s, 6H). NMR data are identical to those found in the literature.190 
 
5.4.6. Friedländer synthesis of 5,8-dimethoxyquinolin-2(1H)-one derivatives 12 
 
2-Amino-3,6-dimethoxybenzaldehyde (2 eq) and piperidine (1 eq) was dissolved in 
ethanol (xx mL). Then, the suitable ester was added and the mixture was refluxed and 
monitored by TLC until the o-aminobenzaldehyde was completely consumed. The 
mixture was cooled to room temperature and the formed precipitate was filtered and 
washed with a small amount of cold ethanol.  
 
5,8-Dimethoxy-2-oxo-1,2-dihydroquinoline-3-carbonitrile (12a) 
 
Prepared from 2-amino-3,6-dimethoxybenzaldehyde (4 mmol); yellow 
solid (880 mg, 96%); 1H NMR (250 MHz, d6-DMSO) δ 11.75 (br s, 1H), 
8.67 (d, J = 0.4 Hz, 1H), 7.26 (d, J = 8.8 Hz, 1H), 6.73 (d, J = 8.8 Hz, 1H), 
3.87 (s, 3H), 3.84 (s, 3H). NMR data are identical to those found in the 
literature.190  
 
Ethyl 5,8-dimethoxy-2-oxo-1,2-dihydroquinoline-3-carboxylate (12b) 
 
Prepared from 2-amino-3,6-dimethoxybenzaldehyde (4 mmol); 
yellow solid (980 mg, 88%); 1H NMR (250 MHz, CDCl3) δ 8.72 (s, 2H), 
8.66 (s, 2H), 7.10 (d, J = 8.0 Hz, 1H), 6.69 (d, J = 8.0 Hz, 1H), 4.43 (q, J 
= 7.1 Hz, 2H), 3.60 (s, 6H), 1.41 (t, J = 7.1 Hz, 3H). NMR data are 
identical to those found in the literature.190 
 
5.4.7. Synthesis of 2,5,8(1H)-quinolinetriones 13 
 
 
Cerium ammonium nitrate (2.2 eq.) was added portionwise to a suspension of the 
suitable 5,8-dimethoxy-2(1H)-quinolinone (1 eq. ) in acetonitrile-water (5-2 mL per 
mol). The orange solution was stirred at room temperature for 1 h and then diluted 
 
190 Blanco, M.M.; Avendaño, C.; Cabezas, N.; Menéndez, J. C. Heterocycles, 1993, 36, 1387-1398. 
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with water and extracted with CHCl3 (3 x 50 mL). The combined organic layers were 
dried over sodium sulphate, filtered and the solvent was removed under vacuum.  
 
3-Methylquinoline-2,5,8(1H)-trione (13a) 
 
Prepared from quinolinone 8b (0.5 mmol); orange solid (98mg, 76%); 
mp: 207 °C; 1H NMR (250 MHz, CDCl3) δ 9.78 (br s, 1H), 7.78 (q, J = 1.1 
Hz, 1H), 6.90 (d, J = 10.4 Hz, 1H), 6.85 (d, J = 10.4 Hz, 1H), 2.27 (d, J = 1.1 
Hz, 3H); 13C NMR (63 MHz, CDCl3) δ 182.6, 179.6, 162.0, 138.4, 138.2, 
135.6, 134.8, 132.0, 115.2, 17.5; IR (neat, cm-1): 2920, 1637.  
 
3-Ethylquinoline-2,5,8(1H)-trione (13b) 
 
Prepared from quinolinone 8c (0.7 mmol); orange solid (78 mg , 62%); 
mp: 165-167 °C; 1H NMR (250 MHz, CDCl3) δ 9.58 (br s, 1H), 7.76 (t, J = 
1.2 Hz, 1H), 6.90 (d, J = 10.4 Hz, 1H), 6.86 (d, J = 10.4 Hz, 1H), 2.67 (qd, J 
= 7.4, 1.2 Hz, 2H), 1.26 (t, J = 7.4 Hz, 3H); 13C NMR (63 MHz, CDCl3) δ 
182.71, 179.6, 161.6, 143.8, 138.3, 135.4, 134.8, 130.1, 115.2, 24.0, 12.1; 
IR (neat, cm-1): 2919, 1635; elemental analysis (%) calcd. for C11H9NO3: C 65.02, H 
4.46, N 6.89, found: C 64.56, H 4.42, N 6.73. 
 
2,5,8-Trioxo-1,2,5,8-tetrahydroquinoline-3-carbonitrile (13c) 
 
Prepared from quinolinone 12a (0.5 mmol); orange solid (76 mg, 76%); 
1H NMR (250 MHz, d6-acetone) δ 11.68 (br s, 1H), 8.54 (s, 1H), 7.14 (d, J 
= 10.4 Hz, 1H), 7.06 (d, J = 10.4 Hz, 1H). NMR data are identical to those 
found in the literature.190  
 
Ethyl 2,5,8-trioxo-1,2,5,8-tetrahydroquinoline-3-carboxylate (13d) 
 
Prepared from quinolinone 12b (0.5 mmol); orange solid (96 mg, 
78%); 1H NMR (250 MHz, CDCl3) δ 9.63 (s, 1H), 8.66 (s, 2H), 7.00 (d, J 
= 1.0 Hz, 2H), 4.43 (q, J = 7.1 Hz, 2H), 1.41 (t, J = 7.1 Hz, 3H). NMR 
data are identical to those found in the literature.190 
 
5.4.8. Synthesis of tryptamine-quinone hybrids 14 
 
The suitable quinone 13 (0.22 mmol, 1.2 eq.) was dissolved in CHCl3 (5 mL) and then 
tryptamine (1.0 eq) was added portionwise. The mixture was vigorously stirred for 1 h 
and the reaction was monitored by TLC. When tryptamine was no longer detected, the 
solvent was removed under vacuum and the residue was chromatographed on silica 
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gel using a 90:10:1 CH2Cl2:MeOH: Et3N mixture as eluent. The residue was recrystalized 
from CHCl3-hexane to give the desired compound.  
 
4-Methyl-6-[(2-(1H-indol-3-il)ethyl)amino]quinoline-2,5,8(1H)-trione (14a) 
 
Prepared from tryptamine (0.85 mmol); red solid (45 mg, 
24%); mp: >250 °C; 1H NMR (500 MHz, d6-DMSO) δ 11.30 
(s, 1H), 10.87 (s, 1H), 8.00 (t, J = 5.8 Hz, 1H), 7.56 (d, J = 7.8 
Hz, 1H), 7.34 (d, J = 7.8 Hz, 1H), 7.25 (s, 1H), 7.07 (t, J = 7.5 
Hz, 1H), 6.99 (t, J = 7.5 Hz, 1H), 6.36 (s, 1H), 5.61 (s, 1H), 
3.50 (q, J = 7.3 Hz, 2H), 3.01 (t, J = 7.3 Hz, 2H),), 2.45 (app. s, 3H); 13C NMR (126 MHz, 
d6-DMSO) δ 179.07, 160.48, 150.35, 149.45, 143.16, 136.22, 127.07, 126.39, 123.15, 
122.81, 121.01, 118.33, 118.18, 111.42, 110.93, 110.80, 94.51, 42.84, 23.31, 21.66;  IR 
(neat, cm-1): 3301, 3276, 1651, 1618, 1568, 1460, 1369, 1278, 740; HRMS (MALDI-
TOF): found m/z 370.1168 [M+Na+]+, calcd.for C20H17N3O3Na 370.1174. 
 
6-[(2-(1H-Indol-3-yl)ethyl)amino]-2,5,8-trioxo-1,2,5,8-tetrahydroquinoline-3-
carbonitrile (14b) 
 
Prepared from 5-methoxytryptamine (0.3 mmol); purple 
solid (40 mg, 62%); mp: >250 °C; 1H NMR (250 MHz, d6-
DMSO) δ 12.82 (s, 1H), 10.91 (s, 1H), 8.53 (s, 1H), 8.26 (t, 
J = 5.9 Hz, 1H), 7.58 (d, J = 7.8 Hz, 1H), 7.36 (d, J = 7.8 Hz, 
1H), 7.27 (d, J = 2.0 Hz, 1H), 7.09 (t, J = 7.8 Hz, 1H), 7.01 
(t, J = 7.8 Hz, 1H), 5.76 (s, 1H), 3.53 (q, J = 7.0 Hz, 2H), 3.03 (t, J = 7.0 Hz, 2H); 13C NMR 
(63 MHz, d6-DMSO) δ 177.5, 174.5, 160.4, 149.2, 146.2, 144.4, 136.6, 127.4, 123.6, 
121.4, 118.7, 118.5, 115.9, 111.8, 111.6, 111.3, 106.3, 97.5, 43.3, 23.7; IR (neat, cm-1): 
3353, 3228, 2343, 1665, 1578, 1560, 1461, 1255, 741; HRMS (MALDI-TOF): found m/z 
359.1135 [M+1]+, calcd. for C20H15N4O3 359.1144. 
 
Ethyl 6-[(2-(1H-indol-3-yl)ethyl)amino]-2,5,8-trioxo-1,2,5,8-tetrahydroquinoline-3-
carboxylate (14c) 
 
Prepared from tryptamine (0.85 mmol); purple solid 
(66 mg, 32%); mp: >250 °C; 1H NMR (250 MHz, d6-
DMSO) δ 12.20 (br s, 1H), 10.91 (br s, 1H), 8.31 (s, 1H), 
8.12 (t, J = 5.0 Hz, 1H), 7.58 (d, J = 7.8 Hz, 1H), 7.36 (d, 
J = 7.8 Hz, 1H), 7.28 (s, 1H), 7.09 (t, J = 7.8 Hz, 1H), 
7.01 (t, J = 7.8 Hz, 1H), 5.70 (s, 1H), 4.26 (q, J = 7.1 Hz, 2H), 3.52 (q, J = 6.8 Hz, 2H), 3.03 
(t, J = 6.8 Hz, 2H), 1.30 (t, J = 7.1 Hz, 3H); 13C NMR (63 MHz, d6-DMSO) δ 177.6, 164.6, 
154.0, 149.3, 139.8, 138.8, 136.3, 127.1, 123.2, 121.8, 121.1, 118.4, 118.3, 111.5, 
111.0, 110.6, 97.1, 60.6, 42.9, 23.4, 14.2. IR (neat, cm-1): 3250, 3222, 1720, 1562, 1468, 
1256, 1228, 738; HRMS (MALDI-TOF): found m/z 406.1404 [M+1]+, calcd. for 
C22H20N3O5 406.1403. 
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6-[(2-(5-Methoxy-1H-indol-3-yl)ethyl)amino]-2,5,8-trioxo-1,2,5,8-
tetrahydroquinoline-3-carbonitrile (14d) 
 
Prepared from 5-methoxytryptamine (0.85 mmol); 
purple solid (92 mg, 43%); mp: >250 °C; 1H NMR (500 
MHz, d6-DMSO) δ 12.79 (br s, 1H), 10.70 (br s, 1H), 8.53 
(s, 1H), 8.24 (t, J = 6.0 Hz, 1H), 7.23 (d, J = 8.7 Hz, 1H), 
7.21 (d, J = 2.1 Hz, 1H), 7.05 (d, J = 2.1 Hz, 2H), 6.71 (dd, 
J = 8.7, 2.1 Hz, 1H), 3.77 (s, 3H), 3.51 (dd, J = 13.8, 7.0 
Hz, 2H), 2.98 (t, J = 7.0 Hz, 2H); 13C NMR (126 MHz, d6-DMSO) δ 177.5, 174.1, 160.0, 
153.4, 149.2, 145.9, 144.4, 131.7, 127.8, 124.2, 115.7, 112.4, 111.5, 111.1, 106.6, 
100.4, 97.4, 79.6, 55.7, 43.4, 23.8; IR (neat, cm-1): 3294, 2228, 1656, 1586, 1562, 1316, 
1260, 1210, 790; HRMS (MALDI-TOF): found m/z 411.1087 [M+Na+]+, calcd. for 
C21H16N4O4Na 411.1070. 
 
3-Methyl-6-[(2-(5-methoxy-1H-indol-3-il)ethyl)amino]quinolin-2,5,8(1H)-trione (14e) 
 
Prepared from 5-methoytryptamine (0.3 mmol); purple 
solid (40 mg, 56%); mp: desc. at 148 °C; 1H RMN (250 
MHz, d6-DMSO) δ 11.57 (s, 1H), 10.69 (s, 1H), 8.31 (s, 
1H), 7.96 (s, 1H), 7.72 (s, 1H), 7.23-7.19 (m, 2H), 7.04 (s, 
1H), 6.70 (d, J = 7.1 Hz, 1H), 5.57 (s, 1H), 3.75 (s, 3H), 
3.49-3.42 (m, 2H), 2.97 (t, J = 7.6 Hz, 2H), 2.06 (s, 3H); 13C 
RMN (63 MHz, d6-DMSO) δ 178.5, 175.3, 162.3, 153.0, 148.5, 131.3, 127.4, 123.8, 
112.1, 111.2, 110.8, 99.9, 95.1, 79.2, 55.3, 42.9, 23.4, 16.5; IR (neat, cm-1): 3326; 3218 , 
1649 , 1624 , 1255, 1200; HRMS (MALDI-TOF): found m/z 400.1278 [M+Na+]+, calcd.for 
C21H19N3O4Na 400.1273. 
 
3-Ethyl-6-[(2-(5-methoxy-1H-indol-3-il)ethyl)amino]quinoline-2,5,8(1H)-trione (14f) 
 
Prepared from 5-methoytryptamine (0.3 mmol); 
purple solid (33mg, 47%); mp: desc. at 151 °C; 1H RMN 
(250 MHz, d6-DMSO) δ 10.71 (d, J = 1.0 Hz, 1H), 7.99 
(br s, 1H), 7.64 (s, 1H), 7.22 (d, J = 8.8 Hz, 2H), 7.20 (s, 
1H), 7.04 (d, J = 2.4 Hz, 1H), 6.70 (dd, J = 8.8, 2.4 Hz, 
1H), 5.58 (s, 1H), 3.75 (s, 3H), 3.51 – 3.42 (m, 2H), 2.97 (t, J = 7.2 Hz, 2H), 2.43 (qd, J = 
7.4 Hz, 1.0 Hz, 2H), 1.11 (t, J = 7.4 Hz, 3H); 13C RMN (63 MHz, d6-DMSO) δ 178.6, 175.3, 
161.9, 153.1, 148.5, 140.3, 137.7, 131.3, 129.7, 127.5, 123.8, 112.1, 111.2, 110.8, 99.9, 
95.2, 55.3, 23.4, 22.9, 12.3; IR (neat, cm-1): 3361, 3035, 1643, 1624, 1254, 1206; HRMS 
(MALDI-TOF): found m/z 392.1606 [M+1]+, calcd. for C22H22N3O4 392.1611. 
 
Methyl-6-[(2-(5-methoxy-1H-indol-3-il)ethyl)amino]quinoline-2,5,8(1H)-trione (14g) 
 
Prepared from 5-methoxytryptamine (0.85 mmol); 
purple solid (88 mg, 47%); mp: 241 °C; 1H NMR (250 
MHz, d6-DMSO) δ 11.34 (s, 1H), 10.71 (s, 1H), 8.03 (t, J = 
5.9 Hz, 1H), 7.23 (d, J = 6.3 Hz, 1H), 7.21 (s, 1H), 7.05 (d, J 
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= 2.4 Hz, 1H), 6.72 (dd, J = 8.8, 2.4 Hz, 1H), 6.37 (d, J = 0.9 Hz, 1H), 5.63 (s, 1H), 3.77 (s, 
3H), 3.49 (q, J = 7.1 Hz, 2H), 2.98 (t, J = 7.1 Hz, 2H), 2.46 (d, J = 0.9 Hz, 3H); 13C NMR (63 
MHz, d6-DMSO) δ 179.5, 174.7, 160.9, 153.4, 150.7, 149.8, 131.7, 130.7, 129.9, 127.8, 
124.2, 112.4, 111.5, 111.1, 100.3, 94.9, 79.5, 55.6, 43.3, 23.8, 22.0; IR (neat, cm-1): 
3360, 3276, 1653, 1573, 1453, 1372, 1215, 755; HRMS (MALDI-TOF): found m/z 
378.1431 [M+1]+, calcd. for C21H20N3O4 378.1454. 
 
5.4.9. Synthesis of 5,8-dimethoxy-3-[((2-(5-methoxy-1H-indol-3-yl)etil)amino)-
methyl]quinolin-2(1H)-one (15) 
 
 
Quinoline 9a (0.4 mmol, 1 eq.) and 5-methoxytriptamine (0.4 mmol, 1 eq.) were 
dissolved in anhydrous CH2Cl2 (10 mL) under argon atmosphere and 4Å molecular 
sieves were added. The mixture was stirred at room temperature for 1 h. The imine 
formation was monitored by 1H-RMN. Then, the reaction was cooled to 0 °C and 
sodium triacetoxyborohydride (1.3 eq.) was added portionwise and the mixture was 
stirred at room temperature overnight. When the reaction was finished a saturated 
Na2CO3 solution was added and it was extracted with CH2Cl2 (3 x 50 mL). The combined 
organic layers were dried over anhydrous sodium sulphate, filtered and the solvent 
was removed to give 105 mg (62%) of the title compound as a white solid.   
Mp: 122-124 °C; 1H NMR (250 MHz, CDCl3) δ 8.18 (s, 1H), 8.05 (s, 1H), 7.20 (d, J = 8.8 
Hz, 1H), 7.05 (d, J = 2.0 Hz, 1H), 6.94 (d, J = 2.4 Hz, 1H), 6.83 (d, J = 8.7 Hz, 1H), 6.75 (dd, 
J = 8.8, 2.4 Hz, 1H), 6.48 (d, J = 8.7 Hz, 1H), 3.91 (s, 3H), 3.87 (s, 5H), 3.74 (s, 3H), 3.12 – 
2.97 (m, 4H); 13C NMR (63 MHz, CDCl3) δ 161.8, 154.0, 149.8, 139.7, 133.1, 131.6, 
128.9, 128.7, 127.6, 123.4, 112.4, 112.4, 112.1, 110.9, 110.1, 101.5, 100.2, 56.3, 55.8, 
55.8, 49.5, 48.7, 25.3; IR (neat, cm-1): 3221, 1643, 1617, 1249, 1211; elemental 
analysis (%) calcd. for C23H27N3O4,: C 67.46, H 6.65, N 10.26, found: C 67.61, H 6.77, N 
10.11. 
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6.1. Calcium homeostasis and neurodegenerative diseases  
Calcium plays a central role as a second messenger in all cell types and is related to 
several biochemical pathways that include motility-related processes involving the 
cytoskeleton, secretion processes, enzyme phosphorylation/dephosphorylation and 
cellular death. Calcium is essential in excitable cells, particularly in neurons where it is 
crucial for synaptic transmission and neuronal plasticity in the neuron environment 
signalling process.  
To maintain a suitable brain function, all these processes and the movement of Ca2+ 
through the plasma membrane, endoplasmic reticulum and mitochondria are 
coordinated and controlled by a complex network formed by a vast array of Ca2+ ion 
channels, pumps and exchangers, together with G-coupled receptors and Ca2+ binding 
proteins. All these proteins contribute to Ca2+ homeostasis and have been described as 
the “neuronal Ca2+ signalling toolkit”.191  
6.1.1. Plasma membrane Ca2+ flow in neuronal physiology 
The Ca2+ influx across the cell membrane is operated by Ca2+ channels, which are 
classified into three groups according to their opening mechanism: voltage-gated 
calcium channels (VGCC), receptor-operated calcium channels (ROCC) and store-
operated calcium channels (SOCC).192 
VGCCs play a central role in neuronal impulse generation and propagation and cellular 
homeostasis associated to Ca2+ entry. These receptors are constituted by five subunits, 
namely α1, α2, β, γ and δ. They are divided into three families, Cav 1, Cav 2, Cav 3, 
depending on the α1 pore-forming subunit. Also, VGCCs can be classified into six 
classes (L, N, P, P, Q, R and T) based on the type of current accomplished. Cav 2 
channels are responsible for neurotransmitter release and initiation of synaptic 
transmission.193 
ROCC activation was performed by extracellular ligands, usually neurotransmitters, like 
the most important excitatory neurotransmitter in the brain, L-glutamate.  This 
 
191  Brini, M.; Calì, T.; Ottolini, D.; Carafoli, E. Cell. Mol. Life Sci., 2014, 71, 2787-2814. 
192  Prakriya, M.; Feske, S.; Gwack, Y.; Srikanth, S.; Rao, A.; Hogan, P. G. Nature 2006, 443, 230-233. 
193  Miyashita, T.; Oda, Y.; Horiuchi, J.; Yin, J. C.; Morimoto, T.; Saitoe, M. Neuron 2012, 74, 887-898. 
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neurotransmitter can activate two types of ionotropic receptors, namely alpha-amino-
3-hydroxy-5-methyl-4-isoxazole propionic acid receptors (AMPAR) and N-methyl-D-
aspartate receptors (NMDAR). Both are formed by 4 different subunits and are 
primarily permeable to Na+, but become permeable to Ca2+.  
SOCC are opened by the release of Ca2+ from endoplasmic reticulum. This store-
operated calcium entry was proposed as a mechanism to ensure the refilling of 
intracellular Ca2+ stores and thus contribute to Ca2+ homeostasis.194 
After depolarization, the membrane Ca2+ gradient should be recovered by the 
extrusion of Ca2+ to the extracellular space or to an intracellular Ca2+ reservoir. Ca2+ 
extrusion to the extracellular space is achieved by a plasma membrane Ca2+ ATPase 
(PMCA) and a plasma membrane Na+/Ca2+ exchanger (NCXplasm). The latter transporter 
exists in three different isoforms (NCX-1, -2 and -3), which remove calcium from the 
cytoplasm using the Na+ gradient. These three isoforms are widely expressed in 
neurons and muscles, making it difficult to ascribe a specific function to each 
exchanger. Nevertheless, the NCX-2 isoform is particularly abundant in neurons, 
suggesting a pivotal role for this exchanger in neuronal Ca2+ homeostasis. 
The PMCA pump is a P-type ATPase, which obtains energy from ATP to remove the 
cytosolic Ca2+. PMCA transporters are expressed in four different isoforms (PMCA-1, -2, 
-3 and -4), specifically distributed in the tissues. The isoforms 2 and 3 are more 
abundant in neurons and their malfunction has been reported in several 
neurodegenerative disorders.195, 196 
The main membrane proteins involved in calcium transport through the cell 
membrane are summarized in Figure 6.1. 
 
194 Putney Jr, J. W. Cell Calcium 1986, 7, 1-12. 
195  Schultz, J. M; Yang, Y.; Caride, A. J.; Filoteo, A. G.; Penheiter, A. R.; Lagziel, A. Morell, R. J.; Mohiddin 
S. A.; Fananapazir. L.; Madeo, A. C.; Penniston, J. T.; Griffith A. J. N. Engl. J. Med. 2005, 352, 1557-
1564. 
196 Zanni, G.; Calì, T.; Kalscheuer, V. M.; Ottolini, D.; Barresi, S.; Lebrun, N.; Montecchi-Palazzi. L.; Hu, H.; 
Chelly, J.; Bertini, E.; Brini, M.; Carafoli, E. Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 14514-14519. 
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Figure 6.1 
6.1.2. Endoplasmic reticulum as a calcium store  
Endoplasmic reticulum is the major Ca2+ store inside the cell and has an important role 
in Ca2+ homeostasis and several signalling pathways involving Ca2+ release to cytoplasm 
(Figure 6.2). Two receptors take part in the release of calcium from the ER: inositol-
1,4,5-tris-phosphate receptors (InsP3Rs), which are widely expressed in all cell types, 
and ryanodine receptors (RyRs), which are extensively expressed in neurons.  
The activation of RyRs is in principle associated to an increase in intracellular calcium 
level, However these receptors can be triggered by other second messengers like 
cAMP. Their activation causes a selective increase in intracellular Ca2+ concentration.  
While the most important activator of InsP3R is Ca2+, intracellular Ca2+ can also inhibit 
these channels, depending on concentration. A low intracellular Ca2+ concentration 
activates the receptor and the channel is opened, and when the Ca2+ concentration 
achieves a high level these channels close.197  
After a massive Ca2+ entry in the cell, the neuron can restore the calcium resting levels 
by ER reuptake. The Ca2+ is transported into the ER from cytoplasm by the SERCA 
pump. SERCA (sarcoendoplasmic reticulum calcium transport ATPase) is a P-type 
 
197  Taylor, C. W.; Laude, A. J. Cell Calcium 32, 2002, 321-334. 
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ATPase encoded by three different genes, and the alternative splicing generates 
additional isoforms.198 
 
Figure 6.2 
6.1.3. Mitochondria and calcium homeostasis  
Mitochondria are the second major intracellular Ca2+ storage system, together with ER. 
Mitochondria play a pivotal role in the calcium control and homeostasis, due to their 
strategic placement close to both ER and plasma membrane Ca2+ channels,199 which 
enables mitochondria to accumulate in their matrix the Ca2+ released either by ER or 
plasma membrane channels. An increase in the mitochondrial Ca2+ concentration 
causes an improvement in the activity of the Ca2+-dependent NADH dehydrogenases 
involved in the tricarboxylic acid cycle, and hence an increased ATP biosynthesis.200, 201 
As discussed in Chapter 1, the Ca2+-gradient maintenance by pumps and exchangers in 
plasma membrane, endoplasmic reticulum and mitochondria is an ATP-dependent 
event and can consume 80% of total ATP in neuronal cells. 202  
The mitochondrial Ca2+ influx is mediated by the mitochondrial calcium uniporter 
(MCU), using as the driving force the negative electrochemical gradient generated by 
the mitochondrial respiratory chain. This channel is present in the inner mitochondrial 
 
198  Brini, M.; Carafoli, E. Physiol. Rev. 2009, 89, 1341-1378. 
199  Strokin, M.; Reiser, G. Neurochem. Res. 2016, 41, 1250-1262. 
200  McCormack, J. G.; Denton, R. M. Proc. Nutr. Soc. 1990, 49, 57-75. 
201  McCormack, J. G.; Halestrap, A. P.; Denton, R. M. Physiol. Rev. 1990, 70, 391-425. 
202  Engl, E.; Attwell, D. J. Physiol. 2015, 593, 3417-3429. 
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membrane (IMM). MCU binds regulatory proteins such as the MCU regulator 1 
(MCUR1), MCUR2 and the essential MCU regulator (EMRE). MCUR1 has two EF-hand 
Ca2+ domains, i.e., helix-loop-helix motifs able to bind calcium, which participate in the 
regulation of MCU forming a complex together with MCUR1 and EMRE.203 The opening 
of the mitochondrial permeability transition pore (mPTP) is triggered by the 
accumulated Ca2+ reaching a threshold in the mitochondrial matrix or by an increase in 
the formation of radical species. This pore opening causes a strong membrane 
depolarization, diminishing ATP production.204 Thus, mPTP opening is suggested to be 
a first trigger to the activation of cell death mechanisms.205, 206 
Ca2+ efflux from mitochondria plays a fundamental role in the maintenance of 
mitochondrial Ca2+ homeostasis. The calcium efflux rate is controlled by mNCX, a 
Na+/Ca2+ exchanger, localized in the inner mitochondrial membrane. The existence of 
this exchanger was first described in 1974207 and further studies underlined its 
important roles in heart208, brain209  and pancreas.210  Since this transporter also 
mediates Li+/Ca2+ exchange, it is also known as NCLX. mNCX specific and inducible 
ablation causes Ca2+ overload in cells, an increase in radical formation and mPTP 
opening.  
The main proteins involved in calcium transport through the mitochondrial membrane 
are summarized in Figure 6.3. 
 
203  Patron, M.; Checchetto, V.; Raffaello, A.; Teardo, E.; Vecellio Reane, D.; Mantoan, M.; Granatiero, V.; 
Szabò, I.; De Stefani, D.; Rizzuto, R. Mol. Cell 2014, 53, 726-737. 
204  Stavrovskaya, I. G.; Kristal, B. S. Free Radic. Biol. Med. 2005, 38, 687-697. 
205  Zamzami, N.; Marchetti, P.; Castedo, M.; Hirsch, T.; Susin, S. A.; Masse, B.; Kroemer, G. FEBS Lett. 
1996, 384, 53-57. 
206  Vaseva, A. V.; Marchenko, N. D.; Ji, K.; Tsirka, S. E.; Holzmann, S.; Moll, U. M. Cell 2012, 149, 1536-
1548. 
207  Carafoli, E.; Tiozzo, R.; Lugli, G.; Crovetti, F.; Kratzing, C. J. Mol. Cell. Cardiol. 1974, 6, 361-371. 
208  Griffiths, E. J.; Balaska, D.; Cheng, W. H. BBA. Bioenergetics 2010, 1797, 856-864. 
209  Castaldo, P.; Cataldi, M.; Magi, S; Lariccia, V.; Arcangeli, S.; Amoroso, S. Prog. Neurobiol. 2009, 87, 
58-79. 
210  Nita, I. I.; Hershfinkel, M.; Kantor, C.; Rutter, G. A.; Lewis, E. C.; Sekler, I. FASEB J. 2014, 28, 3301-
3312. 
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Figure 6.3 
6.1.4. Calcium deregulation in neurodegenerative disease 
Intracellular calcium deregulation is one of the most striking hallmarks in NDD. Also, 
the poor control of Ca2+ concentrations is connected by a complex biochemical 
network with other malfunctions, including, among others, oxidative stress, energy 
impairment and inadequate proteostasis. Parkinson´s disease is characterized by the 
accumulation of α-synuclein aggregates, which cause impairment in plasmatic 
membrane permeability and lead to an increase in intracellular calcium concentration. 
In amyotrophic lateral sclerosis (ALS), an abnormally high exposition to glutamate 
promotes an increment in Ca2+ entry through AMPA receptors. The connection 
between Alzheimer´s disease (AD) development and Ca2+ deregulation led to the 
elaboration of the calcium hypothesis in AD. In this hypothesis, the aggregation of the 
amyloid beta peptide and other amyloidogenic proteins increases cytosolic Ca2+ entry 
through NMDA activation and by plasmatic membrane impairment. The subsequent 
increase in cytosolic Ca2+ entry causes the opening of VGCC, further increasing Ca2+ 
entry. Particularly interesting is the role of CALHM1, which is hypothesized to have a 
role in the regulation of amyloid metabolism.211  The cytosolic calcium overload 
increases the activity of Ca2+-dependent proteases and the aggregation of Aβ. Also, 
some mutations in proteins related with familiar Alzheimer’s disease like presenilin-1 
 
211  Dreses-Werringloer, U.; Lambert, J. C.; Vingtdeux, V.; Zhao, H.; Vais, H.; Siebert, A.; Jain, A.; Koppel, 
J.; Rovelet-Lecrux, A.; Hannequin, D.; Pasquier, F.; Galimberti, D.; Scarpini, E.; Mann, D.; Lendon, C.; 
Campion, D.; Amouyel, P.; Davies, P.; Foskett, J. K.; Campagne, F.; Marambaud, P. Cell 2008, 133, 
1149-1161. 
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(PS-1) were linked with ER Ca2+ release though RyRs and InsP3Rs.212, 213 These findings 
highlight the importance of calcium in the physiological function and in pathogenesis 
development. Actually, the NMDA antagonists memantine and riluzole have been 
approved for the treatment of AD and ALS, respectively. However, mitochondrial 
calcium modifiers are poorly developed for this purpose in spite the buffering role and 
the control of calcium concentrations near to the plasma membrane and ER by 
mitochondria. Only some VGCC blockers have reached clinical trial stage in AD, 
although their study was discontinued due to cardiovascular side effects.  
6.2. mNCX blockers  
6.2.1. First mNCX antagonists 
The mNCX transporter is a major regulator in the mitochondrial calcium control. 
Intramitochondrial calcium concentration, in turn, regulates other processes like ATP 
formation, mPTP activation and radical species formation. However, the 
neuroprotective role for this transporter in NDDs is still unclear, and selective mNCX 
ligands (agonist and inhibitors) are needed to understand the role played by this 
exchanger in NDD and use it as a target towards the design of neuroprotective 
compounds. 
The first blockers described for mNCX were L-type calcium channel blockers, including 
diltiazem, prenylamine, and verapamil.214 The lack of selectivity of these compounds 
for the various types of calcium channels prevented their use in the pharmacological 
characterization of the mNCX exchanger. Clonazepam and other benzodiazepines also 
were described as mNCX inhibitors,215 but they were not suitable because the outer 
mitochondrial membrane contains specific benzodiazepine receptors that interfere 
with the calcium fluxes promoted by mNCX.216  
 
212  Stutzmann, G. E.; Smith, I.; Caccamo, A.; Oddo, S.; LaFerla, F. M.; Parker, I. J. Neurosci. 2006, 26, 
5180-5189. 
213  Cheung, K. H.; Shineman, D.; Müller, M.; Cárdenas, C.; Mei, L.; Yang, J.; Tomita, T.; Iwatsubo, T.; Lee, 
V. M.; Foskett, J. K. Neuron 2008, 58, 871-883. 
214  Vaghy, P. L.; Johnson, J. D.; Matlib, M. A.; Wang, T.; Schwartz, A. J. Biol. Chem. 1982, 257, 6000-6002. 
215  Matlib, M. A.; Schwartz, A. Life Sci. 1983, 32, 2837-2842. 
216  O’Rourke, B. Annu. Rev. Physiol. 2007, 69, 19-49. 
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6.2.2. CGP-37157, a mNCH inhibitor, as a lead for drug discovery  
The benzothiazepine derivative known as CGP-37157 was the first compound reported 
as a selective mNCX antagonist,217 showing a 20-fold more potent mNCX blocking 
activity that clonazepam or diltiazem. CGP-37157 was therefore regarded as a 
powerful tool to understand the physiology of mNCX and its role in disease 
development. CGP-37157 has been shown to be neuroprotective in a number of 
cellular models. Thus, it provided protection from neuronal death induced by 
veratridine in both chromaffin cells and rat hippocampal slices,218 it also protected rat 
hippocampal slices against glutamate or ischemia/reperfusion-induced stress,219 SH-
SY5Y human neuroblastoma cells against 70 mM K+ stimulation.220  and primary 
cultures of rat cortical neurons against NMDA insults.221 Furthermore, CGP37157 has 
been shown to extend the lifespan of the nematode Caenorhabditis elegans.222 On the 
other hand, it failed to protect either chromaffin cells or rat hippocampal slices against 
the combination of oligomycin A and rotenone, two inhibitors of oxidative 
phosphorylation that induce mitochondrial stress, as mentioned in chapter 3.218b, 219  
 
217  Chiesi, M.; Schwaller, R.; Eichenberger, K. Biochem. Pharmacol. 1988, 37, 4399-4403. 
218 (a) Nicolau, S. M.; de Diego, A. M. G.; Cortés, L.; Egea, J.; González, J. C.; Mosquera, M.; López, M. G.; 
Hernández-Guijo, J. M.; García, A. G. J. Pharmacol. Exp. Ther. 2009, 330, 844-854. (b) Nicolau, S. M.; 
Egea, J.; López, M. G.; García, A. G. Biochem. Biophys. Res. Commun. 2010, 400, 140-144. 
219  González-Lafuente, L.; Egea, J.; León, R.; Martínez-Sanz, F. J.; Monjas, L.; Pérez, C; Merino, C.; de 
Diego, A. M. G.; Rodríguez-Franco, M. I.; García, A. G.; Villarroya, M.; López, M. G.; de los Ríos, C. ACS 
Chem. Neurosci. 2012, 3, 519-529. 
220  Martínez-Sanz, F. J.; Lajarín-Cuesta, R.; Moreno-Ortega, A. J.; González-Lafuente, L.; Fernández-
Morales, J. C.; López-Arribas, R.; Morales, J. C.; López-Arribas, R.; Cano-Abad, M. F.; de los Ríos, C. 
ACS Chem. Neurosci. 2015, 6, 1626-1636. 
221  Ruiz, A.; Alberdi, E.; Matute, C. Cell Death Dis. 2014, 5, e1156. 
222  García-Casas, P.; Arias del Val, J.; Álvarez-Illera, P.; Wojnicz, A.; de los Ríos, C.; Fonteriz, R. I.; 
Montero, M.; Álvarez, J. Front. Aging Neurosci. 2019, 10, 440.  
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Although initially considered a selective mNCX blocker, several studies show the ability 
of CGP-37157 to block additional calcium channels and transporters, including 
SERCA223 and CALHM1.224 This lack of selectivity questions the outcome of experiments 
where CGP-37157 was regarded to have selectivity towards mNCX. 225  The 
pharmacological characterization of CGP-37157 shows additional limitations, including 
the fact that it has always been tested as a racemic mixture, in spite of being chiral. 
Enantiopure CGP-37157 may well improve selectivity and potency as described for the 
case of D-cis-diltiazem, which displays a strong enantioselectivity in mNCX blockade.214 
Another limitation in the pharmacological investigation of CGP-37157 is its poor water 
solubility, which is due to its high lipophillicity. In an effort to address these problems, 
several libraries of CGP-37157 analogues have been prepared,220, 226 and in particular 
the pyridothiazepines I, where the benzene-fused ring of the parent molecule has been 
replaced by a pyridine, show an improved water solubility while keeping the 
neuroprotective properties and having a higher capacity to regulate the mitochondrial 
Ca2+ clearance.226 
Another significant problem posed by CGP-37157 is its short half-life in animal models 
(0.9 h).225 The sulfide moiety undergoes rapid oxidative metabolism, leading to the 
correspinding sulfoxides and sulfones. These metabolites have not been 
pharmacologically characterized and they may well interfere in the in vivo 
experiments.  
 
 
223  Nerumann, J. T.; Diaz-Sylvester, P. L.; Fleischer, S.; Copello, J. A. Mol. Pharmacol. 2011, 79, 141-147. 
224  Moreno-Ortega, A. J.; Martínez-Sanz, F. J.; Lajarín-Cuesta, R.; de los Ríos, C.; Cano-Abad, M. F. 
Neuropharmacology 2015, 95, 503-510. 
225  Pei, Y.; Lilly, M. J.; Owen, D. J.; D'Souza, L. J.; Tang, X. -Q.; Yu, J.; Nazarbaghi, R.; Hunter, A.; Anderson, 
C. M.; Glasco, S.; Ede, N. J.; James, I. W.; Maitra, U.; Chandrasekaran, S.; Moos, W. H.; Ghosh, S. S. J. 
Org. Chem. 2003, 68, 92-103. 
226  Martínez-Sanz, F.-J.; Lajarín-Cuesta, R.; González-Lafuente, L.; Moreno-Ortega, A. J.; Punzón, E.;  
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6.3. Enantioselective sulfoxide synthesis and attempted kinetic 
resolution of the CGP-37157 enantiomers 
From the drug discovery perspective, the transformation of the sulfide group in CGP-
37157 into a sulfoxide can be a good strategy to improve metabolic stability while 
simultaneously increasing the water solubility of the parent molecule (see below). 
Furthermore, it should be possible to carry out the oxidation of sulfide to sulfoxide by 
enantioselective reactions, and also to use such chemistry to isolate the starting sulfide 
in enantiomerically pure form via a kinetic resolution process. For these reasons, we 
embarked on a study of the enantioselective oxidation of the sulphur atom in CGP-
37157. 
6.3.1. Enantioselective synthesis of sulfoxides: Literature precedent 
Sulphur is the fifth commonest atom in drug molecules and sulphur-containing drugs 
have an increasing impact on therapeutic treatments.227,228 Sulphur can exist in several 
forms in organic molecules but the commonest are the sulfide, sulfoxide and sulfone. 
The oxidation state of sulphur is -2 in sulfides and it is in a sp3-hybridization state, 
presenting two electron pairs. However, when the sulfide is oxidized to sulfoxide, the 
sp3-hybridized sulphur atom only has a single electron pair and may be chiral. The 
sulphur atom in sulfoxides displays an oxidation state of 0. Finally, the sulfoxide 
sulphur atom can be oxidized to the S2+ state becoming a sulfone, which is again 
achiral. These oxidation processes are really dynamic in biological media and is carried 
out by several cytochromes. The oxidation from sulfides to sulfoxides is not an 
irreversible pathway and enzymes like methionine sulfoxide reductase (Msr) A and B 
can reduce sulfoxides back to sulfides.  
A particularly interesting property of sulfoxides, compared to sulfides and sulfones, is 
their improved water solubility, due to an increase in the dipole moment and dielectric 
constant.229 An example for this solubility improvement is famotidine sulfoxide, that 
shows a 10.512 mg/mL solubility in water, while that of famotidine itself is 1.565 
 
227 Scott, K. A.; Njardarson, J. T. Top. Curr. Chem. 2018, 376, 5.  
228 Ilardi, E. A.; Vitaku, E.; Njardarson, J. T. J. Med. Chem. 2014, 57, 2832-2842. 
229 Clark, T.; Murray, J. S.; Lane, P.; Politzer, P. J. Mol. Model. 2008, 14, 689-697. 
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mg/mL.230 , 231  The other important difference is the chiral nature of sulfoxides, 
compared with achiral sulfides and sulfones, which is highly relevant to their 
pharmacokinetic and pharmacodynamic properties.232 For instance, esomeprazole, the 
S-(-)-enantiomer of omeprazole, is metabolized at a lower rate than R-omeprazole. The 
chirality of sulfoxides and its pharmacological implications has prompted much interest 
in the development of new synthetic procedures that enable their enantioselective 
synthesis.  
Enantiopure sulfoxides can be synthesised by nucleophilic substitution or by 
asymmetric oxidation of sulfides. The former strategy involves the use of chiral 
sulfinates, and is compromised by the fact that only very few sulfinates are readily 
available. Thus, the most attractive approach to the synthesis of enantiopure 
sulfoxides is based on asymmetric sulfide oxidations, based on metallic complex-
catalysed reactions.  
The first method for the enantiopure synthesis of sulfoxides, described almost 
simultaneously by Kagan and co-workers233 and Modena and co-workers,234 involved 
the use of a titanium complex similar to the one developed by Sharpless for the 
epoxidation of allylic alcohols (Scheme 6.1). The main difference was the use of 1 mol 
equivalent of diethyl tartrate, the source of chirality, in the Kagan method, while 
Modena described the use of a large excess of this reagent. Both research groups 
applied their method to the enantioselective synthesis of biologically active 
compounds. 
 
Scheme 6.1 
 
230  Moh, J. H.; Choi, Y. H.; Lim, K. M.; Lee, K. -W.; Shin, S. S.; Choi, J. K.; Koh, H. J.; Chung, S. Bioorg. Med. 
Chem. Lett. 2004, 14, 1757-1760. 
231  Hajnal, K.; Gabriel, H.; Aura, R.; Erzsébet, V.; Blanka, S. S. Acta. Med. Marisiensis 2016, 62, 102. 
232  Bentley, R. Chem. Soc. Rev. 2005, 34, 609-624. 
233  Pitchen, P.; Dunach, E.; Deshmukh, M. N.; Kagan, H. B. J. Am. Chem. Soc. 1984, 106, 8188-8193. 
234  Di Furia, F.; Modena, G.; Seraglia, R. Synthesis 1984, 325-326. 
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Bolm and Bienewald developed a new method for asymmetric sulfoxidation235 based 
on a vanadium catalyst and using a chiral shift-based ligand derived from a chiral 
alcohol as the source of chirality, and hydrogen peroxide as the oxidant in a 
heterogenous reaction system. This method has the advantage over the previous one 
of requiring only very small amounts of the chiral materials (Scheme 6.2).236 Other 
complexes of metals such as titanium, vanadium, iron, manganese, copper, aluminium, 
zirconium, niobium and molybdenum have been used to catalyse the asymmetric 
oxidation of sulfides, generally in poor enantioselectivities. 
 
Scheme 6.2 
Finally, a combination of peracids with enantiomerically pure oxaziridines, 
hydroperoxides, or hypervalent iodine-based systems can promote the 
enantioselective synthesis of sulfoxides. However, theses method have received a 
limited amount of attention because sulfoxides are obtained in modest enantiopurities 
and the reagents must be used in near stoichiometric amounts, which reduces the 
efficiency of the method on a large scale.236 
6.3.2. Studies towards the synthesis of both enantiomers of CGP-37157 
This part of the thesis was carried out at the laboratory of Professor James C. 
Anderson, University College, London, as part of the requirements for the 
“International Thesis” label. 
(a) Planning of the sulfide kinetic resolution based on an enantioselective 
sulfoxidation 
According to our initial plan, both enantiomers of the enantiopure benzothiazepine 
should be accessible through a kinetic resolution process based on the Kagan chiral 
 
235  Bolm, C.; Bienewald, F. Angew. Chem. Int. Ed. Engl. 1996, 34, 2640-2642. 
236  Agranat, I.; Caner, H. Drug Discov. Today 1999, 4, 313-321. 
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sulfoxide synthesis.237 The sulfoxide and unreacted sulfide would be separated by a 
simple chromatography and a subsequent sulfoxide reduction would provide the 
enantiopure benzothiazepine. The commercial availability of both enantiomers of the 
source of chirality, i.e. diethyl tartrate, ought to provide flexibility for the process. 
(Scheme 6.3). 
 
Scheme 6.3 
If the sulfide oxidation would prove not to be amenable to the planned kinetic 
resolution, an alternative approach would be a kinetic resolution of both 
diastereomers of the sulfoxide, based on the oxidation of one of them to a sulfone 
using a similar catalytic system238 (Scheme 6.4). Then, the sulfoxide and the sulfone 
could be separated, and the sulfoxide reduced to the enantiopure sulfide.  
 
Scheme 6.4 
 
237 Makino, K.; Yoneda, T.; Ogawa, R.; Kanase, Y.; Tabata, H.; Oshitari, T.; Natsugari, H.; Takahashi, H. 
Tetrahedron Lett. 2017, 58, 2885-2888. 
238  Scettri, A.; Bonadies, F.; Lattanzi, A.; Senatore, A.; Soriente, A. Tetrahedron: Asymmetry 1996, 7, 657-
658. 
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To begin our study, the synthesis of the racemic benzothiazepine225 was carried out by 
reduction of the suitable benzophenone, which is commercially available, to the 
corresponding diphenylcarbinol, which was then reacted with methyl thioglycate in the 
presence of trifluoroacetic acid to afford racemic CGP-37157 in good overall yield 
(Scheme 6.5).  
 
Scheme 6.5 
As mentioned above, our planned the next step was a kinetic resolution based on an 
enantioselective sulfide Kagan-Modena oxidation. Several combinations of solvents, 
temperature, chiral ligands (diethyl tartrate, L1; mandelic acid, L2; hydrobenzoin, L3) 
and equivalents of oxidant were tested. Unfortunately, as shown in Scheme 6.6 and 
Table 6.1, all our attempts to stop the reaction at mid-conversion, which would be 
ideal for a kinetic resolution, never gave an enantiometric excess of the sulfoxide 
above 17%. In fact, the best result in terms of enantiomeric excess was only 27% with 
an 89% of conversion (entry 11). This enantiomeric excess was measured by 1H-NMR  
 
Scheme 6.6 
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Table 6.1 
Entry Solvent 
Temperature 
(°C) 
Ligand 
Mmol eq. 
peroxide 
Time 
(h) 
Conversion 
(%) 
ee of 
16 (%) 
1 CH2Cl2 r.t. -- 1.1 24 0 -- 
2 CH2Cl2 -20 L1 1.1 10 0 -- 
3 CH2Cl2 r.t. L1 1.1 4 85 9 
4 CH2Cl2 0 L1 1.1 48 82 22 
5 CH2Cl2 0 L1 0.8 48 60 17 
6 CHCl3 0 L1 1.1 48 91 21 
7 Toluene 0 L1 1.1 48 48 0 
8 CH2Cl2 0 L2 1.1 48 0 - 
9 CH2Cl2 r.t. L2 1.1 48 90 0 
10 CH2Cl2 0 L3 1.1 48 0 - 
11 CH2Cl2 r.t. L3 1.1 48 89 27 
 
using (R)-BINOL as chiral shift reagent. Together with the major trans sulfoxide 16, 
these experiments afforded small amounts of its cis diastereoisomer 17 (dr was about 
3:1 for all experiments) and the corresponding sulfone 18. 
The major diastereoisomer of the sulfoxide was characterized by NMR, and its 
structure was determined to be trans on the basis of NOESY spectra, coupled with ab 
initio calculations. Thus, from NOESY experiments, the NOE 1D spectra can be obtained 
in order to measure the intensity of the NOE effects between the various protons of 
the molecule. To determine the distances between two nuclei (r), a well-known 
approach was employed based on the NOE effect (a), which is inversely proportional to 
6th potency of distance.  
rij= rref (aref/aij)1/6 
The structure of both diastereoisomers was minimized in Spartan, using Hartree-Fock 
calculations at the 6-31G** level. Then, starting from a well-stablished distance such as 
the one between protons A and B and their NOE intensities, the remaining distances 
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were calculated using the above formula. The critical distance calculated between 
protons C and D was 3.6 Å for the minimized trans-diastereoisomer, but smaller in the 
cis-diastereoisomer. The other calculated distances were similar for both 
diastereoisomers (Figure 6.4) 
 
Figure 6.4 
In view of the poor results of the kinetic resolution based on the Kagan procedure, the 
oxidation was attempted based on the Bolm method.235 In this case, the reaction was 
carried out in dichloromethane at room temperature, using a higher excess of the 
vanadium source and the chiral ligand than in the original reference, since no 
conversion took place otherwise. The reaction was fully diastereoselective and no 
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over-oxidation to sulfone was observed, but the best enantioselection was 16% ee, for 
80% conversion (Scheme 6.6 and Table 6.2). 
 
Scheme 6.6 
Table 6.2 
Entry Solvent Temperature (°C) Time 
(h) 
Conversion 
(%) 
ee (%) 
1 CH2Cl2 r.t. 48 80 16 
2 CH2Cl2 0 24 0 - 
3 CHCl3 r.t. 48 78 0 
 
 (b) Attempted resolution based on the use of menthol as an auxiliary  
After the lack of success of the kinetic resolution protocols, a diasteroselective 
nucleophilic attack was attempted using an enantiopure menthyl thioglycate as a chiral 
auxiliary. This strategy had been previously described for the synthesis of thiazolo[2,3-
a]isoquinolines (Scheme 6.7), with a moderate stereoselectivity.239 In this particular 
case, the menthol auxiliary was released as a consequence of a cyclization step. 
 
Scheme 6.7 
In our case, the cyclization step did not take place and instead we isolated compound 
20, arising from the nucleophilic displacement of the hydroxyl in the starting 
diphenylcarbynol 14 by the mercapto group in compound 19, generated by 
 
239  Rozwadowska, M. D.; Sulima, A.; Gzella, A. Tetrahedron: Asymmetry 2002, 13, 2329-2333. 
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esterification of menthol with thioglycolic acid (Scheme 6.8). Not unexpectedly in view 
of the SN1 mechanism that can be presumed for this step, no diasteroselectivity was 
observed. More importantly for our goal, the two diastereoisomers formed due to the 
presence of the menthol moiety were inseparable by chromatographic techniques. 
 
Scheme 6.8 
 
6.4. Preliminary pharmacological characterization of CGP-37157-derived 
sulfoxides and sulfones  
Some pharmacological studies of compounds 16-18 have been carried out at the group 
of Dr. Rafael León (Hospital de la Princesa and Instituto Teófilo Hernando, Universidad 
Autónoma de Madrid), and further characterization is in progress. 
6.4.1. Cytotoxicity 
The cytotoxicity elicited by 16-18 in the AREc32 cell line was measured as MTT 
reduction in the presence of increasing concentrations of the compound under assay 
(24 hours). These studies demonstrated the lower toxicity of these compounds 
compared with the parent sulfide 15 (CGP-37157) (Figure 6.5).  
6.4.2. Nrf2 induction 
The Nrf2/ARE pathway constitutes the main mechanism of the phase II antioxidant 
response and is study is therefore relevant to our purposes. The Nrf2 induction activity 
of compounds (µM) in the AREc32 cell line is represented in bar graph form, 
normalized to basal conditions. (Figure 6.6 and Table 6.3). Interestingly, there is an 
stereoselectivity effect on this activity, since the sulfoxide 16 displays a better Nrf-2 
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induction compared with parent sulfide CGP-37157, while the other sulfoxide 
diastereoisomer (17) and the sulfone 18 show a similar activity compared with the 
parent molecule. These findings are relevant for the in vivo characterization of CGP-
37157, since both the sulfoxide and the sulfone have been characterized as its 
 
Figure 6.5 
 
Figure 6.6 
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Table 6.3 
Compound CD 
CGP-37157 (15) -- 
16 12.81 ± 0.89 
17 >30 
18 >30 
 
metabolites. It is interesting to note that in these experiments the reference molecule 
CGP-37157 was unable to double Nrf2 expression, which decreased at concentrations 
higher than 10 M, probably due to its cytotoxicity. 
 
6.5. Design, synthesis and characterization of a multitarget 
mitochondrial stabilizer for stroke 
Stroke (cerebral ischemia) is one of the commonest causes of morbidity and mortality 
worldwide.240 However, the Food and Drug Administration (FDA) has only approved 
the antithrombotic drug alteplase, a recombinant plasminogen activator, for the 
treatment of ischemic stroke,241 while in Japan the radical scavenger edaravone has 
been in clinical use for several years for the same indication.242 More extensive 
research is needed in the development of drugs to improve the cognitive decline after 
a stroke injury, preventing excitotoxicity and avoiding neuronal death. In this context, 
neuroprotection can be viewed as a useful preventive and therapeutic approach to 
combat the progression of ischemic damage.  
Mitochondrial dysfunction is tightly related to ischemic status 243  and has been 
proposed as a major cause of cell death in this pathology. Mitochondria, the organelles 
related with the energy production in the cell, display a broad spectrum of functions, 
 
240  Sarti, C.; Rastenyte, D.; Cepaitis, Z.; Tuomilehto, J. Stroke 2000,31, 1588-1601. 
241  Hacke, W.; Kaste, M.; Bluhmki, E.; Brozman, M.; Dávalos, A.; Guidetti, D.; Larrue, V.; Lees, K. R.; 
Medeghri, Z.; Machnig, T.; Schneider, D.; von Kummer, R.; Wahlgren, N.; Toni, D.; CASS Investigators. 
N. Engl. J. Med. 2008, 359, 1317-1329. 
242  Kobayashi, S.; Fukuma, S.; Ikenoue, T.; Fukuhara, S.; Kobayashi, S. Stroke 2019, 50, 1805–1811. 
243  Russo, E.; Nguyen, H.; Lippert, T.; Tuazon, J.; Borlongan, C. V.; Napoli, E. Brain Circ. 2018, 4, 84-94. 
Chapter 6. Aza-CGP-37157/Lipoic acid hybrids 
144 
 
some of which are related to ischemia including calcium homeostasis,191 reactive 
oxygen species formation,244 cell cycle control and apoptosis.245  
Mitochondria play a pivotal role in calcium homeostasis by the direct storage of vast 
amounts of Ca2+ from the cytoplasm, as discussed in Section 6.1.3. Glucose and oxygen 
deprivation in ischemia processes leads to an ablation of ATP synthesis and, as a 
consequence, the ATP-dependent Ca2+ extrusion systems from cytosol are unable to 
fulfil their mission. Furthermore, the cytosolic Ca2+ overload causes a massive increase 
in the release of glutamate,246 an excitatory amino acid that increases the intracellular 
Ca2+ overload by activation of the NMDA receptors. Also, NMDA activation contributes 
to increase the amount of Na+ in the cell, increasing the Ca2+ efflux rate by mNCX.247 In 
this connection, it is relevant to note that CGP-37157, an inhibitor of mNCX217  was 
described as a neuroprotector in several neurodegenerative models, including 
stroke.248  
Radical oxygen species (ROS), including superoxide, hydroxyl radical and peroxide, are 
produced under physiological conditions in the brain and are involved in several 
transduction signal pathways. 249 The electron transfer chain (ETC) is an important 
source of electrons in the formation of ROS from the oxygen molecule.250 Under 
normal conditions, the antioxidant cellular machinery balances ROS production.251 
After the occlusion of a blood vessel, an increase in ROS formation is observed. 
Moreover, a second peak in ROS production takes place upon reintroduction of 
oxygen, causing the highly damaging process known as ischemia/reperfusion injury.252 
ROS scavengers can be useful for stroke injury reduction, as well as for most 
neurodegenerative conditions, acting as antioxidants. 
 
244  Rigoulet, M.; Yoboue, E. D.; Devin, A. Antioxid. Redox Signal. 2011, 14, 459-468. 
245  Wang, C.; Youle, R. J. Annu. Rev. Genet. 2009, 43, 95-118. 
246  Hossmann, K. A. Brain Pathol. 1994, 4, 23-36. 
247  Boyman, L.; Williams, G. S.; Khananshvili, D.; Sekler, I.;  Lederer, W. J. J. Mol. Cell. Cardiol. 2013, 59, 
205-213. 
248  Martínez-Sánchez, M.; Striggow, F.; Schröder, U. H.; Kahlert, S.; Reymann, K. G.; Reiser, G. 
Neuroscience 2004, 128, 729-740. 
249  Lei, H.; Kazlauskas, A. Mol. Cell. Biol. 2014, 34, 110-122. 
250  Cino, M.; Del Maestro, R. F. Arch. Biochem. Biophys. 1989, 269, 623-638. 
251  Greenlund, L. J.; Deckwerth, T. L.; Johnson Jr, E.M. Neuron 1995, 14, 303-315. 
252  Abe, K.; Tonomura, M.; Ito, M.; Takai, N.; Imamoto, N.; Rokugawa, T.; Momosaki, S.; Fukumoto, K.; 
Morimoto, K.; Inoue, O. EJNMMI Res. 2015, 5, 37. 
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The most relevant processes to be targeted in stroke are Ca2+ overload, ROS 
production and glial activation, but drugs aiming at only one of them have proved 
inefficient so far, probably due to the complexity of the pathological cascade of events. 
In this context, we envisioned to combine in a single molecule the ability of CGP-37157 
to block the mNCX transporter with the properties of lipoic acid (LA), a well-known 
antioxidant that displays an important effect as neuroprotector.253, 254 LA (as its R 
enantiomer) is also an essential cofactor of the mitochondrial α-ketoacid 
dehydrogenases, playing a critical role in energy metabolism. 
The way to carry out the combination of these two chemical entities needs to be 
carefully designed to prevent the loss of activity of any of the pharmacophores. There 
is only one prior study of structure-activity relationships in the CGP-37157 molecule, 
summarized in Figure 6.7,225 which has some limitations due to the method used to 
estimate mNCX inhibition. Nevertheless, this precedent shows that, while some 
features such as the free NH group, need to be conserved, the sulphur atom is not 
crucial, and can be replaced by nitrogen, thus providing a potential point of 
attachment for a spacer chain. In particular, the N-(2-hydroxyethyl) derivative 19 
showed an activity only slightly inferior to the reference compound CGP-37157 and 
was regarded a good starting point for the design of our hybrid compound.   
 
Figure 6.7 
 
253  Molz, P.; Schröder, N. Front. Pharmacol. 2017, 8, 849. 
254  Moura, F. A.; de Andrade, K. Q.; dos Santos, J. C.; Goulart, M. O. Curr. Top. Med. Chem. 2015, 15, 
458-483. 
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On the other hand, some ester derivatives of LA have been shown to maintain its 
antioxidant activity. Hence, we decided to synthesize ester 20 as a multi-target hybrid 
structure with a potentially promising pharmacological profile in stroke (Figure 6.8).  
 
Figure 6.8 
6.6. Synthesis of an aza-CGP-37157-lipoic acid hybrid 
Since our target compound 20 bears two stereocenters, in principle all possible 
enantiomers of this structure should be studied. However, before embarking on such a 
demanding synthetic project, we decided to start by examining the pharmacological 
profile of lipoic acid esters prepared from the racemic benzothiazepine, which was 
obtained in a previous PhD thesis in the group.255 In brief, the commercially available 
(2-amino-5-chlorophenyl) (2-chlorophenyl) ketone and hydroxyethylamine were 
combined in a sealed tube to yield the corresponding imine 21. This intermediate was 
reduced to obtain the corresponding diamine, whose acylation with bromobenzyl 
bromide followed by hydrolysis yielded the racemic benzothiazepine 19. Finally, the 
target hybrid compound 20 was obtained by coupling the racemic 19 and lipoic acid, 
 
255  Tenti, G. Ph. D. Thesis, Universidad Complutense, 2015. 
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which was employed both in racemic form and as its R enantiomer (Scheme 6.9). The 
pharmacological evaluation of both compounds revealed an interesting 
neuroprotective profile, which differed in both diastereoisomer mixtures, and these 
findings prompted us to start work on the synthesis of all possible enantiomers of the 
structure in pure form, which is the subject of the present Section. 
 
Scheme 6.9 
Our first approach to the synthesis of enantiopure benzodiazepines was focused on 
the development of a procedure for the enantioselective reduction of imine 21, using 
several catalytic systems previously described in the literature. The first of these 
catalysts (I)256 was prepared by formation of an imine from (R)-tert-butylsulfinamide 
(Ellman´s sulfinamide) and naphthalene-2-carbaldehyde, followed by 
diastereoselective addition of a phosphorous ylide to its C=N bond (Scheme 6.10). The 
bifunctional catalyst II, also derived from Ellman´s sulfinamide but containing an 
additional chiral urea fragment, was also assayed. The well-known Corey–Bakshi–
Shibata (CBS) catalyst III is very adequate for the asymmetric reduction of ketones but 
 
256  Chelouan, A.; Recio, R.; Borrego, L. G.; Álvarez, E.; Khiar, N.; Fernández, I. Org. Lett. 2016, 18, 3258-
3261. 
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it normally gives poor results for the case of imines due to their rapid Z-E equilibration. 
In this particular case, however, we reasoned that an intramolecular hydrogen bond 
would maintain 21 as the Z isomer and that therefore the CBS reagent stood a chance 
to give the desired result. Finally, a combination of the chiral phosphoric acid IV and a 
Hantzsch dihydropyridine as a hydride donor 257  was also assayed. In order to 
potentially enhance enantioselection by increasing steric hindrance in one of the sides 
of the C=N double bond while blocking its nucleophilic amino group, we also prepared 
compound 22, the FMOC derivative of 21. 
 
Scheme 6.10 
Unfortunately, all the attempts to perform the reduction of imines 21 and 22 by silyl 
hydride donor in the presence of catalysts I and II failed, which can be due to the low 
reactivity of our imine associated to its doubly aromatic nature and the presence of 
bulky groups around the imine (Scheme 6.11). The CBS reagent III achieved the 
reduction but without enantioselectivity, and the combination of IV with the Hantzsch 
dihydropyridine also failed to reduce the imine. 
 
257  Nugent, T. C.; El‐Shazly, M. Adv. Synth. Catal. 2010, 352, 753–819. 
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Scheme 6.11 
Following the failure of the imine reduction by enantioselective catalysis, we decided 
to resort to the use of above-mentioned Ellman´s sulfinamide, this time as a chiral 
auxiliary. As in the example shown in Scheme 6.10, this compound can react with 
aldehydes in the presence of Lewis acids to yield the corresponding imines, where the 
sulfinamide moiety efficiently directs the stereoselective reduction of the C=N bond. 
Finally, the auxiliary can be removed by acid hydrolysis. This route to a single 
enantiomer of the target 4-(2-hydroxyethyl)-4-aza-CGP37157 was successful, and is 
summarized in Scheme 6.12. Sulfinylimine 23 was prepared from the commercially 
available 2-aminobenzophenone previously employed for the racemic synthesis and 
commercial (R)-tert-butylsulfinamide in the presence of titanium tetraethoxide, and 
was isolated exclusively as a Z isomer. Reduction of the sulfinylimine function to give 
compound 24 was assayed with different reagents, as summarized in Table 6.4. The 
best results corresponded to the use of DIBAL or lithium tri(tert-butoxy)aluminium 
hydride, the latter of which afforded 24 in quantitative yield, as a single diastereomer. 
The reducing agent presumably generates a six-membered transition state shown in 
Figure 6.9, placing the bulkier groups in equatorial positions and allowing a fully 
diastereo controlled intramolecular hydride transfer to the C=N bond.  
Table 6.4 
Entry Reagent Yield dr 
1 NaBH4 quant. 71:29 
2 L-selectride 0 -- 
3 DIBAL quant. 100:0 
4 (t-BuO)3LiAlH quant. 100:0 
N
NH2
Cl
Cl
OH
21
N
H
N
Cl
Cl
OH
22
Fmoc-Cl, 
CH2Cl2,
Fmoc
H-SiCl3, I or II (10 mol%), 
CH2Cl2, 24-48 h
NR
NR
H-SiCl3, I or II (10 mol%), 
CH2Cl2, 24-48 h
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Figure 6.9 
The sulfinamide function was then cleaved by acid hydrolysis with 1M aqueous HCl to 
give the diamine 25 in 85% yield as the S-enantiomer. For the introduction of the 2-
hydroxyethyl chain, this compound was treated with a solution of ethylene oxide in 
THF, in the presence of indium trichloride as a Lewis acid and under microwave 
irradiation,258 affording 26 in a moderate 39% yield because of the unavoidable 
formation of a disubstituted product. The diazepinone ring was generated in 56% yield 
by one-pot acylation/intramolecular alkylation of compound 26 with bromoacetyl 
bromide in the presence of diethylamine, a transformation that was accompanied by 
acylation of the hydroxyl group to give compound 27. Finally, the basic hydrolysis of 
this side chain afforded the 4-(2-hydroxyethyl)-4-aza derivative of CGP37157 28 in 
quantitative yield. This compound was then esterified with (R)-lipoic acid via activation 
of the carboxy group in the presence of a diimide (EDCI) and 4-dimethylaminopyridine 
(DMAP) to furnish the hybrid molecule 29.  
Since both the Ellman sulfinamide and lipoic acid are commercially available as both 
enantiomers, the synthetic route summarized above was be easily adapted to achieve 
the preparation in pure form of the four possible enantiomers of our target structure 
(compounds 29-32).  
 
 
258  The reaction failed under non-catalyzed conditions and in the presence of HCl. 
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Scheme 6.12 
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6.7. Preliminary pharmacological studies 
6.7.1. Cytotoxicity 
The effect of these compounds on cell viability was studied on the AREc32 cell line 
measured as MTT reduction. A low cytotoxicity was observed for all compounds, which 
were better in this regard than CGP-37157 in all cases (Figure 6.10 for the 
enantiomeric aza-CGP-37157 analogues compared with the reference compound and 
Figure 6.11 for the four enantiomers of the aza-CGP-37157/lipoic acid hybrid 
compounds). 
 
Figure 6.10 
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Figure 6.11 
The alcohol (R)-28 and its (S)-enantiomer were both potent Nrf-2 inducers compared 
with CGP-37157, with a slight enantiospecificity in favour of the former (Figure 6.12).  
 
Figure 6.12 
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The enantiopure 32 doubled the activity of its diasteromer 30 as an Nrf-2 inducer, 
showing that the configuration of the lipoic acid fragment (R vs. S) has some 
importance in terms of this property. On the other hand, 29 and 31, having an R 
configuration at the dibenzoazepine stereocenter, were inactive (Figure 6.13).  
 
Figure 6.13 
The CD values (i.e. the concentrations required to double the expression of Nrf2) for all 
these compounds are compared in Table 6.5. 
Table 6.5 
Entry Compound CD 
1 (S)-28  14.39 ± 0.17 
2 (R)-28  11.77 ± 0.51 
3 29 >30 
4 30 26.52 ± 1.29 
5 31 >30 
6 32 11.91 ± 1.32 
7 (S)-LA >600 
8 (R)-LA >600 
9 (±)-LA >600 
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6.8. Experimental section  
General experimental details 
All reagents and solvents were of commercial quality and were used as received. 
Reactions were monitored by thin layer chromatography on aluminium plates coated 
with silica gel and fluorescent indicator. Microwave-assisted reactions were performed 
on a CEM Discover focused microwave reactor. Separations by flash chromatography 
were performed using a Combiflash Teledyne automated flash chromatograph or on 
conventional silica gel columns. Melting points were measured with a Kofler-type 
heating platine microscope from Reichert, 723 model, and are uncorrected. Infrared 
spectra were recorded with an Agilent Cary630 FTIR spectrophotometer with a 
diamond ATR accessory for solid and liquid samples, requiring no sample preparation; 
wavenumbers are given in cm−1. NMR spectroscopic data were obtained using 
spectrometers maintained by the CAI de Resonancia Magnética, UCM, operating at 
250, 300, 400 and 700 MHz for 1H NMR and, 63, 100 and 176 MHz for 13C NMR; 
chemical shifts are given in (δ) parts per million and coupling constants (J) in hertz. 
Elemental analyses were determined by the CAI de Microanálisis, Universidad 
Complutense, using a Leco CHNS-932 combustion microanalyzer. The enantiomeric 
excess analysis has been conducted in a HPLC Agilent 1220 Infinity LC with a chiral 
column ULTRON ES. 
6.8.1. Synthesis of CGP-37157 
(2-Amino-5-chlorophenyl)(2-chlorophenyl)carbinol (14)  
 
2-Amino-2´,5-dichlorobenzophenone (1 g, 3.76 mmol) was dissolved in methanol 
(20mL), sodium borohydride (780 mg) was added and the mixture was stirred at room 
temperature for 3 hours. Water (20 ml) was added to the reaction mixture, extracted 
with ethyl acetate  (3 x 60 mL) and washed with brine (20 mL). The combined organic 
layers were dried over anhydrous sodium sulfate and the solvent was removed in 
vacuo to give 987 mg (98%) of the title compound.  
1H NMR (400 MHz, CDCl3) δ 7.48 – 7.43 (m, 1H), 7.42 – 7.37 (m, 1H), 7.32 – 7.22 (m, 
2H), 7.06 (dd, J = 8.5, 2.5 Hz, 1H), 6.86 (d, J = 2.5 Hz, 1H), 6.61 (d, J = 8.5 Hz, 1H), 6.12 
(s, 1H), 4.05 (br s, 2H), 3.00 (br s, 1H).259 
  
 
259  Nakafuji K.; Muneuchi, A. Jpn. Kokai Tokkyo Koho JP Patent No. 2006032275 A 20060202. 
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7-Chloro-5-(2-chlorophenyl)-1,5-dihydrobenzo[e][1,4]thiazepin-2(3H)-one (15)  
 
Carbinol 14 (1.0 mmol) was mixed with methyl thioglycolate (6 eq) and TFA (2 mL) and 
the reaction was stirred at 85 °C for 24 h. Then, the solution was diluted with CH2Cl2 
(80 mL) and washed with 1.0 M aqueous NaOH solution (20 mL) and brine (20 mL). The 
organic layer was dried over sodium sulfate and the solvent concentrated under 
vacuum. The residue was purified by column chromatography on silica gel using a 4:1 
hexane-ethyl acetate mixture as eluent to give 190 mg (58%) of the desired 
benzothiazepine as a white solid. The corresponding thioether was also isolated as a 
minor component from the crude products (71 mg, 19%). 
7-Chloro-5-(2-chlorophenyl)-1,5-dihydrobenzo[e][1,4]thiazepin-2(3H)-one (15) 
Mp 116 oC; 1H NMR (700 MHz, CDCl3) δ 7.82 (dd, J = 8.0, 1.6 Hz, 1H), 
7.73 (s, 1H), 7.47 – 7.39 (m, 2H), 7.39 – 7.31 (m, 1H), 7.27 (dd, J = 8.1, 
2.6 Hz, 1H), 7.06 (d, J = 8.4 Hz, 1H), 6.71 (d, J = 2.3 Hz, 1H), 6.15 (s, 1H), 
3.33 (d, J = 12.3 Hz, 1H), 3.03 (dd, J = 12.3, 1.8 Hz, 1H); 13C NMR (176 
MHz, CDCl3) δ 169.8, 135.7, 135.0, 134.3, 134.1 , 133.5, 131.0, 130.5, 
129.9, 128.9, 128.2, 127.4, 125.3, 43.7, 31.5; IR (neat, cm-1): 
elemental analysis (%) calcd. for C15H11Cl2NOS: C 55.57, H 3.42, N 4.32, S 9.89; found: 
C 55.41, H 3.56, N 4.27, S 9.77. 
Ethyl 2-[((2-amino-5-chlorophenyl)(2-
chlorophenyl)methyl)thio]acetate 
Pale yellow solid; mp: 94 oC; 1H NMR (700 MHz, CDCl3) δ7.93 (d, 
J = 7.6 Hz, 1H), 7.43 – 7.35 (m, 2H), 7.29 (td, J = 7.7, 1.4 Hz, 1H), 
7.02 (dd, J = 8.5, 2.4 Hz, 1H), 6.76 (d, J = 2.4 Hz, 1H), 6.65 (d, J = 
8.5 Hz, 1H), 5.79 (s, 1H), 4.41 (s, 2H), 4.19 (q, J = 7.1 Hz, 2H), 3.18 
(d, J = 16.1 Hz, 1H), 3.11 (d, J = 16.1 Hz, 1H), 1.28 (t, J = 7.1 Hz, 3H; 13C NMR (176 MHz, 
CDCl3) δ 170.7, 143.9, 135.8, 134.9, 130.6, 130.2, 129.3, 128.7, 128.2, 127.4, 124.7, 
123.1, 117.7, 62.0, 46.2, 33.9, 14.3; IR (neat, cm-1): elemental analysis (%) calcd. for 
C17H17Cl2NO2S: C 55.14, H 4.63, N 3.78, S 8.66; found: C 54.98, H 4.21, N 3.90, S 8.99. 
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6.8.2. Asymmetric oxidation of CGP-37157 
 
Ti(O-i-Pr)4 (149 L, 0.5 mmol) and (R,R)-DET or (S,S)-DET (171 mL, 1 mmol) were 
dissolved in CH2Cl2 (3 mL) at room temperature under nitrogen atmosphere. H2O (0.5 
mmol) was introduced through a septum via a microsyrynge. After 15 min, a solution 
of benzothiazepine 15 (172 mg, 0.5 mmol) in CH2Cl2 (2 mL) was added. The solution 
was cooled to 0 oC, and 0.55 mmol of a cumene hydroperoxide solution in CH2CI2 (1 
mL) are then introduced. The reaction was monitored by TLC. After 48h , water (10 mol 
equiv) was added dropwise by a microsyringe to the solution. A strong stirring was 
maintained for 30 min. The white gel obtained was filtered and thoroughly washed 
with CH2Cl2. The filtrate was kept in the presence of NaOH (10 min) and then 
separated. The organic layer was dried over Na2S04 and the solvent removed under 
reduced pressure to give the crude product. Chromatography on silica gel using a 1:1 
AcOEt-hexane mixture as eluent gave 20 mg  (13%) of cis-sulfoxide 16, 71 mg (41%) of 
trans-sulfoxide 17, 22 mg  (12%) of sulfone 18, and  27 mg of the starting material 15. 
cis-7-Chloro-5-(2-chlorophenyl)-1,5-dihydrobenzo[e][1,4]thiazepin-2(3H)-one 4-oxide 
(16) 
White solid; mp 133oC; 1H NMR (250 MHz, d6-DMSO) δ 10.34 (br s, 
1H), 8.29 – 8.05 (m, 1H), 7.63 – 7.46 (m, 4H), 7.26 (d, J = 8.5 Hz, 1H), 
6.73 (d, J = 2.4 Hz, 1H), 5.44 (s, 1H), 4.26 (d, J = 11.8 Hz, 1H), 3.06 (d, J 
= 11.8 Hz, 1H); 13C NMR (63 MHz, d6-DMSO) δ164.7, 137.2, 133.4, 
132.8, 130.7, 130.4, 130.3, 129.7, 129.2, 129.1, 127.9, 125.9, 59.7, 
57.8.; IR (neat, cm-1): 2913, 1680, 1025; HRMS (ESI): found m/z 
361.9791 [M+Na+]+, calcd for [C15H11Cl2NO3S+Na+] 361.9785. 
trans-7-Chloro-5-(2-chlorophenyl)-1,5-dihydrobenzo[e][1,4]thiazepin-2(3H)-one 4-
oxide (17) 
White solid; mp 141-143oC 1H NMR (700 MHz, d6-DMSO) δ 10.58 (br 
s, 1H), 8.06 (dd, J = 7.6, 1.2 Hz, 1H), 7.72 – 7.67 (m, 2H), 7.61 – 7.58 
(m, 1H), 7.51 (dd, J = 8.5, 2.4 Hz, 1H), 7.26 (d, J = 8.5 Hz, 1H), 6.74 (d, J 
= 2.2 Hz, 1H), 5.59 (s, 1H), 3.87 (d, J = 13.9 Hz, 1H), 3.62 (d, J = 13.9 
Hz, 1H); 13C NMR (176 MHz, d6-DMSO) δ 169.8, 142.9, 139.7, 136.6, 
136.4, 136.1, 135.8, 135.0, 134.9, 133.5, 133.2, 131.0, 73.5, 57.9; IR 
(neat, cm-1): 2924, 1665, 1044; HRMS (ESI): found m/z 361.9771 [M+Na+]+, calcd for 
[C15H11Cl2NO3S+Na+] 361.9785. 
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7-Chloro-5-(2-chlorophenyl)-1,5-dihydrobenzo[e][1,4]thiazepin-2(3H)-one 4,4-
dioxide (18). 
1H NMR (400 MHz, d6-DMSO) δ 10.94 (br s, 1H), 8.26 –8.23 (m 1H), 
7.71 – 7.57 (m, 4H), 7.34 (d, J = 8.6 Hz, 1H), 7.06 (d, J = 2.3 Hz, 1H), 
5.94 (s, 1H), 4.44 (d, J = 13.6 Hz, 1H), 4.25 (d, J = 13.6 Hz, 1H).; IR 
(neat, cm-1): 2926, 2409, 1686, 1132, 1113, 1036; HRMS (ESI): found 
m/z 355.9911[M+H+]+, calcd for [C15H11Cl2NO3S+H+] 355.9909. 
6.8.3. Diasteroselective synthesis of CGP-37157 aza-analogue 
Synthesis of sulfinilimine 23 
 
2-Amino-2´,5-dichlorobenzophenone (1.0 g, 8 mmol), (R,S)-tert-butanesulfinamide (1.0 
eq) and neat Ti(OEt)4 (4.0 eq) were placed in microwaves tube at 100 oC for 1h under 
argon atmosphere. Then, the reaction was cooled to ambient temperature, a mixture 
of water and ethyl acetate was added and resulting slurry was filtered through a plug 
of Celite. The filter cake was washed with ethyl acetate. The organic layer from the 
filtrate was washed with brine, dried over anhydrous Na2SO4, and the solvent was 
removed in vacuo. The residue was purified by column chromatography on silica gel 
using as eluent a 6:4 n-hexane-ethyl acetate mixture to afford 1240 mg (42%) of 23 as 
a yellow solid. 
(R,Z)-N-((2-Amino-5-chlorophenyl)(2-chlorophenyl)methylene)-2-methylpropane-2-
sulfinamide (R-23) 
Mp: 138-139 oC; [α]D25 = - 40.00 (c = 1.00 mg/mL, CHCl3); 1H NMR 
(250 MHz, CDCl3) δ 7.61 – 7.32 (m, 4H), 7.24 – 7.11 (m, 1H), 6.76 
(d, J = 2.3 Hz, 1H), 6.73 (d, J = 8.9 Hz, 1H), 5.90 (br s, 2H), 1.30 (s, 
9H); 13C NMR (63 MHz, CDCl3) δ149.3, 135.5, 133.9, 132.4, 131.0, 
130.9, 130.8, 129.9, 129.7, 127.1, 120.6, 118.6, 117.4, 55.4, 22.4; 
IR (neat, cm-1): 3373, 3273, 1516, 1237, 1053; elemental analysis (%) calcd. for 
C17H18Cl2N2OS: C 55.29, H 4.91, N 7.59, S 8.68; found: C 55.06, H 4.97, N 7.71, S 8.82. 
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(S,Z)-N-((2-Amino-5-chlorophenyl)(2-chlorophenyl)methylene)-2-methylpropane-2-
sulfinamide (S-23) 
[α]D25 = +43.00 (c = 1.09 mg/mL, CHCl3); 1H NMR (250 MHz, CDCl3) δ 
7.61 – 7.32 (m, 4H), 7.24 – 7.11 (m, 1H), 6.76 (d, J = 2.3 Hz, 1H), 
6.73 (d, J = 8.9 Hz, 1H), 5.90 (br s, 2H), 1.30 (s, 9H);  
 
Diastereoselective reduction of sulfinylimine 23 
 
Sulfinylimine 23 (4.33 mmol) was dissolved in anhydrous THF (10 mL/mmol of 23) and 
cooled to 0 οC under argon atmosphere. Lithium tri-tert-butoxyaluminum hydride (1.0 
M solution in THF, 4.0 eq) was added dropwise, and the resulting solution was stirred 
and warmed to room temperature for 4 h The reaction was monitored by TLC and 
after the imine consumption the reaction was diluted with EtOAc (60 mL). The mixture 
was cooled to 0 oC and water (20 mL) was added and the layers were separated. The 
organic phase was washed with brine, dried over anhydrous Na2SO4, and concentrated 
to dryness to give 692 mg (96%) of compound 24 as a single diastereomer, without the 
need of further purification. 
 (R)-N-[(S)-(2-Amino-5-chlorophenyl)(2-chlorophenyl)methyl]-2-methylpropane-2-
sulfinamide (R,S-24) 
 Pale yellow solid; mp: 165 oC; 1H NMR (250 MHz, CDCl3) δ 7.72 
(dd, J = 7.9, 1.7 Hz, 1H), 7.43 – 7.27 (m, 3H), 7.06 (dd, J = 8.5, 2.4 
Hz, 1H), 6.68 (d, J = 8.5 Hz, 1H), 6.46 (d, J = 2.4 Hz, 1H), 5.88 (d, J = 
2.1 Hz, 1H), 4.28 (br s, 2H), 3.53 (d, J = 2.1 Hz, 1H), 1.27 (s, 9H); 13C 
NMR (63 MHz, CDCl3) δ 143.4, 137.8, 133.7, 130.2, 129.4, 129.4, 
129.2, 127.8, 126.9, 125.7, 122.4, 118.1, 56.1, 54.2, 22.7; IR (neat, cm-1): 3358, 3290, 
1632, 1486, 1054; elemental analysis (%) calcd. for C17H20Cl2N2OS: C 54.99, H 5.43, N 
7.54, S 8.63; found: C 55.57, H 5.67, N 7.30, S 8.77. 
(S)-N-[(R)-(2-Amino-5-chlorophenyl)(2-chlorophenyl)methyl]-2-methylpropane-2-
sulfinamide(S,R-24) 
1H NMR (250 MHz, CDCl3) δ 7.80 – 7.63 (m, 1H), 7.43 – 7.21 (m, 
1H), 7.01 (dd, J = 8.5, 2.4 Hz, 1H), 6.65 (d, J = 8.5 Hz, 1H), 6.45 (d, J 
= 2.4 Hz, 1H), 5.87 (d, J = 2.4 Hz, 1H), 4.60 (br s, 2H), 3.64 (d, J = 2.5 
Hz, 1H), 1.25 (s, 9H). 
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Cleavage of the N-tert-butylsulfinyl chiral auxiliary  
 
To a solution of acetyl chloride (4.0 equiv) in a 1:1 mixture of 1,4-dioxane and MeOH 
(20 mL) was added compound 24 (2.69 mmol) and the mixture was stirred at room 
temperature for 3 h. Then, the reaction was concentrated in vacuo to dryness and the 
residue was dissolved in water (20 mL), basified to pH 8 with concentrated aqueous 
NH4OH solution and extracted with EtOAc (3 x 40 mL). The combined organic layers 
were dried over anhydrous Na2SO4 and the solvent was removed under reduced 
pressure to afford 610 mg (85%) of the pure diamine 25 as a colourless oil.  
(S)-2-[Amino(2-chlorophenyl)methyl]-4-chloroaniline (S-25) 
[α]D25 = + 36.00 (c = 1.00 mg/mL, CHCl3); 1H NMR (250 MHz, CDCl3) δ  
7.39 (app dt, J = 7.1, 2.4 Hz, 2H), 7.26 (m, 2H), 7.04 (dd, J = 8.4, 2.4 Hz, 
1H), 6.94 (d, J = 2.4 Hz, 1H), 6.59 (d, J = 8.4 Hz, 1H), 5.50 (s, 1H), 3.01 
(br s, 4H); 13C NMR (63 MHz, CDCl3) δ 144.1, 140.6, 133.5, 129.9, 
128.9, 128.7, 128.5, 128.0, 127.6, 127.4, 122.8, 117.5, 53.5; IR (neat, 
cm-1): 3302, 2970, 1484, 1033; elemental analysis (%) calcd. for C13H12Cl2N2: C 58.45, H 
4.53, N 10.49; found: C 58.28, H 4.39, N 10.79. 
(R)-2-(Amino(2-chlorophenyl)methyl)-4-chloroaniline (R-25) 
[α]D25 = - 36.00 (c = 1.00 mg/mL, CHCl3) 1H NMR (250 MHz, CDCl3) δ; 
7.40 (app dt, J = 7.1, 2.4 Hz, 2H), 7.27 (pd, J = 7.3, 3.5 Hz, 2H), 7.04 (dd, 
J = 8.4, 2.4 Hz, 1H), 6.94 (d, J = 2.4 Hz, 1H), 6.59 (d, J = 8.4 Hz, 1H), 5.50 
(s, 1H), 4.37 (br s, 2H). 
 
Synthesis of 2-[((2-amino-5-chlorophenyl)(2-chlorophenyl)methylene)amino]ethanol 
21 
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In a sealed tube 2-amino-2’,5-dichlorobenzophenone (5 mmol) and ethanolamine (60 
mmol) were stirred at 140 °C overnight. The mixture was cooled to room temperature 
and diluted with CH2Cl2 (60 mL). The organic layer was washed with water (3 x 20 mL), 
dried over anhydrous sodium sulfate and the solvent was removed under vacuum. The 
residue was purified by flash chromatography on silica gel eluting with a 3:1 hexane-
ethyl acetate mixture to give compound 21 (1220 mg, 79%) as a yellow solid. 
Mp: 125 o C; 1H NMR (250 MHz, CDCl3) δ 7.55 – 7.46 (m, 1H), 7.45 – 7.32 (m, 2H), 7.13 
– 7.02 (m, 2H), 6.73 (br s, 2H), 6.66 (d, J = 1.1 Hz, 1H), 6.64 (d, J = 4.9 Hz, 1H), 4.02 – 
3.77 (m, 2H), 3.47 – 3.19 (m, 2H), 1.99 (br s, 1H); 13C NMR (63 MHz, CDCl3) δ169.7, 
147.8, 135.5, 131.5, 131.3, 130.9, 130.3, 130.1, 129.0, 127.5, 120.3, 119.5, 118.0, 63.2, 
55.8; IR (neat, cm-1): 3213, 1612, 1054; elemental analysis (%) calcd. for C15H14Cl2N2O: 
C 58.27, H 4.56, N 9.06; found: C 58.71, H 4.57, N 8.89. 
Synthesis of (±)-2-[((2-amino-5-chlorophenyl)(2-chlorophenyl)methyl)amino]ethanol 
28 
 
To a stirred solution of 21 (7.0 mmol) in a 100:1 MeOH/AcOH mixture (70 mL), cooled 
in an ice bath, NaBH3(CN) (35.0 mmol) was added. The mixture was stirred overnight 
and then, water (30 mL) was cautiously added and the reaction was warmed to room 
temperature. The mixture was extracted with CH2Cl2 (2 x 100 mL). The combined 
organic layers were dried over anhydrous magnesium sulfate, and concentrated under 
vacuum to give compound rac-28 in quantitative yield as a light yellow solid. 
Mp 95 oC; 1H NMR (250 MHz, CDCl3) δ 7.45 – 7.33 (m, 2H), 7.33 – 7.17 (m, 2H), 7.04 
(dd, J = 8.4, 2.5 Hz, 1H), 6.98 (d, J = 2.5 Hz, 1H), 6.60 (d, J = 8.4 Hz, 1H), 5.26 (s, 1H), 
3.73 (t, J = 5.1 Hz, 2H), 2.91 – 2.68 (m, 2H); 13C NMR (63 MHz, CDCl3) δ 144.5, 138.1, 
134.0, 130.1, 129.4, 129.0, 128.6, 128.2, 127.5, 127.0, 123.0, 117.8, 61.9, 60.6, 49.8; IR 
(neat, cm-1): 3234, 2925, 2848, 1485, 1468, 1034; elemental analysis (%) calcd. for 
C15H16Cl2N2O: C 57.89, H 5.18, N 9.00; found: C 55.10, H 4.91, N 8.35. 
(R)-2-(((2-Amino-5-chlorophenyl)(2-chlorophenyl)methyl)amino)ethan-1-ol (R-26) 
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To a solution of diamine 25 (490 mg, 1.8 mmol) in dioxane (1 mL) placed in a 
microwaves tube was added a 2.5-3.3 M THF ethylene oxide solution (2.5mL) and 
indium trichloride (0.18 mmol). The mixture was irradiated at 100 ºC for 1h under 
argon atmosphere. Then, the reaction was cooled to room temperature, diluted wit  
ethyl acetate (30 mL) and washed with saturated sodium carbonate solution (10 mL) 
and water (10 mL). The organic layer was dried over anhydrous Na2SO4 and solvent 
was removed under reduced pressure. The residue was purified by column 
chromatography on silica gel using as eluent a 6:4 n-hexane-ethyl acetate mixture to 
afford 220 mg (39%) of the desired compound. 
(S)-2-(((2-Amino-5-chlorophenyl)(2-chlorophenyl)methyl)amino)ethan-1-ol (S-26) 
[α]D25 = + 81.00 (c = 0.9 mg/mL, CHCl3) ee 93% The enantiomers 
were separated by HPLC (ULTRON ES OVM Chiral Analytical 
Reverse Phase, 5μm, 4.6 mm x 150 L, buffer H2PO4 20 mM pH 
5.9/ MeOH 80:20, flow 1.0 mL/min, retention time 4.560 min 
(major), 5.210 min (minor); 1H NMR (250 MHz, CDCl3) δ 7.44 – 
7.33 (m, 2H), 7.32 – 7.18 (m, 2H), 7.03 (dd, J = 8.4, 2.5 Hz, 1H), 6.97 (d, J = 2.4 Hz, 1H), 
6.60 (d, J = 8.4 Hz, 1H), 5.25 (s, 1H), 3.72 (t, J = 5.1 Hz, 2H), 2.90 – 2.65 (m, 2H). 
(R)-2-(((2-amino-5-chlorophenyl)(2-chlorophenyl)methyl)amino)ethan-1-ol (R-26) 
[α]D25 = - 78.00 (c = 1.00 mg/mL, CHCl3) ee 95% The enantiomers 
were separated by HPLC (ULTRON ES OVM Chiral Analytical 
Reverse Phase, 5μm, 4.6 mm x 150 L, buffer H2PO4 20 mM pH 
5.9/ MeOH 80:20, flow 1.0 mL/min, retention time 4.603 min 
(minor), 5.023 min (major); 1H NMR (250 MHz, CDCl3) δ 7.44 – 
7.33 (m, 2H), 7.31 – 7.18 (m, 2H), 7.03 (dd, J = 8.4, 2.5 Hz, 1H), 6.96 (d, J = 2.5 Hz, 1H), 
6.59 (d, J = 8.4 Hz, 1H), 5.25 (s, 1H), 3.74 – 3.70 (dd, J = 4.8, 1.0 Hz, 1H), 3.69 (d, J = 4.8 
Hz, 1H), 2.88 – 2.64 (m, 2H). 
Synthesis of 2-(7-chloro-5-(2-chlorophenyl)-2-oxo-2,3,4,5-tetrahydro-1H-
benzo[e][1,4]diazepin-4-yl)ethyl 2-bromoacetate 
 
To a stirred solution of compound 26 (420 mg, 1.35 mmol) in CH2Cl2 (15 mL) at 0 °C 
was added bromoacetyl bromide (305 mL, 3.5 mmol). The stirring was continued at 0 
°C for 1 hour and then at room temperature for 16 hours. DIEA (3.5 mL, 20 mmol) was 
added, and the reaction was stirred at 50 °C for 5 h. The mixture was cooled to room 
temperature, diluted with CH2Cl2 (30 mL) and washed with water (20 mL). The organic 
Chapter 6. Aza-CGP-37157/Lipoic acid hybrids 
163 
 
layer was dried over anhydrous Na2SO4 and concentrated to dryness. The crude 
product was purified by column chromatography on silica gel eluting with a gradient 
from hexane to 6:4 hexane-ethyl acetate to give 1.9 g (59%) of compound 27 as a 
white solid. 
2-(7-Chloro-5-(2-chlorophenyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-4-
yl)ethyl 2-bromoacetate 
Mp:148-149 oC; 1H NMR (250 MHz, CDCl3) δ 8.28 (br s, 1H), 7.66 – 7.57 (m, 1H), 7.44 – 
7.32 (m, 3H), 7.25 (dd, J = 8.4, 2.2 Hz, 2H), 6.99 (d, J = 8.4 Hz, 1H), 6.61 (d, J = 2.2 Hz, 
1H), 5.29 (s, 1H), 4.41 (ddd, J = 11.8, 7.9, 4.3 Hz, 1H), 4.21 (dt, J = 11.8, 4.8 Hz, 1H), 3.86 
(s, 2H), 3.56 (d, J = 15.5 Hz, 1H), 3.45 (dd, J = 15.5, 1.2 Hz, 1H), 3.06 (dt, J = 14.2, 4.3 Hz, 
1H), 2.98 – 2.80 (ddd, J = 14.2, 7.9, 4.8 Hz, 1H); 13C NMR (63 MHz, CDCl3) δ 171.4, 
167.2, 136.9, 136.6, 134.6, 132.7, 130.9, 130.8, 130.4, 130.3, 129.7, 129.1, 127.3, 
122.2, 65.0, 63.9, 52.8, 52.0, 25.9; IR (neat, cm-1): 2956, 1735, 1666, 905; elemental 
analysis (%) calcd. for C19H17BrCl2N2O3: C 48.33, H 3.63, N 5.93; found: C 48.18, H 3.52, 
N 5.82. 
(S)-2-(7-Chloro-5-(2-chlorophenyl)-2-oxo-1,2,3,5-tetrahydro-4H-
benzo[e][1,4]diazepin-4-yl)ethyl 2-bromoacetate (S-27) 
1H NMR (250 MHz, CDCl3) δ 8.49 (br s, 1H), 7.68 – 7.61 (m, 
1H), 7.50 – 7.33 (m, 3H), 7.26 (dd, J = 8.5, 2.2 Hz, 1H), 7.02 (d, 
J = 8.5 Hz, 1H), 6.63 (d, J = 2.2 Hz, 1H), 5.31 (s, 1H), 4.43 (ddd, 
J = 11.7, 7.9, 4.3 Hz, 1H), 4.24 (dt, J = 11.7, 4.9 Hz, 1H), 3.88 (s, 
2H), 3.58 (d, J = 15.5 Hz, 1H), 3.48 (dd, J = 15.5, 1.3 Hz, 1H), 
3.09 (dt, J = 14.2, 4.3 Hz, 1H), 2.92 (ddd, J = 14.2, 7.9, 4.9 Hz, 
1H). 
(R)-2-(7-Chloro-5-(2-chlorophenyl)-2-oxo-1,2,3,5-tetrahydro-4H-
benzo[e][1,4]diazepin-4-yl)ethyl 2-bromoacetate (R-27) 
1H NMR (250 MHz, CDCl3) δ 8.90 (s, 1H), 7.66 – 7.59 (m, 1H), 
7.47 – 7.33 (m, 3H), 7.26 (d, J = 2.3 Hz, 1H), 7.05 (d, J = 8.5 Hz, 
1H), 6.64 (d, J = 2.2 Hz, 1H), 5.32 (s, 1H), 4.44 (ddd, J = 11.8, 
7.9, 4.4 Hz, 1H), 4.24 (dt, J = 11.8, 4.9 Hz, 1H), 3.88 (s, 2H), 
3.59 (d, J = 15.5 Hz, 1H), 3.49 (dd, J = 15.5, 1.1 Hz, 1H), 3.09 
(dt, J = 14.2, 4.4 Hz, 1H), 3.02 – 2.86 (ddd, J = 14.2, 7.9, 4.9 Hz, 1H). 
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Synthesis of 7-chloro-5-(2-chlorophenyl)-4-(2-hydroxyethyl)-4,5-dihydro-1H-
benzo[e][1,4]diazepin-2(3H)-one 
 
Compound 27 (1 mmol) was dissolved in methanol and a 10% KOH methanol solution 
(10 mL) was added. The reaction was monitored by TLC and additional 10% KOH 
methanol solution was added until the starting material was no longer detected. Then, 
the reaction was diluted with water (20 mL), neutralized with 2M HCl solution and 
extracted with CHCl3 (3 x 40 mL). The combined organic layers were dried over sodium 
sulphate, filtered and the solvent was removed in vacuo. No further purification was 
needed. 
rac-7-Chloro-5-(2-chlorophenyl)-4-(2-hydroxyethyl)-4,5-dihydro-1H-
benzo[e][1,4]diazepin-2(3H)-one (19) 
Mp: 163 oC; 1H NMR (250 MHz, CDCl3) δ 8.48 (s, 1H), 7.48 – 7.42 
(m, 1H), 7.35 – 7.19 (m, 5H), 6.98 (d, J = 8.5 Hz, 1H), 6.82 (d, J = 
2.3 Hz, 1H), 5.39 (s, 1H), 3.85 – 3.57 (m, 2H), 3.52 (s, 2H), 3.02 – 
2.80 (m, 2H), 2.50 (br s, 1H); 13C NMR (63 MHz, CDCl3) δ 173.0, 
137.0, 135.8, 134.4, 131.5, 131.1, 130.8, 130.7, 130.1, 129.8, 
129.2, 127.4, 121.9, 65.8, 58.8, 55.1, 52.4.; IR (neat, cm-1): 3396, 
2925, 1676, 1040; elemental analysis (%) calcd. for C17H16Cl2N2O2: C 58.14, H 4.59, N 
7.98; found: C 58.46, H 4.72, N 7.74. 
 (5S)-7-Chloro-5-(2-chlorophenyl)-4-(2-hydroxyethyl)-4,5-dihydro-1H-
benzo[e][1,4]diazepin-2(3H)-one (S-28) 
[α]D25 = +114 (c = 1.00 mg/mL, CHCl3); ee 93% The enantiomers 
were separated by HPLC (ULTRON ES OVM Chiral Analytical 
Reverse Phase, 5μm, 4.6 mm x 150 L, buffer H2PO4 20 mM pH 
5.9/ i-PrOH80:20, flow 1.0 mL/min, retention time 4.643 min 
(minor), 5.090 min (major); 1H NMR (250 MHz, CDCl3) δ 8.48 (s, 
1H), 7.48 – 7.42 (m, 1H), 7.35 – 7.19 (m, 5H), 6.98 (d, J = 8.5 Hz, 
1H), 6.82 (d, J = 2.3 Hz, 1H), 5.39 (s, 1H), 3.85 – 3.57 (m, 2H), 3.52 (s, 2H), 3.02 – 2.80 
(m, 2H), 2.50 (br s, 1H). 
(5R)-7-Chloro-5-(2-chlorophenyl)-4-(2-hydroxyethyl)-4,5-dihydro-1H-
benzo[e][1,4]diazepin-2(3H)-one (R-28) 
 [α]D25 = - 116.00 (c = 1.04 mg/mL, CHCl3); ee 97% The enantiomers 
were separated by HPLC (ULTRON ES OVM Chiral Analytical 
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Reverse Phase, 5μm, 4.6 mm x 150 L, buffer H2PO4 20 mM pH 5.9/ CH3CN 80:20, flow 
1.0 mL/min, retention time 4.427 min (major), 5.457 min (major); 1H NMR (250 MHz, 
CDCl3) δ 8.48 (s, 1H), 7.48 – 7.42 (m, 1H), 7.35 – 7.19 (m, 5H), 6.98 (d, J = 8.5 Hz, 1H), 
6.82 (d, J = 2.3 Hz, 1H), 5.39 (s, 1H), 3.85 – 3.57 (m, 2H), 3.52 (s, 2H), 3.02 – 2.80 (m, 
2H), 2.50 (br s, 1H). 
6.8.4. Synthesis of 2-(7-chloro-5-(2-chlorophenyl)-2-oxo-2,3,4,5-tetrahydro-1H-
benzo[e][1,4]diazepin-4-yl)ethyl 5-(1,2-dithiolan-3-yl)pentanoate (20) 
 
Compound 28 (50 mg, 0.14 mmol), α-lipoic acid (racemic mixture (±), (R)-(+)- 
enantiomer or (S)-(-)- enantiomer) (0.17 mmol) and DMAP (0.43 mmol) were dissolved 
in anhydrous dichloromethane (5 mL) in argon atmosphere. The mixture was cooled at 
0 °C and a solution of EDCI (0.17 mmol) in anhydrous dichloromethane (2 mL) was 
added dropwise. The reaction was kept at room temperature for 16 hours. Then, the 
reaction was diluted with dichloromethane (30 mL), washed with water (10 mL), dried 
over anhydrous Na2SO4 and the solvent was removed under reduced pressure. The 
residue was purified by column chromatography in silica gel eluting with a gradient 
from hexane to 6:4 hexane-ethyl acetate to give 49 mg (65%) of compound 29 as a 
colourless viscous oil.  
1H NMR (250 MHz, CDCl3) δ 8.50 (s, 1H), 7.66 – 7.55 (m, 1H), 7.48 – 7.41 (m, 1H), 7.37 
(m, 2H), 7.32 – 7.24 (m, 1H), 7.02 (d, J = 8.4 Hz, 1H), 6.64 (d, J = 1.8 Hz, 1H), 5.33 (s, 
1H), 4.40 – 4.25 (m, 1H), 4.25 – 4.10 (m, 1H), 3.68 – 3.42 (m, 3H), 3.29 – 2.98 (m, 3H), 
2.97 – 2.80 (m, 1H), 2.57 – 2.41 (m, 1H), 2.36 (t, J = 7.2 Hz, 2H), 2.01 – 1.84 (m, 1H), 
1.80 – 1.59 (m, 4H), 1.59 – 1.39 (m, 2H); 13C NMR (63 MHz, CDCl3) δ 173.4, 172.0, 
137.0, 136.6, 134.6, 132.6, 130.8, 130.6, 130.4, 130.2, 129.6, 129.0, 127.1, 122.2, 65.1, 
62.1, 56.4, 53.0, 52.2, 40.3, 38.6, 34.7, 34.1, 28.9, 24.7; IR (neat, cm-1): 2927, 1728, 
1665, 1483, 1034; elemental analysis (%) calcd. for C24H26Cl2N2O3S2: C 54.85, H 4.99, N 
5.33, S 11.89; found: C 55.47, H 5.08, N 5.16, S 11.75. 
2-((S)-7-Chloro-5-(2-chlorophenyl)-2-oxo-1,2,3,5-tetrahydro-4H-
benzo[e][1,4]diazepin-4-yl)ethyl 5-((S)-1,2-dithiolan-3-yl)pentanoate (29) 
[α]D25 = + 165.00 (c = 1.00 mg/mL, CHCl3); 1H NMR (300 
MHz, CDCl3) δ 8.71 (s, 1H), 7.62 – 7.52 (m, 1H), 7.44 – 
7.38 (m, 1H), 7.35 – 7.29 (m, 2H), 7.24 (dd, J = 8.5, 2.2 
Hz, 1H), 7.00 (d, J = 8.5 Hz, 1H), 6.61 (d, J = 2.2 Hz, 1H), 
5.30 (s, 1H), 4.34 – 4.23 (m, 1H), 4.20 – 4.05 (m, 1H), 
3.61 – 3.42 (m, 4H), 3.22 – 2.97 (m, 3H), 2.95 – 2.79 
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(m, 1H), 2.53 – 2.38 (m, 1H), 2.32 (t, J = 7.3 Hz, 2H), 1.97 – 1.80 (m, 1H), 1.74 – 1.58 (m, 
4H), 1.52 – 1.39 (m, 2H). 
2-((R)-7-Chloro-5-(2-chlorophenyl)-2-oxo-1,2,3,5-tetrahydro-4H-
benzo[e][1,4]diazepin-4-yl)ethyl 5-((S)-1,2-dithiolan-3-yl)pentanoate (30) 
[α]D25 = + 140.00 (c = 1.00 mg/mL, CHCl3); 1H NMR (300 
MHz, CDCl3) δ 8.30 (br s, 1H), 7.63 – 7.54 (m, 1H), 7.44 
– 7.39 (m, 1H), 7.38 – 7.27 (m, 2H), 7.24 (dd, J = 8.4, 
2.2 Hz, 1H), 6.97 (d, J = 8.4 Hz, 1H), 6.61 (d, J = 2.2 Hz, 
1H), 5.30 (s, 1H), 4.35 – 4.21 (m, 1H), 4.21 – 4.09 (m, 
1H), 3.61 – 3.39 (m, 3H), 3.22 – 2.96 (m, 3H), 2.94 – 
2.78 (m, 1H), 2.51 – 2.39 (m, 1H), 2.32 (td, J = 7.3, 1.6 
Hz, 2H), 1.96 – 1.83 (m, 1H), 1.72 – 1.58 (m, 4H), 1.52 
– 1.38 (m, 2H). 
2-((S)-7-Chloro-5-(2-chlorophenyl)-2-oxo-1,2,3,5-tetrahydro-4H-
benzo[e][1,4]diazepin-4-yl)ethyl 5-((R)-1,2-dithiolan-3-yl)pentanoate (31) 
[α]D25 = - 138.00 (c = 0.9 mg/mL, CHCl3) 1H NMR (300 
MHz, CDCl3) δ 8.31 (br s, 1H), 7.56 – 7.47 (m, 1H), 7.38 
– 7.31 (m, 1H), 7.31 – 7.22 (m, 2H), 7.17 (dd, J = 8.5, 
2.2 Hz, 1H), 6.91 (d, J = 8.5 Hz, 1H), 6.55 (d, J = 2.2 Hz, 
1H), 5.23 (s, 1H), 4.30 – 4.14 (m, 1H), 4.14 – 4.00 (m, 
1H), 3.55 – 3.32 (m, 3H), 3.16 – 2.88 (m, 3H), 2.87 – 
2.67 (m, 1H), 2.47 – 2.31 (m, 1H), 2.25 (t, J = 7.3 Hz, 
2H), 1.93 – 1.74 (m, 1H), 1.66 – 1.53 (m, 4H), 1.48 – 
1.29 (m, 2H). 
2-((R)-7-Chloro-5-(2-chlorophenyl)-2-oxo-1,2,3,5-tetrahydro-4H-
benzo[e][1,4]diazepin-4-yl)ethyl 5-((R)-1,2-dithiolan-3-yl)pentanoate (32) 
[α]D25 = - 160.00 (c = 1.00 mg/mL, CHCl3); 1H NMR (300 
MHz, CDCl3) δ 8.41 (br s, 1H), 7.62 – 7.51 (m, 1H), 7.45 
– 7.38 (m, 1H), 7.37 – 7.27 (m, 2H), 7.24 (dd, J = 8.5, 
2.2 Hz, 1H), 6.98 (d, J = 8.5 Hz, 1H), 6.61 (d, J = 2.2 Hz, 
1H), 5.30 (s, 1H), 4.35 – 4.22 (m, 1H), 4.21 – 4.09 (m, 
1H), 3.61 – 3.40 (m, 3H), 3.23 – 2.96 (m, 3H), 2.93 – 
2.78 (m, 1H), 2.52 – 2.38 (m, 1H), 2.32 (td, J = 7.3, 1.5 
Hz, 2H), 1.97 – 1.82 (m, 1H), 1.73 – 1.57 (m, 4H), 1.54 
– 1.38 (m, 2H). 
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7.1. Galectins: structure, function and location. 
7.1.1. Introduction to galectins 
Lectins are a large group of specific carbohydrate-binding molecules that take part in 
several molecular and cellular recognition process like promoting the migration of 
immune cells through the endothelium, activation or inhibition of T or B cells, cytokine 
secretion and signalling, recognition of pathogen-associated patterns of glycan-
containing molecules like lipopolysaccharide (LPS), among others.260 
Galectins are a subset of lectins defined by a common carbohydrate recognition 
domain (CRD). The CRD motif has a β-sheet sandwich structure conformed by two 
antiparallel β-sheet layers (Figure 7.1). This structure contains a pocket in which 
carbohydrates can be recognized. The term galectin was proposed in 1994,261 because 
the short carbohydrate ligand for most galectins contains lactosamine, i.e. galactose 
and N-acetylglucosamine bound by a β-linkage. In mammalians there are 15 different 
subtypes of galectins and are widespread localized in cytoplasm, nucleus, extracellular 
matrix. Although they lack enzymatic activity, galectins are involved in cell cycle 
regulation, immune response and apoptosis. Hence, galectins are attractive targets for 
the development of selective modulators.  
 
Figure 7.1: Structure of galectin-3. PDB: 5NF9 
 
260  Thiemann, S.; Baum, L. G. Annu. Rev. Inmmun. 2016, 34, 243-264. 
261  Barondes, S. H.; Castronovo, V.; Cooper, D. N. W.; Cummings, R. D.; Drickamer, K.; Felzi, T.; Gitt, M. 
A.; Hirabayashi, J.; Hughes, C.; Kasai, K. -I.; Leffler, H.; Liu, F. -T.; Lotan, R.; Mercurio, A. M.; Monsigny, 
M.; Pillai, S.; Poirer, F.; Raz, A.; Rigby, P. W. J.; Rini, J. M.; Wang, J. L. Cell 1994, 76, 597-598. 
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In mammalians, galectins are classified into thee subfamilies, namely prototype, 
chimera and tandem-repeat according to their structure. The prototype subfamily is 
formed by galectins-1, -2, -5, -7, -10, -11, -13, -14 and -15 and is characterized by the 
formation of homodimers non-covalently joined by the back of CDR.  
Galectin-4, -6, -8, -9 and -12 form the tandem-repeat or bivalent subset. These 
galectins are formed by two different CDR moieties linked by a flexible peptide. These 
galectins can show linkers with varied lengths,262 caused by alternative splicing of 
linker-encoding RNA.263  
The chimera type is a subset of galectins formed by galectin-3 in mammalians. This 
galectins have the CRD in C-terminal and can dimerize in this point.264 However, the N-
terminal domain is responsible for the multimerization of chimera-type galectins  
resulting in a pentamer.265 This multimerization process allows galectin-3 to bind 
multivalent glycan ligands in a surface (Figure 7.2).266 
 
 
Figure 7.2 
 
262  Sato, M.; Nishi, N.; Shoji, H.; Seki, M.; Hashidate, T.; Hirabayashi, J.; Kasai, K. -I.; Hata, Y.; Suzuki, S.; 
Hirashimata, M.; Nakamura, T. Glycobiology 2002, 12, 191-197. 
263  Spitzenberger, F.; Graessler, J.; Schroeder, H. E. Biochimie 2001, 83, 851-862. 
264  Yang, R. Y.; Hill, P. N.; Hsu, D. K.; Liu, F. T. Biochemistry 1998, 37, 4086-4092. 
265  Lepur, A.; Salomonsson, E.; Nilsson, U. J.; Leffler, H. J. Biol. Chem. 2012, 287, 21751-21756. 
266  Ahmad, N.; Gabius, H. J.; André, S.; Kaltner, H.; Sabesan, S.; Roy, R.; Bingcan, L.; Macaluso, F.; Brewer, 
C. F. J. Biol. Chem. 2004, 279, 10841-10847. 
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The galectins can be found in the cytosol, participate in protein-protein interactions 
and take part in several intracellular events. For example, galectin-3 regulates 
apoptosis and autophagy.267, 268 Also, galectins -3 and -1 can moved to the nucleus and 
stabilize protein-DNA interactions, promoting transcription.269 However, the best-
known and studied role for galectins is the binding to cell surface glycolipids and 
glycoprotein receptors. Galectins are synthetized in cytoplasm by free ribosomes,270 
and are not able to be exported by the endoplasmic reticulum-Golgi secretory 
pathway.271 These galectins are secreted by a non-classical pathway by accumulation 
in the cytosolic side of the plasma membrane and secreted by exosomes or formation 
of vesicles. Also, some evidences shown the ability of these molecules to directly 
translocate through membranes by a poorly understood mechanism.272, 273 
7.1.2. Role of Gal-3 in neuroinflammation 
The role of galectin-3 in neuroinflammation remains controversial. Their role in the 
CNS remains poorly known and both neuroprotective or neuroinflammatory roles were 
reported by different studies.  
Some recent evidences seem to point to a deleterious role of galectin 3 in brain injury 
and degeneration. In acute brain inflammation, an increased release of galectin-3 was 
described.274 Also, binding and subsequent activation of TLR4 was described, rising the 
proinflammatory microglia M1 phenotype. Thus, galectin-3 has a role in ischemic 
environment and contributes to the long-term proinflammatory response.  
On the other hand, galectin-3 induces a neuroprotective effect via crosslinking of 
growth factor receptors (GFRs) by oligomerized galectin-3, avoiding their removal from 
 
267  Yu, F.; Finley, R. L.; Raz, A.; Kim, H. R. C. J. Biol. Chem. 2002, 277, 15819-15827. 
268  Shi, Y.; He, B.; Kuchenbecker, K. M.; You, L.; Xu, Z.; Mikami, I.; Yagui-Beltran, A.; Genevieve, C.; Yu-
Chin, L.; Okamoto, J.;  Bravo, D. T. Int. J. Cancer 2007, 121, 1175-1181. 
269  Patterson, R. J.; Wang, W.; Wang, J. L. Glycoconj. J. 2002, 19, 499-506. 
270  Rabinovich, G. A.; Rubinstein, N.; Fainboim, L. J. Leukoc. Biol. 2002, 71, 741-752. 
271  Cooper, D. N.; Barondes, S. H. J. Cell Biol. 1990, 110, 1681-1691. 
272  Nickel, W. Eur. J. Biochem. 2003, 270, 2109-2119. 
273  Cho, M.; Cummings, R. D. J.Biol. Chem. 1995, 270, 5207-5212. 
274  Burguillos, M. A.; Svensson, M.; Schulte, T.; Boza-Serrano, A.; García-Quintanilla, A.; Kavanagh, E.; 
Santiago, M.; Viceconte; N.; Oliva-Martin, M. J.; Osman, A. M.; Salomonsson, E.; Amar, L.; Persson, 
A.; Blomgren, K.; Achour, A.; Englund, E.; Leffler, H.; Venero, J. L.; Joseph, B.; Deierborg, T. Cell 
Reports 2015, 10, 1626-1638. 
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the cell surface by endocytosis and leading to an improvement in GF signalling.275, 276 
Galectin 3 can also induce alternative microglia activation by CD98 binding.277 As 
discussed in the introduction, microglia activation is a hallmark in NDDs and brain 
injuries like stroke. 
Furthermore, Boza-Serrano and co-workers278 noted overexpression of galectin-3 in a 
5xFAD AD mouse model, defined by 5 linked AD mutations. These mice display a 
decrease both in load and size of β-amyloid plaques. Also, galectin-3 downregulation in 
this mouse model leads to a change in size and morphology of dystrophic neurites, 
which recover the irregular morphology. Besides, the downregulation in galectin-3 
promotes an important decrease in microglial cells in the neighbourhood of βA 
plaques. All these biological relevant alterations may be due to the binding of galectin-
3 to TREM2 (triggering receptor expressed on myeloid cells 2), which is tightly related 
to AD progression. Both galectin-3 and TREM2 colocalize in the βA plaques of AD 
samples.  
7.1.3. Galectin-3 modulators 
As described above, the roles of galectin-3 in neurodegenerative disease and ischemia 
are unclear. However, there is much evidence for an important microglial phenotype 
tuning by galectin-3. For this reason, the design of new selective modulators of the 
function of galectin-3 in the neuroprotective phenotype in microglia offers a pathway 
for a better understanding of these pathologies and can be regarded as an innovative 
target in NDD.  
  
 
275  Lalancette-Hébert, M; Swarup, V.; Beaulieu, J. M.; Bohacek, I.; Abdelhamid, E.; Weng, Y. C.; Sato, S.; 
Kriz, J. J. Neurosci. 2012, 32, 10383–10395. 
276  Partridge, E. A.; Le Roy, C.; Di Guglielmo, G. M.; Pawling, J.; Cheung, P.; Granovsky, M.; Nabi, I.R.; 
Wrana, J. L.; Dennis, J. W. Science 2004, 306, 120-124. 
277  MacKinnon, A. C.; Farnworth, S. L.; Hodkinson, P. S.; Henderson, N. C.; Atkinson, K. M.; Leffler, H.; 
Nilsson, U. J.; Haslett, C.; Forbes, S. J.; Sethi, T. J. Immunol. 2008, 180, 2650-2658. 
278  Boza-Serrano Ruiz, A.; Sánchez-Varo, R.; García-Revilla, J.; Jiménez-Ferrer Y. Y.; Paulus, A.; 
Wennström, M.; Vilalta, A.; Allendorf, D.; Dávila, J. C.; Stegmayr, J.; Jiménez, S.; Roca-Ceballos M. A.; 
Navarro-Garrido, V.; Swanberg, M.; Hsieh, C. L.; Real, L. M.; Englund, E.; Linse, S.; Leffler, H.; Nilsson, 
U. J.; Brown, G. C.; Gutiérrez, A.; Vitorica, J.; Venero, J. L. Acta Neuropathol. 2019, 138, 251-273. 
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7.2. Design of selective galectin-3 modulators279  
The design was carried out via a fragment-based approach, by virtual screening of 
different drug-like fragments in the Maybridge database in several galectins, choosing 
the fragments with the best scores and proper orientation and conformation to bind 
the position 3 of OMe-Lac in their binding site. Then, from the 106 fragments that fulfil 
the conditions previously described, the heterocycle-disaccharide hybrid was built. 
Finally, the 106 structures were docked in galectins-1, -3 and 9. The lowest scoring 
energy lactose-like configuration was chosen. Also, commercial ability and synthetic 
accessibility criteria were applied (Figure 7.3).  
 
Figure 7.3 
The compounds that were finally chosen as synthetic targets are shown in Figure 7.4.  
  
 
279  The design briefly summarized in this Section was carried out by the group led by Dr. Sonsoles 
Martín Santamaría at CIB-CSIC and is described here to complete the background of this chapter.  
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Figure 7.4 
7.3. Synthesis of heterocyclic-OMe-Lac derivatives as galectin ligands 
Scheme 7.1 shows the synthetic pathway employed to obtain the benzoic acid 
derivative 36 from the commercially available material 33. The first step was a 
chemoselective reduction of the carboxylic acid to alcohol, followed by nitro group 
reduction with iron in aqueous hydrochloric acid to afford compound 35 in 
quantitative overall yield for both steps and without the need for purification. The 
construction of the pyrrole ring was out by a microwave-assisted Clauson-Kaas 
reaction to obtain compound 36a (R = H) in 81% yield and by Paal-Knor reaction, again 
under microwave irradiation, to yield compound 36b (R = Me) in 62% yield. Then the 
alcohol functions from 36 were transformed into azides 37, under Mitsunobu 
conditions, and the ester was finally hydrolysed with methanolic potassium hydroxide 
to give the acids 38. The azide groups were expected to be reduced to the desired 
amines in the hydrogenation process required at a later stage to remove the benzyl 
ether used as protection of the lactose hydroxyls (see below).  
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Scheme 7.1 
Compound 43 was synthesized from the commercially available benzoyl chloride 
derivative 39 by the route shown in Scheme 7.2. The first step was the synthesis of the 
benzyl ester 40, which was achieved in quantitative yield by treatment with benzyl 
alcohol. Then the first attempt to obtain the compound 42 was carried out under 
Ullman coupling conditions. However, compound 41 from aromatic nucleophilic  
 
Scheme 7.2 
Chapter 7. Carbohydrate heterocyclic hybrids as galectin modulators 
176 
 
substitution was obtained instead of the desired product. In order to obtain the 
suitable fluorinated compound 42, another coupling reaction was required, and a 
palladium-catalyzed coupling Buchwald reaction in the presence of BINAP gave the 
best results with a 36% yield. In the final step the benzyl ester moiety from 42 was 
hydrolyzed, affording compound 43.  
Compound 45 was synthetized from 4-(bromomethyl)benzoic acid 44 and 
monoprotected Cbz-piperazine by nucleophilic substitution (Scheme 7.3). The Cbz 
protecting group was expected to be removed at a later stage by catalytic palladium 
hydrogenation, along with the lactose O-benzyl protecting groups.  
 
Scheme 7.3 
Similarly, compound 48 was synthetized by SN2 substitution starting from 
commercially available 47 and 3-hydroxypirimidine 46, albeit in modest yield (Scheme 
7.4).  
 
Scheme 7.4 
The last stages of the synthesis are being carried out at the group of Professor Stefan 
Oscarson at Centre for Synthesis and Chemical Biology, University College Dublin, 
according to the two-step route summarized in Scheme 7.5. 
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Scheme 7.5 
 
7.4. Experimental section 
General experimental details 
All reagents and solvents were of commercial quality and were used as received. 
Reactions were monitored by thin layer chromatography on aluminium plates coated 
with silica gel and fluorescent indicator. Microwave-assisted reactions were performed 
on a CEM Discover focused microwave reactor. Separations by flash chromatography 
were performed using a Combiflash Teledyne automated flash chromatograph or on 
conventional silica gel columns. Melting points were measured with a Kofler-type 
heating platine microscope from Reichert, 723 model, and are uncorrected. Infrared 
spectra were recorded with an Agilent Cary630 FTIR spectrophotometer with a 
diamond ATR accessory for solid and liquid samples, requiring no sample preparation; 
wavenumbers are given in cm−1. NMR spectroscopic data were obtained using 
spectrometers maintained by the CAI de Resonancia Magnética, UCM, operating at 
250, 300, 400 and 700 MHz for 1H NMR and, 63, 100 and 176 MHz for 13C NMR; 
chemical shifts are given in (δ) parts per million and coupling constants (J) in hertz. 
Elemental analyses were determined by the CAI de Microanálisis, Universidad 
Complutense, using a Leco CHNS-932 combustion microanalyzer. The enantiomeric 
excess analysis has been conducted in a HPLC Agilent 1220 Infinity LC with a chiral 
column ULTRON ES. 
 
7.4.1. Synthesis of fragment 38 
Methyl 3-(hydroxymethyl)-5-nitrobenzoate (34) 
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A solution of 3-(methoxycarbonyl)-5-nitrobenzoic acid (1.0 g, 4.5 mmol) in THF (30 mL) 
was cooled to 0°C. Then, a 1 M borane tetrahydrofuran complex solution (8.9 mL, 8.9 
mmol) was cautiously added over 15 min and the reaction mixture was stirred at room 
temperature overnight. The excess of borane was quenched with methanol (5 mL) at 
0°C and concentrated in vacuo The solid residue was dissolved in ethyl acetate (60 mL), 
washed with saturated aqueous sodium carbonate solution (2 × 30 mL), then brine (30 
mL), and dried over sodium sulphate. The solvent was removed under reduced 
pressure to afford 1.83 g (98%) of the title compound as a white solid, which was used 
in the next step without further purification. 
Mp: 78-79 °C; 1H NMR (250 MHz, CDCl3) δ 8.68 (s, 1H), 8.40 (s, 1H), 8.30 (s, 1H), 4.86 
(s, 2H), 3.98 (s, 3H), 3.09 (br s, 1H); 13C NMR (63 MHz, CDCl3) δ 165.5, 148.7, 144.2, 
133.5, 132.1, 125.6, 123.7, 63.8, 53.3; IR (neat, cm-1): 3485, 1708, 1522, 1349, 1294; 
HRMS (ESI): found m/z 210.0408 [M]+, calcd. for C9H8NO5 210.040.  
 
Methyl 3-amino-5-(hydroxymethyl)benzoate (35) 
 
Compound 34 (1.76 g, 8.4 mmol) was dissolved in methanol (30 mL) and a 1M HCl 
solution was added (10 mL) and then, Fe powder (14 g, 25 mmol). The mixture was 
refluxed for 4 h. Then, the reaction was diluted with ethyl acetate (50 mL) and was 
washed with saturated sodium carbonate solution (3 x 20 mL). The organic layer was 
dried over sodium sulphate, filtered, and the solvent was removed under reduce 
pressure to give 1.25 g (82%) of a pale yellow solid, that was used in the next step 
without further purification. 
Mp: 96-97 °C; 1H NMR (250 MHz, d6-DMSO) δ 7.14 – 7.03 (m, 2H), 6.78 (s, 1H), 5.35 (s, 
2H), 5.16 (t, J = 5.8 Hz, 1H), 4.41 (d, J = 5.7 Hz, 2H), 3.80 (s, 3H); 13C NMR (63 MHz, d6-
DMSO) δ 167.7, 149.7, 144.6, 130.8, 117.1, 115.4, 113.5, 63.5, 52.6; IR (neat, cm-1): 
3338, 1703, 1604, 1437, 1243, 1017; HRMS (ESI): found m/z 204.0631 [M]+, calcd. for 
C9H11NNaO3 204.0636.  
Methyl 3-(hydroxymethyl)-5-(1H-pyrrol-1-yl)benzoate (36a) 
 
Compound 35 (1 mmol) was placed in a microwave tube and 2,5-
dimethoxytetrahydrofuran (2 mmol) was added. The mixture was irradiated at 100 °C 
for 10 min and monitored by TLC. The mixture was diluted with CHCl3 (20 mL) and 
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washed with water (2 × 10 mL), dried over sodium sulphate, filtered, and the solvent 
was removed under reduced pressure. The crude product was purified by flash 
chromatography on silica gel using a 1:4 ethyl acetate-petroleum ether mixture as 
eluent, affording 188 mg (81%) of the expected compound as a white solid.  
Mp: 84-85 °C; 1H NMR (250 MHz, CDCl3) δ 7.94 (s, 1H), 7.85 (s, 1H), 7.60 (s, 1H), 7.18 – 
7.10 (m, 2H), 6.42 – 6.33 (m, 2H), 4.77 (s, 2H), 3.94 (s, 3H), 2.70 (br s, 1H); 13C NMR (63 
MHz, CDCl3) δ 167.1, 143.8, 141.8, 132.5, 125.3, 123.3, 121.0, 120.0, 111.8, 65.2, 53.2; 
IR (neat, cm-1): 3247, 1710, 1599, 1487, 1434, 1351, 1260; HRMS (ESI): found m/z 
230.0823 [M]+, calcd.for C13H12NO3 230.0813.  
Methyl 3-(2,5-dimethyl-1H-pyrrol-1-yl)-5-(hydroxymethyl)benzoate (36b) 
 
Compound 35 (1 mmol) was placed in a microwave tube and 2,5-hexanedione (2 
mmol) was added. The mixture was irradiated at 100 °C for 1 h and monitored by TLC. 
The mixture was diluted with CHCl3 (20 mL) and washed with water (2 × 10 mL), dried 
over sodium sulphate, filtered, and the solvent was removed under reduced pressure. 
The crude product was purified by flash chromatography on silica gel using a 1:4 ethyl 
acetate-petroleum ether mixture as eluent, affording 136 mg (62%) of the expected 
compound as a colourless oil.  
1H NMR (250 MHz, CDCl3) δ 8.10 (s, 1H), 7.84 (s, 1H), 7.47 (s, 1H), 5.93 (s, 2H), 4.83 (s, 
2H), 3.95 (s, 3H), 2.42 (s, 1H), 2.05 (s, 6H); 13C NMR (63 MHz, CDCl3) δ 166.8, 143.2, 
139.9, 131.8, 131.2, 129.1, 128.7, 127.3, 106.6, 64.5, 52.9, 13.5; IR (neat, cm-1): 3239, 
1702, 1610, 1481, 1434, 1338, 12656; HRMS (ESI): found m/z 258.1123 [M]+, calcd. for 
C15H16NO3 258.1136. 
Synthesis of methyl 3-(azidomethyl)-5-(1H-pyrrol-1-yl)benzoate derivatives 37 
 
The suitable alcohol 36a-b (2 mmol), sodium azide (2.4 mmol), and triphenylphosphine 
(2.4 mmol) were placed in a round bottom flask and dissolved in DMF (8 mL). Then, 
CCl4 was added dropwise and the reaction was stirred at 70 °C for 2 h. The mixture was 
diluted with water (30 mL) and extracted with diethyl ether (2 x 20 mL). The combined 
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organic layers were dried over sodium sulphate, flltered, and the solvent was removed 
in vacuo. The residue was purified by flash chromatography on silica gel using a 1:4 
ethyl acetate-hexane mixture as eluent. 
Methyl 3-(azidomethyl)-5-(1H-pyrrol-1-yl)benzoate (37a) 
Colourless oil (512 mg, 97%); 1H NMR (250 MHz, CDCl3) δ 8.19 – 
7.99 (m, 1H), 7.94 – 7.84 (m, 1H), 7.60 – 7.49 (m, 1H), 7.22 – 7.09 
(m, 2H), 6.43 – 6.40 (m, 2H), 4.49 (s, 2H), 3.99 (s, 3H); 13C NMR (63 
MHz, CDCl3) δ 166.5, 141.8, 138.2, 132.7, 126.3, 124.1, 121.3, 
119.7, 111.8, 54.6, 53.1; IR (neat, cm-1): 2094, 1718, 1602, 1490, 
1433, 1355, 1255,1195, 1070; HRMS (ESI): found m/z 279.0860 
[M]+, calcd. for C13H12N4NaO2 279.0853. 
Methyl 3-(azidomethyl)-5-(2,5-dimethyl-1H-pyrrol-1-yl)benzoate (37b) 
Yellow oil (224 mg, 79%); 1H NMR (250 MHz, CDCl3) δ 8.11 – 8.04 
(m, 1H), 7.92 (t, J = 1.6 Hz, 1H), 7.47 – 7.39 (m, 1H), 5.96 (s, 2H), 
4.51 (s, 2H), 3.98 (s, 3H), 2.07 (s, 6H); 13C NMR (63 MHz, CDCl3) δ 
166.3, 140.2, 137.6, 132.4, 132.3, 129.5, 129.1, 128.7, 106.8, 54.3, 
53.0, 13.5; IR (neat, cm-1): 2920, 1721, 1434, 1397, 1221; HRMS 
(ESI): found m/z 285.1369 [M]+, calcd. for C15H17N4O2 285.1346. 
Synthesis of 3-(azidomethyl)-5-(1H-pyrrol-1-yl)benzoic acid derivatives 38 
 
The suitable ester 37a-b (0.5 mmol) was dissolved in methanol and a 10% KOH 
methanol solution (5 mL) was added. The reaction was monitored by TLC and 
additional 10% KOH methanol solution was added until the starting material was no 
longer detected. Then, the reaction was diluted with water (10 mL), neutralized with 
2M HCl solution and extracted with CHCl3 (3 x 20 mL). The combined organic layers 
were dried over sodium sulphate, filtered and the solvent was removed in vacuo. No 
further purification was needed. 
3-(Azidomethyl)-5-(1H-pyrrol-1-yl)benzoic acid (38a) 
Pale brown solid (quant.); mp: 113-114 °C; 1H NMR (250 MHz, CDCl3) 
δ 10.04 (s, 1H), 8.16 – 8.12 (m, 1H), 7.96 (s, 1H), 7.64 (s, 1H), 7.20 (t, J 
= 2.2 Hz, 2H), 6.44 (t, J = 2.2 Hz, 2H), 4.53 (s, 2H); 13C NMR (63 MHz, 
CDCl3) δ 171.5, 141.8, 138.4, 131.7, 126.7, 124.9, 121.8, 119.6, 111.9, 
54.4; IR (neat, cm-1): 2842, 2095, 1693, 1596, 1488, 1280; HRMS 
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(ESI): found m/z 241.0719 [M]+, calcd. for C12H9N4O2 241.0731. 
3-(Azidomethyl)-5-(2,5-dimethyl-1H-pyrrol-1-yl)benzoic acid (38b) 
Brown solid (quant.); mp: 108-109 °C; 1H NMR (250 MHz, CDCl3) δ 
10.60 (s, 1H), 8.16 (s, 1H), 8.01 (t, J = 1.6 Hz, 1H), 7.51 (t, J = 1.7 Hz, 
1H), 5.98 (s, 2H), 4.55 (s, 2H), 2.10 (s, 6H); 13C NMR (63 MHz, CDCl3) δ 
171.5, 140.4, 137.9, 133.3, 131.4, 130.0, 129.2, 129.1, 107.0, 54.2, 
13.5; IR (neat, cm-1): 2918, 2097, 1694, 1461, 1416, 1234; HRMS 
(ESI): found m/z 269.10232 [M]+, calcd. for C14H13N4O2 269.1044.  
7.4.2. Synthesis of fragment 43 
Benzyl 2-fluoro-5-iodobenzoate (40) 
 
To a solution of 2-fluoro-4-iodobenzoyl chloride (0.5 mmol) in anhydrous CH2Cl2 (10 
mL) cooled at 0 °C, under argon atmosphere, benzyl alcohol was added (1 mmol) and 
the mixture was stirred at room temperature for 2 h. Then, the reaction was diluted 
with CH2Cl2 (15 mL) and washed with water (2 x 10 mL). The organic layer was dried 
over sodium sulphate, filtered and the solvent was removed under reduced pressure. 
The residue was chromatographed on silica gel using a 4:1 hexane-ethyl acetate 
mixture as eluent, yielding 135 mg (73%) of the desired compound as colourless oil. 
1H NMR (250 MHz, CDCl3) δ 8.25 (dd, J H-F= 6.7 Hz, JH-H = 2.4 Hz, 1H), 7.79 (ddd, JH-H = 
8.7, 2.4 Hz, J H-F= 4.4 Hz, 1H), 7.53 – 7.29 (m, 6H), 6.91 (dd, J H-F= 10.3 Hz, JH-H = 8.7 Hz, 
1H), 5.38 (s, 2H); 13C NMR (63 MHz, CDCl3) δ 163.2 (d, J = 3.8 Hz), 162.3 (d, J = 261.7 
Hz), 143.7 (d, J = 8.8 Hz), 141.1, 135.8, 129.1 (2C), 128.9, 128.7 (2C), 121.1 (d, J = 10.6 
Hz), 119.7 (d, J = 23.4 Hz), 87.0, 87.0, 67.8; IR (neat, cm-1): 1718, 1478, 1289, 1269, 
1237; HRMS (ESI): found m/z 378.9621 [M+Na]+, calcd. for C14H10FINaO2 378.9602.  
Benzyl 4-(3-((benzyloxy)carbonyl)-4-fluorophenyl)piperazine-1-carboxylate (42) 
 
Ethyl 2-fluoro-5-iodobenzoate (0.7 mmol), Cbz-piperazine (0.85 mmol), CsCO3 (0.9 
mmol), (±)-BINAP (0.02 mmol), Pd(AcO)2 (0.02 mmol) and 1,4-dioxane (3 mL) were 
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placed in a microwave tube. The mixture was irradiated at 120 °C for 1 h. Then, the 
reaction was filtered over Celite and the solvent was removed under vacuum. The 
mixture was purified by flash chromatography on silica gel eluting with a gradient from 
hexane to 8:1 hexane-ethyl acetate mixture to afford 115 mg (26%) of the title 
compound as a brown oil. 
1H NMR (250 MHz, CDCl3) δ 7.54 – 7.32 (m, 11H), 7.14 – 7.04 (m, 2H), 5.42 (s, 2H), 5.21 
(s, 2H), 3.76 – 3.64 (m, 4H), 3.20 – 3.04 (m, 4H); 13C NMR (63 MHz, CDCl3) δ 165.0 (d, J 
= 4.1 Hz), 157.0 (d, J = 252.5 Hz), 155.6, 147.9 (d, J = 2.7 Hz), 137.0, 136.2, 129.0 (2C), 
129.0 (2C), 128.6 (d, J = 5.4 Hz), 128.5 (2C), 128.4 (2C), 123.7 (d, J = 8.3 Hz), 120.0, 
119.0 (d, J = 23.7 Hz), 118.0 (d, J = 23.7 Hz), 67.8, 67.4, 50.3 (2C), 44.1 (2C); IR (neat, 
cm-1): 1696, 1498, 1421, 1235, 1216; HRMS (ESI): found m/z 471.1738 [M+Na]+, calcd. 
for C26H25FN2NaO4 471.1691. 
5-[4-((Benzyloxy)carbonyl)piperazin-1-yl]-2-fluorobenzoic acid (43) 
 
The benzyl ester 42 (0.5 mmol) was dissolved in methanol and a 10% KOH methanol 
solution (5 mL) was added. The reaction was monitored by TLC and additional 10% 
KOH methanol solution was added until the starting material was no longer detected. 
Then, the reaction was diluted with water (10 mL), neutralized with 2M HCl solution 
and extracted with CHCl3 (3 x 20 mL). The combined organic layers were dried over 
sodium sulphate, filtered and the solvent was removed in vacuo. No further 
purification was needed. 
Brown oil (quant.); 1H NMR (250 MHz, CDCl3) δ 9.97 (br s, 1H), 7.55 (dd, J = 6.0, 2.9 Hz, 
1H), 7.47 – 7.32 (m, 4H), 7.22 – 7.05 (m, 2H), 5.21 (s, 2H), 3.81 – 3.59 (m, 4H), 3.28 – 
3.02 (m, 4H); 13C NMR (63 MHz, CDCl3) δ 169.4 (d, J = 3.4 Hz), 157.5 (d, J = 256.4 Hz), 
155.7, 147.8, 136.8, 129.0 (2C), 128.6, 128.5 (2C), 124.7 (d, J = 8.2 Hz), 120.4, 118.3 (d, 
J = 11.3 Hz), 118.0 (d, J = 2.6 Hz), 67.90, 50.4 (2C), 44.1 (2C); IR (neat, cm-1): 1695, 
1498, 1429, 1236, 1217; HRMS (ESI): found m/z 357.1243 [M]+, calcd. for C19H18FN2O4 
357.1256.  
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7.4.3. Synthesis of fragment 45 
4-[(4-((Benzyloxy)carbonyl)piperazin-1-yl)methyl]benzoic acid (45) 
 
To a solution of Cbz-piperazine (1 mmol) and triethylamine (1.1 mmol) in THF (10 mL) 
under argon atmosphere was added 4-(bromomethyl)benzoic acid (1 mmol) ant the 
mixture was stirred at reflux overnight. The reaction was cooled to room temperature, 
and a white precipitate was collected by filtration. The white solid was washed with 
THF (2 x 10 mL) to afford a white solid (308 mg, 87%). 
Mp: 177-178 °C; 1H NMR (250 MHz, d6-DMSO) δ 7.91 (d, J = 8.2 Hz, 2H), 7.43 (d, J = 8.2 
Hz, 2H), 7.40 – 7.28 (m, 5H), 5.08 (s, 2H), 3.47 – 3.31 (m, 4H), 2.44 – 2.29 (m, 4H); 13C 
NMR (63 MHz, d6-DMSO) δ 167.7, 154.7, 143.4, 137.3, 130.3, 129.7, 129.2, 128.8, 
128.2, 127.9, 66.5, 61.8, 52.7, 43.8; IR (neat, cm-1): 1695, 1446, 1426, 1238; HRMS 
(ESI): found m/z 353.1507 [M]+, calcd. for C20H21N2O4 353.1467. 
7.4.4. Synthesis of fragment 48 
4-[(3-Hydroxypiperidin-1-yl)methyl]benzoic acid (48) 
 
4-(Bromomethyl)benzoic acid (1 mmol) was added to a solution of 3-
hydrohypyperidine (1 mmol) and triethylamine (1.1 mmol) in THF (10 mL) under argon 
atmosphere and the mixture was stirred at room temperature overnight. The reaction 
was cooled at room temperature, and a white precipitate was collected by filtration. 
The white solid was washed with THF (2 x 10 mL) to afford a white solid (55 mg, 24 %). 
Mp: 181 °C 1H NMR (250 MHz, d6-DMSO) δ 7.90 (d, J = 8.1 Hz, 2H), 7.41 (d, J = 8.1 Hz, 
2H), 4.67 (bs, 1H), 3.65 – 3.36 (m, 3H), 2.85 – 2.71 (m, 1H), 2.71 – 2.55 (m, 1H), 1.97 – 
1.54 (m, 4H), 1.54 – 1.31 (m, 1H), 1.17 – 0.95 (m, 1H); 13C NMR (63 MHz, d6-DMSO) δ 
167.7, 144.1, 130.0, 129.6, 129.1, 66.4, 62.1, 61.5, 53.4, 33.6, 23.0; IR (neat, cm-1): 
3313, 1596, 1558, 1371, 1321, 1093; HRMS (ESI): found m/z 234.1125 [M]+, calcd. for 
C13H16NO3 234.1136. 
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1. The microwave-assisted, three-component reaction of -dicarbonyl compounds, -
haloesters and primary amines provides a fully regioselective access to 
functionalized 2-pyrrolin-5-one derivatives. 
2. 4-Arylmethylene-2-pyrrolin-5-ones, which can be viewed as analogues to natural 
antioxidant cinnamic acid derivatives, are readily accessible by simple Knoevenagel 
chemistry. They have an interesting pharmacological profile, with generally low 
toxicity for human neuronal cells and good ability to induce the Nrf2-ARE 
antioxidant pathway. They also show a good neuroprotective activity against 
oxidative stress generated by blockade of the mitochondrial electron transport 
chain of  SH-SY5Y neuroblastoma cells with rotenone-oligomycin. They are also 
neuroprotective against damage caused by the hyperphosphorylation induced by 
the phosphatase inhibitor okadaic acid. 
3. The acylation of the C-4 position of 2-pyrrolin-5-one derivatives provides cyclic 
analogues of curcumin, a natural antioxidant and neuroprotectant. These 
compounds had also an interesting profile when compared to curcumin, with a 
lower cytotoxicity, similar or higher radical scavenging activities and a similar 
activity as inhibitors of the aggregation of the AcPHF6 peptide, a suitable model to 
study tau protein aggregation inhibition. 
4. A 1,3-dipolar cycloaddition-based three-component reaction from -amino acids 
and isatin, which generate in situ a 1,3-dipole, and 4-arylmethylene-2-pyrrolin-5-
ones, acting as the dipolarophile, provides dispiro compounds bearing three 
adjacent stereocenters with full regio- and diastereoselectivity. These compounds 
are structurally related to the oxindole alkaloid rhynchophylline and were potent 
neuroprotectors, both in the rotenone-oligomycin and the okadaic acid models. 
5. Hybrid compounds containing vinylogous melatonin and 2,5,8-quinolinetrione 
structural fragments were constructed from the unsubstituted quinones and 
tryptamine derivatives by a regioselective Michael addition-oxidation process. 
These compounds have a very potent antioxidant activity. 
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6. The use of Ellman’s sulfinamide as a chiral auxiliary allows a fully diastereoselective 
reduction of a highly hindered diaryimine that corresponds to the aromatic 
fragment of the mNCX inhibitor CGP-37157. The product of this reaction was 
transformed in six steps into an aza-CGP-37157-lipoic acid hybrid compound. This 
chemistry could be extended to the preparation of all possible enantiomers of the 
hybrid compound. Their pharmacological study has shown the existence of 
enantiospecificity in the induction of the Nrf2-ARE pathway. 
7. Multistep routes, usually based on Pd-catayzed cross-coupling reactions, have 
allowed the preparation of four heterocyclic molecules needed for the preparation 
of the corresponding heterocyclic galactose hybrids, designed as galectin 
modulators via a fragment-based approach. 
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Methyl 1-butyl-2-methyl-5-oxo-4,5-dihydro-1H-pyrrole-3-carboxylate (1b) 
1H-NMR (250 MHz, CDCl3) 
 
13C-NMR (63 MHz, CDCl3) 
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Methyl 1-benzyl-2-methyl-5-oxo-4,5-dihydro-1H-pyrrole-3-carboxylate (1f) 
1H NMR (250 MHz, CDCl3) 
 
13C NMR (63 MHz, CDCl3) 
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Methyl 1-allyl-2-methyl-5-oxo-4,5-dihydro-1H-pyrrole-3-carboxylate (1j) 
1H NMR (250 MHz, CDCl3) 
 
13C NMR (63 MHz, CDCl3) 
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Methyl 1-(2-hydroxyethyl)-2-methyl-5-oxo-4,5-dihydro-1H-pyrrole-3-carboxylate (1k) 
1H NMR (250 MHz, CDCl3)
 
13C NMR (63 MHz, CDCl3) 
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Ethyl 2-methyl-5-oxo-4,5-dihydro-1H-pyrrole-3-carboxylate (1n) 
1H NMR (250 MHz, CDCl3) 
 
13C NMR (63 MHz, CDCl3) 
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Ethyl 2,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrrole-3-carboxylate (1o) 
1H NMR (250 MHz, CDCl3) 
 
13C NMR (63 MHz, CDCl3) 
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Ethyl 2-methyl-5-oxo-4-phenyl-4,5-dihydro-1H-pyrrole-3-carboxylate (1q) 
1H NMR (250 MHz, CDCl3) 
 
13C NMR (63 MHz, CDCl3) 
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Methyl 1-(2-(1H-indol-3-yl)ethyl)-2-methyl-5-oxo-4,5-dihydro-1H-pyrrole-3-
carboxylate (1u) 
1H NMR (250 MHz, CDCl3) 
 
13C NMR (63 MHz, CDCl3) 
 
  
Representative spectra 
199 
 
 
4-[(4-Chlorobenzyl)oxy]-3-methoxybenzaldehyde (2a) 
1H NMR (250 MHz, CDCl3) 
 
13C NMR (63 MHz, CDCl3) 
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4-[(2-Fluorobenzyl)oxy]-3-methoxybenzaldehyde (2c) 
1H NMR (250 MHz, CDCl3) 
 
13C NMR (63 MHz, CDCl3) 
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Methyl (Z)-4-benzylidene-2-methyl-5-oxo-1-phenethyl-4,5-dihydro-1H-pyrrole-3-carboxylate 
(3a)  
1H NMR (250 MHz, CDCl3) 
 
13C NMR (63 MHz, CDCl3) 
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Methyl (Z)-4-[4-[(2-chlorobenzyl)oxy]-3-methoxybenzylidene]-2-methyl-5-oxo-1-phenethyl-
4,5-dihydro-1H-pyrrole-3-carboxylate (3g)  
1H NMR (250 MHz, CDCl3) 
 
13C NMR (63 MHz, CDCl3) 
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Methyl (Z)-4-(3,4-dihydroxybenzylidene)-2-methyl-5-oxo-1-phenethyl-4,5-dihydro-1H-
pyrrole-3-carboxylate (3i)  
1H NMR (250 MHz, CDCl3) 
 
13C NMR (63 MHz, CDCl3) 
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1H-pyrrole-3-carboxylate (3k)  
1H NMR (250 MHz, CDCl3) 
 
13C NMR (63 MHz, CDCl3) 
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Methyl (Z)-1-butyl-4-((E)-1-hydroxy-3-(3,4,5-trimethoxyphenyl)allylidene)-2-methyl-5-oxo-
4,5-dihydro-1H-pyrrole-3-carboxylate (4b) 
1H NMR (250 MHz, CDCl3) 
 
13C NMR (63 MHz, CDCl3) 
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Ethyl (Z)-1-butyl-4-((E)-1-hydroxy-3-(3,4,5-trimethoxyphenyl)allylidene)-2-methyl-5-oxo-4,5-
dihydro-1H-pyrrole-3-carboxylate (4e) 
1H NMR (250 MHz, CDCl3) 
 
13C NMR (63 MHz, CDCl3) 
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Methyl (Z)-1-butyl-4-((E)-1-hydroxy-3-(4-hydroxy-3-methoxyphenyl)allylidene)-2-methyl-5-
oxo-4,5-dihydro-1H-pyrrole-3-carboxylate (4f) 
1H NMR (250 MHz, CDCl3) 
 
13C NMR (63 MHz, CDCl3)
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Methyl (3S*,3'R*,4'R*)-1''-butyl-1',5''-dimethyl-2,2''-dioxo-4'-phenyl-1'',2''-
dihydrodispiro[indoline-3,2'-pyrrolidine-3',3''-pyrrole]-4''-carboxylate (5a) 
1H NMR (250 MHz, CDCl3) 
 
13C NMR (63 MHz, CDCl3) 
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Methyl (3S*,3'R*,4'R*)-1,1''-dibenzyl-1',5''-dimethyl-2,2''-dioxo-4'-phenyl-1'',2''-
dihydrodispiro[indoline-3,2'-pyrrolidine-3',3''-pyrrole]-4''-carboxylate (5g) 
1H NMR (250 MHz, CDCl3) 
 
13C NMR (63 MHz, CDCl3) 
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Ethyl (1'R*,2'R*,3S*,7a’S)-1''-butyl-5''-methyl-2,2''-dioxo-1'-phenyl-1'',2'',5',6',7',7a'-
hexahydro-1'H-dispiro[indoline-3,3'-pyrrolizine-2',3''-pyrrole]-4''-carboxylate (6b) 
1H NMR (250 MHz, CDCl3) 
 
13C NMR (63 MHz, CDCl3) 
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4b NOESY 
 
 
 
 
 
  
Representative spectra 
212 
 
N-(2,5-Dimethoxyphenyl)acetamide (7a) 
1H RMN (250 MHz, CDCl3) 
 
13C RMN (63 MHz, CDCl3) 
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2-Chloro-5,8-dimethoxyquinoline-3-carbaldehyde (8a) 
1H RMN (250 MHz, CDCl3) 
 
13C RMN (63 MHz, CDCl3) 
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2-Chloro-3-methyl-5,8-dimethoxyquinoline (8b) 
1H RMN (250 MHz, CDCl3) 
 
13C RMN (63 MHz, CDCl3) 
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5,8-Dimethoxy-2-oxo-1,2-dihydroquinoline-3-carbaldehyde (9a) 
1H RMN (250 MHz, CDCl3) 
 
13C RMN (63 MHz, CDCl3) 
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5,8-Dimethoxy-3-methylquinolin-2(1H)-one (9b) 
1H RMN (250 MHz, MeOD) 
 
13C RMN (63 MHz, MeOD) 
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2-Amino-3,6-dimethoxybenzaldehyde (11) 
1H NMR (250 MHz, CDCl3) 
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5,8-Dimethoxy-2-oxo-1,2-dihydroquinoline-3-carbonitrile (12a) 
1H NMR (250 MHz, d6-DMSO) 
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3-Methylquinoline-2,5,8(1H)-trione (13a) 
1H NMR (250 MHz, CDCl3) 
 
13C NMR (63 MHz, CDCl3) 
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2,5,8-Trioxo-1,2,5,8-tetrahydroquinoline-3-carbonitrile (13c) 
1H NMR (250 MHz, d6-acetone) 
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4-Methyl-6-[(2-(1H-indol-3-il)ethyl)amino]quinoline-2,5,8(1H)-trione (14a) 
1H NMR (500 MHz, d6-DMSO) 
 
13C NMR (126 MHz, d6-DMSO) 
 
  
Representative spectra 
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6-[(2-(5-Methoxy-1H-indol-3-yl)ethyl)amino]-2,5,8-trioxo-1,2,5,8-tetrahydroquinoline-3-
carbonitrile (14d) 
1H NMR (500 MHz, d6-DMSO) 
 
13C NMR (126 MHz, d6-DMSO) 
 
  
Representative spectra 
223 
 
3-Methyl-6-[(2-(5-methoxy-1H-indol-3-il)ethyl)amino]quinolin-2,5,8(1H)-trione (14e) 
1H RMN (250 MHz, d6-DMSO) 
 
13C RMN (63 MHz, d6-DMSO) 
 
 
  
Representative spectra 
224 
 
5,8-Dimethoxy-3-[((2-(5-methoxy-1H-indol-3-yl)etil)amino)-methyl]quinolin-2(1H)-
one (15) 
1H NMR (250 MHz, CDCl3) 
 
13C NMR (63 MHz, CDCl3) 
 
 
Representative spectra 
225 
 
(2-Amino-5-chlorophenyl)(2-chlorophenyl)carbinol (14)  
1H NMR (400 MHz, CDCl3)  
 
  
Representative spectra 
226 
 
7-Chloro-5-(2-chlorophenyl)-1,5-dihydrobenzo[e][1,4]thiazepin-2(3H)-one (15) 
1H NMR (700 MHz, CDCl3) 
 
13C NMR (176 MHz, CDCl3) 
 
  
Representative spectra 
227 
 
Ethyl 2-[((2-amino-5-chlorophenyl)(2-chlorophenyl)methyl)thio]acetate 
1H NMR (700 MHz, CDCl3) 
 
13C NMR (176 MHz, CDCl3) 
 
  
Representative spectra 
228 
 
cis-7-Chloro-5-(2-chlorophenyl)-1,5-dihydrobenzo[e][1,4]thiazepin-2(3H)-one 4-oxide (16) 
1H NMR (250 MHz, d6-DMSO) 
 
1H NMR (250 MHz, d6-DMSO) 
 
 
 
  
Representative spectra 
229 
 
trans-7-Chloro-5-(2-chlorophenyl)-1,5-dihydrobenzo[e][1,4]thiazepin-2(3H)-one 4-oxide (17) 
1H NMR (700 MHz, d6-DMSO) 
 
 
 
  
Representative spectra 
230 
 
7-Chloro-5-(2-chlorophenyl)-1,5-dihydrobenzo[e][1,4]thiazepin-2(3H)-one 4,4-dioxide (18). 
1H NMR (400 MHz, d6-DMSO) 
 
13C NMR (100 MHz, d6-DMSO) 
 
 
  
Representative spectra 
231 
 
(R,Z)-N-((2-Amino-5-chlorophenyl)(2-chlorophenyl)methylene)-2-methylpropane-2-
sulfinamide (R-23) 
1H NMR (250 MHz, CDCl3) 
 
13C NMR (63 MHz, CDCl3) 
 
  
Representative spectra 
232 
 
(R)-N-[(S)-(2-Amino-5-chlorophenyl)(2-chlorophenyl)methyl]-2-methylpropane-2-sulfinamide 
(R,S-24) 
1H NMR (250 MHz, CDCl3) 
 
13C NMR (63 MHz, CDCl3) 
 
  
Representative spectra 
233 
 
(S)-2-[Amino(2-chlorophenyl)methyl]-4-chloroaniline (S-24) 
1H NMR (250 MHz, CDCl3) 
 
13C NMR (63 MHz, CDCl3)
 
  
Representative spectra 
234 
 
2-[((2-Amino-5-chlorophenyl)(2-chlorophenyl)methylene)amino]ethanol 21 
1H NMR (250 MHz, CDCl3) 
 
 
13C NMR (63 MHz, CDCl3) 
 
  
Representative spectra 
235 
 
 (±)-2-[((2-Amino-5-chlorophenyl)(2-chlorophenyl)methyl)amino]ethanol 28 
1H NMR (250 MHz, CDCl3)  
 
13C NMR (63 MHz, CDCl3) 
 
  
Representative spectra 
236 
 
rac-2-(7-Chloro-5-(2-chlorophenyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-4-
yl)ethyl 2-bromoacetate (27) 
1H NMR (250 MHz, CDCl3)  
 
13C NMR (63 MHz, CDCl3)  
 
  
Representative spectra 
237 
 
7-Chloro-5-(2-chlorophenyl)-4-(2-hydroxyethyl)-4,5-dihydro-1H-benzo[e][1,4]diazepin-2(3H)-
one 
1H NMR (250 MHz, CDCl3)  
 
13C NMR (63 MHz, CDCl3)  
 
  
Representative spectra 
238 
 
2-(7-Chloro-5-(2-chlorophenyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-4-yl)ethyl 
5-(1,2-dithiolan-3-yl)pentanoate (20) 
1H NMR (250 MHz, CDCl3)  
 
13C NMR (63 MHz, CDCl3)  
 
  
Representative spectra 
239 
 
Methyl 3-(hydroxymethyl)-5-nitrobenzoate (34) 
1H NMR (250 MHz, CDCl3) 
 
13C NMR (63 MHz, CDCl3) 
 
  
Representative spectra 
240 
 
Methyl 3-amino-5-(hydroxymethyl)benzoate (35) 
1H NMR (250 MHz, d6-DMSO) 
 
13C NMR (63 MHz, d6-DMSO) 
 
  
Representative spectra 
241 
 
Methyl 3-(hydroxymethyl)-5-(1H-pyrrol-1-yl)benzoate (36a) 
1H NMR (250 MHz, CDCl3) 
 
13C NMR (63 MHz, CDCl3) 
 
  
Representative spectra 
242 
 
Methyl 3-(azidomethyl)-5-(1H-pyrrol-1-yl)benzoate (37a) 
1H NMR (250 MHz, CDCl3) 
13C NMR (63 MHz, CDCl3) 
 
  
Representative spectra 
243 
 
3-(Azidomethyl)-5-(1H-pyrrol-1-yl)benzoic acid (38a) 
1H NMR (250 MHz, CDCl3) 
13C NMR (63 MHz, CDCl3) 
 
  
Representative spectra 
244 
 
4-[(4-((Benzyloxy)carbonyl)piperazin-1-yl)methyl]benzoic acid (45) 
1H NMR (250 MHz, d6-DMSO) 
 
13C NMR (63 MHz, d6-DMSO) 
 
  
Representative spectra 
245 
 
4-[(3-Hydroxypiperidin-1-yl)methyl]benzoic acid (48) 
1H NMR (250 MHz, d6-DMSO) 
 
13C NMR (63 MHz, d6-DMSO) 
 
  
Representative spectra 
246 
 
Benzyl 2-fluoro-5-iodobenzoate (40) 
1H NMR (250 MHz, CDCl3) 
 
13C NMR (63 MHz, CDCl3) 
 
  
Representative spectra 
247 
 
Benzyl 4-(3-((benzyloxy)carbonyl)-4-fluorophenyl)piperazine-1-carboxylate (42) 
1H NMR (250 MHz, CDCl3) 
 
13C NMR (63 MHz, CDCl3) 
 
  
Representative spectra 
248 
 
5-[4-((Benzyloxy)carbonyl)piperazin-1-yl]-2-fluorobenzoic acid (43) 
1H NMR (250 MHz, CDCl3) 
 
13C NMR (63 MHz, CDCl3) 
 
 
 
